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Abstract 
Integrin αIIbβ3 is the central protein in haemostasis and thrombosis; its activation is the 
first step in a cascade of biochemical processes which leads to platelet activation, 
spreading and clotting. The mechanism of integrin activation and molecular details of 
platelet activation are still being worked out so tools which aid in this process are useful 
in both diagnostic and therapy development. Many questions remain on the 
conformational changes in the key integrin responsible for stimulating thrombosis and 
methods of preventing or forcing adhesion of platelets on solid surfaces is key in 
medical devices and diagnostics respectively.  
 
This work exploits the RGD peptide sequence (recognises fibrinogen which plays a key 
role in platelet activation), for both exploring conformational status of αIIbβ3 integrin in 
solution and tracking it in platelets and also for binding and releasing platelets from 
substrates.  
 
The former focusses on novel ruthenium(II) polypyridyl metal complex probes with 
long luminescent lifetimes which through changes to their photophysics and anisotropy 
can be used to determine the activation status of an integrin. In addition, the application 
of two stokes shifted probes: ruthenium(II) polypyridyl complexes, developed in this 
programme and also a near infra-red BODIPY in neurological tissue imaging is 
reported. Ru(II)
 
binding to β-amyloid protein aggregates (linked to Alzheimer’s disease) 
is also presented, proving that the application of ruthenium complexes in biology is 
diverse, presenting huge potential in a wide variety of areas including tissue imaging 
and diagnostics. 
 
The latter focusses on novel means of binding or preventing binding of human blood 
platelets to planar or nanostructured surfaces which through chemical or geometrical 
modifications can be used to alter the binding ability, morphology and activation status 
of platelets, an aspect which is vital towards managing thrombus related diseases. 
 
Overall, this thesis introduces some new probes and tools which may have significant 
value and insight to offer in study and prevention of thrombosis. 
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1.0   Introduction 
1.0.1   Thrombosis 
Thrombosis is the formation of a blood clot inside a blood vessel, causing blood flow 
restriction throughout the circulatory system.  Platelet aggregation plays a key role in 
thrombosis, instigated on exposure of platelets to an injured blood vessel. When a blood 
vessel ruptures the von Willebrand Factor protein (vWF) adheres to the exposed sub-
endothelium and undergoes conformational changes. Platelets adhere to vWF via a 
glycoprotein receptor (Ib-IX-V) resulting in platelet activation. Consequential signalling 
occurs to the glycoprotein receptor, integrin αIIbβ3 (GPIIb/IIIa)  that lies across the 
plasma membrane of platelets causing conformational changes that allow the receptor to 
bind fibrinogen, see Figure 1.1.
(1)
   
 
Fibrinogen (Fg) is a dimeric glycoprotein, 340 kDa in weight and is known as the 
primary ligand for the αIIbβ3 receptor. Fibrinogen is symmetrical and contains three 
putative integrin binding sites; an RGD motif within the Aα chain, Aα
572-575
 (RGDS) 
and a non-RGD dodecapeptide sequence in the γ chain (C-terminal γ400-411). A second 
RGD motif exists, Aα 
95-98 
(RGDF) but it is thought that this motif is masked within a 
coil domain and so cannot participate in mediating platelet aggregation. Both RGDS 
and the non-RGD dodecapeptide γ400-411 sequences mediate platelet aggregation.  For 
example, the αIIbβ3 receptor can bind to the RGDS sequence on one platelet and then 
cross-links to a corresponding αIIbβ3 receptor of another platelet instigating platelet 
aggregation, see Figure 1.1.  Because of its key role in thrombosis, αIIbβ3 is deemed 
the “central” integrin in this process. Thus understanding αIIbβ3 behaviour and 
identification of its activation states is crucial in predicting thrombotic risk, advancing 
therapeutic approaches towards managing thrombosis related diseases and the 
potential of integrin αIIbβ3 as a target in diagnostics. 
 
It is also noteworthy that collagen, located in the matrix underlying vascular endothelial 
cells, is not exposed to flowing blood. After injury, however, blood will flow directly 
over sub-endothelial structures including connective tissue that contains a high 
percentage of collagen. When collagen becomes exposed to flowing blood, platelets 
rapidly adhere, spread, become activated and begin to form an aggregate. Thus collagen 
is known as one of the major activators of the platelet response after injury. The 
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resulting arterial thrombus can decelerate blood flow with serious consequences e.g. 
stroke or myocardial infarction.
(2,3) 
If clotting becomes too severe the clot can break 
away to form an embolus transporting to other parts of the body resulting in embolisms 
which present further serious consequences e.g. pulmonary embolisms.
(4)
 
 
Figure 1.1: Process of thrombus formation. At a site of vascular injury vWF adheres 
to the exposed sub-endothelium undergoing conformational changes. This allows 
GPIb-IX-V to bind to the surface of vWF resulting in the activation of the platelets.  
vWF then binds to the activated platelet integrin protein GPIIb/IIIa (αIIbβ3). αIIbβ3 also 
undergoes conformational changes allowing Fg to bind to its surface resulting in 
platelet aggregation. In addition, collagen becomes exposed to flowing blood 
following vascular injury allowing platelets to rapidly adhere, spread and activate 
aiding platelet aggregation.
 (5, 6)
 
 
 
 
 
 
 
 
 
Endothelial cells
ECM 
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1.1   αIIbβ3 (GPIIb/IIIa) Integrin Receptor
 
1.1.1   αIIbβ3 Structure and Function 
The term ‘integrin’ was first published in 1987 to describe a family of heterodimeric 
(αβ) transmembrane receptors.(7) The αIIbβ3 integrin protein is the most abundant 
integrin on the platelet surface with approximately 50,000-80,000 copies per cell.
(8-10)
 
The α subunit consists of a heavy chain (entirely extracellular) and light chain (a short 
cytoplasmic tail (CT), transmembrane region and short extracellular domain). The β 
subunit consists of a single polypeptide with a short CT, a single transmembrane 
region and a large extracellular domain, see Figure 1.2.
(9)
 The membrane proximal 
regions of the CT are well conserved with the membrane-proximal sequences GFFKR 
and LLXXXHDRRE being conserved in the α and β subunits respectively.  
 
Figure 1.2: Structure of αIIbβ3 integrin receptor. The head region comprises the αI 
domain and β‐propeller domain of the α subunit (light shade) and βI domain of the β 
subunit (dark shade).The leg region comprises the thigh, calf‐1, calf‐2 of the α subunit 
and the hybrid domain, N‐terminal PSI (plexin, semaphorin, and integrin) domain, 
four I‐EGF (epidermal growth factor) repeats, and β‐tail domain. A metal-ion 
dependant adhesion site (MIDAS) is indicated by black spheres. The GFFKR motif on 
the α subunit and corresponding LLXXXHDRKE motif in the β subunit are highly 
conserved. The β cytoplasmic domain contains a talin binding 
asparagine‐proline‐(any amino acid)‐phenylalanine (NPXF) motif.(11) 
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Integrins are regarded as ‘two-faced’ receptors; one face orientating to the 
extracellular space interacting with the extracellular membrane (ECM) ligands and the 
other orientating to the cell interior interacting with cytoplasmic proteins.
(9)
  These 
processes have been widely accepted as ‘inside-out’ and ‘outside-in’ activation.  As a 
result, protein binding to either face can trigger bidirectional activation and provides 
integrins with many functions within the body including cell adhesion and platelet 
aggregation.
(12)
   
 
A hallmark of the integrin family is the ability of individual family members to 
recognise multiple ligands. The preference of any given integrin among its ligands is 
determined by relative affinity, availability within a specific microenvironment, and 
the conformational state of the ligand, which controls exposure of the integrins ligand 
binding site. Each integrin heterodimer contains 3–5 divalent cation binding sites.(13) 
Together these cations have great influence on integrin function acting as effectors
(14, 
15)
 (increasing ligand binding affinity) and antagonists
(14,15)
 (decreasing ligand 
affinity). 
 
The β subunit contains a plexin-sempahorin-integrin (PSI) domain, a hybrid domain, a 
βI domain, and four cysteine-rich epidermal growth factor (EGF) repeats. The βI 
domain contains an Mg
2+
 coordinating metal-ion dependant adhesion site (MIDAS) 
and site adjacent to MIDAS (ADMIDAS) binding an inhibitory Ca
2+
 ion. αIIbβ3 has 
been reported as an extremely Ca
2+
 dependant heterodimer requiring μM 
concentrations of Ca
2+
 to maintain complex stability.
(14)
 Studies investigating the 
effect of Mn
2+
 on integrin structure and function has shown it to displace inhibitory 
Ca
2+
, resulting in conformational changes and integrin activation.
(14)
 Thus the 
investigation of divalent cations is important in αIIbβ3 structure and activation studies. 
 
Carrel et al.
(16)
 through the use of electron microscopy (EM) suggested both units of 
αIIbβ3 consist of a ‘head’ and ‘tail’ region with each ‘tail’ penetrating the plasma 
membrane with subunits making contact in the ‘head’ region. In 2001 and 2002, X-ray 
crystallography provided the first high resolution structure of the closely related αVβ3 
integrin, identifying multiple structural domains that are also common with the αIIbβ3 
integrin.
(17-19)
 Takagi et al.
(15)
 reported a conformational change in the crystal structure 
of the extracellular domain of αVβ3 to a bent conformation in the presence of Ca
2+
 and 
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to an extended conformation in the presence of Mn
2+
, a well known integrin activator, 
giving rise to the introduction of the ‘switchblade’ hypothesis (the extended 
conformation of αVβ3 represents the active state and the bent shape represents the 
resting state), presented in Figure 1.3.  
 
Figure 1.3:  Model of αIIbβ3 based on the αVβ3 crystal structure and illustration of the 
‘switchblade’ hypothesis of αIIbβ3 conformational changes as a result of integrin 
activation. An equilibrium between the (lef) bent and (b) extended form illustrates the 
‘switchblade’ hypothesis of activation.(15) (Right) illustrates integrin clustering 
fibrinogen binding, which contains two RGD sequences that recognise platelet 
integrin αIIbβ3. Integrin clustering is discussed in greater detail in section 1.1.4. 
Conversely, the ability of the bent form to bind ligands with high affinity has also been 
reported suggesting a proposed ‘deadbolt’ model for inside-out activation (where the 
integrin protein is locked in the bent state).
(20, 21)
 
 
Thus, a complete understanding of 
the global rearrangements in integrin conformation remains elusive.
 
 
1.1.2   αIIbβ3 Integrin Receptor Activation 
Activation of αIIbβ3 in platelets is tightly regulated through a process termed ‘inside-
out’ signalling, Figure 1.4, (a).(9,22) For example, the agonist, thrombin, catalyzes the 
conversion of fibrinogen (factor I) into long, sticky threads of insoluble fibrin (factor 
Ia). The fibrin threads form a mesh that traps platelets, blood cells, and plasma aiding 
the clotting process.  Following platelet activation, vWF can bind to the activated 
platelet integrin protein αIIbβ3 initiating an intracellular signalling response such as the 
binding of talin (discussed further in section 1.1.4) which results in αIIbβ3 
conformational changes that provides the extracellular domain of αIIbβ3 with a high 
affinity for ligand binding.
(1,21,23) However αIIbβ3 activation can also occur as a result of 
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‘outside-in’ signalling.(9,24) Extracellular ligands such as fibrinogen bind to the αIIbβ3 
extracellular domains promoting integrin clustering and conformational changes that 
are transmitted to the cytoplasmic tails resulting in the recruitment of enzymes, 
effectors and adaptors (e.g. calpain, kindlins and focal adhesion kinase (FAK)) to form 
integrin-based signalling complexes, Figure 1.4, (b). 
 
Figure 1.4: Bidirectional activation of integrin. αIIbβ3 equilibrates between resting and 
activated states. Conversion from the resting to the activated state involves a series of 
conformational transitions. (a) Inside-out signalling: agonist dependant intracellular 
signals support the interaction of regulatory ligands such as talin with integrin 
cytoplasmic tails leading to conformational changes. (b) Outside-in signalling: 
extracellular ligand binding promotes integrin clustering and conformational 
changes.
(9) 
 
1.1.3   Inside-out Activation      
Much interest has been focussed on the structure of cytoplasmic tails and the effects of 
activation on these tails. In 2000, Vinogradova et al.
(25)
 reported the first nuclear 
magnetic resonance (NMR) structure for an isolated αIIb tail. Results suggest that the 
isolated αIIb tail forms an N-terminal α-helix followed by a turn which possibly 
straightens out upon integrin activation. Ulmer et al.
(26)
 suggested the αIIb and β3 tails 
were largely unstructured with the N-terminus of β3 forming a helix. Vinogradova’s 
group later reported the formation of a complex between the membrane-proximal 
helixes of both αIIb and β3 CT when added together in solution. Mutational analysis 
methods suggest the membrane-proximal region interaction is stabilised by a salt 
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bridge or ‘clasp’ between the conserved arginine residue in the α tail and the aspartate 
residue in the β tail and by hydrophobic interactions directly to the N-terminal of both 
residues.
(27,28)  
Many others suggest the ‘clasp’ supports integrin stability in the resting 
state.
(24,29,30)
 Disruption of the ‘clasp’ between αIIb and β3 CT has been widely reported 
as critical for full integrin activation with separation of the transmembrane helices 
strongly associating with higher αIIbβ3 affinity for ligand binding.
(23,28,31)
 Fluorescence 
resonance energy transfer (FRET) studies further showed that activation is associated 
with an alteration in separation/orientation of the α and β CT relative to each other.(32)  
 
Crystallography, EM and NMR has provided significant structural and conformational 
information on integrins, however, these measurements have a number of limitations; 
crystallography and EM can only observe static conformation and NMR can detect the 
structure of small domains but is only successful if the molecules are highly pure.
(33)
 
In 2012, Chen et al.
(34)
 reported for the first time, the ability to monitor single integrin 
sensitivity on living cells using a biomembrane force probe (BFP). BFP is a method 
similar to atomic force microscopy (AFM) except that the soft spring of the sensor is 
this time the membrane of the cell held by suction in a micro-pipette. It uses the 
deformation of a cell membrane under tension as a force sensor. The tension in the cell 
membrane is controlled by a suction pipette that sets the hydrostatic pressure 
difference across its membrane. The advantage of this technique is that the stiffness of 
the force sensor (e.g. the tension) can be set at will, allowing for the measurement of a 
very large range of forces. The αLβ2 expressing target cell was driven to contact a bead 
which was functionalised with ICAM-1 (or anti-αLβ2) for bond formation. It was then 
retracted a distance and held still. The bead displacement was monitored in real time at 
1,600 Hz with 3-nm precision which was sufficient for resolving the 10–25-nm 
displacements that take place when an integrin changes conformation from extended 
to bent form.  
 
Thus, the ability to monitor single integrin sensitivity, monitoring bending and 
unbending conformational changes on living cells was achieved. Real-time, reversible 
switches between the bent and extended conformation of a single integrin on the 
surface of a living cell was presented. This was achieved via measurement of its 
nanometer-scale headpiece displacement, bending and unbending frequencies and 
molecular stiffness changes. Distance changes compatible with predicted distance 
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changes caused by unbending and bending of αLβ2 were observed. Comparing 
displacements measured using Jurkat cells, polymorphonuclear neutrophils and K562 
cell lines all transfected to express αLβ2 presented common values regardless of cell 
type indicating results were integrin specific. The up down frequencies were also 
shown to be cation dependent as changing the physiological mixture of Ca
2+
 and Mg
2+
 
(1 mM each), which favours integrin bent conformations to 1 mM Mn
2+  
produced 
changes in the up down frequencies indicating changes from a bent to extended 
conformation. This model provided real-time insights into the inner workings of 
integrins in-vitro which had not been previously achieved. 
 
The role of the short cytoplasmic domains has been the focus of much research into 
the molecular mechanisms of integrin activation. A highly conserved amino acid 
sequence, KVGFFKR exists immediately proximal to the transmembrane-spanning 
region in the α-cytoplasmic domains of all integrins. Mutation and deletion studies 
suggest this motif is associated with the regulation of integrin affinity, modifications 
to ligand recognition by the integrin and possible receptor conformation which occurs 
following ligand occupancy.
(29,35,36) 
  
 
Stephens et al.
(35) 
examined the functional effects of the motif using a synthetic 
peptide sequence, Pal-KVGFFKR (Pal-FF). Results suggested that the lipid soluble 
peptide mediated platelet activation in a highly specific manner. Replacing each amino 
acid with an alanine residue confirmed which residue was responsible for the 
biological activity. Results confirmed the response was highly specific residing 
predominantly in the GFFK region corresponding to the αIIb CT.  
 
In 2006, the same research group investigated further the role of the KVFFKR motif in 
integrin IIb3 function using two sequence speciﬁc complementary model systems, 
palmityl-peptides in platelets, and mutant IIb3-expressing Chinese hamster ovary 
(CHO) cell lines. Aggregation studies confirmed the two phenylalanine amino acids in 
pal-FF peptide to be critical for stimulating platelet aggregation. In CHO cells, 
confocal microscopy confirmed that substituting both alanines induced constitutive 
integrin activation but prevented actin stress ﬁber formation upon adhesion to 
fibrinogen suggesting that IIb3-mediated cytoskeletal reorganisation is also 
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dependent on F
992
 and F
993
. This further highlights a critical role for the two 
phenylalanine residues in both of these IIb3-mediated processes.
(37)
 
 
In addition, Moran et al.
(38) 
using the same cell permeable peptide pal-FF showed 
systematic replacement of F
992
-F
993
 with amino acids of greater or lesser 
hydrophobicity demonstrated that hydrophobic amino acids such as phenylalanine 
were essential for agonist potency while hydrophilic amino acids such as glycine (G) 
caused a switch in the biological activity resulting in platelet aggregation inhibition. 
The results suggest that eliminating critical protein-protein interactions mediated 
through hydrophobic amino acids, particularly F
993
 favours anti-thrombotic pathways 
in platelets and may be of great importance regarding anti-platelet or anti-integrin drug 
development.  
 
Binding of talin, a major actin-binding protein, to integrin β tails is also widely 
reported to represent a final common step in “inside-out” integrin activation 
pathways.
(39)
 Talin, the first cytoplasmic protein reported to bind to integrins
(39)
, 
consists of a large C-terminal rod domain that contains bundles of alpha helices and 
an N-terminal FERM (four-point-one, ezrin, radixin, moesin) domain with three 
subdomains: F1, F2, and F3, see Figure 1.5.
(40-45)
 The F3 subdomain is a sandwich of 
two orthogonal antiparallel β-sheets followed by an α-helix and resembles a PTB 
domain (phosphotyrosine binding domain). This PTB domain often recognises peptide 
ligands containing β turns formed by NPxY motifs.(46) The F3 subdomain of the 
FERM domain contains the major integrin-binding site presenting the highest affinity 
for integrin β tails and is sufficient to activate integrins(42,43,45), although the C-terminal 
rod has also shown lower-affinity integrin binding also.
(42,45)
 Binding is reported to 
occur  through a variant of the classical PTB domain-NPxY interaction.
(44)
 NPxY 
motifs are highly conserved in integrin β tails, and mutation studies have shown that 
disrupting this motif perturbs β turn formation, resulting in talin binding inhibition and 
in turn interference with integrin activation confirming formation of this talin–integrin 
complex to play a critical role in integrin activation.
(26,42,43,47)
 Furthermore, knockdown 
talin expression studies via ribonucleic acid (RNA) interference selectively revealed 
that talin is essential for integrin activation in response to physiological agonists.
(48)
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Binding of the talin head to the cytoplasmic domain of integrin β subunits is thought to 
activate integrins by disrupting a salt bridge between the α- and β-integrin subunits, 
leading to separation of their cytoplasmic domains.
(49) 
FRET studies have supported 
the cytoplasmic-domain separation model using transfected K562 cells expressing the 
integrin subunits αL and β2 C-terminally tagged with cyan fluorescent protein (CFP) 
and yellow fluorescent protein (YFP) respectively. The FRET efficiency between the 
integrin subunits was significantly decreased by the expression of the talin head.
(50) 
Thus the association of the cytoskeletal protein talin with integrin β cytoplasmic 
domains is a critical step during integrin activation and regulation of this step may be a 
final common element in the signalling pathways that control integrin activation. 
 
Figure 1.5: Structure of talin illustrating also the binding partners which includes the 
-integrin binding site located in the FERM and the lower affinity binding site located 
near the C-terminus.
(51)  
 
1.1.4   Outside-in Activation 
In addition to conformational changes reported for “inside-out” signalling, platelet 
activation promotes integrin clustering within the plane of the membrane.
(52)
 The αIIbβ3 
clustering mechanism may be induced by a variety of mechanisms including the 
binding of multivalent ligands such as fibrinogen
(53)
, ligand self association
(54)
, lateral 
motion of integrins with other membrane proteins
(55)
 and reversible linkage to the actin 
cytoskeleton
(56)
. Integrin conformational changes and clustering are complimentary 
and may be mechanistically linked but tend to play different roles in bidirectional 
signalling. For example, conformational change is dominant in regulating ligand 
binding to αIIbβ3 while clustering is important for inducing phosphorylation by 
triggering the activation of tyrosine kinases such as Src and Syk during “outside-in” 
signalling.
(57,58)
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One of the earliest fibrinogen binding studies investigated the effect of microclustering 
on the activation of Src and Syk protein kinases following fibrinogen binding to αIIbβ3 
with results presenting the requirement of fibrinogen binding to integrin for tyrosine 
kinase activation.
(59)
 Studies involving both purified proteins as well as in-vitro 
protein-protein interactions in living cells
(60)
 has presented the following sequence of 
events for the assembly of αIIbβ3 clustering induced signalling complex: current 
structural models suggest that the 140 Src family kinases are membrane associated and 
maintained in a “clamped,” inactive state through intramolecular interactions between 
the SH2 domain and a C-terminal phosphotyrosine motif at Tyr529 (Y529), and the 
SH3 domain and a polyproline motif in the linker region between the SH2 domain and 
the N-lobe of the catalytic domain.
(61)
 In platelets, c-Src (and several other Src family 
kinases), upon binding to αIIbβ3 through interaction of the β3 cytoplasmic tail with the 
SH3 domain may become partially unclamped but not fully active as Tyr529 remains 
phosphorylated by integrin-associated Csk. Upon αIIbβ3 ligation, Src becomes 
clustered and Csk dissociates from the integrin complex resulting in 
dephosphorylation of Tyr529 by an unidentified tyrosine phosphatase and 
autophosphorylation of Tyr418 (Y418) in the Src activation loop. Consequently, the 
now unclamped Src is fully active to phosphorylate downstream effectors, for 
example, phosphorylation of substrates such as the adaptor protein ADAP (adhesion 
and degranulation-promoting protein) which have implications in signalling to the 
actin cytoskeleton. These cytoskeletal rearrangements allow platelets to adopt their 
characteristic shape and initiate migration via dynamic connections between integrins 
and filamentous (F-) actin.
(59,62) 
 
The effect of integrin clustering on related ligands has also been reported, for example, 
soluble CD40 ligand has also been shown to bind and induce “outside-in” signalling 
through αIIbβ3 with the additional requirement of αIIbβ3 clustering for signalling 
initiation.
(63)
 Other transmembrane proteins such as tetraspanins
(64,65)
 and cell surface 
heparin sulfate proteoglycans such as syndecans
(66,67)
 known to have modulatory roles 
that affect integrin-mediated functions such as adhesion and migration exist but 
remain relatively unexplored. Thus in order to gain better understanding of outside-in 
signalling it will be necessary to dissect the relative contributions of integrins and 
other cell surface receptors such as those mentioned. Overall, clustering has been 
identified as a critical step during integrin activation and regulation of this step may be 
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an additional final common element in the signalling pathways that control integrin 
activation. 
 
Numerous amino acid sequences have been isolated from macromolecular ligands for 
outside-in signalling studies. Two peptides in particular have been identified which 
define the recognition specificity of αIIbβ3 by fibrinogen as well as other adhesive 
ligands of the receptor; KQAGDV and RGD, Figure 1.6.  
 
Figure 1.6: Ribbon diagram of fibrinogen presenting two amino acid sequences; 
KQAGDV and RGD. α, β and γ subunits are shown in green, red and blue 
respectively. The unstructured C-terminal regions of the α and γ subunits containing  
RGD and KQAGDV sequences are shown as dashed lines.
(68)
 
 
RGD (Arg-Gly-Asp) is the most widely studied sequence in integrin investigations.
(69)  
Around half of the 24 known integrins bind to ECM molecules in an RGD dependant 
manner. RGD was first identified as a sequence contained in fibronectin.
(70)
 The RGD 
peptide was previously identified as an effective inhibitor of fibrinogen binding to 
platelets. It has been suggested that this inhibitory activity of RGD peptides may 
correspond to an allosteric mechanism where binding of RGD to αIIbβ3 alters the 
conformation of the receptor such that the recognition of the γ-chain sequence is 
downgraded.
(69)   
 
Parise et al.
(71)
 examined the effects of four peptides on the structure of purified 
platelet αIIbβ3; RGDS, LGGAKQAGDV, KGDS and RGES. The order of potency of 
these peptides was reported as follows: RGDS>LGGAKQAGDV>KGDS>RGES. The 
same order of potency was observed for the ability of these peptides to inhibit 
fibrinogen binding to platelets. In addition, RGDS, but not RGES, decreased the 
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intensity of the intrinsic protein fluorescence of αIIbβ3. Finally, the decapeptide and 
RGDS decreased the sedimentation coefficient of αIIbβ3 from 8.5 to 7.7 or 7.4 S 
respectively, whereas RGES had minimal effect. Peptide-induced unfolding of the 
αIIbβ3 complex was suggested by the accompanied increase in Stoke's radius from 74 to 
82 Å with RGDS or 85 Å with the decapeptide. This change in conformation is 
suggestively related to changes in the function of αIIbβ3 on the platelet surface that 
occur when adhesive peptides from the αIIbβ3 binding domains of these proteins bind to 
αIIbβ3. 
 
It is broadly accepted that receptor occupancy causes conformational changes to 
αIIbβ3.
(72)  
Studies such as those presented in this section have provided the missing link 
to understanding how other ligands such as vWF and fibronectin could also bind to 
αIIbβ3 as their amino acid sequences were deduced and found to contain an RGD 
sequence also.
(73)
 As a result RGD peptides have become extremely valuable in 
defining the recognition specificity of αIIbβ3 and other integrins presenting significant 
potential as targets in diagnostics and therapeutics.
(69)
 
 
1.1.5   Limitations        
Understanding αIIbβ3 activation and the mechanisms involved has advanced 
significantly in recent years. However, details on the nature of the signalling pathways 
leading to platelet activation remain incomplete. The role of tail binding of the integrin 
to a number of cytoskeletal proteins (e.g. talin) in regulating activation of αIIbβ3 
through inside-out activation is known to be of significant importance but the 
mechanistic details remain unresolved.
(9,22)
 Important progress was made through 
confirmation of the cytoskeletal protein talin binding to the β3 tail of αIIbβ3 and 
evidence that this leads to conformational changes and integrin activation.
(42,44,48,74-76)
  
Reports have also suggested that integrin αIIbβ3 is required to be located in a 
phospholipid bilayer for activation to occur (attributed to the conformation about the 
cytoplasmic tails induced in the membrane/cytoplasm environment).
(31,74-76) 
However, 
the role of membrane composition and structure on these tail binding events remains 
unresolved. 
 
While much research has focussed on β tail binders such as talin, the α-tail which may 
also play an important role in regulating integrin activation and conformational change 
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remains unstudied. The influence of membrane composition and structure on integrin 
behaviour is currently poorly understood. Thus further investigations are required to 
provide insights and advances towards developing therapeutical approaches to 
thrombosis. 
 
In addition to physiological stimuli, the bifunctional reducing agent DTT, addition of 
divalent cations such as Mn
2+
, removal of the divalent cation Ca
2+
 with 
ethylenediaminetetraacetic acid (EDTA) and RGD-like peptide drugs (Eptifibatide) 
have all been shown to induce integrin activation in a number of systems.
(77-80)  
Such 
chemical activators, have provided key insights into the gross structural changes of 
αIIbβ3.
(80,81) 
 
 
 
1.2   Introduction to Molecular Photophysics 
The Jablonski diagram, Figure 1.7, presents the electronic states and the radiative 
transitions that can occur within an excited chromophore. Excitation involves 
absorption of a photon of light energy which excites the chromophore to a higher 
vibronic state. There are then numerous ways in which the molecule may lose excess 
energy in returning back to the original ground state energy level which may be either 
radiative or non-radiative in nature. 
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Figure 1.7: Jablonski diagram illustrating the numerous radiative (straight arrows) 
and non-radiative (curly arrows) processes involved in the absorption-relaxation 
phenomena of a molecule following excitation by a photon of light energy.
(82)  
 
In the case of non-radiative processes, internal conversion (IC) occurs between energy 
levels of the same multiplicity (e.g. singlet to singlet). When vibrational energy levels 
strongly overlap electronic energy levels, the excited electron can transition from a 
vibration level in one electronic state to another vibration level in a lower electronic 
state.
(83)
 
 
Intersystem crossing (ISC), also an isoenergetic non-radiative deactivation process, 
occurs in contrast to internal conversion between energy levels of differing 
multiplicity (e.g. singlet to triplet) as the vibrational energy levels within the singlet 
and triplet states overlap. Although both states are electronic isomers of one another, 
importantly they differ in terms of the electronic spin configurations in each state.  It is 
important to note that ISC is significantly enhanced in the presence of heavy 
paramagnetic atoms such as ruthenium, a transition metal investigated as part of this 
thesis. The photophysics of various ruthenium (II) complexes are discussed in Chapter 
3 of this thesis. 
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Alternatively, a molecule may lose energy through luminescence. The main types are; 
fluorescence and phosphorescence. Fluorescence is the most common emission 
process in organic molecules, while phosphorescence is common for many 
luminescent transition metal complexes including the ruthenium (II) polypyridyl 
complexes, discussed further in Chapter 3. According to Hund’s Rule, a singlet state 
will be of higher energy than a triplet state of the same configuration, thus fluorescent 
emission will always occur at shorter wavelengths than phosphorescence. The 
absorption will also appear at a shorter wavelength than the emission wavelength as 
some of the original energy is lost via non-radiative pathways. Although there is 
typically overlap between absorption and fluorescence at room temperature as it is 
highly likely that some of the molecules are already present in a vibrationally excited 
state.
(83)
  
 
Another important deactivation pathway may also occur; bimolecular quenching 
through energy transfer or electron transfer. Unlike the previous processes which are 
unimolecular, these pathways can be inter or intramolecular. Molecular oxygen is a 
well known quencher of luminescence by energy transfer.
(84,85)
 Its ground state is a 
triplet and it has two singlet states. It can quench either triplet or singlet excited states, 
e.g. triplet-triplet annihilation. The effect of molecular oxygen quenching on 
ruthenium(II) polypyridyl complexes is presented and discussed in Chapter 3. 
  
1.2.1   Luminescent Lifetimes () and Quantum Yields (φf)  
Both luminescent decay lifetimes and quantum yields are two very important 
quantitative characteristics of a luminophore. The denotations stated in Eqn. 1.1 to 
1.13 are as follows:  is the luminescent lifetime, kr is the rate constant for the 
radiative pathway and knr is the rate constant for the non-radiative pathway. 
 
Determining the lifetime of a chromophore is important as it indicates how long a 
chromophore remains in an excited energy state and therefore the time available for 
the excited fluorophore to interact with or diffuse through its environment. The 
lifetime is easily affected by the molecule’s surrounding environment, including 
solvents and oxygen content. Consider a dilute solution of a fluorescent species [A] 
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(mol L
-1
), the rate of disappearance of excited molecules is expressed by the following 
differential equation: 
 
            (Eqn. 1.1) 
 
Assuming [A*]0 is the concentration of the excited molecule at time 0, integration of 
Eqn. 1.1 leads to 
 
              (Eqn. 1.2) 
 
Where *, the lifetime of the excited state, is given by 
 
               (Eqn. 1.3) 
 
The fluorescence quantum yield is a fractioned value (Φf) reflecting the ratio of 
photons absorbed by a species to photons emitted through fluorescence.  
 
  Φf =  Number of photons absorbed           (Eqn. 1.4) 
   Number of photons emitted 
 
Substances with larger fluorescence quantum yields, approaching unity, e.g. 
Rhodamine 6G (φ = 0.95(86) in ethanol), display the brightest emissions, however 
quantum yields can never achieve unity as there will always be some energy lost as a 
result of Stokes losses. Near unity can be achieved if the radiationless decay rate is 
much lower than the rate of radiative decay, that is knr<kr, where knr and kr represents 
all possible single rate non-radiative and radiative decay processes e.g. IC, ISC, 
phosphorescence (P) and fluorescence (F). Both represent rate constants for 
depopulation of the excited state. Eqn. 1.5 can then be measured as follows: 
                       (Eqn. 1.5) 
Using the radiative lifetime as previously defined in Eqn. 1.3, a relationship between 
lifetime and the fluorescent quantum yield can also be measured: 
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                      (Eqn. 1.6) 
  
Together with emission lifetimes the quantum yield may be used to estimate 
unimolecular rate constants for radiationless processes such as IC and ISC within the 
system. The steady-state approximation for the concentration of the first excited 
singlet energy state [S1] assumes that the rate of absorption of light (Iabs) is equal to the 
combined rates of deactivation of [S1]: 
 
            (Eqn. 1.7) 
 
As all complexes discussed in this thesis are phosphorescent and do not fluoresce, it 
should also be noted that steady-state approximations for phosphorescent complexes, 
(emission from the triplet state [T1]) also assumes that the rate of absorption of light is 
equal to the combined rates of deactivation of [T1], presented in Eqn.  1.8: 
 
             (Eqn 1.8) 
 
Working from Eqn. 1.3 a quantum yield lifetime relationship can be measured as 
follows for both singlet and triplet state situations: 
 
                   (Eqn. 1.9) 
                    (Eqn. 1.10) 
 
Thus key quantum yield states for all possible transitions can be measured as follows: 
 
                         (Eqn. 1.11) 
               (Eqn. 1.12) 
             (Eqn.1.13) 
 
Generally, as temperature increases, the probability of non-radiative decay processes 
occurring increases, leading to a decrease in both quantum yield and lifetime. As the 
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phosphorescent lifetimes of the triplet state are generally long, the probability of 
deactivation from solvent collisions is higher than that observed for fluorescence. For 
Ru(II) complexes there is also the complication of thermal population of 
3
MC states 
leading to fast vibrational decay. 
 
1.2.2   Charge Transfer Transitions in Metal Complexes 
Ideal polypyridyl ligands generally have σ donor orbitals on the nitrogens and π donor 
and π* acceptor orbitals delocalised on the aromatic rings, e.g. 2,2’-bipyridine (bpy) 
and 1,10-phenanthroline (phen). One of the most widely studied Ru(II) complexes  is 
[Ru(bpy)3]
2+
 (where bpy = bipyridine), and so can be used as a prototype to explain 
similar processes occurring in similar ruthenium(II) polypyridyl complexes discussed 
in Chapter 3. The electronic structure and photophysical properties are presented in 
Figure 1.8. 
 
Figure 1.8: Absorbance and emission spectra modified from reference [87].
(87)
 
Emission spectrum of 20 µM [Ru(bpy)3]
2+
 in acetonitrile solution excited at 451 nm 
with a slit width of 5 nm and normalised to 1 arbitrary unit. 
 
 
Ligand based 
Transitions 
(High energy) 
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Following photo-excitation, a dπ orbital electron from Ru is promoted to an anti-
bonding π* orbital of one of the bipyridyl ligands presenting a short-lived singlet 
MLCT transition.
(88)  
Spin orbit coupling promotes rapid inter-system crossing with 
unit efficiency to yield a 
3
MLCT state.
(89) 
This excited triplet state comprises a 
manifold of four low-lying MLCT levels, the lowest energy is the most triplet in 
nature, and in turn the most radiative. The lower three triplet states, separable only at 
low temperatures are approximately 200 cm
-1
 apart.
(90) 
 In contrast, the highest energy 
MLCT occurs 400-1000 cm
-1
 higher from the others and is thermally accessible.
(90,91) 
The transitions responsible for the characteristic photophysical properties of 
[Ru(bpy)3]
2+
 are π-π* transitions presented between 300 and 500 nm.  Emission occurs 
at approximately 600 nm when excited into the MLCT band at 452 nm with a lifetime 
in the region of 400 ns and 800 ns and a quantum yield of 0.016 and 0.062 in aerated 
and dearated media respectively.
(92,93) 
These properties are environmentally sensitive 
as the absorption band has been reported to be solvatochromic.
(91,94,95)
 along with the 
quantum yield and lifetime both deemed temperature dependent
(93)
 (decreases with 
increasing temperature). 
 
1.2.3   Anisotropic Decay: Rotational Correlation Time (µs) 
Luminescence anisotropy is a powerful tool in biological and polymer research. It is a 
simple, but effective means of identifying changing protein conformation and can be 
used to provide insight into the changing dimensions of a protein with activation. 
Anisotropy measurements are based on the relative polarisation of a molecule’s 
emission from its excitation and depends strongly on the phenomenon that light 
emitted by a fluorophore has unequal intensities along different axis of polarisation. 
The principle of fluorescence anisotropy is illustrated in Figure 1.9. The sample is 
excited with vertically polarised light. The electric vector of the excitation light is 
oriented parallel to the z-axis (vertical). The emission intensity is measured via a 
polariser. First the emission detector is orientated in the direction (parallel to) of the 
vertically polarised light, presenting an intensity denoted I||. Accordingly, the polariser 
is placed perpendicular to the light excitation presenting an intensity denoted I. 
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Figure 1.9: Schematic diagram illustrating the process of anisotropy 
measurements.
(84) 
 
Anisotropy can be measured through both steady-state and time-resolved 
spectroscopy. Steady-state anisotropy is determined by assessing the integrated 
luminescence intensity of the luminophore determined under parallel and 
perpendicular polarisation and is measured as follows: 
 
           (Eqn. 1.14) 
    
Where r is anisotropy,  is the fluorescence intensity parallel to the electric vector of 
the incident beam and  is the fluorescence intensity perpendicular to the electric 
vector of the incident beam 
 
Time-resolved anisotropy is measured by Eqn. 1.15 below: 
 
                   (Eqn. 1.15) 
 
Where the limiting anisotropy, R0 is the anisotropy measured at the time of 
photoselection, t is time (t=0), rot is the rotational correlation time (μs) 
 
Time-resolved anisotropy monitors the rate of depolarisation of a species. This allows 
a kinetic mechanism for the time-dependant loss of orientation to be developed, which 
in turn provides molecular dynamic information about the molecule including 
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rotational diffusion of the whole macromolecule, independent motion of the segment 
in the macromolecule containing the fluorophore (segmental motion) and independent 
local motion of the probe which may be covalently or non-covalently bound to the 
macromolecule. These depolarisation processes have characteristic rates, illustrated in 
Figure 1.10. Depending on the size of the macromolecule, depolarisation of the 
rotational diffusion occurs over nanoseconds to milliseconds.
(96,97)
 Time-scales for 
segmental motions however are a function of the size of the segment and type of 
motion. Depolarisation generally occurs quicker compared to the rotational diffusion 
of the whole macromolecule. Free fluorophores present the fastest depolarisation rate 
with rapid stochastic molecular rotation. No correspondence takes place between the 
orientation of the electric field vector of the excitation light and the polarisation of the 
emitted photons presenting an anisotropy value of 0 (I|| = I). 
 
Figure 1.10: Illustration depicting the expected anisotropy decay curve of a free 
fluorophore tagged short peptide (green) that can undergo fast rotations, and the 
curve generated by the same peptide when bound to a large antibody (red). The blue 
decay curve depicts the bi-exponential decay expected from a population where 50% 
of the fluorophore tagged short peptides are bound to antibody, and 50% remain free 
unbound dye-peptide. Adapted from reference (85). 
(85) 
 
An effective probe for assessing protein conformational change should ideally have a 
long luminescent lifetime so that it persists in the excited state for long enough to 
“record” protein motion, which is typically on the nanosecond to microsecond time-
scale. The most widely used probes in biological investigations are fluorescent, 
organic chromophores. They possess limited environmental sensitivity due to their 
short lifetimes (<10 ns) and have limited value in time resolved anisotropy 
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measurements, as their decay times are typically shorter than rotational times of large 
proteins. In addition, organic fluorophores tend to suffer from self quenching, due to 
overlap of their absorption and emission spectra and from poor photostability. In 
contrast Ru(II) polypyridyl complexes present: 
 
 Large Stokes shifts 
 Near Infrared (IR) emission (eliminating biological autofluorescence) 
 Long luminescent lifetimes  
 Enhanced photostability  
 Polarised emission 
 
Consequently, these complexes are finding increased efficacy in biological 
applications such as cell imaging.
(98) 
The long luminescent lifetimes of ruthenium 
complexes (typically 200 ns  to 1 µs) and polarised emission is particularly useful in 
time-resolved measurements applied to analysis of biodynamic processes such as 
membrane diffusion
(99) 
and protein folding.
(100)
 The emission maxima of ruthenium 
complexes are observed in the region of 600–700 nm which is within the biological 
window, reducing interference from autofluorescence. Furthermore, Ru(II) 
luminophores are oxygen sensitive which makes them particularly susceptible to 
changes in environment, for example in reporting on protein conformational change to 
proteins they are bound to. Thus Ru(II) probes conjugated to the αIIbβ3 integrin protein 
recognising sequence RGD was employed to investigate protein presence and 
conformation following chemical activation and denaturation. These probes acted as 
successful protein conformation reporters due to the previously stated long 
luminescent lifetimes and extreme oxygen sensitivity. These findings are discussed in 
more detail in Chapter 4 of this thesis. 
 
1.3   Metal Complexes used for Cellular Uptake and Imaging  
Just as they are useful for protein labelling, these same properties make metal 
complexes useful for cell imaging. One of the key objectives of this thesis was the 
synthesis and identification of suitable ruthenium metal complexes for potential 
conjugation to cell surface receptor peptides such as the RGD sequence for application 
in protein conformation assessment, cellular imaging and cell detection. Consequently, 
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a series of ruthenium(II) metal complexes were prepared and fully characterised, see 
Chapter 3. Until recently, the use of metal complexes in biology has been largely 
limited to DNA binding and oxygen sensing.
(93,101-104)
 In the last few years, however, a 
diverse range of transition metals of iridium, rhenium and ruthenium complexes are 
increasingly being reported for their design and application in cell imaging.
(105-108)
  
 
In recent years, metal complex application in cell imaging has risen 
immensely.
(104,105,109,110) 
The biological activity of ruthenium complexes was ﬁrst 
examined by Francis Dwyer in the 1950s, where bacteriostatic and antiviral activities 
were observed for a family of tris(polypyridyl) complexes.
(111)
 To date, ruthenium 
complexes have dominated the area of DNA binding
(112-114)
 and anti-cancer 
therapeutics with two ruthenium anticancer drugs (NAMI-A and KP1019) successfully 
reaching clinical trials.
(115-118)
 Most DNA research has involved derivatives of Ru(II) 
probes with dipyridophenazine (dppz) ligands.
(101,102,113,114)
 Both ground and excited 
state electrochemical and photophysical investigations of  [Ru(phen)2(dppz)]
2+
 suggest 
the MLCT is directed from the metal centre to the phenazine ring, and the major non-
radiative deactivation pathway for the complex may involve the protonation of the 
phenazine nitrogen atoms in the excited state, likely driven by hydrogen bonding.
(119)
   
 
Svensson et al.
(120)
 report how slight modifications to the lipophilicity of the (dppz) 
ligand of the [Ru(phen)2(dppz)]
2+
 complex influenced its localisation throughout the 
membrane, its DNA binding ability and its cellular uptake in CHO cells. Figure 1.11 
illustrates the varying distribution of this complex throughout the cell structure using 
confocal fluorescence microscopy. A decrease in alkyl chain length resulted in a 
higher emission intensity in the nucleus compared to the cytoplasm, complex D2, 
Figure 1.11, (A), while the most lipophilic complex resided mainly on the outside of 
the nucleus of the fixed CHO cells, complex D6, Figure 1.11, (C). It must be noted 
for most cell studies to date including those of the Svenssons group, 1% dimethyl 
sulfoxide (DMSO) was used to optimise complex solubility. However, organic 
solvents such as DMSO have been shown to disrupt the cell membrane, inducing cell 
diffusion, differentiation and modifying the membrane permeability presenting itself 
as a very effective means of permeabilizing the cell membrane.
(120-122)
 As a result, 
throughout our work, DMSO and other organic solvents were avoided as much as 
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possible in cell studies to ensure uptake was due to the complex and not from 
permeabilization. 
 
 
Figure 1.11: Confocal fluorescence microscopy images showing the distribution of 
ruthenium(II) complexes in fixed CHO cells. D2 (A), D4 (B) and D6 (C) (10μM in 1% 
DMSO/serum free medium) were added to cells in fixed methanol for 15 minutes and 
excited at 488 nm.
(120)
 
 
1.3.1   Ruthenium Conjugated Polypeptides 
A major barrier in the application of ruthenium in cell imaging existed with their 
inability to cross the membrane spontaneously without the aid of solvents such as 
DMSO. In 2008 for the first time, our group reported two novel ruthenium polypeptide 
conjugates; one conjugated to five (Ru-Ahx-R5) and one conjugated to eight (Ru-Ahx-
R8) arginine residues, illustrated in Figure 1.12.
(105)
 Neugebauer et al.
(105)
 reported 
passive transport of the octarginine dye-conjugate [Ru(bpy)2(picCOOH)Arg8]
10+
 
across the cell membrane of SP2 myeloma cells, more importantly without the 
presence of organic solvents. Octaarginine specificity was confirmed, as transport of 
the parent dye and shorter Ru-Ahx-R5 conjugate across the cell membrane did not 
occur. Diffusion could only be achieved with detergent treatment, DMSO treatment or 
ethanol treatment. The octa-arginine dye-peptide transport proved fast and was 
complete after 10-15 minutes at room temperature. SP2 myeloma cells in a buffered 
solution were exposed to 3.5 x 10
-5
 M of [Ru(bpy)2(picCOOH)-Arg8]
10+
. Intense 
luminescence within the cells cytoplasm was observed after only 3 minutes as shown 
in Figure 1.12, (a). The dye-peptide continued to distribute throughout the cell 
cytoplasm across the cellular plasma in a non-selective manner over a remaining 
period of 10 minutes, Figure 1.132 (b). 
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Figure 1.12: Above: Structure of [Ru(bpy)2(picCOOH)Arg8]
10+
. Below: Luminescence 
confocal images (λex = 458 nm, λem = 610 nm) of an SP2 myeloma cell incubated 
with [Ru(bpy)2(picCOOH)Arg8]
10+
 (3.5 × 10
−5
 M in PBS) after (a) 3 minutes and (b) 
after 5 minutes. (c) SP2 cell incubated with the parent complex 
[Ru(bpy)2(picCOOH)]
2+
 (3.5 × 10
−5
 M in PBS) for 26 minutes and (d) for 5 minutes 
after permeabilizing the cell with Triton (1% v/v).
(105) 
 
Fluorescence lifetime imaging microscopy (FLIM) measurements also demonstrated 
for the first time the capacity of these dye-peptide conjugates in cell oxygen sensing, 
by determining the average lifetime of the dye across various cell components. The 
results presented in Figure 1.13 indicate that the shortest lifetimes of the dye resided 
in the membrane as expected due to the higher solubility of molecular oxygen in the 
cell membrane causing a decrease in the lifetime of the ruthenium probe.  
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Figure 1.13: (a) Fluorescence intensity image and (b) false colour FLIM image of 
[Ru(bpy)2(picCOOH)Arg8]
10+
 (3.5 x 10
-5
 M in PBS buffer) in SP2 myeloma cells after 15 
minutes incubation.(105) 
 
More recently, our group reported an additional pH sensitive ruthenium polypyridyl 
labelled cell penetrating peptide, [Ru(dppz)2PIC-Arg8]
10+
 to show successful passive 
transport of the complex across the cell membrane.
(123)
 As the pH of the cytoplasm had 
a direct effect on both the lifetime and relative Raman peak intensities of the 
ruthenium(II) multimodal probe, both pH (via Raman peak intensities) and oxygen 
concentrations (via lifetime of the dye) within the cell could be measured. As 
mentioned earlier (dppz) displays a ‘molecular switching effect’, thus only the 
membrane associated and protected dye molecules emit phosphorescence. As a result 
luminescence does not represent true dye distribution. Thus for the first time, 
resonance Raman mapping was employed as a complementary technique to assess 
ruthenium dye distribution within cells as it does not rely on the emission of the dye. 
 
Barton et al.
(124)
 have also explored the area of ruthenium-peptide conjugates in an 
attempt to introduce specific targeting of these complexes in the cell. The nuclear 
entry of a series of luminescent ruthenium peptide conjugates of a shorter sequence 
and lower charge was investigated. Results confirmed the small nuclear specific 
tetrapeptide RrRK (where r=Darginine) facilitated nuclear localisation of the 
ruthenium complex with increased cellular uptake compared to analogous 
unconjugated complexes, Figure 1.14. This complex was also concentration specific, 
with observation of nuclear targeting occurring above a threshold of 30 µM. 
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Figure 1.14: (Left) Chemical structure of Ru-RrRK ruthenium peptide conjugate. 
(Right) Confocal luminescence image of HeLa cells incubated with 40 µM Ru-RrRK 
for 2 hours at 37°C.
(124)
 
  
Most recently our group reported specific nuclear targeted delivery of live mammalian 
cells using a Nuclear Localisation Signal (NLS) peptide; NF-κB via the synthesis of two 
ruthenium complexes, [Ru(dpp)2PIC-βAla-NF-κB]
6+
 and [Ru(bpy)2PIC-βAla-NF-κB]
6+
, 
Figure 1.15.
(125)
 Both conjugates successfully penetrated the nuclear membrane, unlike 
the parent complex. Strong co-localisation of both dyes with the commercial nuclear 
stain, DAPI was observed, indicating in both cases, that the complex-NLS conjugates 
penetrate the nuclear envelope. Dye distribution depended greatly on the hydrophobicity 
of the metal complex. Hydrophilic bpy was primarily localised in the nucleus. For the 
hydrophobic dpp based complex, although the dye penetrated the nuclear envelope, the 
highest intensity dye concentration was observed in the nucleolus. The dpp complex is 
strongly lipophilic compared to the bpy analogue which may drive binding of this 
complex to the nucleolus. As ruthenium polypyridyl complexes have a widely reported 
strong interaction with DNA and their ability to induce photocleavage, targeted delivery 
of such complexes to nucleus and nucleolus provides an important step toward the 
therapeutic/clinical applications of these complexes. 
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Figure 1.15: Nuclear Localisation and uptake of [Ru(bpy)2PIC-βAlaNFκB]
6+
 into live 
CHO cells. Live cells were seeded at 5 x 10
5
 cells onto glass-bottomed dishes for 24 
hours before addition of the ruthenium complexes (40 µM for 16 hours at  37 
o
C) and 
DAPI (300 nM for 30 minutes. at 37 °C). Images were acquired using a Zeiss LSM510 
Confocal microscope, 63x oil immersion lens, 458 nm laser line for Ru and 375nm for 
DAPI. DAPI and the backscatter refection are presented in top and bottom right 
images. The yellow line represents the fluorescence intensity profile in the graph to the 
left generated using ImageJ image analysis software.
(125)
 
 
1.3.2   RGD Peptide Conjugates 
The RGD sequence as described in section 1.1.4 is the most widely studied sequence 
in integrin investigations. The most commonly used dye-RGD conjugate reported in 
literature to date is the commercially available Infrared (IR) IRDye®800CW RGD 
optical probe, 1,4,7,10-tetra-azacyclodecane-N,N',N'',N'''-tetraacetic acid (DOTA, 
known chelator) and cypate (dye). These probes exhibit absorption/emission maxima 
in the region of 800 nm matching the near infrared (NIR) absorption minima for body 
fluids and tissues resulting in excellent tissue penetration.  
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Houston et al.
(126)
 investigated increased blood supply in solid tumours through new 
vessel formation through the preparation of a dual-labelled RGD agent using 
diethylenetriaminepentaacetate (DTPA), IRDye®800CW and 
111
In. This group 
demonstrated the feasibility of combined nuclear/near infrared fluorescence (NIRF) 
imaging using the dual-labelled probe introducing a new approach to cross validate 
NIRF imaging with nuclear imaging producing higher quality images. Edwards et 
al.
(127)
 conjugated RGD to cypate and DOTA and radiolabelled with 
111
In for dual-
labelling which provided the ability to use the probe with different radiometals due the 
chelating DOTA using single photon emission computed tomography (SPECT) 
imaging. Ye at al.
(128)
 provided evidence of a targeted therapeutic that could be 
monitored by multimodal imaging via development of a multifunctional RGD imaging 
probe, again for NIRF imaging. High affinity binding to the αvβ3 integrin with receptor 
speciﬁc binding in vitro, as well as comparable optical and nuclear imaging results in 
mice was observed. 
 
As stated earlier, integrins also play a central role in thrombus formation with integrin 
αIIbβ3 deemed the “central” integrin in thrombosis. Thus RGD peptide labels are of 
huge interest to this area of research. However very little literature utilises dye labelled 
RGD for integrin/platelet studies. Recently, a novel imaging agent (P975) consisting 
of a single gadolinium moiety attached to a cyclic (RGD) peptide has been developed 
to target activated platelets within thrombi, through binding to their αIIbβ3 integrin in 
mouse models of arachidonic acid–induced carotid thrombosis.(129) This probe lead to 
a 4-fold greater change in contrast-to-noise ratio after contrast injection compared to 
surgery controls. P975 also bound specifically to αIIbβ3 integrin. 
 
In summary, the value of labelled RGD peptide conjugates in the area of thrombosis 
research remains relatively unexplored. The reports discussed here are limited to IR 
imaging techniques. The synthesis of the novel ruthenium-RGD conjugates prepared 
in this thesis is to our knowledge, the first reported for the investigation of RGD as a 
peptide target for integrin binding. The environmentally sensitive ruthenium dye 
broadens the investigation of RGD as a peptide target for integrin binding, allowing 
the measurement of both steady-state and time-resolved spectroscopy, anisotropy and 
confocal imaging to investigate integrin presence and conformation in both the resting 
and chemically activated state (via Mn
2+ 
and DTT). 
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1.4   Introduction to Single Cell Capture 
Large cell population studies have contributed significant progress in monitoring bulk 
mechanical, electrochemical and genetic changes, however as all cells act differently, 
a vast amount of important information regarding the activity and dynamics of single 
molecules remains unidentified. The introduction of single cell detection provides the 
ability to monitor these unexplored parameters providing detailed information of 
single individual cells under specific conditions, and so is of vital importance in many 
biological areas including cell signalling
(130)
 and heterotypic biological systems.
(131)
 
Since the introduction of flow cytometery in the early 1950’s single cell detection has 
grown immensely providing in depth knowledge of cell interactions at single cell 
levels. 
 
1.4.1   Methods of Single Cell Capture 
1.4.1.1   Flow Cytometry (FC) 
The flow cytometer, first introduced in 1965 by Mack Fulwyler
(132)
, is a laser based 
system for cell counting and cell sorting, achieved through suspending cells in a 
stream of fluid and passing them by an electronic detection apparatus which allows 
simultaneous multiparametic analysis of each cell type. The light hits the cells, causing 
scatter relating to various cell characteristics such as granularity and size. The 
scattered light is collected by multiple detectors, one for scattered light in line with the 
beam (forward scatter or FSC), one for right angle scatter (side scatter or SSC) and 
three for fluorescent scatter, green (FL1), red (FL2) and deep red (FL3). This data 
provides information about the cells, presented in the form of 2-D dot plot of 
fluorescent intensities or a 1-D histogram. 
 
The study of mammalian cells was widely reported in the 1970’s, through the 
application of FC, exclusively with the use of laser illumination. Studies with other 
biological systems such as microorganisms (e.g. bacteria) were impossible however, 
due to the limiting size of microbial cells, almost 200 times smaller than that of the 
human cell. This was resolved in the late 1970’s with advancements in the optical 
technology of the system, allowing for the investigation of microbial cells. For 
example, in 1978, several types of microorganisms such as an alga (Chlorella sp.), a 
bacterium (E. coli) and several yeasts were investigated by Hutter and Eipel, using 
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FC.
(133)
 DNA content and total cell protein measurements were performed successfully 
using a dual staining technique and the measurement of autoﬂuorescence was also 
demonstrated for algal chlorophyll.  
 
Consequently, FC has been established as a robust method for single cell 
investigations. Advances in this system are constantly occurring, for example, Wu et 
al.
(134)
 have recently published the development of a microfluidic FC device which has 
the ability to carry out single cell microRNA (non-coding small RNAs that have cell 
type and cell context-dependent expression and function) analysis. This group 
employed flow fluorescent in situ hybridisation (flow-FISH) using locked-nucleic acid 
probes combined with rolling circle amplification (RCA signal amplification dye) to 
detect the presence and localisation of miRNA. Furthermore, this approach allowed 
the simultaneous detection of both gene-products thought to be targeted by the miRNA 
together with miRNA in the same cells, presented in Figure 1.16. This method has the 
additional advantages of utilising only 170 nl of reagent per experimental condition, 
and is the first report to date to achieve direct detection of miRNA in single cells using 
FC. 
 
Figure 1.16: Simultaneous detection of CD69 and miR155 using imaging and flow-
FISH flow cytometry. (A) Images of Jurkat cells showing RCA amplified miR155 
signal (green dots in the cytosol), CD69 proteins stained with Qdot705 (red), and the 
nucleus (blue). (B)Median values of miR155 fluorescence and CD69-Qdot705 
fluorescence collected via flow cytometry.
(134) 
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1.4.1.2   Lab-on-a-chip (LOC) Technology/ Microfluidics 
Lab on a chip (LOC) technology integrates multi-parameter laboratory functions on a 
single chip of millimetre up to a few square centimetres in size. The first LOC, a gas 
chromatograph analysis system, was introduced in 1979 by S. C. Terry. The multi-
parameter abilities of LOC technology did not arise however until LOC popularity 
rose in the late 1980’s/early 1990’s introducing developments such as micropumps, 
flow sensors and the concept of integrating multiple laboratory processes to perform 
chemical analysis, referred to as Micro Total Analysis Systems (µTAS). It was the 
introduction of µTAS to the LOC systems that extended the use of LOC systems to a 
complete laboratory analysis that was usually done at laboratory scale e.g. cleaning 
and separation. Consequently there is growing interest in the use of this technique for 
a wide variety of fields such as chemical analysis, medical diagnostics and more 
specifically to this discussion, single cell analysis.
(135)
 
 
In 1999, Fu et al.
(136)
 reported advancements in the previously discussed flow 
cytometry technique with the novel development of a disposable micro-fabricated 
fluorescence activated cell sorter (µFACS) for sorting multiple biological entities. This 
system provided higher sensitivity, lower running cost with the use of less solvent and 
sample as well as no cross-contamination compared to the conventional FC systems. 
In addition, Escherichia coli cells expressing green fluorescent protein were 
successfully separated from non fluorescing E. Coli cells without disrupting the 
integrity of the cells reporting viability after extraction from the sorting instrument. It 
was concluded that these devices could function as either stand-alone devices or as 
components of an integrated microanalytical chip. 
 
The ability of LOC systems to accurately measure, handle and analyse very small 
volumes has opened the door for the analysis of the intracellular entities of single 
intact cells. For example Hong et al.
(137)
 developed a microfluidic device with 
integrated pneumatic valves capable of isolating single cells and then lysing them 
using a chemical lysis buffer. This group further reported the ability to extract and 
recover messenger RNA from the cell lysate of a single cell. More recently, Liu et 
al.
(138)
 reported the development of a novel DNA FISH sample-preparation method 
using a centimetre sized array. It was found that an unpatterned self-assembled 
monolayer (SAM) of (3-Aminopropyl)triethoxysilane (APTES) (which makes glass 
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positively charged) could immobilise a monolayer of nonadherent K562 human 
leukemic cells. In addition, the adherence of K562 cells to an unpatterned bioinert 
polyethylene glycol (PEG) silane SAM was investigated which confirmed no 
adherence occurred on the surface. Consequently a mixture of APTES and PEG silane 
was selected to prepare the cell adhesive islands and cell-repelling background 
respectively.  
 
Using the FISH model, cells were precisely positioned and separated from their 
neighbours, presented in Figure 1.17. This group achieved large scale high throughput 
data acquisition and analysis of single intact cells which, at the time, conventional 
sample preparation methods for FISH could not support 
 
 
Figure 1.17: (a) Fluorescence micrograph of cell array after the FISH process. (b) 
Fluorescence micrograph of FISH results. FISH signals (red dots) are present in the 
cell nuclei (blue). (c) Histogram of the percentage of cells with different numbers of 
FISH signals per cell. (d) Analysis of the FISH image (b) by the FISH Finder 
program.
(138)
 
 
LOC technology has many advantages; low sample volume, faster analysis and 
response times, small size, lower fabrication costs and most importantly the ability to 
run multiple laboratory preparation steps simultaneously. As a result LOC technology 
has made huge advancements over the years as can be clearly seen from this 
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discussion. The small size, small volumes and cheap fabrication make these 
instruments ideal candidates for medical diagnostic application.  For example, Sato et 
al.
(139)
 developed the first microchip-based system useful for clinical diagnoses with 
short analysis time, high sensitivity and easy procedures using a bead-bed 
immunoassay microchip system for cacinoembryonic antigen (CEA) identification, a 
commonly used marker for colon cancer. Polystyrene beads were coated with anti-
CEA antibody and introduced to a microchannel. A serum sample containing CEA 
antibody as well as a second conjugated colloidal gold antibody was introduced to the 
channel, binding to the beads, resulting in an antigen-antibody complex which was 
detected using thermal lens microscopy (TLM). Sandwich immunoassay achieved 
highly selective and sensitive determination of trace amounts of CEA in the sera 
sample via the use of three antibodies in the assay. This system was found to achieve a 
detection limit dozens of times lower than the conventional enzyme-linked 
immunosorbent assay (ELISA) method as well as reducing the overall analysis time 
from 45 hours to 35 minutes.  
 
1.4.1.3   Array Technology 
As with LOC technology, array technology or the patterning of surfaces has also had a 
strong impact in research fields including protein expression, enzyme activity and 
more recently cell-ligand interactions.
(140)
 The advantage of arrays and patterned 
surfaces is the promotion of accuracy and reproducibility in cell capture and 
positioning via the anchorage of probes to the surface through the immobilisation of 
functionally active biological species e.g. peptides.  
 
Our research group have a strong interest in the utilisation of array technology, more 
specifically nanostructured metal interfaces. A schematic of the preparation of these 
arrays is presented in Figure 1.18. A key interest in the use of metals for these arrays 
comes from the plasmonic fields that can be generated optically at these surfaces, the 
volume is available for filling and they are electrochemically addressable making them 
significantly interesting for multimodal investigations. In 2009, Jose et al.
(141)
 reported 
for the first time, the beneficial effect of spherical cap architecture of gold nanocavity 
arrays, 240, 430, 600 and 829 nm in size on the photophysics of self-assembled 
monolayers of a ruthenium luminophore, [Ru(bpy)2(Qbpy)]
2+ 
selectively modified at 
either the top surface or inside the cavity walls. The top modified gold nanocavity 
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arrays showed the greatest enhancement in both Raman and luminescence signal from 
the self assembled monolayer probes suggesting that localised surface plasmons, at the 
top surfaces of the nanocavity arrays play the dominant role in plasmonic 
enhancement for these spherical arrays. The relative enhancement of spectral intensity 
of cavity to top surface was greatest for the smallest diameter arrays presenting 170 
times Raman signal enhancement for dye adsorbed at the top surfaces for the 240 nm 
array compared with a relative enhancement factor of just 6 for the 820 nm diameter 
array. The large enhancement factors at the top surface of smaller cavity sizes is 
attributed to the relative ratio of localised and propagating surface plasmon, e.g. for 
smaller cavity sizes the top surface is more nanostructured and a greater percentage of 
the plasmonic field is localised and excitable by incident irradiation. The ability to 
change the shape of these arrays has also been published with the easy control of 
shape from truncated spheres to cuboids.
(142)
 
 
Figure 1.18: Preparation of gold cavity array; (a) assembly of polystyrene spheres 
(nm-µm diameter size range available) on a planar gold surface, (b) electrochemical 
deposition of gold between sphere voids, (c) removal of polystyrene spheres by 
sonication in tetrahydrofuran (THF) and SEM image of the resulting cavity array. 
Chemical modification of the array is possible via incubation with the desired 
thiolated species overnight at room temperature.
(141)
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Following this study, Mallon et al.
(143)
 demonstrated selective chemical modiﬁcation 
of a gold nano-cavity array via nanoscale templating to create ﬁbrinogen patterned 
cavities with a bioinert/blocking polyethylene glycol modiﬁed top surface. Application 
of a reducing state potential to the array readily released the protein from the cavities, 
however denaturing the protein, thus a more advanced approach is required. Despite 
this however, this method provided significant advantages for bio-patterning such as 
easy selective modification and the ability to release concentrated pockets of protein 
electrochemically in a time-controlled manner. The curved cavity also provides a 
larger surface area for the attachment of proteins. As mentioned for Jose’s work, the 
use of gold metal in the preparation of the arrays provides plasmonic enhancement 
which can facilitate sensing, opening up the possibility for spatially and rate controlled 
protein delivery and sensor development. In this thesis, I aim to exploit this to enable 
capture of single platelets, discussed further in Chapter 5.   
 
The ability to prepare single nanocavity ultramicroelectrodes has also been 
reported.
(144)
 In this method a single sphere (r=410nm) was deposited on a 5 µm sized 
electrode. The resulting small volume of the cavity, <300 picolitres, has the ability for 
possible integration with microfluidic systems such as those discussed for the LOC 
technique, section 1.4.1.2 making it an ideal candidate for biosensing and useful in 
medical diagnostics due to the cheap preparation, high sensitivity and fast analysing 
nature of microfluidic systems. A further study confirmed the assembly of a lipid 
bilayer across 820 nm gold nanocavity arrays. Such lipid modiﬁed arrays may ﬁnd 
application in the study of transmembrane proteins.
(145)
  
 
Torres et al.
(146)
 reported the analysis of T Cell activation by supported lipid bilayer-
tethered ligands on nanowell arrays. Lipid bilayers remained stable and mobile on top 
of the polydimethylsiloxane (PDMS). Modifying the ligands tethered bilayer 
successfully altered the structure and resulting synapses of single T cells as expected, 
presented in Figure 1.19. Furthermore, the characterisation of secreted cytokines from 
the activated T cell clones was achieved via microengraving in both antigen and pan-
specific manners. In summary this report allowed a detailed investigation on the 
influence of synapse on the activation of single T cells and their complex responses. 
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Figure 1.19: Live-cell imaging of T cell activation and formation of the immunological 
synapse. T cells (HA:D7 clone cell specific for the peptide HA306–318) were activated 
at 37 °C with the supported bilayers (inside nanowells of 30 µm width) containing (A) 
pMHC and ICAM-1, (B) anti-CD3 (attached via mono-biotinylated rabbit-anti-mouse 
Fab’ fragment) and ICAM-1, or (C) anti-CD3 only. The visible fluorescence 
surrounding the wells is due to out-of-focus intensity coming from the Alexa 488-
labeled streptavidin or Alexa 647-labeled ICAM-1 attached to the supported lipid 
bilayer (SLB) at the sidewalls. Scale bar represents 20 mm.
(146)
 
 
In summary the use of array technology has undergone huge advancements in recent 
years, but there is still a long way to go in terms of advancement and exploitation of 
such arrays. Thus this thesis investigated the potential of these gold cavity arrays as 
focal adhesion points for platelet capture using the RGD peptide sequence and the 
nanopatterning of the array, discussed further in Chapter 5. 
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1.5   Interfacial Self Assembly 
Molecular self assembly (SA) is a spontaneous process where a disordered system of 
pre-existing components forms an ordered system as a result of local interactions 
amongst the components themselves. SA can be explained via three distinct features; 
order, interactions and building blocks. The SA structure must have a higher order 
than the isolated component e.g. shape. Weak interactions such as dispersion and Van 
der Waals have a strong influence in material synthesis, determining the physical 
properties of liquids, solubility of solids, and the organisation of molecules in 
biological membranes. The final distinctive feature of SA is that building blocks 
include not only molecules but a range of nano and mesoscopic structures of varying 
shapes and characteristics. Importantly these building blocks can be easily synthesised 
via conventional chemical procedures. Consequently the use of SA has extended the 
scope of material science immensely from the formation of colloids, lipid bilayers to 
self-assembled monolayers (SAMs) to name but a few. The use of the SAM process 
exploited in this thesis is discussed in greater detail in section 1.5.1. 
 
1.5.1   Formation of Self Assembled Monolayers (SAMs) 
Self-assembled monolayers (SAMs) result from the spontaneous formation and 
organisation of molecules on the surface by physi- or chemisorption. Generally the 
latter is more important where the molecule possesses a functional group that holds a 
strong affinity to the substrate, chemisorbing onto the substrate surface. These SAMs 
consist of a head group, tail and reactive end functional group as presented in Figure 
1.20.  
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Figure 1.20: Scheme of the formation of a self-assembled alkyl thiol monolayer. SAMs 
are formed by simply immersing a substrate into a solution of the surface-active 
material.
(147) 
 
Early studies of SAMS focussed mostly on assemblies formed by organosulfurs 
(alkanethiol, dialkyl sulphides etc.) onto gold or silver substrates. 
(148,149)
 Two 
kinetically distinct absorption steps have been reported for alkanethiol SAM formation 
of gold substrates. Nuzzo et al.
(150)
 reported an initial very fast adsorption step which 
takes a few minutes.
(150)
 At this stage the contact angles are close to their limiting 
values and the film thickness about 80-90% of its maximum. This is followed by a 
second slow step, lasting multiple hours, through which the final thickness and contact 
angle of the film is reached. In alkane thiols, adsorption is strongly dependant on thiol 
concentration as well as alkyl chain length. At 1mM the first adsorption step was 
complete after 1 minute while an increase to ~100 minutes was observed at the lower 
concentration of 1 µM. Faster kinetics were also reported for longer alkyl chain length 
thought to be due to increased lateral Van der Waals forces along the longer chains. 
This group further confirmed strong coordination of the sulfur donor atoms to the gold 
substrate with stabilisation of the monolayer via weak Van der Waals forces between 
the methylene groups.
(151)
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Since the early 1990s, however a wide variety of substrates and reactive functional 
groups has been established, for SAM formation from planar surfaces using silicon 
wafers and glass slides to highly curved nanostructures, including nanorods and 
colloids. The variety of both substrates and monolayer forming molecules has greatly 
expanded SAM applications to chemical sensing, nano-scale lithography, solar energy 
conversion, corrosion protection, insulation, lubrication and the study of cell adhesion 
to extracellular components.
(152)
 
 
Despite a widely established range of surfaces and functional groups, the most popular 
substrate to date remains gold.
(153)
 Gold is relatively inert and so does not oxidise at 
temperatures below its melting point, it does not react with atmospheric O2, is easily 
layed down via electro-deposition or sputtering methods and is easy to pattern via 
lithographic methods. In contrast to other metal surfaces, the Au bond is extremely 
strong presenting a bond strength of approx. 100 kJ mol
-1
 providing surface stability 
against temperature and solvent changes.
(152)
 In addition, its adsorption is rapid. 
Furthermore a wide range of terminated thiol compounds exists which extend surface 
investigations with the ability to alter hydrophobicity and chemical reactivity.
(150)
 
Nanostructured gold, as discussed earlier, is also a useful plasmonic substrate 
exhibiting visible/NIR excitable localised surface plasmons and also permits 
electrochemical addressability which can be utilised in sensing.
(141-143)
 
 
1.5.2   SAMs as Model Biological Surfaces 
For biological investigations an ideal SAM surface should have the following 
properties; (1) the ability to inhibit non-specific binding, (2) allow modifications to the 
composition and density of the immobilised ligands/biomolecules and (3) present the 
ligands of interest in a structurally well-defined manner with minimal influence from 
the surface, e.g. blocked binding sites. To date the most commonly biologically-
resistant surfaces are composed of PEG and alkanethiol, which have been 
implemented widely to form stable inert surfaces, eliminating non-specificity in 
biological investigations.
(154,155)
  
 
In a study focussed on controlling cell adhesion to biomaterials, Groth et al.
(154)
 
determined cell binding affinity of human fibroblasts depended greatly on surface 
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terminating functional groups. Methyl (CH3), bromine (Br) and vinyl (CH=CH2) 
groups which form hydrophobic surfaces while amine (NH2) and carboxyl (COOH) 
functions lead to wettable surfaces. PEG and hydroxyls (OH) groups create wettable 
substrata. SDS-PAGE of the proteins adsorbed from bovine serum presented less 
binding to PEG and OH than CH3, NH2 and COOH. Cell binding of human fibroblasts 
on CH3, PEG and OH terminated SAMs were very weak while strong attachment and 
spreading was observed with COOH and NH2, Figure 1.21. This strong interaction of 
fibroblasts with the latter SAMs was linked to an enhanced activity of integrins as 
confirmed after antibody-tagging of living cells. 
 
Figure 1.21: Percentages of human fibroblasts attached to SAMs after incubation for 
2 hours in medium containing 10% FBS.
(154)
  
 
Arima and Iwota later investigated the effect of wettability on the binding of human 
umbilical vein endothelial cells (HUVECs) and HeLa cells using mixtures of a range 
of alkanethiols carrying the terminal methyl (CH3), hydroxyl (OH), carboxylic acid 
(COOH) or amino (NH2) groups.
(155)
 Optimum HUVEC binding was observed on 
CH3/OH (20:80 ratio) mixed SAMs with a water contact angle of 40°. Cell adhesion 
was found to increase with decreasing water contact angle up to 60–70° levelling off at 
CH3/COOH and CH3/NH2 mixed SAMs. For HeLa cells, optimum binding was 
observed on CH3/OH (10:90 ratio) and CH3/COOH (10:90 ratio) mixed SAMs with a 
water contact angle of 50°. Results suggest cell adhesion to greatly depend on surface 
wettability as well as surface functional group, in correlation with that reported earlier 
by Groth et al.
(154)
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PEG and alkanethiol have been widely implemented as biological adhesive inhibitors 
in the preparation of patterned surfaces and arrays. A prime example of this was 
discussed in section 1.4.1.2 where Liu et al.
(138)
 achieved large scale high throughput 
data acquisition and analysis of single intact cells via a mixture of APTES and PEG 
silane on a glass slide to prepare the cell adhesive islands and cell-repelling 
background respectively.  
 
Bioinert materials have been extended to the investigation of platelet binding and 
activation. Most recently Shen and Lin reported the effects of solvent and alkanethiol 
(SAM) concentration on platelet compatibility using 4 types of solvent; deionised 
water, PBS, methanol and ethanol and two alkanethiol concentrations; 2 mM or 
0.1 mM. SAMs prepared in 0.1 mM solution and 2 mM ethanol solution presented the 
highest platelet compatibility, attributed a more organised conformation and enhanced 
hydrophilic properties. This study demonstrated that optimising solvent and 
concentration conditions could control the structural organisation of SAMs and, 
consequently, modify biomedical properties. 
 
Yamaoka et al.
(156)
 recently reported a novel chemical strategy for designing 
haemocompatibile biomaterial surfaces. Four different surfaces using two hydrophillic 
polymers: PEG and polyrotaxanes (PRX) containing α-cyclodextrin was investigated. 
Either one or both terminals of the PEG or PRX were immobilised onto a gold surface 
resulting in grafts (1 terminal bound) or loops (both terminals bound). Better 
suppression of platelet adhesion was observed on the graft surfaces compared to loop 
surfaces for both polymers, presented in Figure 1.22. Platelets adhesion to the PRX 
surfaces was significantly less than the PEG surfaces, possibly because of the mobile 
nature of the α-cyclodextrin molecules that were threaded on the PEG chain. Results 
confirmed different modes of dynamic features, sliding/rotation of α-cyclodextrin and 
polymer chain mobility, effectively suppressed platelet adhesion in spite of the similar 
hydrophillicity.  
45 
 
 
                               
Figure 1.22: Top: morphology of adhering platelets on surfaces coated with (A) 
tri(ethylene glycol) (TEG), (B) poly(ethylene glycol) PEG-graft, (C) PEG-loop, (D) 
polyrotaxane PRX-graft, and (E) PRX-loop. Actin nodules in adhered platelets were 
stained by rhodamine-phalloidin (scale bar =10 μm). Bottom: area of adhered 
platelets/μm2 for all modified surfaces listed in (a).(156) 
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1.5.3   RGD modified SAM’s for Biological Applications 
SAM technology has become of great interest in the area of cell-ligand interactions. 
The introduction mixed SAMs presenting ligands of interest in a structurally well-
defined manner against a background that resists the nonspecific adsorption of other 
biomolecules and cells is increasingly being explored. As this thesis focuses primarily 
on αIIbβ3 integrin investigations, the tri-peptide RGD, specific for the head of this 
integrin will be discussed in detail as a prime example of the advantage of introducing 
mixed SAMs for surface investigations. 
 
RGD is the most widely studied sequence in integrin investigations with 8 of the 24 
known integrins binding to extra-cellular membrane molecules in an RGD dependant 
manner.
(69) 
In the mid 1980s, Pierschbacher and Ruoslahti found that many 
extracellular matrix proteins contain the tripeptide RGD and that this short peptide is 
an important ligand for cell adhesion.
(157,158)
 The RGD recognition motif has also 
reported useful properties for their use in surface chemistry such as high stability 
towards heat treatment, low pH, enzymatic degradation, easy characterisation and cost 
effectiveness.
(70)
 Accordingly, the RGD sequence is by far the most widely employed 
peptide sequence for stimulating cell adhesion on synthetic biomaterials.
(70)
 
 
Many of the RGD surfaces fabricated following the introduction of the RGD peptide 
in the mid 1980’s had not been shown to resist the non-specific adsorption of adhesive 
ligands expressed by the attached cells; within hours, the molecular composition of the 
surface changed uncontrollably. Whitesides et al.
(159)
 introduced specificity to RGD 
binding studies using SAMs of oligo(ethylene glycol) (OEG) terminated 
alkanethiolates on gold, demonstrating that surfaces presenting OEG moieties 
inhibited protein absorption.
(159)
 Later this group developed mixed SAMs using 
solutions that contained both (EG)6OGRGD and (EG)3OH terminated alkanethiolates, 
presenting RGD groups at an “inert” interface.(160) It was reported that RGD alone was 
sufficient to maintain long-term specific attachment and survival of cells with bovine 
capillary endothelial cells attaching and spreading on SAMs at xRGD ≥ 0.00001, with 
spreading of cells reaching a maximum at xRGD ≥ 0.001, presented in Figure 1.23. 
Addition of soluble RGD peptide to the culture medium resulted in detachment of 
cells only from the region of the substrate presenting the immobilised peptides, further 
demonstrating the specificity of the cell-peptide interaction. 
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Figure 1.23: Adhesion of endothelial cells to mixed SAMs presenting RGD groups and 
tri(ethylene glycol) groups; nominal values of xRGD are indicated on the plot. The 
photographs above the bar graph illustrate the amount of cell attachment and cell 
spreading observed for a given SAM: (A) cells on Fibronectin-coated on (CH2)15 CH3 
SAM; (B) cells are attached and spread; (C) cells are attached and spread; (D) cells 
are attached but do not spread; (E) cells are unable to attach.
(160) 
 
 
In 2003, Mrksich et al.
(161)
 prepared three examples of biochips based on monolayers 
that present maleimide and penta(ethylene glycol) groups. The maleimide groups react 
efficiently with thiol-terminated ligands, whereas the penta(ethylene glycol) groups 
prevent the nonspecific adsorption of protein to the substrate. Using this methodology, 
three biochips were prepared, the final of which was RGD for studies of integrin-
mediated cell adhesion. To demonstrate the suitability of this substrate for mammalian 
cell culture, the peptide CGGRGDS-NH2 was immobilised at monolayers presenting 
the maleimide group. To demonstrate the specificity of the interaction between cells 
and immobilised peptides, two monolayers substrates were investigated. One half 
consisted of hydrophobic hexadecanethiolate groups coated with the cell adhesion 
protein Fibronectin, the other half presented penta-(ethylene glycol) groups and 
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maleimide-RGD conjugates, Figure 1.24, (A). 3T3 fibroblasts attached efficiently to 
both regions of the substrate, Figure 1.24, (B). As reported for Whitesides et al.
(160)
, 
addition of soluble GRGDS-NH2 peptide (2mM in PBS, pH7.4) to the culture medium 
resulted in detachment of cells only from the region of the substrate presenting the 
immobilised peptides, demonstrating the specificity of the cell-peptide interaction, 
Figure 1.24, (C).  
 
 
Most recently, similar to Mrksich et al.
(161)
, Yoon and Mufrod investigated the ability 
to quantitatively characterise the adhesion and detachment of anchorage-dependent 
NIH 3T3 fibroblast cells via electrochemical desorption of thiol terminated SAMs 
from gold surfaces.
(162)
 An array of identical gold surfaces patterned on a pyrex glass 
substrate was surface-modified with a thiol functionalised RGD peptide and 
reductively desorbed with activation potential to spatiotemporally manipulate both 
NIH 3T3 fibroblast cell adhesion and detachment, presented in Figure 1.25. An 
advantage to this method was the ability to retain cells living and intact for the 
Figure 1.24: (A) Substrates presenting gold substrate 
with one half hexadecanethiol (2 mM in EtOH) and 
the other half a monolayer presenting RGD 
conjugated maleimide and penta-(ethylene glycol) 
groups. (B) Swiss 3T3 fibroblasts attached to regions 
of the substrate presenting the RGD peptide and 
fibronectin. (C) Addition of soluble GRGDS-NH2 
(2mM in PBS),detached cells from the RGD side of 
the substrate while cells attached to fibronectin did 
not.
(161)
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duration of the experiment, thus allowing the quantification of cell adhesion and 
detachment mimicking the in vivo environment. This method provided the possibility 
of investigating the effect of the size and geometric shape of gold surfaces on cell 
adhesion. The findings in this report lead to the following propositions for gold surface 
design: the gold surface for single cell adhesion must be larger than (or at least 
comparable to) the size of a single cell in a floating state; the geometric shape of the 
gold surface, when its area is limited, should ideally be an equilateral triangle or 
square. This device has potential application as a platform for studies of molecular 
biomechanics of the cell. 
 
Figure 1.25: Optical and immunofluorescent images of the spatiotemporal 
manipulation of cell adhesion. Left: gold surface is activated via a potential resulting 
in cell desorption while the right one is inactivated presenting adhered cells. Cells are 
stained for actin with rhodamine-phalloidin (red) and for cell nucleus with DAPI 
(blue).
(162)
 
 
The use of RGD SAM surfaces in cellular studies has been reported widely as 
confirmed in the discussion above. Platelet binding interactions using SAM modified 
surfaces however, remains relatively unexplored. In 2003, Textor et al.
(163)
 reported 
the advantages of using bioinert PEG molecules for the elimination of non-specific 
protein adhesion on metal surfaces, as discussed in detail for cell studies earlier. In this 
study a graft polymer poly(l-lysine)-graft-poly(ethylene glycol) (PLL-g-PEG), RGD  
and a control RDG derivative (PLL-g-PEG/PEG-peptide) were assembled onto 
titanium-oxide surfaces. These substrates were exposed to full heparinised blood 
plasma and the adsorbed masses measured via in situ ellipsometry. No significant 
protein adsorption was observed on any of the modified titanium surfaces during 
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exposure to plasma for 30 minutes at 22 °C or 37°C. Contrastingly, approximately 350 
ng/cm
2
 of adsorbed plasma proteins were observed for clean, uncoated titanium 
surfaces, summarised in Figure 1.26. 
 
Figure 1.26: Blood plasma protein adsorption onto smooth titanium (oxide) surfaces 
coated with (A) PLL-g-PEG, (B) PLL-g-PEG/PEG-RGD, (C) PLL-g-PEG/PEG-RDG 
and (D) bare titanium (oxide). The white bars refer to the adsorbed polymer and the 
gray bars indicate the total adsorbed mass per unit area after subsequent incubation 
in heparinised blood plasma. No significant mass change was observed upon plasma 
exposure (P>0.05).
(163)
 
 
Hall et al.
(164)
 reported similar results using an alternative bioinert complex, the natural 
biopolymer hyaluronan (HA) in the investigation of platelet binding to stainless steel 
surfaces. Labelled HA was covalently attached to stainless steel surfaces and 
confirmed to have relative uniform coverage on the surface. Scanning electron 
microscopy alone was used to assess platelet binding to all surfaces. No protein 
adsorption was observed following incubation with human platelet rich plasma while 
HA derivatised RGD presented platelet attachment and spreading, presented in Figure 
1.27.  
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Figure 1.27: SEM micrographs of various samples after exposure to human platelet 
rich plasma for 30 minutes. All micrographs are 1800 µm; the scale bar represents 20 
µm. Left: stainless steel coated with HA. Right: stainless steel coated with RGD-
HA.
(164)
 
 
Martins et al.
(165)
 investigated the effect of surface wettability on fibrinogen (Fg) 
adsorption, platelet adhesion and platelet activation to gold surfaces using varied ratios 
of methyl and hyrdroxy terminated alkanethiols (C15CH3 vs. C11OH). A linear 
decrease in Fg adsorption, platelet adhesion and activation with increasing 
hydrophillicity (OH groups) was observed.  Platelet adhesion and activation studies 
were investigated further with and without pre-adsorbed fibrinogen (Fg), albumin and 
plasma on the surface. In the case of pre-immersed proteins, Fg adsorption was related 
to high platelet adhesion and activation, albumin, adhesion and activation was 
observed only for SAMS containing C11OH. In the case of plasma, platelet adhesion 
was minimal on SAMs with 65% and 100% C11OH explained possibly by the higher 
albumin affinity of the SAMs with 65% C11OH and lower protein adsorption 
associated with SAMS of 100% C11OH. This report further confirmed the usefulness 
of alkanethiols as bioinert materials for the elimination of non-specific adsorption of 
proteins. 
 
Currently a wide variety of synthetic polymeric materials are available for medical 
applications including implants and tissue engineering matrices. One of the main 
limitations regarding this area of research is inflammation, infection as well as 
thrombosis and embolisation as a result of foreign body reactions to potential 
biomedical implants.
(166)
 In multi-cellular situations, cell adhesion receptors play a 
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prime role in the contact of cells with neighbouring cells and the surrounding ECM. 
Among these is the integrin family, which influence a wide variety of cellular 
processes including cell differentiation, migration and most importantly 
haemostasis.
(7,76,157)
 The use of cell binding motifs such as RGD discussed here may 
provide the breakthrough required in producing cell friendly biomaterials. The 
capability of these modified surfaces to induce integrin specific interactions even in 
the presence of whole blood provides potential in the application of these surfaces for 
biomedical devices such as vascular stents and heart valve cages and also as potential 
surface sensor investigations advancing therapeutical approaches towards managing/ 
preventing thrombosis related diseases. 
 
Alternatively, the preparation of biocompatible surfaces for cell capture in advancing 
diagnostics and sensing is also of vital importance. This thesis investigates this 
hypothesis, using RGD, PEG and alkanethiol in an attempt to capture and control 
single blood platelet adhesion to gold cavity arrays. 
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1.6   Conclusion 
Over the past number of years, research in the application of inorganic chromophores 
for the investigation of biological processes has escalated, with their utilisation in a 
wide range of areas from medical to nanoscience. The large stokes shift, long lifetime, 
intense luminescence and photostability of inorganic probes has dominated organic 
complexes. The additional advantage of tuning the photophysical characteristics via 
ligand substitution has strengthened the use of these complexes as potential 
multimodal molecular probes. Ruthenium(II) polypyridyl complexes are among a wide 
range of chromophores investigated widely in cellular imaging. Introducing specificity 
to these complexes in their application to biological systems is thus becoming more 
popular but still remains largely unexplored. Introducing specificity to luminescent 
complexes through the conjugation of target peptides will strengthen the potential of 
these dyes as probes towards advancing diagnostics and therapeutics. 
 
The second part of this Chapter focuses on the preparation of self-assembled 
monolayers (SAMs) on metal surfaces, particularly gold. As the RGD sequences has 
great influence on most cell interactions such as cell adhesion and differentiation it is 
the most commonly used sequences in SAM investigations. RGD SAMs have been 
shown to possess the potential to control cellular interactions such as attachment and 
detachment in an area relative to cell size while also retaining cells intact for 
prolonged periods of time. The introduction of nanostructures has introduced 
additional advantages including simple preparation, electrochemical addressability and 
increased surface area. As a result cavity arrays utilisation in cell interaction studies 
has significant potential. Although literature in this area has been bombarded with cell 
binding studies very little investigations regarding platelet adhesion has been reported. 
Broadening SAM investigations towards for example, platelet binding may strengthen 
the potential use of these arrays as diagnostic tools for platelet binding and activation 
processes which may provide the advancements required to manage/prevent 
thrombosis related diseases. 
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2.0   Synthesis and Photophysical Studies  
The specific experimental methods used for each individual chapter are discussed in 
detail within the experimental section of that chapter. However, some general methods 
and instrumentation used for all chapters are presented below. 
 
2.0.1   Nuclear Magnetic Spectroscopy (NMR) Spectroscopy 
1
H NMR spectra were recorded on a Brüker AC 400 MHz spectrometer using deuterated 
DMSO-d6 as solvent for homonuclear lock. Peak positions are relative to TMS (0 ppm 
chemical shift). All NMR spectra were analysed using Topspin NMR software. 
 
2.0.2   Mass Spectrometry 
Mass spectrometry was carried out in University College Dublin (UCD), Ireland using 
both a high resolution Bruker Esquire LC_00050 electron spray interface (ESI) with a 
positive ion polarity and a high resolution LaserTof by matrix assisted laser desorption 
ionisation-time of flight (MALDI-TOF). 10 mg/ml concentration of α-cyano-4-hydroxy 
cinnamic acid matrix (acts as a proton source to encourage ionisation of the analyte and 
rapidly absorb laser radiation) was dissolved in 1:1 H2O containing 0.1% trifluoroacetic 
acid (TFA) and acetonitrile containing 0.1% TFA. 2 µl of 1:1 solution of peptide to 
matrix was applied to the MALDI plate. Samples were dissolved in HPLC grade 
methanol or acetonitrile. 
 
2.0.3   Absorption Spectroscopy 
UV-VIS spectra were recorded on a Varian Cary 50 spectrophotometer. Samples were 
analysed in a quartz cuvette with a path length of 1 cm with a spectral range of 190-800 
nm unless otherwise stated. All measurements were performed at room temperature and 
were background corrected prior to every measurement. 
 
2.0.4   Emission Spectroscopy 
Emission spectra were recorded on a Varian Cary Eclipse fluorescence 
spectrophotometer with an excitation and emission slit width of 10 nm with a spectral 
range of 480 - 800 nm for all samples. All experiments were performed using a 1 cm 
path length quartz cuvette. All measurements were performed at room temperature and 
were background corrected prior to every measurement. 
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2.0.5   Calculating Quantum Yields  
The phosphorescent quantum yield of the metal complexes were estimated by matching 
the MLCT absorbance transition of both the complex and standard [Ru(bpy)3]
2+
 (φstandard 
= 0.0642 in acetonitrile).
 
Both solutions were excited into the MLCT absorbance close 
to the maximum and the corresponding emission recorded. All quantum yield 
experiments were performed three times. Quantum yields were performed according to 
previous literature
(1, 2)
 and were calculated according to the following equation:  
 
                
         
(Eqn. 2.1) 
 
2.0.6   Thin Layer Chromatography (TLC) 
Thin layer chromatography (TLC) was performed on glass silica gel (Merck, 250 μm 
thickness) plates. The plates were immersed in a beaker containing the mobile phase of 
interest and analysed under UV light (254 nm and 365 nm). 
 
2.0.7   Chromatographic Techniques  
Compounds were purified manually using Silica (50 µm gel particle size). The column 
was monitored via TLC using glass silica gel (Merck, 250 μm thickness) plates and 
analysed under UV light (254 nm and 365 nm). 
 
2.0.8   Freeze Drier 
All samples were lyophilised using a Labcono FreeZone 2.5 freeze drier system.  
Samples were dissolved/diffused in deionised water and fully frozen in liquid nitrogen 
prior to attachment to the freeze drier. The samples were left overnight to ensure 
complete removal of water. 
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2.1   Cell Studies  
2.1.1   Media Preparation 
Chinese hamster ovarian cells (CHO-K1, ATCC no. CCL-61) were a kind gift from 
Professor Niamh Moran, Department of Molecular and Cellular Therapeutics, Royal 
College of Surgeons in Ireland. Two types of transfected CHO cell types were grown; 
wild type (WT), CHO-WT (no integrin αIIbβ3 expression); CHO-αIIbβ3 (expressing 
resting αIIbβ3). Cells were grown in DMEM Hams F-12 with L-glutamine and 15 mM 
 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) supplemented with 
10% foetal calf serum, 1% pen/strep, 1mg/ml G418  and 250 µg/ml zeocin at 37 °C with 
5% CO2. Cells were harvested or split when they reached 90% confluence. 
 
2.1.2   Determination of Cell Number 
Cells were washed with PBS, 2 ml of accutase was added and the T25 flask placed in 
the incubator for 2-3 minutes. Following incubation, the cell solution was transferred to 
a 50 ml tube and centrifuged for 4 minutes at 200 x g. The supernatant was removed 
and the cell pellet re-suspended in 1 ml media. A 20 µl cell suspension was transferred 
to a 500 µl eppendorf. 20 µl trypan blue was added to the cell solution. 20 µl of the 
mixture was released onto each counting chamber under the edge of the coverslip and 
the suspension drawn under the coverslip via capillary action, see Figure 2.1. This was 
repeated for the second counting chamber. A hand held counter was used to count the 
cells on the counting chambers using a 40x magnification. All of the cells in the 1mm 
centre square and the four corner squares were counted as each square of the 
haemocytometer represents a total volume of 10
4
 cm
3
 (1 cm
3
 is equivalent to 1 ml) the 
cell count could be calculated as follows: 
  
Cells/ml = average count per square x dilution factor x 10
4     
  (Eqn. 2.2) 
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Figure 2.1:  Schematic diagram illustrating the cell counting apparatus an  protocol.
(3)
 
 
2.1.3   Fluorescence Activated Cell Sorting (FACS) 
In this thesis, the FACS Calibur instrument (Royal College of Surgeons in Ireland) was 
used as a quick and reliable method to quantify the percentage expression of integrin 
αIIbβ3 on two transfected CHO cell types; CHO-WT (no integrin), CHO-αIIbβ3 (resting 
integrin). Two fluorescein isothiocyanate (FITC) labelled antibodies were used; CD41 
(binds to resting and activated αIIbβ3) and PAC-1 (binds to activated αIIbβ3). Cells were 
detached from culture via accutase and re-suspended in 100 µl PBS resulting in a total 
cell count of ~1 x 10
5
. 50 µl of cells were added to FACS tubes, followed by 50 µl of 
the desired FITC labelled antibody and incubated at 37°C for 10 minutes.  PBS was 
then added to stop the reaction. FITC was excited at 490 nm and emission monitored at 
520-540 nm.  
 
2.1.4   Confocal Fluorescence Microscopy   
Confocal microscopy is a technique originally patented in 1957 which succeeded in 
overcoming the limitations of traditional wide-field fluorescence microscopes. Confocal 
microscopy is used to increase the optical resolution and contrast of a micrograph via 
point illumination and a spatial pinhole, eliminating out-of-focus light in specimens that 
are thicker than the focal plane, illustrated in Figure 2.2. A laser beam is passed through 
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a light source aperture and focused by an objective lens onto a small focal volume 
within or on the surface of a specimen. Fluorescent light from outside the sample 
volume is eliminated as the luminescence from the sample is focused by a dichroic 
mirror onto a pinhole aperture, yielding very high, sub-micron spatial resolution. 
 
Luminescence images were recorded on a Zeiss LSM510 Meta confocal microscope 
using a 64x oil immersion objective lens (NA 1.4). The 458 nm argon ion laser line was 
used for ruthenium samples, 488 nm for Alexa Fluor® 488 goat anti-mouse secondary 
antibody and phycoerythrin (PE) labelled CD62P and 540 nm HeNe laser excitation for 
tetramethylrhodamine-5-(and 6)-isothiocyanate (TRITC)-phalloidin samples. Optical 
density filters were reduced to 0.1% transmission to reduce any effects of 
photobleaching. 
 
 
Figure 2.2: Schematic illustrating the components of a confocal microscope.
(4) 
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2.2   Instrumentation used for Peptide Synthesis  
2.2.1   High Performance Liquid Chromatography (HPLC) Analysis  
Chromatographic purification was carried out on a Varian HPLC Chromatography 
Workstation using a Phenomenex Gemini (C-18) reverse-phase chromatography 
column. The Gemini C-18 (250mm x 2.5 mm) was used at 1 ml per minute with linear 
gradient programmes. The UV detector was monitored for the peptides at a wavelength 
of 214 nm. Solvent A consisted of deionised H2O containing 0.1% TFA and solvent B 
consisted of acetonitrile containing 0.1% TFA. The gradient ran over 30 minutes going 
from 5% to 65% of solvent A. 
 
2.3   Instrumentation used for Platelet Adhesion Assays 
2.3.1   Raman Spectroscopy: Resonance Raman (RR) and Surface Enhance Raman 
Spectroscopy (SERS) 
Raman spectroscopy has a key advantage over IR due to its ability to detect extremely 
low frequency modes (10–600 cm-1) and is based on the inelastic scattering of 
monochromatic light. Inelastic scattering and insensitivity to water refers to the change 
in frequency of the photons in monochromatic light upon interaction with a sample. 
When a sample is illuminated with the monochromatic laser source, photons of the laser 
light are absorbed by the sample and then reemitted. The frequency of the reemitted 
photons is shifted up or down in comparison with original monochromatic frequency, 
referred to as the Raman effect. This Raman effect leads to two types of strong 
enhancements of the Raman signal: Resonance Raman (RR) spectroscopy and surface-
enhanced Raman spectroscopy (SERS).
(2)
 
 
Resonance Raman (RR) scattering occurs when the incident laser beam coincides with 
an optical transition of a compound leading to the population of an electronically 
excited state. RR presents significant enhancement of up to six orders of magnitude of 
the Raman signal originating principally from the Franck Condon modes (e.g. those 
distorted by the optical transition) of the compound in question.
(2, 4)
 As a result RR 
scattering can provide additional information on the chromophores being irradiated in 
an electronic transition. This technique has been used in the past to assign the MLCT 
excited states for many complexes.
(5)
 However, using this technique, fluorescence may 
prove problematic as the excitation may excite an emissive state or coincide with the 
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absorption of the molecule, creating significant fluorescence background which can 
cause significant signal interference. This problem is overcome through using for 
example, metal ligand complexes (e.g. ruthenium), where the Stokes shifts are typically 
100 – 200 nm eliminating the excitation/absorption overlapping issue. 
 
Surface Enhanced Raman Spectroscopy (SERS) is a surface sensitive technique, first 
reported in the late 1970’s by Fleischmann, Hendra and McQuillan who noted a 1014 to 
10
15
 order of magnitude enhancement via absorption of pyridine on an 
electrochemically roughened silver surface.
(6)
 Since this finding, enhancement factors in 
the order of 10
20
 have been successfully achieved and SERS has even been used in 
single molecule detection.
(7)
 It is normally performed on silver or gold substrates with 
roughened nanoscale surfaces as they can produce chemically and structurally stable 
high quality arrays with absorbance. Due to localised surface plasmons, the 
enhancement effect is generally accepted to occur through two mechanisms depending 
on the nature of interaction of analyte with the substrate; electromagnetic enhancement 
and chemical enhancement. 
 
Electromagnetic enhancement occurs when localised surface plasmons of the metal are 
excited by the incident laser leading to an increase in the electric field at the metal 
interface which subsequently enhances the electric field of the incident light. Raman 
intensities are proportional to the electric field strength enhancing the local 
electromagnetic field leading to a large enhancement of Raman signal (typically 10
4
 - 
10
10 
enhancement).
 (4)
 
 
Chemical enhancement may also occur where a molecule is chemisorbed to the metal 
surface arising from resonant enhancement of charge transfer transitions between metal 
and analyte. Chemisorption can lead to changes in the polarisability of the molecule due 
to the formation of the surface complexes with the metal. Consequently, vibrational 
modes initially forbidden in the normal Raman spectrum can be observed when the 
species is adsorbed onto a roughened metal surface, with the chemical enhancement 
providing one to two orders of magnitude enhancement. It is assumed that 
electromagnetic enhancement is the prime contributor to the SERS observation.
(4)
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Raman measurements for both chemically modified surfaces and platelet samples were 
carried out using a Peltier cooled (−70 °C) charge coupled device (CCD) camera 
(255×1024 pixels) attached to a HORIBA Jobin-Yvon Labram HR 1000 spectrometer 
coupled to a Digital Instruments Bioscope II with an inverted microscope. Samples 
were excited with a 785 nm diode laser source. The spectrometer was equipped with 
diffraction gratings of 600 grooves/ mm and the slit allowed the spectral resolution of 2 
cm
−1
.  
 
The area of the laser spot on the samples was 1 μm in diameter. The laser power at the 
sample set from 1 to 2 mW using the inbuilt laser power control. Data acquisition times 
used in the Raman experiments was 30 seconds. The Raman band of a silicon wafer at 
520 cm
−1
 was used to calibrate the spectrometer and the accuracy of the spectral 
measurement was estimated to be approximately 2 cm
−1
. The spectral data acquired 
were analysed using LabSpec software.  
 
2.3.2   Atomic Force Microscopy (AFM) 
Atomic Force microscopy, first published by Binnig, Quate and Gerber in 1986, is a 
high resolution scanning probe method designed to measure multiple properties of a 
sample including height, friction and magnetism with a nanoscale cantilever tip as 
shown in Figure 2.3. It works by measuring the changing deflections of the sharp tip. 
The AFM process involves bringing the tip as close as possible to the surface to be 
imaged. Forces from the surface applied to the tip bends the cantilever upwards. The 
amount of bending, measured by a laser spot reflected on to a split photo detector, 
allows the force to be calculated. By keeping the force constant while scanning the tip 
across the surface, the vertical movement of the tip follows the surface profile and is 
recorded as the surface topography by the AFM.
(8, 9) 
 
Although the AFM single image scan sensitivity range is smaller and scanning speed 
slower than SEM, AFM has one important main advantage over SEM: it is capable of 
imaging wet samples (does not require biological samples to be dehydrated/dried which 
is required for SEM). No pre-treatment is required eliminating possible damage to the 
sample. In addition, most AFM models can work optimally in ambient air environments 
providing perfect environments to study biological molecules and even living 
organisms.
(9)
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Figure 2.3: Diagram of basic principles of AFM. A cantilever with tip moves along as 
close as possible to the surface and experiences atomic forces. The laser and 
photodiode are utilised to measure those forces. Diagram adapted from reference 
[10].
(10)
 
 
The AFM measurements presented in this thesis were carried out using a Veeco 
Bioscope II Multimode Atomic Force Microscope with a Nanoscope III controller. 
Samples were imaged in tapping mode in air using a MikroMasch Ultrasharp 
noncontact 15 series tip with a resonant frequency of approx. 325 Khz and force 
constant of approx. 40 N/m. All images were taken at a scan rate below 0.5 Hz and at a 
512 samples/line resolution. 
 
2.3.3   Scanning Electron Microscope (SEM) 
Scanning Electron microscopy, illustrated in Figure 2.4, in contrast to conventional 
microscopy produces images (under high vacuum) via a focussed beam of high-energy 
electrons generating multiple signals at the surface of solid specimens that contain 
information about the samples surface topography and composition. SEM produces 
multiple types of signals including secondary electrons (SE) and back-scattered 
electrons (BSE). The signals result from interactions of the electron beam with atoms at 
or near the surface of the sample. In the most common or standard detection mode, SE 
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imaging, the SEM can produce very high-resolution images of a sample surface, 
revealing details less than 1 nm in size.
(11)
 
 
Back-scattered electrons (BSE) are beam electrons that are reflected from the sample 
by elastic scattering. The intensity of the BSE signal is strongly related to the atomic 
number of the specimen. Thus BSE images can provide information about the 
distribution of different elements in the sample. Characteristic X-rays are emitted when 
the electron beam removes an inner shell electron from the sample, causing a higher-
energy electron to fill the shell and release energy. These characteristic X-rays are used 
to identify the composition and measure the abundance of elements in the sample. 
 
For conventional SEM imaging, electrically conductive specimens are desired to 
prevent the accumulation of electrostatic charge at the surface. Nonconductive 
specimens charge when scanned by the electron beam, especially in SE imaging mode 
which can interfere with image quality. Therefore coating the species with an ultrathin 
coating of electrically conducting material (e.g. gold) through for example, low-
vacuum sputter coating is usually required for optimum results. In addition, SEM 
suffers the inability to examine samples in wet conditions. Thus the investigation of 
biological materials, e.g. cells is limited. However, for such samples, common 
dehydration methods do exist such as air drying after alcohol dehydration, critical point 
drying and hexamethyldisilazane (HMDS) drying.
7
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Figure 2.4: A schematic representation of SEM. Display image represents an example 
of a 5.4µm microcavity array prepared as part of this thesis. Schematic adapted from 
reference [12].
(12) 
 
This thesis employed conventional SEM imaging on gold planar surfaces and 
microcavity arrays. Alcohol dehydration was carried out to investigate the topography 
and composition of platelet binding to all gold modified surfaces. Bound platelets were 
dehydrated (described Chapter 5, section 5.1.8), sputter-coated with a thin layer of gold 
(~30 nm thick) and imaged using a Hitachi S3400n SEM, Tungsten system instrument. 
All images were collected using identical conditions at 5.00 kV accelerating voltage 
unless otherwise stated. 
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Chapter 3: Synthesis and Characterisation of 
Ruthenium(II) Polypyridyl Luminophores 
and Luminophore-Peptide Conjugates  
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Glossary: Ruthenium(II) Polypyridyl Luminophores 
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3.0   Introduction 
Transition metal complexes have many advantages over traditional organic 
fluorophores; large Stokes shift, long luminescent lifetimes and enhanced photo-
stability. Moreover, the emission maxima of ruthenium complexes are observed in the 
region of 600-700 nm which is outside of interfering auto-fluorescence.
 
In addition, 
transition metal complexes offer synthetic flexibility where by changing the ligands can 
be used to tune the absorption and emission characteristics of the complex and the 
environmental sensitivity e.g. toward oxygen or pH. 
 
Transition metals centres are particularly attractive moieties for DNA studies as they 
exhibit well defined coordination geometries and possess distinctive photophysical 
properties enhancing their application as DNA binding agents. The first studied 
ruthenium DNA binding complex was [Ru(phen)3]
2+
.
(1-3)
 However, the exact binding 
mechanism between [Ru(phen)3]
2+ 
and DNA remains unclear.
(1-4)
 
 
Ruthenium complexes employing a dipyrido[3,2-a:2′,3′-c]phenazine, (dppz), ligand 
have excelled in research due to their molecular “light-switch” nature, only emitting in 
aprotic environments such as DNA
(5,6)
 and aprotic solvents
(7)
, Figure 3.1. Pioneering 
work by Barton and Sauvage presented [Ru(bpy)2dppz]
2+
 as an improvement on the 
previous [Ru(phen)3]
2+
 DNA probe.
(5,8)
 [Ru(bpy)2dppz]
2+
 is non-emissive in aqueous 
buffer solution but intercalates between the bases of DNA, protecting it from quenching 
by hydrogen bonding, thus increasing the emission intensity of the dppz containing 
complex. The increased stacking area of the DPPZ ligand compared to phenanthroline, 
increases the affinity for DNA by a minimum of three orders of magnitude relative to 
[Ru(phen)3]
2+
.  
 
Shortly after the development of [Ru(bpy)2dppz]
2+
, substituting the bipyridines (bpy) 
with phenanthrolines (phen=1,10-phenanthroline) presented identical “light-switch” 
properties in the presence of DNA.
(6,9)
 Consequently, DNA binding and spectroscopic 
properties of numerous structural analogues of the two prototype complexes have since 
been studied intensively in aid of advancing dppz-based complexes as useful reporter 
molecules for DNA.
(9-11) 
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Figure 3.1: Chemical structure of [Ru(phen)2(dppz)]
2+
 and photophysics in aqueous 
(H2O) and non-aqueous (CH3CN) media.
(7)  
 
It is evident that [Ru(bpy)2dppz]
2+
 and [Ru(phen)2dppz]
2+
 binding occurs in an 
intercalative manner.
(5,6,12,13)
 In addition, the comparable binding geometry of 
[Ru(phen)2(dppz)]
2+
 to actinomycin D suggests that the metal complex is also bound 
from the DNA minor groove.
(12)  
Most recently, using combined analysis of calorimetric 
and photophysical data, two intercalation geometries of  the binding of the synthetic 
polynucleotide, [poly(dAdT)]2, to pure Δ and Λ enantiomers of [Ru(phen)2dppz]
2+
 and 
[Ru(bpy)2dppz]
2+
 has been reported.
(14)
 Two emission lifetimes were presented; the 
short lifetimes were attributed to complexes centred in the intercalation pocket while the 
long lifetime were suggested to arise from a canted binding geometry found only at the 
ends of contiguous sequences of bound ligands. It is suggested that both repulsive 
interligand and favourable DNA backbone interactions modulated by allosteric changes 
in DNA conformation accounts for the simultaneous cooperative and anti-cooperative 
features of the binding, resulting in predominant formation of only short contiguous 
sequences of bound ligands. This suggests that although the dppz moiety is important 
for introducing intercalation properties to metal polypyridyl complexes, the ancillary 
ligands also inﬂuence the binding characteristics of these complexes, thus disproving 
current literature assumptions that phen and bpy complexes can be used interchangeably 
in DNA binding studies. 
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Biological applications of dppz containing ruthenium complexes have been limited to 
DNA and direct protein binding. Introducing specificity to the complex via peptides or 
alternative targets will broaden its use in research which our research group and 
Barton’s group have started to investigate.(15,16)  Consequently, one of the aims of this 
chapter was to synthesise the “light-switching” [Ru(dppz)2]Cl2 starting material and 
through the functionalities presented in Figure 3.2, introduce protein targeting via 
attachment of the αIIbβ3 integrin specific head binding arginine-glycine-aspartic acid 
(RGD) peptide sequence. 
 
    X = COOH = [Ru(dppz)2PIC-COOH]
2+
 
    
X
 
= NHS = [Ru(dppz)2PIC-NHS]
2+ 
 
 
 
 
  
 
  
 
Figure 3.2:  Chemical structure of dppz containing ruthenium(II) polypyridyl complexes 
synthesised as part of this thesis. 
 
Ruthenium complexes employing the tris(4,7-diphenyl-1,10-phenanthroline), dpp 
ligand, first introduced by Turro et al.
(17)
 in 1985, is another ruthenium based 
fluorophore of choice in DNA binding studies as it is a well known luminescent dye 
quenched dynamically by oxygen. The long lifetime of this ruthenium based probe 
extends the reach of other time-resolved techniques, e.g. anisotropy 
(18-20)
 and the ability 
to analyse longer lived biodynamics that cannot be investigated by the short lived 
organic probes e.g. membrane diffusion.
(21)
  
 
For example, Szmacinski et al.
(18)
 reported the synthesis of a range of dpp containing 
ligands to have a lifetime range of from 345 ns to 3.8 µs in deoxygenated aqueous 
solutions under a variety of conditions and allowed measurements of rotational 
correlation times up to 7.5 µs, more than 3 fold times greater than those previously 
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reported by the same group. [Ru(dpp)2(mcbpy)]
2+
, Figure 3.3, had a lifetime of 
approximately 2 µs when bound to human serum albumin (HSA) which allowed the 
measurement of rotational correlation times up to 8 µs.
(22)
 
 
Figure 3.3: (Top) Structure of [Ru(dpp)2(mcbpy)]
2+
, (Bottom) Intensity decays of 
[Ru(dpp)2(mcbpy)]
2+
 covalently bound to HSA (Ru–HSA) and the free form in the 
absence and presence of HSA in deoxygenated aqueous solutions. 
b 
values in brackets 
are the mean lifetimes in air equilibrated solutions.
(18)
 
 
Thus the second aim of this chapter was to synthesise the oxygen sensitive 
[Ru(dpp)2]Cl2 starting material and through the functionalities presented in Figure 3.4 
introduce specificity via attachment of the αIIbβ3 integrin specific head binding peptide 
SHC-Ahx-GRGDS (for cysteine to maleimide conjugation) and NH2G-Ahx-GRGDS (for 
amine to NHS conjugation). 
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     X = NO2 = [Ru(dpp)2PIC-NO2]
2+ 
    X = NH2= [Ru(dpp)2PIC-NH2]
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    X = Mal = [Ru(dpp)2PIC-maleimide]
2+ 
    X = COOH = [Ru(dpp)2PIC-COOH]
2+ 
    
X
 
= NHS = [Ru(dpp)2PIC-NHS]
2+ 
 
 
 
 
 
 
 
Figure 3.4:  Chemical structure of dpp containing Ru(II) polypyridyl complexes 
synthesised as part of this thesis. 
 
One of the most widely studied Ru(II) complexes is [Ru(bpy)3]
2+
 (where 
bpy=bipyridine). [Ru(bpy)2PIC-COOH]
2+
, like all other bpy containing ruthenium 
complexes has long aqueous lifetimes (>800 ns), large Stokes shifts, and good 
photostability promoting them as attractive luminophores biologically. In addition, bpy 
containing ruthenium complexes are exceptionally water soluble with increased 
emission in water strengthening its advantages for biological applications. Its 
photophysical properties and conjugation to biomolecules, such as polypeptides has 
been reported by many including our group.
(5,15,23)
 Thus the third aim of this chapter 
was to synthesise the highly water soluble [Ru(bpy)2]Cl2, Figure 3.4 [Ru(bpy)2]Cl2 
provides the flexibility of the attachment of a range of ligands. The attachment of 
functional groups such as the carboxyl functionality may be used to conjugate the 
luminophore to amino groups located on proteins or peptides as shown previously by 
our group and is also applied as part of this chapter.
(24,25)
 In this thesis, the widely 
published DCC/NHS coupling technique was implemented as the cross-linking agent 
for attachment to the αIIbβ3 head specific peptide sequence, NH2G-Ahx-GRGDS.
(26,27)
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                         X= COOH = [Ru(bpy)2PIC-COOH]
2+
 
           X = NHS = [Ru(bpy)2PIC-NHS]
2+ 
  
 
 
 
 
 
Figure 3.5:   Chemical structure of bpy containing Ru(II) polypyridyl complexes 
synthesised as part of this thesis. 
 
3.0.1   Ruthenium Conjugated Probes 
Direct conjugation of ruthenium complexes to biological species is widely 
reported.
(5,15,25)
 For example, Ryan et al.
(28) 
successfully conjugated a range of proteins 
to a series of ruthenium polypyridyl complexes confirming binding using steady-state 
spectroscopic measurements. In 1994, DeGraff et al.
(29)
 reported the first measurement 
of rotational correlation times for a series of Ru(II) complexes demonstrating the 
potential of ruthenium complexes as probes for slow dynamic processes that can occur 
in macromolecular systems. Since then many groups have directly conjugated 
ruthenium complexes to proteins including Kang et al.
(30)
 who successfully conjugated a 
ruthenium probe to immunoglobulin G (IgG) and immunoglobulin M (IgM), monitored 
the rotational diffusion and compared the anisotropy of each protein. This group 
strengthened the suggestion that ruthenium conjugates may be successful probes for the 
investigation of protein hydrodynamics.   
 
Metal complexes have been previously applied to cellular imaging
(31,32)
, but in a limited 
way because they generally do not cross the membrane spontaneously. In 2008, for the 
first time, our group successfully created a cell permeable ruthenium complex (Ru-Ahx-
R8) which could be used to measure O2 concentration inside live cells.
(24)
 More recently, 
our ruthenium polypyridyl labelled cell penetrating peptide [Ru(dppz)2PIC-Arg8]
10+
 
showed successful passive transport of the complex across the cell membrane.
(15)
 
 
N
N
Ru
N
N
N
N N
H
N
X
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As mentioned, investigating the idea of producing peptide targeting ruthenium 
complexes has become of interest to our laboratory in recent times. Most recently our 
group reported nuclear targeted delivery of live mammalian cells by a nuclear 
localisation signal (NLS) peptide; NF-κB via the synthesis of two ruthenium complexes 
[Ru(dpp)2PIC-βAla-NF-κB]
6+
 and [Ru(bpy)2PIC-βAla-NF-κB]
6+
.
(33)
 Both conjugates 
(40 µM, 16 hours incubation at 37 °C) successfully penetrated the nuclear membrane 
and localised within the nucleus unlike the parent complex or cell permeable complexes 
bound to octaarginine peptides discussed earlier. As ruthenium polypyridyl complexes 
have a widely reported strong interaction with DNA and their ability to induce 
photocleavage, the novel presentation of targeted delivery of such complexes to the 
nucleus provides an important step toward the therapeutic/clinical applications of these 
complexes. 
 
Barton et al.
(34)
 also reported the conjugation of  [Ru(phen)(bpy)(dppz)]
2+ 
to cell 
penetrating peptides such as D-octaarginine to increase uptake efficiency, but lead to 
trapping in endosomes below a threshold concentration (below 20 µM). At 20 µM or 
above, substantial staining of the nucleus and cytosol was observed. The shorter nuclear 
targeting signal peptide, RrRK  (where r = D-arginine), was also studied and was found 
to have a lower degree of uptake and higher threshold concentration (100 µM) 
compared to the octaarginine conjugate, consequently increasing the cytotoxicity of this 
target dye towards cells.
(16) 
The studies presented by our group and Barton’s group 
provide a basis for the future design and optimization of metal complexes for biological 
application. 
 
In conclusion, although ruthenium has been fairly widely used in direct conjugation of 
proteins and DNA, ruthenium-peptide targets for the investigation of specific 
interactions with proteins to our knowledge has not yet been reported.
 
Here, reported for 
the first time, the head specific αIIbβ3 integrin peptide sequences C-Ahx-GRGDS and G-
Ahx-GRGDS conjugated to [Ru(dpp)2PIC-Maleimide]
2+
, [Ru(dpp)2PIC-NHS]
2+
 and 
[Ru(bpy)2PIC-NHS]
2+
 is presented. All inorganic dyes synthesised were fully 
characterised by NMR and high resolution mass spectrometry (HR-MS). 
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3.1   Experimental Procedure 
Chemicals 
All chemicals were purchased from Sigma Aldrich and used without any further 
purification unless otherwise stated. Cysteine (-SH) terminated C-Ahx-GRGDS and 
amine (-NH2) terminated G-Ahx-GRGDS peptides were supplied by Celtek Peptides 
unless otherwise stated. All commercial peptide identity and purity was manufacturer 
guaranteed and confirmed by MALDI-TOF-MS and HPLC, see Appendix 1. All 
reactions were performed in air unless otherwise stated. ESI-MS and MALDI-TOF were 
measured by the CSCB facility in University College Dublin (UCD), Ireland. All 
instrumentation used is described in Chapter 2.
 1
H NMR spectra were recorded on a 
Brüker AC 400 MHz spectrometer using deuterated DMSO-d6 as solvent for 
homonuclear lock. Peak positions are relative to TMS (0 ppm chemical shift).  All NMR 
spectra were analysed using Topspin NMR software. 
 
3.1.1   Ligand Synthesis 
The molecular structure of all ligands used in this thesis is presented in Figure 3.6. 
N
N N
H
N
COOH
N
N N
H
N
NO2
N
N N
H
N
NH2
 
 PIC-COOH   PIC-NO2   PIC-NH2 
N
NN
N
         
N
N
 
 dppz    dpp 
Figure 3.6: Chemical structure of 2-(4-carboxyphenyl)imidazo[4,5-f][1,10 phenanthro 
line (PIC-COOH),2-(4-nitrophenyl)imidazo[4,5f][1,10]phenanthroline (PIC-NO2), 2-(-
4aminphenyl)imidazo[4,5f][1,10]phenanthroline (PIC-NH2), 4,7-Diphenyl-1,10-phenan 
throline (dpp) and dipyrido[3,2-a:2′,3′-c]phenazine (dppz). 
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Synthesis of 2-(4-carboxyphenyl)imidazo[4,5-f][1,10]phenanthroline:            
(PIC-COOH) 
N
N
O
O
Phendione
+
HO
O H
4-carboxybenzaladehyde
N
N N
H
N
COOH
2-(4-carboxylphenyl)imidazo[4,5.f][1,10]phenanthroline
CH3COONH4 / CH3COOH
Reflux 160oC 3 hours
 
Scheme 3.1: Synthesis reaction scheme for the preparation of 2-(4-carboxy 
phenyl)imidazo[4,5-f][1,10]phenanthroline: (PIC-COOH). 
 
The compound was synthesised according to a method modified from literature.
(24)
   
0.42 g (2 mmol) of 1,10-phenanthroline5,6-dione (phendione), 0.36 g (2.4 mmol) of 4-
carboxybenzaldehyde and 3.08 g (40 mmol) of ammonium acetate (CH3COONH4) were 
refluxed in 50 ml glacial acetic acid (CH3COOH) at 160°C for 3 hours. The solution 
was allowed to cool to room temperature.  The addition of water aided precipitation.   
 
The solid was filtered and washed with cold water, methanol and diethyl ether.  The 
material was lyophilised to yield the ligand as a yellow solid (0.54 g, 79%).  Molecular 
weight: 340.33 g/mol. 
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 13.96 (s, 1H), 13.04 (s-broad, 1H), 9.06 (d, 
2H), 8.95 (d, 2H, J = 8 Hz), 8.42 (d, 2H, J = 8.4 Hz), 8.19 (d, 2H, J = 8 Hz), 7.88 (d, 2H, 
J = 13.2 Hz).  
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Synthesis of 2-(4-nitrophenyl)imidazo[4,5-f][1,10]phenanthroline: (PIC-NO2)  
N
N
O
O
Phendione
+
NO2
O H
4-nitrobenzaladehyde
N
N N
H
N
NO2
2-(4-nitrophenyl)imidazo[4,5.f][1,10]phenanthroline
CH3COONH4 / CH3COOH
Reflux 160oC 3 hours
 
Scheme 3.2: Synthesis reaction scheme for the preparation of 2-(4-nitrophenylimidazo 
[4,5-f][1,10]phenanthroline: (PIC-NO2). 
 
 0.20 g (1 mmol) of 1,10-phenanthroline5,6-dione, 0.17 g (1 mmol) of 4-
nitrobenzaldehyde and 1.47 g (19 mmol) of ammonium acetate (CH3COONH4) were 
refluxed in 15 ml glacial acetic acid glacial acetic acid (CH3COOH) at 130°C for 5 
hours. The solution was allowed to cool to room temperature.  The addition of water 
aided precipitation.   
 
The solid phases were filtered and washed with cold water, methanol and dried with 
diethyl ether.  The material was lyophilised to yield the ligand as a yellow solid (0.25 g, 
80%).  Molecular weight: 341.32 g/mol. 
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 9.06 (dd, 2H, J = 1.6 Hz, J = 1.6 Hz), 8.95 
(dd, 2H, J = 1.6 Hz, J = 1.6 Hz), 8.55 (q, 4H, J = 9.2 Hz, J = 10.4 Hz, J = 9.2 Hz), 7.88 
(m, 2H). 
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Synthesis of 2-(4-aminophenyl)imidazo[4,5-f][1,10]phenanthroline: (PIC-NH2)   
N
N N
H
N
NH2
2-(4-aminophenyl)imidazo[4,5.f][1,10]phenanthroline
N
N N
H
N
NO2
2-(4-nitrophenyl)imidazo[4,5.f][1,10]phenanthroline
EtOH / N2H4 / 5% Pd/C
Reflux 100oC 4 hours
 
Scheme 3.3: Synthesis reaction scheme of 2-(4-aminophenyl)imidazo[4,5-f][1,10] 
phenanthroline: (PIC-NH2).  
 
0.25 g (0.7 mmol) of 2-(4-nitrophenyl)imidazo[4,5-f][1,10]phenanthroline  (PIC-NO2), 
0.05 g (0.43 mmol) of palladium 5% weight on activated carbon (Pd/C) and 177 μl 
(5.67 mmol ) of hydrazine hydrate (N2H4) were refluxed in 20 ml absolute ethanol 
(EtOH) at 100°C for 4 hours.  The solution was left in the fridge overnight.   
 
The solution was filtered through celite which was compacted with dichloromethane: 
methanol solution and the filtrate evaporated to dryness.  The material was lyophilised 
to yield the ligand as a yellow solid (0.14g, 65%).  Molecular weight: 311.34 g/mol. 
 
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 13.31 (s, 1H), 9.00 (d, 2H, J = 1.6 Hz), 8.89 
(d, 2H, J = 1.6 Hz), 7.97 (d, 2H, J = 8.8 Hz), 7.8 (s, 2H), 6.74 (d, 2H, J = 8.4 Hz), 5.64 
(s, 2H). 
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Synthesis of dipyrido[3,2-a:2’,3′-c]phenazine: (dppz) 
 
N
N
O
O
Phendione
MeOH
Reflux, 4h 160oC
N
N N
NNH2
NH2
1,2 Phenylenediamine Dipyrido[3,2-a:2',3'-c]phenazine  
Scheme 3.4: Synthesis reaction scheme of dipyrido[3,2-a:2′,3′-c]phenazine: (dppz). 
 
The compound was synthesised according to a method modified from the literature.
(15)
 
0.29 g (1.4 mmol) of phendione and 0.15 g of 1,2phenylenediamine (1.4 mmol) were 
added to approximately 20 ml of methanol (MeOH) and refluxed for 3- 4 hours, after 
which a powder suspension formed. This suspension was vacuum filtered on a glass frit 
and washed with MeOH and dried with diethyl ether yielding the ligand as pale 
yellow/cream solid (0.29 g, 67 %). Molecular Weight: 282.09 g/mol. 
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 9.50 (dd, 2H, J = 1.6 Hz), 9.21 (dd, 2H, J = 
1.6 Hz), 8.38 (m, 2H, J = 2.4 Hz, J = 3.2 Hz), 8.07 (m, 2H, J = 2.8 Hz, J = 3.2 Hz), 7.95 
(m, 2H, J = 4.4 Hz, J = 3.6 Hz). 
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3.1.2   Ruthenium(II) Polypyridyl Luminophore Synthesis 
Synthesis of Ruthenium(II)-(bis-4,7-diphenyl-1,10-phenanthroline)dichloride:   
[Ru(dpp)2]Cl2
N
N
Ru
N
N
Cl
Cl
NN
DMF under N2
Reflux at 200oC,4-6 h
RuCl3.3H20
4,7-Diphenyl-1,10-phenanthroline
Ruthenium(bis4,7diphenyl1,10phenanthroline)
dichloride
Scheme 3.5: Synthesis reaction scheme of ruthenium(II)-(bis-4,7-diphenyl-1,10-phenan 
throline)dichloride:[Ru(dpp)2]Cl2. 
 
0.10 g (0.38 mmol) of ruthenium(III) chloride trihydrate (RuCl3.3H2O), 0.25 g (0.76 
mmol) of 4,7-diphenyl-1,10-phenanthroline (dpp) and 0.11 g (2.66 mmol) of lithium 
chloride (LiCl) were dissolved separately in 20 ml aliquots of anhydrous N, N-
dimethylformamide (DMF) and degassed for 15-20 minutes. Ruthenium and dpp were 
added to a 100 ml round-bottomed flask and allowed stir at 100°C for 15 minutes. LiCl 
was added drop-wise over a 20 minute period. The solution mixture was refluxed at 
200°C under nitrogen (N2) until the reaction turned dark purple (4-6 hours).   
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. The material was lyophilised to yield a dark purple 
solid (0.20g, 63%).   Molecular weight: 836.77 g/mol. 
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 10.42 (d, 2H, J = 6 Hz), 8.26 (dd, 2H, J = 12 
Hz), 8.07 (dd, 2H, J = 6 Hz), 7.86 (d, 2H, J = 10.8 Hz), 7.74 (m , 3H, J =12 Hz ), 7.56 
(m, 5H, J = 12 Hz), 7.40 (d, 1H) 
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Synthesis of Ruthenium(II)(bis-4,7-Diphenyl-1,10-phenanthroline)- 
2(4nitrophenyl)imidazo[4,5-f][1,10]phenanthroline: [Ru(dpp)2PIC-NO2]
2+
 
N
N
Ru
N
N
Cl
Cl
N
N N
H
N
NO2
EtOH/H2O reflux
48h
2-(4-nitrophenyl)imidazo[4,5-
f][1,10]phenanthroline
Ruthenium-(bis-4,7-diphenyl-1,10-
phenanthroline)dichloride
N
N
Ru
N
N
N
N N
H
N
NO2
Ruthenium-(bis-4,7-diphenyl1,10phenanthroline)-2-(4-
nitrophenyl) imidazo [4,5-f] [1,10]phenanthroline.  
Scheme 3.6: Synthesis reaction scheme of ruthenium(II)(bis-4,7-diphenyl-1,10 
phenanthroline)-2(4-nitrophenyl)imidazo[4,5-f][1,10]phenanthroline:  
[Ru(dpp)2PIC-NO2]
2+
. 
 
0.20 g (0.23 mmol) of ruthenium-(bis-4,7-diphenyl-1,10-phenanthroline)dichloride 
(Ru(dpp)2Cl2) and 0.07 g (0.22 mmol) of 2-(4-nitrophenyl)imidazo[4,5f] 
[1,10]phenanthroline (PIC-NO2) were refluxed in 30 ml ethanol:water (1:2) at 100°C 
over 48 hours.  Lithium perchlorate (LiClO4
-
)
 
solution was added to aid precipitation.   
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. The material was lyophilised to yield an orange 
solid (0.22g, (94%).  (HR-ESI-MS): molecular weight calculated: 1106.26 m/z (M
+
), 
observed 1106.25 m/z (M
+
). 
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm)  9.14 (d, 2H, J = 8 Hz), 8.59 (m, 2H, J = 8.8 
Hz), , 8.34 (d, 2H, J = 5.2 Hz), 8.26 (d, 4H, J = 10.8 Hz), 8.18 (d, 2H, J = 4 Hz), 7.91 
(m, 2H, J = 6 Hz), 7.82 (d, 2H, J = 5.6 Hz), 7.76 (d, 2H, J = 5.6 Hz), 7.63 (m, 24H) 
Synthesis of Ruthenium(II) (bis-4,7-diphenyl-1,10-phenanthroline)- 
2(4aminophenyl)imidazo[4,5-f][1,10]phenanthroline: [Ru(dpp)2PIC-NH2]
2+
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N
N
Ru
N
N
Cl
Cl
N
N N
H
N
NH2
EtOH/H2O reflux
48h
2-(4-aminophenyl)imidazo[4,5-
f][1,10]phenanthroline
Ruthenium-(bis-4,7-diphenyl-1,10-
phenanthroline)dichloride
N
N
Ru
N
N
N
N N
H
N
NH2
Ruthenium-(bis-4,7-diphenyl-1,10-phenanthroline)-2-(4-
aminophenyl)imidazo[4,5-f] [1,10]phenanthroline.  
Scheme 3.7: Synthesis reaction scheme of ruthenium(II) (bis-4,7-diphenyl-1,10-
phenanthroline)-2(4-aminophenyl)imidazo[4, 5-f] [1, 10] phenanthroline:  
[Ru(dpp)2(PIC-NH2)]
2+
. 
 
0.15 g (0.17 mmol) of ruthenium-(bis-4,7-diphenyl-1,10-phenanthroline)dichloride 
(Ru(dpp)2Cl2) and 0.06 g (0.20 mmol) of 2-(4-aminophenyl)imidazo[4,5f][1,10] 
phenanthroline (PIC-NH2) were refluxed in 25 ml ethanol:water (1:2) at 100°C over 48 
hours. LiClO4
- 
solution was added to aid precipitation.   
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. The material was lyophilised to yield a dark orange 
solid (0.09g, 53%).  (HR-ESI-MS): molecular weight calculated: 1076.29 m/z (M
+
), 
observed 1076.18 m/z (M
+
). 
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 9.09 (d, 2H, J = 8 Hz), 8.34 (d, 2H, J = 5.6 
Hz), 8.26 (m, 4H), 8.14 (d, 2H, J = 4.8 Hz), 8.01 (d, 2H, J = 8.4 Hz), 7.88 (m, 2H), 7.82 
(d, 2H, J = 5.2 Hz), 7.76 (d, 2H, J = 5.6 Hz ), 7.61 (m, 24H), 6.76 (d, 2H, J = 8.8 Hz) 
Synthesis of Ruthenium(II) (bis-4,7-diphenyl-1,10-phenanthroline)-2(4carboxy 
phenyl)imidazo [4,5-f][1,10]phenanthroline: [Ru(dpp)2PIC-COOH]
2+
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Ruthenium(bis-4,7-diphenyl-1,10-
phenanthroline)dichloride
N
N
Ru
N
N
 
N
N N
H
N
COOH
EtOH/H2O reflux
48h
2-(4-carboxylphenyl)imidazo[4,5-
f][1,10]phenanthroline
N
N
Ru
N
N
N
N N
H
N
COOH
Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4-
carboxyphenyl)imidazo[4,5-f] [1,10]phenanthroline
 
Scheme 3.8: Synthesis reaction scheme of ruthenium(II)(bis-4,7-diphenyl-1,10-
phenanthroline)-2(4-carboxyphenyl)imidazo[4,5-f][1,10]phenanthroline:  
[Ru(dpp)2(PIC-COOH)]
2+
. 
 
0.20 g (0.23 mmol) of ruthenium(II)-(bis-4,7-diphenyl-1,10-phenanthroline)dichloride 
(Ru(dpp)2Cl2) and 0.095 g (0.30 mmol) of 2-(4-carboxylphenyl)imidazo[4,5f][1,10] 
phenanthroline (PIC-COOH) ligand was refluxed in 30 ml ethanol:water (1:2) at 100°C 
for 48 hours. LiCLO
4-
 solution was added to aid precipitation.   
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent.  The material was lyophilised to yield an orange 
solid (0.15 g, 59%).   
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 9.12 (d, 2H, J = 8.4 Hz ), 8.44 (d, 2H, J = 8.4 
Hz ), 8.32 (d, 2H, J = 5.6 Hz ), 8.24 (m , 3H), 8.15 (dd, 2H J = 8 Hz), 7.87 (t, 2H, J = 
5.6 Hz), 7.79 (d, 2H, J = 5.2 Hz ), 7.74 (d, 2H, J = 5.6 Hz ), 7.61 (m, 24H). 
13
C NMR 
(DMSO-d6): 25.72, 67.61, 126.61, 127.10, 128.69, 128.75, 129.76, 130.27, 120.48, 
130.57, 136.02, 136.06, 145.85, 148.43, 148.54, 148.66. (HR-ESI-MS): molecular 
weight calculated: 1105.27 m/z (M
+
), observed 1105.25 m/z (M
+
). 
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Synthesis of Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4-N-hydroxyl 
succinimidylphenyl)imidazo[4,5-f][1,10]phenanthroline:  
[Ru(dpp)2PIC-NHS]
2+
 
N
N
Ru
N
N
N
N N
H
N
COOH
Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4-
carboxyphenyl)imidazo[4,5-f] [1,10]phenanthroline                                               
N
N
Ru
N
N
N
N N
H
N O
O
N
O
O
Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4-N-hydroxy
succinimidylphenyl)imidazo[4,5-f] [1,10]phenanthroline  
Scheme 3.9: Synthesis reaction scheme of ruthenium(II)(bis-4,7-diphenyl-1,10-
phenanthroline)-2(4-N-hydroxysuccinimidylphenyl)imidazo[4,5f][1,10]phenanthroline: 
[Ru(dpp)2PIC-NHS]
2+
. 
 
0.20 g (0.23 mmol) of ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4carboxy 
phenyl)imidazo[4,5-f][1,10]phenanthroline ([Ru(dpp)2PIC-COOH]
2+
),  0.05 g (0.43 
mmol) of N-Hydroxysuccinimide (NHS) and 0.08 g (0.38 mmol) of N,N'-
dicyclohexylcarbodiimide (DCC) were dissolved in 30 ml anhydrous acetonitrile 
(MeCN) and allowed stir at room temperature for 4-6 hours.   
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. The material was lyophilised yielding an 
orange/red solid (0.21g, 75%).   
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 9.14 (d, 2H, J = 8 Hz), 8.57 (d, 2H, J = 8.4 
Hz ), 8.38 (2, 2H, J = 5.6 Hz), 8.32 ( d, 2H, J = 5.2 Hz), 8.25 (m , 3H), 8.18 (dd, 2H J = 
8 Hz), 7.94 ( t, 2H, J = 6.4 Hz), 7.80 (d, 2H, J = 5.6 Hz), 7.75 ( d, 2H, J = 5.2 Hz), 7.61 
(m, 24H).
 13
C NMR (DMSO-d6): 24.43, 25.19, 25.72, 25.51, 33.31, 47.46, 128.05, 
128.12, 129.15, 129.67, 129.86, 129.94, 135.42, 147.93, 148.00, 156.57, 170.298, 
172.79. (HR-ESI-MS): 1202.5062 m/z observed, 1203.2795 m/z calculated. 
 
 
 
N C N
N,N'-dicyclohexylcarbodiimide
                  (DCC)
N OH
O
O
N-hydroxysuccinimide
           (NHS)
Anhydrated MeCN
Stirred at room 
temp for 24 h
+ 
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Synthesis of Ruthenium(II) (-bis-4,7-diphenyl-1,10-phenanthroline)-2(4-maleimido 
lphenyl)imidazo[4,5-f][1,10]phenanthroline: [Ru(dpp)2PIC-Maleimide]
2+       
                           
N
N
Ru
N
N
N
N N
H
N O
O
N
O
O
N
O
O
NH2
Anhydrated MeCN
   DIPEA/DCM
Stirred at room temp for 48 h
N
N
Ru
N
N
N
N N
H
N O
HN
N
O
O
Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4-N-hydroxy
succinimidylphenyl)imidazo[4,5-f] [1,10]phenanthroline
N-(2-aminoethyl)maleimide
Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4maleimidolphenyl)
imidazo[4,5-f] [1,10]phenanthroline
 
Scheme 3.10: Synthesis reaction scheme of ruthenium(II)(bis-4,7-diphenyl-1,10 
phenanthroline)-2(4maleimidolphenyl)imidazo[4,5-f][1,10]phenanthroline:  
[Ru(dpp)2-PIC-Maleimide]
2+
. 
 
0.20 g (0.16 mmol) of ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4-N-
hydroxysuccinimidylphenyl)imidazo[4,5-f][1,10]phenanthroline, [Ru(dpp)2PIC-NHS]
2+ 
, 0.09 g (0.33 mmol) of 2-aminoethylmaleimide and 300 μl N,N-diisopropylethylamine 
(DIPEA) were dissolved in 8 ml dichloromethane and 2 ml anhydrous MeCN and 
stirred at room temperature for 48 hours.  
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. The material was lyophilised yielding an 
orange/red solid (0.18g, 92%). (HR-ESI-MS): molecular weight calculated, 1228.31 m/z 
(M
+
), observed 1228.14 m/z (M
+
) 
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 9.22 (dd, 2H, J = 8.4 Hz, 7.6 Hz), 8.43 (d, 
2H, J = 8.4 Hz), 8.35 (d, 2H, J = 5.2 Hz ), 8.28 (m, 6H), 8.04 (d, 2H, J = 8.4 Hz), 7.98 
(m, 2H), 7.83 (d, 2H, J = 5.6 Hz ), 7.77 (t, 2H, J = 4.8 Hz), 7.68 (m, 24H), 7.04 (s, 2H, J 
= 8 Hz). 
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Synthesis of Ruthenium(II)(bis-dipyrido[3,2-a:2′,3′-c]phenazine)dichloride: 
[Ru(dppz)2]Cl2  
N
N
N
N
Ru
N
N
N
N
Cl
Cl
Ruthenium(II)(bis-dipyrido [3,2-a:2',3'-c] 
phenazine) dichloride
RuCl3.3H2O
N
N N
N
Dipyrido [3,2-a:2',3'-c]phenazine
DMF under N2
Reflux at 200oC,4-6h
Scheme 3.11: Synthesis reaction scheme of ruthenium(II)(bis-dipyrido[3,2-a:2′,3′c] 
phenazine)dichloride: [Ru(dppz)2]Cl2. 
 
 The compound was synthesised according to a method modified from the literature.
(15)
  
0.20 g (0.76 mmol) of RuCl3.3H2O, 0.43g (1.5mmol) of dipyrido[3,2-a:2′,3′-c] 
phenazine (dppz) and 1.7 g (40 mmol) of LiCl were dissolved separately in 5 ml 
aliquots of degassed anhydrous DMF (15 ml total). Ruthenium and dppz were added to 
a 100 ml round-bottomed flask and allowed stir at 100°C for 15 minutes. LiCl was 
added drop-wise over a 20 minute period. The solution mixture was refluxed at 200°C 
under N2 until the reaction turned dark purple (4-6 hours).   
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. The material was lyophilised to yield a dark purple 
solid (0.22 g, 39%). Molecular weight: 736.57 g/mol. 
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 9.55 (d, 2H, J = 8 Hz), 9.21 (d, 2H, J = 4 Hz), 
8.41 (m, 2H, J = 4 Hz, J = 3.6 Hz), 8.08 (m, 2H, J = 3.6 Hz) 7.95 (m, 10H), 7.72 (m, 
2H, J = 4.8 Hz). 
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Synthesis of Ruthenium(II)(bis-dipyrido[3,2-a:2′,3′-c]phenazine)-2(4carboxyphen 
yl)imidazo[4,5-f][1,10]phenanthroline: [Ru(dppz)2PIC-COOH]
2+
 
N
N
N
N
Ru
N
N
N
N
Cl
Cl
N
N N
H
N
COOH
EtOH/H2O reflux
48h
2-(4-carboxylphenyl)imidazo[4,5-
f][1,10]phenanthroline
N
N
N
N
Ru
N
N
N
N
N
N N
H
N
COOH
Ruthenium(II)(bis-dipyrid0[3, 
2-a:2',3'-c]phenazine) 
dichloride.
Ruthenium(II)(bis-dipyrido [3,2-a:2',3'-c]phenazine)
-2(4-carboxyphenyl)imidazo[4,5-f] [1,10]phenanthroline
 
Scheme 3.12: Synthesis reaction scheme of ruthenium(II) (bis-dipyrido[3,2-a:2′,3′c] 
phenazine)-2(4-carboxyphenyl)imidazo[4,5-f][1,10]phenanthroline: 
[Ru(dppz)2(PIC-COOH)]
2+
. 
 
 
The compound was synthesised according to a method modified from the literature.
(15)
 
0.05 g (0.07 mmol) of ruthenium(II)(bis-dipyrido[3,2-a:2′,3′-c]phenazine)dichloride, 
[Ru(dppz)2]Cl2 and 0.03 g (0.09 mmol) of 2-(4-carboxylphenyl)imidazo[4,5-
f][1,10]phenanthroline (PIC-COOH) ligand were refluxed in 15 ml ethylene glycol 
(C2H2O6) at 250°C for 48 hours. LiCLO
4-
 solution was added to aid precipitation.   
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. The material was lyophilised to yield an orange 
solid (0.03 g, 42 %).   
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 9.61 (m, 2H, J = 8 Hz), 9.10 (t, 4H, J = 8.4 
Hz), 8.52 (m, 2H, J = 3.6 Hz), 8.46 (d, 4H, J = 8.4 Hz), 8.25 (m, 10H, J = 8 Hz,  J = 5.6 
Hz, J = 3.6 Hz), 8.02 (s, 1H), 7.90 (m 8H, J = 5.6 Hz). (HR-ESI-MS): molecular weight 
calculated:  1005.18m/z (M
+
), observed 1005.32m/z (M
+
). 
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Synthesis of Ruthenium(II)(bis-2, 2-bipyridyl)-2(4-N-hydroxysuccinimidylphenyl)  
imidazo[4,5-f][1,10]phenanthroline: [Ru(bpy)2PIC-NHS]
2+
 
                                                      
 
 
 
 
Scheme 3.13: Synthesis reaction scheme of ruthenium(II)(bis-2,2-bipyridyl)-2(4-N-
hydroxysuccinimidylphenyl)imidazo[4,5-f][1,10]phenanthroline:[Ru(bpy)2(PIC-
NHS)]
2+
 
 
0.05 g (0.06 mmol) of ruthenium(II)(bis-2,2-bipyridyl)-2(4-carboxylphenyl)imidazo 
[4,5-f][1,10]phenanthroline, [Ru(bpy)2PIC-COOH]
2+
, 0.05 g (0.43 mmol) of N-
hydroxysuccinimide (NHS) and 0.08 g (0.38 mmol) of DCC were dissolved in 10 ml 
anhydrous MeCN and allowed stir at room temperature for 4-6 hours.   
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. The material was lyophilised yielding an 
orange/red solid (0.038 g, 75 %).   
 
1
H NMR (400 MHz, DMSO-d6): δ (ppm) 14.73 (s, 1H), 9.13 (t, 2H, J = 6 Hz), 8.87 (d, 
2H, J = 5.6 Hz), 8.84 (d, 2H, J = 4.8 Hz), 8.57 (d, 2H, J = 5.2 Hz), 8.40 (d,2H, J = 5.6 
Hz), 8.22 (t, 2H, J = 5.2 Hz), 8.11 (m, 4H), 7.98 (m, 2H), 7.84 (d, 2H, J = 3.6 Hz), 7.61 
(m, 4H), 7.35 (t, 2H, J = 4.8 Hz). (HR-ESI-MS): Molecular weight calculated: 850.84 
m/z (M
+
), 850.14 m/z (M
+
) observed.  
 
 
 
 
 
 
 
 
 
N C N
N,N'-dicyclohexylcarbodiimide
                  (DCC)
N OH
O
O
N-hydroxysuccinimide
           (NHS)
Anhydrated MeCN
Stirred at room 
temp for 24 h
+ 
 
N
N
Ru
N
N
N
N N
H
N
Ruthenium(II)(bis-2,2-bipyridyl)-
2(4-carboxylphenyl)imidazo[4,5-f]
[1,10]phenanthroline
O
OH
N
N
Ru
N
N
N
N N
H
N O
O N
O
O
Ruthenium(II)(bis-2,2-bipyridyl)-2(4-N-hydroxy
succinimidylphenyl)imidazo[4,5-f][1,10]phenanthroline
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3.1.3   RGD and KVGFFKR Peptide Synthesis 
Synthesis of C-Ahx-GRGDS, C-Ahx-KVGFFKR and Pal-C-Ahx-KVGFFKR 
Prior to purchasing peptides commercially, peptide synthesis was first attempted 
manually using an Applied Biosystem ABI 433A Synthesiser (0.1 mmol scale), an 
automated standard Solid Phase Peptide Synthesiser (SPPS). 10 equivalents of each 
protected amino acid were used. The amine group on the resin was Fmoc protected 
initially but was available for amino acid coupling as a result of piperidine (20% NMP) 
deprotection. The sequence was assembled with monitoring of the Fmoc deprotection 
by UV at 301nm. 
 
The peptide was cleaved from the resin and to deprotect the amino acid side-chains once 
assembly of the sequence was complete. The resin was placed in a test tube with 
magnetic stirrer and a cleavage cocktail was added: 3.6 ml TFA (80%), 200 μl water 
(5%), 200 μl TIS or TIPS (5%) and 200 μl TA (5%). The mixture was let stir for 4½ h. 
 
After stirring, the solution was transferred to a Teflon tube fitted with a filter.  Diethyl 
ether (~10ml) was added to the peptide and placed in the freezer for 10-15 minutes to 
aid precipitation.  The product was centrifuged at 123x10
3
 x g for 5 minutes. The 
supernatant was decanted off and carefully disposed of. The product was washed with 5 
ml ether (X2) followed by air drying for 1 hour.  The product was lyophilised overnight 
using a Thermo Electron Corporation, Modulyop-230 Freeze Dryer.  HPLC was carried 
out to purify each product yielding: C-Ahx-GRGDS, 9.1 mg (12%); C-Ahx-KVGFFKR, 
15 mg (14%); Pal-C-Ahx-KVGFFKR, 10mg (8%).   
(HRMS-MALDI-TOF):  
C-Ahx-GRGDS, 748.86 m/z (M
+
) calculated, 748.91 m/z (M
+
), observed      
C-Ahx-KVGFFKR, 1097.51 m/z (M
+
) calculated, 1097.50 m/z (M
+
) observed 
Pal-C-Ahx-GRGDS 1335.93 m/z (M
+
) calculated, 1335.39 m/z (M
+
) observed. 
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3.1.4   Ruthenium Conjugation to the RGD Peptide Sequence 
Synthesis of Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)2(4maleimidolph 
enyl)imidazo[4,5-f][1,10]phenanthroline-C-Ahx -GRGDS:  
[Ru(dpp)2PIC-Mal-RGD]
2+
 via maleimide to cysteine conjugation 
N
N
Ru
N
N
N
N N
H
N O
HN
N
O
O
Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4maleimidolphenyl)
imidazo[4,5-f][1,10]phenanthroline
C-ahx-GRGDS
DMF/PBS
Stir at room temp for 4 h
N
N
Ru
N
N
N
N N
H
N
Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4 maleimidolphenyl)
imidazo[4,5-f][1,10]phenanthroline-C-ahx-GRGDS
O
HN
N
O
O
C-Ahx-GRGDS
 
Scheme 3.14: Synthesis reaction scheme of ruthenium(II)(bis-4,7-diphenyl-1,10 
phenanthroline)2(4maleimidolphenyl)imidazo[4,5-f][1,10]phenanthroline-C-Ahx-
GRGDS:  [Ru(dpp)2PIC-RGD]
2+
 via maleimide to cysteine conjugation. 
 
0.02 g (0.016 mmol) of ruthenium(II) (bis-4,7-diphenyl-1,10-phenanthroline)-2(4-malei 
midolphenyl)imidazo[4,5-f][1,10]phenanthroline, ([Ru(dpp)2PIC-Maleimide]
2+
), was 
dissolved in the minimum amount of degassed anhydrous DMF (~500 µl). 0.015 g (0.02 
mmol) of commercial C-Ahx-GRGDS  peptide was dissolved in 4.5 ml degassed PBS, 
pH 7.4 and quickly added to the dissolved ruthenium complex. The mixture was stirred 
under N2 for 4 hours.  
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. Yield: 0.007 g (22%). Molecular weight calculated: 
1956.40 m/z (M
+
), observed (HR-MALDI-TOF): 1956.72 m/z (M
+
). 
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Synthesis of Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(carboxypheny 
l)imidazo[4,5-f][1,10]phenanthroline-G-Ahx-GRGDS: [Ru(dpp)2PIC-RGD]
2+
 via 
NHS to amine conjugation 
N
N
Ru
N
N
N
N N
H
N O
O
N
O
O
Ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4-N-hydroxy
succinimidylphenyl)imidazo[4,5-f] [1,10]phenanthroline
DMF/PBS
Stir at room temp for 4 h
N
N
Ru
N
N
N
N N
H
N O
G-Ahx-GRGDS
ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4-carboxyphenyl)imidazo
[4,5-f][1,10]phenanthroline-G-ahx-GRGDS  
Scheme 3.15: Synthesis reaction scheme of ruthenium(II)(bis-4,7-diphenyl-1,10-phena 
nthroline)-2(carboxyphenyl)imidazo[4,5-f][1,10]phenanthroline-G-Ahx-GRGDS: 
[Ru(dpp)2PIC-RGD]
2+
 via NHS to amine conjugation. 
 
0.020 g (0.016 mmol) of ruthenium(II)(bis-4,7-diphenyl-1,10-phenanthroline)-2(4-N-
hydroxysuccinimidylphenyl)imidazo[4,5f][1,10]phenanthroline, [Ru(dpp)2PIC-NHS]
2+
, 
was dissolved in the minimum amount of degassed anhydrous DMF (~500 μl). 0.004 g 
(0.006 mmol) of commercial amine terminated G-Ahx-GRGDS  peptide was dissolved 
in 4.5 ml degassed PBS, pH 7.4 and quickly added to the dissolved ruthenium complex. 
The mixture was stirred under N2 for 4 hours.  
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. Yield: 0.015 g (53%).  
 
1
H NMR (DMSO-d6): δ (ppm) 14.55 (s, 1H), 9.12 (d, 2H, J = 8.4 Hz ), 8.46 (d, 2H, J = 
8.4 Hz ), 8.34 (d, 2H, J = 5.6 Hz ), 8.25 (m , 3H), 8.15 (dd, 2H J = 8 Hz), 7.87 (t, 2H, J 
= 5.6 Hz), 7.81 (d, 2H, J = 5.2 Hz ), 7.76 (d, 2H, J = 5.6 Hz ), 7.63 (m, 24H). 
13
C NMR 
(DMSO-d6): 24.43, 25.27, 33.31, 47.45, 126.03, 126.48, 128.10, 129.13, 129.65, 
129.87, 129.95, 135.39, 135.43, 148.02. (HR-MALDI-TOF): Molecular weight 
calculated: 1748.57 m/z (M
+
), observed 1748.62 m/z (M
+
). 
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Synthesis of Ruthenium(II) (bis-2, 2-bipyridyl)-2(4-carboxylphenyl)imidazo[4, 
5f][1,10]phenanthroline-G-Ahx-GRGDS:  
[Ru(bpy)2PIC-RGD]
2+
 via NHS to amine conjugation 
N
N
Ru
N
N
N
N N
H
N O
O N
O
O
G-Ahx-GRGDS
PBS pH 7.4
Stir at room temp,4h
Ruthenium(II)(bis-2,2-bipyridyl)-2(4-N-hydroxy
succinimidylphenyl)imidazo[4,5f][1,10]phenanthroline
N
N
Ru
N
N
N
N N
H
N O
G-Ahx-GRGDS
Ruthenium(II)(bis--2,2-bipyridyl))-2(4-carboxyphenyl)imidazo[4,5f]
[1,10]phenanthroline-G-Ahx-GRGDS  
Scheme 3.16: Synthesis reaction scheme of ruthenium(II) (bis-2, 2-bipyridyl)-2(4 carbox 
ylphenyl)imidazo[4,5-f][1,10]phenanthroline-G-Ahx-GRGDS: [Ru(bpy)2 PIC-RGD]
2+
 
via NHS to amine conjugation 
 
0.02 g (0.016 mmol) of ruthenium(II) (bis-2,2-bipyridyl)-2(4-N-hydroxysuccinimidyl 
phenyl)imidazo[4,5f][1,10]phenanthroline, ([Ru(bpy)2PIC-NHS]
2+
), was dissolved in 
the minimum amount of degassed anhydrous DMF (~500 μl).  0.04 g (0.006 mmol) of 
commercial amine terminated G-Ahx-GRGDS  peptide was dissolved in 4.5 ml 
degassed PBS, pH 7.4 and quickly added to the dissolved ruthenium complex. The 
mixture was stirred under N2 for 4 hours.  
 
The product was purified by column chromatography on alumina using methanol-
dichloromethane (1:9 v/v) as eluent. Yield: 0.012 g (57%).  
 
1
H NMR (400 MHz, DMSO-d6): d (ppm) 14.43 (s, 1H), 9.11 (d, 2H, J = 8.4 Hz), 8.85 
(d, 2H, J = 8 Hz), 8.81 (d, 2H, J = 8 Hz), 8.43 (d, 2H, J = 8.4 Hz), 8.20 (m, 4H), 8.11 (t, 
2H, J = 6.4 Hz), 8.08 (m, 2H), 7.92 (m, 2H), 7.83 (d, 2H, J = 5.2 Hz), 7.59 (m, 4H), 7.33 
(t, 2H, J = 6 Hz). (HR-MALDI-TOF):  Molecular weight calculated: 1397.09 m/z (M
+
), 
observed 1397.23m/z (M
+
). 
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3.2   Results and Discussion 
3.2.1   Synthesis 
All ruthenium complexes prepared in this thesis contained an imidazole containing 
ligand PIC or its derivatives, presented in Figure 3.7. The addition of ammonium 
acetate acts as an acid catalyst to form a 1,10-phenanthroline 5,6-diimine intermediate. 
This intermediate is reactive towards aldehydes and so an aldol-type condensation takes 
place to form a second intermediate. The complex then undergoes a two hydrogen shift 
and loss of a water molecule to form the required imidazole complex.
(35)
 The ligands 
synthesised in this thesis were easily obtained and did not require any further 
purification steps beyond filtration. 
 
Figure 3.7:  Mechanism of imidazole ligand formation.
(35) 
 
The synthesis of [Ru(dpp)2PIC]
2+
, [Ru(dppz)2PIC]
2+
 and [Ru(bpy)2PIC]
2+
 was 
conducted. Complexation to [Ru(L-L)2Cl2]
2+
, where (L-L) is dpp, bpy or dppz, occurs 
whenever the two chloride ligands are first replaced with water molecules which are 
more labile that Cl
-
, allowing displacement by desired ligands of water. It was noted 
that adding a slight excess of ligand to the reactions and allowing reactions to take place 
overnight produced the highest yields and purity of the desired ruthenium complexes. In 
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the cases where purification was required this was easily achieved by column 
chromatography. The synthesis of both [Ru(dpp)2PIC]
2+
 and [Ru(bpy)2PIC]
2+
 proved 
straight forward.   
 
Conversely, [Ru(dppz)2PIC]
2+
 was a much more challenging synthesis. Initially it was 
hoped that both dpp and dppz containing Ru(II) complexes would be synthesised due to 
the oxygen sensitivity of the dpp complex and the alternative water sensitivity of the 
dppz complex. However, yields remained relatively low ~20% compared to 60-80% for 
the dpp and bpy ruthenium complexes. This yield was unrealistic for the requirements 
of this thesis, consequently it was decided that [Ru(dpp)2PIC]
2+
 and [Ru(bpy)2PIC]
2+
 
would be focussed on for RGD peptide conjugation. 
 
Two synthesis pathways were investigated for the conjugation of the ruthenium 
complexes to the RGD peptide sequence. Synthesis pathway I involved attachment of 
aminoethylmaleimide to [Ru(dpp)2PIC-COOH]
2+
 via a DCC/NHS coupling reaction, 
Scheme 3.10. The maleimide terminus was then available for reaction with the thiol 
functionality located at the cysteine (C) amino acid of C-Ahx-GRGDS, Scheme 3.14.  
 
Protein binding studies with [Ru(dpp)2PIC-RGD]
2+
 via maleimide to cysteine 
conjugation were initially successful (discussed further in chapter 4). However it was 
noted over time that the ruthenium to maleimide bond was extremely unstable with 
NMR confirming loss of the distinct maleimide peak at ~7 ppm of the solid state 
complex after only a few days following synthesis and purification. MBS, m-
maleimidobenzoyl-N-hydroxysuccinimide (NHS) has been described as less stable 
compared to alternative maleimide materials due to the aromatic ring adjacent to its 
maleimide functionality.
(36)
 This unstable compound is not recommended for preparing 
freeze-dried samples as the process required to purify the complex can result in loss of 
activity via hydrolysis. As the NHS ester is also known to undergo hydrolysis
(37)
 it 
would require repetitive synthesis of these steps at small scale to prevent hydrolysis 
occurring followed by the additional final conjugation step to the peptide moiety. Thus 
this synthesis pathway, although successful, was deemed too time-consuming and 
unreliable. Synthesis pathway II was subsequently followed. 
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Synthesis pathway II involved formation of an active NHS ester to [Ru(dpp)2PIC-
COOH]
2+
 and [Ru(bpy)2PIC-COOH]
2+
, Scheme 3.9 and 3.13. The NHS ester was then 
available for reaction with the amine functionality located at the glycine (G) amino acid 
of the G-Ahx-GRGDS peptide moiety, Scheme 3.15 and 3.16. NHS esters have been 
reported to undergo rapid hydrolysis in aqueous environments.
(37)
 However NHS esters 
have a half life on the order of hours under physiological solutions. For optimum 
results, excess peptide and the use of organic solvents can eliminate the issue of 
hydrolysis.
(37)
 In this work, the NHS ester was formed in acetonitrile. The active ester 
was then conjugated to the G-Ahx-GRGDS peptide at a 3:1 peptide: ruthenium ratio and 
not left stirring for more than 6 hours. The resulting conjugate was stable and binding 
studies were reproducible, discussed further in Chapter 4 of this thesis.   
 
3.2.2 
1
H-NMR Discussion 
HR-MS combined with 
1
H-NMR was utilised to confirm the structure and purity of the 
synthesised complexes in this chapter. All NMR and HR-MS are located in Appendix 1. 
The full 
1
H-NMR data for the uncoordinated [PIC-X] ligands (
1
H-NMR numbering 
scheme presented in Figure 3.8) are presented in Table 3.1. The presence of an electron 
withdrawing substituent on the ligand draws electron density away from nearby protons 
producing a deshielding effect (downfield chemical shift), while an electron donating 
group causes a shielding effect (upfield chemical shift) in the 
1
H-NMR spectrum. These 
effects are observed between the electron donating amino and electron withdrawing 
nitro functionalised ligands; the protons located at H6 and H7 on the amino (PIC-NH2) 
functionalised ligand are shifted upfield to 6.74 ppm, whereas the corresponding 
protons on the nitro functionalised (PIC-NO2) ligand are shifted downfield to 8.55 ppm. 
N
N N
H
N
X
1
2
3 4
5 6
78
9
10
11
 
Figure 3.8:  [PIC-X] ligand illustrating 
1
H-NMR analysis numbering scheme. 
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Table 3.1:  
1
H-NMR resonances for the uncoordinated [PIC-X] ligands, where X = 
COOH, NO2 and NH2 respectively. All spectra were recorded in DMSO-d
6
.  
Proton 
[PIC-COOH] 
ppm 
Proton 
[PIC-NO2] 
ppm 
Proton 
[PIC-NH2] 
ppm 
H4 (N-H) 
13.96 
(s, 1H) 
H4 (N-H) 
14.13 
(s, 1H) 
H4 (N-H) 
13.31 
(s, 1H) 
Carboxyl-H 
13.09 
(s, 1H) 
H1, H11 
9.06 
(dd, 2H) 
H1, H11 
9.00 
(d, 2H) 
H1, H11 
9.06 
(d, 2H) 
H3, H9 
8.95 
(dd, 2H) 
H3, H9 
8.89 
(dd, 2H) 
H3, H9 
8.95 
(d, 2H) 
H5, H8 
H6, H7 
8.55 
(q, 4H) 
H6, H7 
6.74 
(d, 2H) 
H6, H7 
8.42 
(d, 2H) 
H2, H10 
7.88 
(m, 2H) 
H5, H8 
7.97 
(d, 2H) 
H5, H8 
8.19 
(d, 2H) 
  H2, H10 
7.80 
(m, 2H) 
H2, H10 
7.88 
(d, 2H) 
  Amino-NH2 
5.64 
(s, 2H) 
 
The 
1
H-NMR spectra proton assignments and a comparison of the relative shifts (∆ 
ppm) of the uncoordinated [PIC-X] ligand (Table 3.1) versus the [PIC-X] ligand 
coordinated to all dpp, bpy and dppz containing ruthenium complexes is summarised in 
Table 3.2.  It should be noted that the protons on the imidazole ring (H4) were not 
always observed; these protons may be easily exchanged between the two nitrogens on 
the imidazole ring in solution and may not appear on the 
1
H-NMR spectra.
(38)
 Those that 
were observed however presented chemical shifts with a ∆ ppm range between 0.47 and 
0.77 demonstrating remarkable sensitivity to the identity of the carboxyl, nitro, NHS 
and amino substituents. 
 
In all cases, significant upfield chemical shifts are observed at the H3 and H9 protons of 
the coordinated [PIC-X] ligands with a ∆ ppm range between -0.75 to -0.91 attributed to 
an induced aromatic ring current effect. When protons are above or below the plane (or 
in the middle) of the aromatic ring a ring current is induced which may result in 
diamagnetic anisotropy of the protons causing a strong upfield chemical shift, a 
phenomenon previously reported for ligand coordination with ruthenium complexes.
(39) 
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Table 3.2: 
1
H-NMR resonances and relative shift (∆ ppm) of the coordinated PIC-X relative to uncoordinated [PIC-X] ligand for all ruthenium complexes synthesised, 
where X is COOH, NO2, NH2, NHS, maleimide or RGD. All spectra were recorded in DMSO-d
6
. 
 
Ru(dpp) complexes Ru(dppz) complex Ru(bpy) complexes 
(PIC-COOH) 
protons 
ppm 
∆ 
ppm 
(PIC-NO2) 
Protons 
ppm 
 
∆ 
ppm 
(PIC-NH2) 
Protons 
ppm 
∆ 
ppm 
(PIC-NHS) 
Protons 
ppm 
∆ 
ppm 
(PIC-Mal) 
Protons 
ppm 
∆ 
ppm 
(PIC-RGD) 
Protons 
ppm 
∆ 
ppm 
(PIC-COOH) 
Protons 
ppm 
∆ 
ppm 
(PIC-NHS) 
Protons 
ppm 
∆ 
ppm 
(PIC-RGD) 
Protons 
ppm 
∆ 
ppm 
    
H4 (N-H) 
13.91 
(S, 1H) 
0.60     
H4 (N-H) 
14.55 
(S, 1H) 
0.59   
H4 (N-H) 
14.73 
(S, 1H) 
0.77 
H4 (N-H) 
14.43 
(S, 1H) 
0.47 
H1, H11 
9.12 
(d, 2H) 
0.06 
H1, H11 
9.14 
(d, 2H) 
0.08 
H1, H11 
9.09 
(d, 2H) 
0.09 
H1, H11 
9.14 
(d, 2H) 
0.07 
H1, H11 
9.22 
(d, 2H) 
0.16 
H1, H11 
9.12 
(d, 2H) 
0.06 
H1, H11 
9.10 
(t, 4H) 
0.04 
H1, H11 
9.13 
(d, 2H) 
0.07 
H1, H11 
9.11 
(d, 2H) 
0.05 
H6.H7 
8.44 
(d, 2H) 
0.02 
H6’, H7 
H5,H8 
8.59 
(m, 2H) 
0.04 
H6,H7 
6.76 
(d, 2H) 
002 
H6’,H7 
8.38 
(d,2H) 
-0.04 
H6’,H7 
8.43 
(d, 2H) 
 
0.01 
H6.H7 
8.46 
(d, 2H) 
0.04 
H6.H7 
8.46 
(d, 4H) 
0.04 
H6.H7 
8.40 
(d, 2H) 
-0.02 
H6.H7 
8.43 
(d, 2H) 
0.01 
H5,H8 
8.24 
(m, 4H) 
0.05   
H5,H8 
7.88 
(m, 2H) -0.09 
H5,H8 
8.25 
(m, 4H) 
0.06 
H5,H8 
8.28 
(m, 4H) 
0.09 
H5,H8 
8.25 
(m, 4H) 
0.06 
H5,H8 
8.25 
(m, 10H) 
0.06 
H5,H8 
8.22 
(m, 4H) 
0.03 
H5,H8 
8.20 
(m, 4H) 
0.01 
H3,H9 
8.15 
(d, 2H) 
-0.80 
H3, H9 
8.18 
(d, 2H) 
-0.77 
H3, H9 
8.14 
(d, 2H) 
-0.75 
H3,H9 
8.18 
(m, 4H) 
-0.77 
H3,H9 
8.04 
(d, 2H) 
-0.91 
H3,H9 
8.15 
(dd, 2H) 
-0.80 
H3,H9 
8.02 
(s, 1H) 
-0.93 
H3,H9 
8.11 
(dd, 2H) 
-0.84 
H3,H9 
8.08 
(dd, 2H) 
-0.87 
H2,H10 
7.87 
(t, 2H) 
-0.01 
H2,H10 
7.91 
(m, 2H) 
0.03 
H2,H10 
7.82 
(d, 2H) 
0.02 
H2,H10 
7.80 
(m, 2H) 
-0.08 
H2,H10 
7.83 
(d, 2H) 
-0.05 
H2,H10 
7.87 
(t, 2H) 
-0.01 
H2,H10 
7.90 
(m, 8H) 
0.02 
H2,H10 
7.84 
(t, 2H) 
-0.04 
H2,H10 
7.92 
(t, 2H) 
0.04 
        
Maleimide, 
7.04 
(s, 2H) 
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3.2.3   Ruthenium Complexes: Photophysics 
3.2.3.1   Absorbance, emission, quantum yield (φ) and lifetime (µs) 
A summary of the photophysical data for all ruthenium complexes synthesised is 
presented in Table 3.3. All quantum yield spectra are presented in Appendix 1.  
 
 Table 3.3: Photophysical properties of all ruthenium complexes synthesised.  
a 
carried 
out in in HPLC grade acetonitrile, 20 x 10
-6
M concentration.
b 
lifetime in aerated HPLC 
grade acetonitrile,
 c 
lifetime in degassed HPLC grade acetonitrile, 
d 
lifetime in aerated 
PBS, pH 7.4, 
e 
lifetime in degassed PBS pH 7.4. All values presented are an average of 
n = 3. * results are reproduced from reference (40) and ** reproduced from (41).
(40, 41)
 
Complex 
Abs
 a
, 
λmax 
(nm) 
ɛa 
(dm3/mol
-
1/cm
-1
) 
 
Em
a
, 
λmax 
(nm) 
Lifetime
 
Aerated
b 
(µs) 
Lifetime
 
Degassed
c 
(µs) 
 
Quantum 
Yield
a 
(φ) 
 
[Ru(dpp)2 
PIC-NO2]
2+
 
465 
320 
280 
17,288 ± 1,598 
20,378 ± 2,352 
57,867 ± 4,452 
614 0.18 ± 0.04 0.89 ± 0.02 0.012± 0.002 
[Ru(dpp)2 
PIC-NH2]
2+ 
462 
320 
280 
12,644 ± 2,093 
25,430 ± 2,276 
56,030 ± 5,001 
613 0.16 ± 0.01 0.72 ± 0.03 0.012 ± 0.003
 
[Ru(dpp)2 
PIC-COOH]
2+
 
462 
320 
278 
17,681 ± 1,522 
12,746 ± 2,952 
67,425 ± 4,908 
607 0.20
  
± 0.04 1.47 ± 0.12 0.020 ± 0.003 
[Ru(dpp)2 
PIC-NHS]
2+
 
466 
320 
278 
13,730 ± 1,052 
26,069 ± 2,276 
57,504 ± 5,052 
612 0.28 ± 0.01 1.7 ± 0.03 0.022 ± 0.002 
[Ru(dpp)2 
PIC-Mal]
2+
 
465 
320 
280 
14,327 ± 1,048 
27,962 ± 2,332 
57,242 ± 5,862 
 
613 
 
0.12 ± 0.01
 
2.3 ± 0.20 0.029 ± 0.001 
[Ru(dppz)2 
PIC-COOH]
2+
 
461 
357 
279 
5, 076 ± 2,473 
11,511 ± 3,135 
43,487 ± 5,512 
603 0.17 ± 0.02 0.70 ± 0.04 0.027± 0.002 
*[Ru(bpy)2 
PIC-COOH]
2+
 
457 
330 
285 
13,033 
23,946 
61,318 
608 0.16
 
0.50 0.068
 
[Ru(bpy)2 
PIC-NHS]
2+
 
452 
354 
278 
14,728 ± 2,254 
20,258 ± 3,844 
50,089 ± 5,986 
607 
0.16 ± 0.04 
 0.51 ± 0.08
d
 
0.45 ± 0.12 
0.85 ± 0.14
e
 
0.045 ± 0.001
 
0.058 ± 0.004
d 
[Ru(bpy)3]
2+
 
450 nm 
285 nm 
191 nm 
5,196± 1,384 
11,928 ± 3,452 
43,396 ± 4,956 
601 
 
0.18 ± 0.01
 0.46 ± 0.02 
 
**0.016
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Figure 3.9 shows the absorbance spectra for all ruthenium complexes synthesised as 
part of this thesis. All dpp ruthenium complexes synthesised exhibited three electronic 
transition averages at approx. 280 nm, 320 nm and 465 nm with average molar 
extinction coefficients (Ɛ) of 59,213, 22,517 and 13,134 dm3/mol-1/cm-1 respectively.   
Similar to dpp, the dppz containing complex exhibited three electronic transitions at 
approx. 280 nm,  320 nm and 461 nm with average molar extinction coefficients (Ɛ) of 
43,487 Mol
-1
cm
-1
, 11,511 Mol
-1
cm
-1
 and 5,076 Mol
-1
cm
-1
.    
 
The bpy containing complex, [Ru(bpy)2PIC-NHS]
2+
,
 
exhibited three electronic 
transitions at approx. 280nm, 340 nm and 460 nm with average molar extinction 
coefficients (Ɛ) of 50,089/51,950 Mol-1cm-1, 20,258/22,895 Mol-1cm-1 and 14,728 
/14,198 Mol
-1
cm
-1
 (PBS/ACN) respectively. This complex was the only Ru(II) complex 
that exhibited full solubility in water. [Ru(bpy)3]
2+
 is widely reported as highly soluble 
in water with a reported emission at 600 nm in water at room temperature.
(42)
 Merely 
substituting one of the bpy moieties for alternative ligands has been shown to 
alter/reduce the solubility characteristics of this dye, increasing its preference for 
organic solvents along with a red shifted emissive spectrum.
(43)
  
 
In all cases, the strong absorbance band at approximately 280 nm may be assigned to π-
π* transitions within the dpp, bpy or dppz ligand, while the shoulder at approximately 
360 nm is attributed to the π-π* transitions of the PIC ligand containing the two 
ionisable protons on the imidazole ring as this transition exhibits environmental 
sensitivity (e.g. pH dependence).
(40)
 The benzimidazole spacer exerts little effect on the 
absorbance spectra as the energies and absorbance profiles of these transitions are 
almost indistinguishable. 
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Figure 3.9: Absorbance spectra of dpp, dppz and bpy containing ruthenium complexes; 
20 x 10
-6
 M concentration in HPLC grade acetonitrile (MeCN) or PBS pH 7.4, labelled 
accordingly. 
Figure 3.10 presents the emission spectra for all ruthenium complexes in HPLC grade 
acetonitrile or PBS, pH 7.4 (20 x 10
-6
 M in each case), labelled accordingly. All 
ruthenium complexes presented comparable emission characteristics, see Table 3.3. 
[Ru(bpy)2PIC-NHS]
2+
 presented increased luminescence intensity in water  presenting a  
quantum yield (φ) of 0.045 ± 0.001/0.058 ± 0.004 (acetonitrile/PBS) and luminescent 
lifetimes of 0.16 ± 0.04/0.51 ± 0.08 µs and 0.45 ± 0.12/0.85 ± 0.14 µs in aerated and 
degassed acetonitrile/PBS respectively. This increase in water is more unusual but has 
been reported as characteristic for ruthenium complexes containing the PIC ligand.
(23, 24)
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Figure 3.10:Emission spectra (20 x 10
-6
 M concentration for all dpp, bpy and dppz 
containing ruthenium complexes; [Ru(dpp)2PIC-COOH]
2+
 (λex 462 nm), [Ru(dpp)2PIC-
NO2]
2+
 (λex 465 nm), [Ru(dpp)2PIC-NH2]
2+ (λex 462 nm), [Ru(dpp)2PIC-NHS]
2+(λex 466 
nm) and [Ru(dpp)2PIC-Maleimide]
2+(λex 465 nm), [Ru(dppz)2PIC-COOH]
2+(λex 461 
nm) and [Ru(bpy)2PIC-NHS]
2+(λex 461 nm ) in acetonitrile (MeCN) or PBS pH 7.4, 
labelled accordingly. Slit width was 5 nm in all cases. Samples are not absorbance 
matched. 
 
In summary all ruthenium complexes synthesised as part of this thesis displayed similar 
optical properties with the exception of NO2 and NH2 which were red shifted with 
reduced intensity; the quantum yield reduced to 0.012 The decreased fluorescence 
intensity and quantum yield observed here is not unusual in NO2 containing 
complexes.
(44)
 Near complete quenching of a complexes luminescence has been 
reported when the nitro group is located in the ortho or para-position. This decrease in 
luminescence can be attributed to the capture of the photoexcited electron by the strong 
electron withdrawing nitro group.  In addition, the bpy complexes present an additional 
advantage, presenting good solubility in water, high quantum yields and long lifetimes 
in PBS, pH 7.4. 
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One of the greatest advantages of dppz complexes is the extreme sensitivity to water. 
Hydrogen bonding to the phenazine nitrogens on the dppz ligand results in quenching of 
the excited state, stabilizing the non-emissive state located on the phenazine portion of 
the dppz ligand which in turn “switches” the emission off.(5,45) Consequently, the effect 
of this quenching on emission was studied. Sequential aliquots of water was added to a 
0.035 mM stock concentration of [Ru(dppz)2PIC-COOH]
2+
 and the emission recorded, 
excited at 461 nm and emission at approx. 610 nm, Figure 3.11. As the concentration of 
water increased (50 µl increments) the emission intensity decreased due to the hydrogen 
bonding of the phenazine nitrogens discussed earlier.
(5,45,46)
  It was noted that the 
emission from [Ru(dppz)2PIC]
2+
 steadily decreases with increased water concentration 
and is almost fully quenched at a water concentration of ~6 M. 
 
Figure 3.11: Water quenching effect on [Ru(dppz)2PIC]
2+
 (0.035 mM  concentration in 
acetonitrile); λex 461nm,λem 610 nm. Slit width 5 nm. 
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3.3   RGD and KVGFFKR Peptides 
3.3.1   Synthesis 
The synthesis of the peptides discussed in this chapter were carried out using the 
automated Solid Phase Peptide Synthesis (SPPS) technique performed on an Applied 
Biosystem ABI 433A Synthesiser. 1 mmol (10 fold molar excess) quantities of each 
protected amino acids were used. The Fmoc protected amine group on the resin was 
available for amino acid coupling following piperidine (20% in NMP) deprotection. The 
peptides were elongated from the C-terminus (carboxylic acid functional group) to the 
N-terminus (amino group). The sequences were assembled with monitoring of the Fmoc 
deprotection by UV at 301 nm. 
 
3.3.2   Characterisation 
MALDI-TOF mass spectrometry was carried out to confirm the structure of the three 
synthesised peptides, spectra are presented in Appendix 1. C-Ahx-GRGDS, molecular 
ion was centred at m/z= 748 g/mol, C-Ahx-KVGFFKR, molecular ion was centred at 
m/z= 1097 g/mol and Pal-C-Ahx-KVGFFKR, molecular ion centred at m/z= 1335 
g/mol. HPLC was carried out to purify each peptide. Following purification lyophilizing 
each product, low yields were obtained: C-Ahx-GRGDS, 9.1 mg (12%); C-Ahx-
KVGFFKR, 15 mg (14%); Pal-KVGFFKR, 10mg (8%). Thus it was concluded that 
manual synthesis, although successful and of high purity, due to cost were not suitable 
for the requirements of this thesis. Consequently, the peptides conjugated to the 
ruthenium complexes presented in this chapter were purchased commercially from 
Celtek Peptides.  
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3.4   Ruthenium Conjugated Peptides 
3.4.1   Synthesis  
As shown previously by our research group, fluorophores can be conjugated to the N-
terminus of resin-bound peptides before other protecting groups are removed and the 
labelled peptide is released from the resin.
(15,23,33)
 Alternatively, peptides can potentially 
be conjugated to amine reactive labels, or thiol reactive labels, if a cysteine has been 
used for the peptide, as commonly used in protein modifications. In this thesis, for the 
first time, both thiol and amine reactive conjugation protocols were employed for the 
conjugation of the C-Ahx-GRGDS or G-Ahx-GRGDS peptide moieties to Ru(II) 
polypryidyl complexes. 
 
The thiol reactive conjugation technique was carried out first due to the fact that 
although sulfohydryl groups may be present in the peptide sequence, they are not as 
numerous as primary amines, thus may provide higher specificity and selectivity to the 
conjugation process. The maleimide group reacts efficiently with sulfohydryl groups at 
a specific pH range between pH 6.5 and 7.5 resulting in a stable thioether linkage. At 
higher pH ranges (>pH 8.5) the rate of hydrolysis is increased which may result in the 
formation of non-reactive maleamic acid.
(37)
 The dpp containing Ru(II) complex was 
conjugated through reacting the maleimide group on the PIC ligand with the cysteine 
functionality on the RGD polypeptide. The alternative dpp and bpy containing 
Ruthnium(II) dyes were conjugated through a single reactive NHS active ester group on 
the PIC ligand with the amine functionality on the RGD polypeptide. As a result of the 
selective coupling reactivity they generally do not contain isomers or other competing 
functional groups that may in turn lower the synthetic yields further. 
 
Coupling of [Ru(dpp)2PIC-Maleimide]
2+
 to the polypeptide gave a moderate yield (7 
mg, 22%). It is assumed that as the maleimide is left in solution for a maximum of 6 
hours, a certain amount of hydrolysis is unavoidable leading to lower yields. In contrast, 
coupling of both [Ru(dpp)2PIC-NHS]
2+
 and [Ru(bpy)2PIC-NHS]
2+
 to the polypeptide 
presented better yields (15mg (53%) and 12 mg 57%). HR-MADLI-TOF was used as 
standard to confirm the structure of all dye-conjugates, presented in Appendix 1.
(33)
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3.4.2   Ruthenium Peptide Conjugates: Photophysics 
3.4.2.1   Absorbance, emission, quantum yield (φ) and lifetime (µs) 
A summary of the photophysical data for all parent ruthenium and peptide conjugate 
complexes synthesised is presented in Table 3.4. All quantum yield spectra are 
presented in Appendix 1. Conjugation of ruthenium to the peptide did not significantly 
alter the absorbance or emission characteristic of the complexes, Figure 3.12. In all 
cases, both the lifetimes and quantum yields were increased for the peptide conjugated 
ruthenium complexes. Similar increases in both lifetime and quantum yield have been 
observed previously for other metal complexes on conjugation of peptide attributed to 
some weak exclusion of oxygen from the metal centre.
(47)
 
 
Table 3.4:Photophysical comparison of the parent complexes [Ru(dpp)2PIC-
Maleimide]
2+
, [Ru(dpp)2PIC-NHS]
2+
 and [Ru(bpy)2PIC-NHS]
2+
 compared to the 
peptide conjugates [Ru(dpp)2PIC-Maleimide-RGD]
2+
, [Ru(dpp)2PIC-RGD]
2+
 and 
[Ru(bpy)2PIC-RGD]
2+
 in HPLC grade acetonitrile (20 x10
-6
 M concentration).* 
reproduced from reference (40).
(40)
  
 
 
Complex 
Abs
a
,
 
λmax 
(nm) 
Extinction 
Coefficient
a
, 
ɛ 
(dm
3
mol
-1
cm
-1
) 
Em
a
,
 
λmax 
(nm) 
Lifetime
 
Aerated
b 
(µs) 
Lifetime
 
Degassed
c 
(µs) 
Quantum 
Yield
a 
(φ) 
[Ru(dpp)2 
PIC-COOH]
2+
 
462 
320 
278 
17,681 ± 1,522 
12,746 ± 2,952 
67,425 ± 4,908 
607 0.20
  
± 0.04 1.47 ± 0.12 0.020 ± 0.003 
[Ru(dpp)2 PIC-
Mal-RGD]
2+
 
465 
320 
283 
14,100 ± 1,142 
27,960 ± 2,022 
66,530 ± 4,592 
615 0.26 ± 0.02 3.0 ± 0.15 0.031 ± 0.001 
 
[Ru(dpp)2PIC-
RGD]
2+
 
465 
345 
281 
14,327 ± 1,375 
15,600 ± 1,922 
61,110 ± 5,942 
611 0.49 ±0.07 2.30 ±0.04 0.030 ± 0.002 
*[Ru(bpy)2 
PIC-COOH]
2+
 
457 
330 
285 
13,033 
23,946 
61,318 
608 0.16
 
0.50 0.068
 
 
[Ru(bpy)2PIC-
RGD]
2+
 
455 
330 
283 
13,252 ± 1,002 
15,622 ± 2,193 
59,973 ± 4,353 
615 
0.23 ± 0.03
 
0.52 ± 0.04
d
 
0.58 ± 0.10
 
1.05 ± 0.15
e
 
0.055 ± 0.002 
0.062 ± 0.003
d
 
116 
 
 
Figure 3.12: Absorbance and emission spectra comparison of the parent complexes 
[Ru(dpp)2PIC-Maleimide]
2+
, [Ru(dpp)2PIC-NHS]
2+
 and [Ru(bpy)2PIC-NHS]
2+
compare 
ed to the peptide conjugates [Ru(dpp)2PIC-Maleimide-RGD]
2+
, [Ru(dpp)2PIC-RGD]
2+
 
and [Ru(bpy)2PIC-RGD]
2+
 in HPLC grade acetonitrile (MeCN) or PBS, pH 7.4 
(20 x10
-6
 M concentration) labelled accordingly 
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3.5   Conclusion 
This chapter detailed the synthesis of the dpp, dppz and bpy containing Ru(II) 
complexes. All synthesis was successful, presenting good yields (>50%) with the 
exception of the dppz containing complex. Although synthesis of the dppz containing 
ruthenium complex was successful, yields were low (<40%) rendering the complex too 
time consuming for the requirements of this thesis.  
 
The conjugation of these luminophores to the αIIbβ3 integrin specific C-Ahx-GRGDS 
and G-Ahx-GRGDS peptide was also described. Three peptides; C-Ahx-GRGDS, C-
Ahx-KVGFFKR and Pal-C-Ahx-KVGFFKR were synthesised first, in-house, via the 
SPSS method, however, as with dppz, yields were too low (<20%) for the requirements 
of this thesis. Thus peptides were purchased commercially for conjugation to the 
ruthenium complexes. 
 
Two synthetic methods for peptide conjugation were explored; cysteine-maleimide and 
NHS-amine conjugation. The cysteine-maleimide conjugation method was highly 
unstable and presented low yields (< 25%), while the NHS-amine conjugation method 
proved stable with good yields (>50%), thus NHS-amine was considered the optimal 
method for peptide conjugation. The dpp containing ruthenium complexes presented 
oxygen sensitivity, reflected in the lifetime studies e.g. [Ru(dpp)2PIC-COOH]
2+
 
exhibited luminescent lifetimes of 0.20 ± 0.04 µs and 1.47 ± 0.12 µs in aerated and 
degassed acetonitrile respectively. A comparison of bpy containing complexes in both 
acetonitrile and PBS presented good water solubility, oxygen sensitivity and high 
emission quantum yields. The dppz containing complex presented water sensitivity and 
exhibited “light-switching” properties as well as oxygen sensitivity consistent with 
other reports of related dppz containing complexes. 
All peptide conjugates presented a slight increase in lifetime and quantum yield e.g. the 
[Ru(dpp)2PIC-COOH]
2+
 parent complex presented a quantum yield of 0.020 ± 0.003 
and luminescent lifetimes of 0.20 ± 0.04 µs and 1.47 ± 0.12 µs in aerated and degassed 
acetonitrile, while the peptide conjugate, [Ru(dpp)2PIC-RGD]
2+
, presented a quantum 
yield (φ)of 0.030 ± 0.002 and luminescent lifetimes of 0.49 ± 0.07 µs and 2.3 ± 0.04 µs 
in aerated and degassed acetonitrile. This phenomenon has been previously reported, 
and is attributed to a small protection effect towards the Ru centre from oxygen.  
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Glossary: Ruthenium(II) Polypyridyl Peptide Conjugates 
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2+, dpp-RGD2 
[Ru(bpy)2PIC-RGD]
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4.0   Introduction 
The integrin IIb3 (GPIIb/IIIa) is a heterodimeric glycoprotein cell adhesion receptor 
that lies across the plasma membrane of human platelets. Its physiological function is 
intimately linked to the process of platelet activation and thrombosis.
(1) 
Multiple 
conformational forms of αIIbβ3 are known to exist, each with different adhesion 
properties toward its primary ligand, fibrinogen. In its native or ‘resting’ state αIIbβ3 
assumes a bent conformation with low binding affinity towards fibrinogen.
(2)
 In its 
“activated” state, typically formed when platelets encounter physiological stimuli such 
as ADP or thrombin via the inside–out mechanism, αIIbβ3 undergoes a gross 
conformational change to a structure with high affinity for fibrinogen. The exact 
structural details of the conformational changes that can occur between the most 
extreme states of resting and activation remain controversial, but the distinct difference 
between the two conformations is well accepted.
(2, 3)
   
 
Fibrinogen, (MW 340 Kda) is the primary ligand for IIb3.
(4, 5) 
It contains three 
potential integrin binding sites; an RGD motif within the Aα chain, Aα
572-575
 (RGDS) 
and a non-RGD dodecapeptide sequence in the γ chain (C-terminal γ400-411). A second 
RGD motif exists, Aα 
95-98 
(RGDF) but it is thought that this motif is masked within a 
coil domain and so cannot participate in mediating platelet aggregation. Both RGDS 
and the non-RGD dodecapeptide γ400-411 sequences (AGD) mediate platelet aggregation 
by first binding to the αIIbβ3 receptor on one platelet and then cross-linking to a 
corresponding receptor of another platelet. Affinity cross-linking of RGD peptides and 
site-directed mutogenesis studies suggest that the RGD ligand binding site is located 
between amino acids asp
109 
(D)
 
and glu
172
 (G) of the β sub-unit near/at the Mg2+ metal-
ion dependant adhesion site (MIDAS).
(6-8)
 When RGD binds to integrin IIb3, the 
MIDAS (Mg
2+)
 coordinates the (D) side chain of the ligand, while the arg (R) side chain 
binds to the asp residue on the α sub-unit. Figure 4.1 illustrates the reported mode of 
RGD binding and crystal structure of integrin αIIbβ3. Platelet aggregation can be 
instigated on exposure of platelets to ruptured atherosclerotic plaque. The resulting 
arterial thrombus can decelerate blood flow with serious consequences in the case of 
stroke or myocardial infarction. Because of its key role in thrombosis αIIbβ3 is deemed 
the “central” integrin in this process, thus understanding its behavior and its “activation 
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status” is crucial in predicting thrombotic risk and in advancing therapeutic approaches 
towards managing thrombosis related diseases.   
 
    
Figure 4.1: (A) Sketch of the extracellular portion of integrin αvβ3 based on the X-ray 
crystal structure reported by Xiong et al.
(9)
 The two non-covalently associated subunits 
V (blue) and 3 (grey) bend into a compact form in the crystal structure. A small RGD 
peptide ligand (green) binds to this receptor at the interface between the propeller of V 
and the A domain (I-like domain) on 3. Note: a not-to-scale schematic cell membrane is 
shown. (B) Crystal structure of entire extracellular domain of αIIbβ3; RGD peptide is 
presented in green. (C) Crystal structures close of up views (i and ii) of the region 
surrounding MIDAS of integrin before (i) and after (ii) RGD ligand peptide soaking.  
Hydrogen and coordination bonds are shown in dashed lines. Metal ions in the βA 
domain (β3 sub-unit) are presented as spheres. This figure was adapted from references 
(10-12).
(10-12)
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In addition to physiological stimuli, many chemical agents can induce integrin 
activation.
(13-16) 
These include the bifunctional reducing agent, DTT, divalent cations 
Mn
2+
, EDTA (due to its chelation of the divalent cation Ca
2+
 from the integrin structure) 
and RGD-containing peptide drugs such as Eptifibatide. Such chemical agents have 
provided key insights into the gross structural changes accompanying activation of 
αIIbβ3.
(16, 17)
 Although there is evidence that significant variation in conformational states 
occur depending on the chemical activators applied, there has not to our knowledge, 
been a systematic study directed toward comparison of the conformational 
modifications following treatment of αIIbβ3 by the commonly employed chemical 
activators. This report addresses the differential changes in integrin conformation 
resulting from the different chemical activators, and uses time resolved luminescence 
anisotropy from a long-lived metal complex as a means of assessing integrin 
conformational state.   
 
Luminescence anisotropy is a simple, but effective means of monitoring changing 
protein conformation and can be used to quantify associated changes to the dimensions 
of the protein. To be useful in this regard, the probe should, ideally, have a long 
luminescent lifetime so that it persists in the excited state for long enough to “record” 
protein rotational motion, which is typically on the nanosecond to microsecond time-
scale. The most widely used probes in biological investigations are fluorescent, organic 
chromophores. They possess limited environmental sensitivity due to their short 
lifetimes (<10ns) and thus have limited value in time resolved anisotropy 
measurements, as their decay times are typically much shorter than rotational times of 
large proteins. In addition, organic fluorophores tend to suffer from self quenching, due 
to overlap of their absorption and emission spectra and from poor photostability. In 
contrast Ru(II) polypyridyl complexes exhibit polarised emission with large stokes 
shifts, and have long luminescent lifetimes (as their emission is formally 
phosphorescent, arising from a triplet metal to ligand charge transfer state, 
3
MLCT) and 
enhanced photostability. Consequently they are being increasingly applied in biological 
applications such as cell imaging
(18)
 and in the analysis of biodynamic processes such as 
membrane diffusion
(19) 
and protein folding.
(20) 
The emission maxima of ruthenium 
complexes are observed in the region of 600–700nm which is within the biological 
window and thus reduces interference from autofluorescence. Furthermore, 
ruthenium(II) luminophores are oxygen sensitive which makes them especially 
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responsive to changes in their environment. For example if protein binding changes the 
accessibility of molecular oxygen to the complex, large changes in luminescence 
intensity and lifetime can result. 
 
Direct conjugation of ruthenium complexes to biomolecules such as proteins, peptides 
or DNA has been widely reported.
(21-25) 
For example, Ryan et al.
(26)
 successfully 
conjugated a range of proteins to a ruthenium polypyridyl complex confirming binding 
using steady-state spectroscopic measurements. In 1994, DeGraff et al.
(27)
 reported the 
first measurement of rotational correlation times for a series of ruthenium(II) 
complexes. This group demonstrated that ruthenium complexes make excellent probes 
for slow dynamic processes that can occur in macromolecular systems.
(20)
 Since then 
many groups have directly conjugated ruthenium complexes to protein. Kang et al.
(28)
 
successfully conjugated a ruthenium (II) polypyridyl probe to immunoglobulin G (IgG) 
and immunoglobulin M (IgM) and monitored the rotational diffusion of the proteins and 
compared the anisotropy of each protein. This work demonstrated that ruthenium probes 
could be used for the investigation of protein hydrodynamics. However, although 
ruthenium has been fairly widely used in direct conjugation of proteins, ruthenium 
peptide targets for the investigation of specific interactions with proteins by 
luminescence anisotropy, to our knowledge, has not yet been reported. 
 
As discussed in Chapter 1 and Chapter 3, direct conjugation of ruthenium complexes to 
biomolecules such as proteins, peptides or particularly DNA has been widely 
reported.
(21-25)
 However, ruthenium-peptide targets for the investigation of specific 
interactions with proteins by luminescence anisotropy, to our knowledge, has not yet 
been reported. 
 
This Chapter uses the three novel luminescent peptide-probes synthesised as part of 
Chapter 3; [Ru(dpp)2PIC-Maleimide-RGD]
2+
, [Ru(dpp)2PIC-RGD]
2+ 
and [Ru(bpy)2PIC 
-RGD]
2+ 
where dpp is 4,7-diphenyl-1,10-phenanthroline and bpy is 2,2-bipyridine. 
These three complexes will be referred to as dpp-RGD1, dpp-RGD2 and bpy-RGD 
respectively throughout the rest of this Chapter, see glossary for chemical structures. 
The very strong sensitivity of the hydrophobic dpp containing complexes to O2 is 
important as small changes to O2 accessibility of the metal centre can cause large 
changes in luminescent lifetime and quantum yield which can be useful in reflecting 
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protein binding. Furthermore, the exceptionally long lifetime of the peptide conjugates 
makes them particularly suitable for studying rotational correlation times of very high 
molecular weight proteins. The contrasting hydrophilic nature and complimentary 
oxygen sensitivity of the bpy containing complex is also important as this may affect 
the binding nature of the metal conjugate into the RGD binding pocket located at the 
head of the integrin αIIbβ3 protein. 
 
The application of these peptide complexes as molecular probes to report on integrin 
binding and activation status was investigated using steady state and time-resolved 
luminescence spectroscopy. αIIbβ3 was treated with the Ru(II) polypyridyl complexes 
conjugated to an RGD peptide and the binding constant and the luminescence 
anisotropy compared before and after it had been treated with the common activators 
DTT and Mn
2+
. Live cell studies using confocal microscopy investigating the selective 
binding of the peptide probes to integrin in live cells is also presented.  
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4.1   Experimental Procedure 
Chemicals 
DMEM nutrient mixture F-12 HAM media, 100 ml accutase, 1mg/ml G418, 500 ml 
37% paraformaldehyde (PFA) solution, calcium chloride (CaCl2), sodium chloride 
(NaCl), manganese dichloride (MnCl2), dithiothreitol (DTT), trizma hydrochloride 
(TrisHCl) and bovine serum albumin (BSA) were purchased from Sigma Aldrich. CD41 
and PAC-1 antibodies were purchased from BD Biosciences. G-Ahx-GRGDS and C-
Ahx-GRGDS peptides were made to order by Celtek Biosciences.  Eptifibatide (N6-
(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L--aspartyl-L-trypto 
phanyl-L-prolyl-cysteinamide,cyclic(1–6)-disulfide), also known as Integrilin, was 
purchased from Peptides International. All commercial peptide identity and purity was 
manufacturer guaranteed, confirmed by MALDI-TOF-MS and HPLC, see Appendix 1. 
Purified human platelet glycoprotein integrin αIIbβ3 was purchased from Enzyme 
Research Laboratories. Foetal calf serum was purchased from Biosera. CD41 (clone 
SZ22) monoclonal antibody was obtained from Beckman Coulter. Secondary goat anti-
mouse IgG Alexa Fluor 488 and 250 µg/ml Zeocin were obtained from Invitrogen.  
 
4.1.1   Photophysical Measurements 
Emission spectra were recorded on a Cary Eclipse Varian luminescence 
spectrophotometer with a 4 mm x 10 mm quartz cuvette, slit width of 10 nm with a 
spectral range of 480-800 nm for all samples. Protein and ruthenium-peptide final 
concentrations for emission and time-resolved emission anisotropy studies were 
approximately 1.1-0.8 µM in all cases (Protein: ruthenium-peptide ratios ranged from 
1:1 to 1.3:1). The same sample and cuvette were used for recording luminescence 
spectra and luminescent decay data. All measurements were performed at room 
temperature and were background corrected prior to every measurement 
 
Luminescent lifetimes were obtained using a Picoquant FluoTime 100 Time Correlated 
Single Photon Counting (TCSPC) system using a Thurlby Thandar Instruments (TTi) 
TGP110 10MHz pulse generator, excited at 450 nm with a 510 nm narrow band pass 
dielectric filter. Typical pulse rates of the excitation source were 1 x 10
5
s
-1
, with typical 
pulse widths of 300 ps. 10,000 counts was collected for each lifetime measurement. All 
measurements were performed in triplicate using Nanoharp software. In the case of 
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degassed samples, samples were degassed with nitrogen for 20-30 minutes prior to 
analysis. An exponential decay function was fit to each decay plot to extract the lifetime 
information using FluoFit software and the calculation of the luminescent lifetimes was 
obtained using the following equation: 
 
                    (Eqn. 4.1) 
 
Where I(t) is the intensity at time t, I(0) is the intensity at time 0 and τ is the luminescent 
lifetime. 
 
Due to the intrinsically long lifetimes of the ruthenium complexes all data was fitted to 
mono/bi-exponential decay functions to the baseline of the decay curve using tail-fit. An 
ideal x
2 
value of between 0.9-1.1 was observed for all sample measurements. 
 
Time-resolved emission anisotropy was measured on the PicoQuant Fluotime 100 
TCSPC system (excitation wavelength of 485 nm with a 510 nm narrow band pass 
dielectric filter) using a Thurlby Thandar Instruments (TTi) TGP110 10MHz pulse 
generator with sheet polarisers to select V polarised excitation from the diode source. 
The G-factor was estimated by tail matching the VV and VH emission decays. Typical 
pulse rates of the excitation source were 1 x 10
5
s
-1
, with typical pulse widths of 300 ps. 
10,000 counts were collected for each anisotropy measurement. All measurements were 
performed in triplicate using Nanoharp software. All experiments were performed using 
the same 1 cm path length quartz cuvette. Protein and ruthenium-peptide final 
concentrations for emission and time-resolved emission anisotropy studies were 
approximately 1.1-0.8 µM in all cases (Protein: ruthenium-peptide ratios ranged from 
1:1 to 1.3:1). Time resolved luminescence anisotropy measurements were analysed to 
yield rotational correlation time, trot values using the bi-exponential model shown in 
(Eqn. 4.2) using Fluofit software. 
             (Eqn. 4.2)    
Where r(t) is the time dependent anisotropy, r0 is the limiting anisotropy,  is the 
luminescent lifetime of the sample 
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4.1.2   Integrin αIIbβ3 Protein Concentration 
Purified human platelet glycoprotein integrin αIIbβ3 was purchased from Enzyme 
Research Laboratories. Glycerol was removed from the sample by dilution 2:1 into 
TrisHCl buffer (150mM NaCl, 1mM CaCl2, 20mM TrisHCl, pH 7.4). Dialysis was 
carried out using an amicon ultra centrifugal filter unit (MWCO 30 kDa). The diluted 
αIIbβ3 protein was centrifuged at 2500 x g until approximately 500 µl remained in the 
filter. Two volumes of buffer were added to the sample and centrifuged again at 2500 x 
g. This step was repeated at least three times. The resulting protein sample (approx. 500 
μl) concentration was determined using absorption spectrometry (Aprotein= 280nm); an 
example is presented in Appendix 2. The sample was stored at 4°C until required but 
was used as soon as possible following preparation. 
 
4.1.3   Peptide Binding and Activation Studies of Integrin αIIbβ3: Mn
2+
and DTT  
The binding of bpy-RGD, dpp-RGD1 and dpp-RGD2 to αIIbβ3 was investigated by 
titrating αIIbβ3 (2.3 μM stock concentration) in TrisHCl buffer (150mM NaCl, 1mM 
CaCl2, 20mM TrisHCl, pH 7.4) into 500 µl of ruthenium-RGD (2.3 μM stock 
concentration). The emission from the complex was excited at 450 nm and the 
corresponding binding curves generated from changes to the peak emission intensity 
centered at approx. 610 nm. The effect of activation on the binding of the RGD 
containing dyes were also investigated using the known activating reagents; DTT and 
Mn
2+
. The concentration of reagent used was 10:1 (DTT or Mn
2+
: αIIbβ3). The DTT and 
Mn
2+
 were added both before and after αIIbβ3 was bound to the ruthenium-RGD probes. 
Control experiments were also carried out in the same manner to assess any contribution 
from non-specific binding using ruthenium-RGD
 
alone, BSA and Eptifibatide (2.3 µM 
stock concentration in all cases). 
 
4.1.4   Determination of Dissociation Constant (Kd) 
The binding of all three ruthenium-RGD peptide probes to integrin αIIbβ3 was 
determined using SigmaPlot 12.0 software (License# 775212810). Binding was 
analysed using the equation for the binding of a ligand to a single binding site, fitting 
the experimental data with Eqn.4.3 in order to obtain the dissociation constant value 
(Kd). This equation is derived from the definition of the dissociation constant, Kd = 
R.L/RL, and the mass balance equation, R0 = R + RL.
(29)
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               (Eqn. 4.3) 
Where RL is the measured binding concentration and is proportional to the 
luminescence intensity; R0 is the total binding site concentration; L is the free ligand 
concentration and is proportional to the concentration of protein to ruthenium-RGD  
 
4.1.5   Cell Culture 
Chinese hamster ovary cells (CHO-K1, ATCC no. CCL-61); CHO-WT (wild type) or 
CHO- αIIbβ3 (CHO transfected with αIIbβ3) were grown in DMEM nutrient mixture F-12  
HAM media supplemented with 10% foetal calf serum, 1 mg/ml G418 and 250 µg/ml 
Zeocin at 37°C with 5% CO2. A FACS Calibur instrument was used as a quick and 
reliable method to quantify the percentage expression of integrin αIIbβ3 on the two CHO 
cell types. Two fluorescein isothiocyanate (FITC) labeled antibodies were used; CD41 
binds to resting and activated αIIbβ3 and PAC-1 binds to activated αIIbβ3. Cells were 
harvested after accutase treatment (5 minutes incubation at 37°C) and re-suspended in 
100 µl PBS resulting in total cell count of ~1 x 10
5
. 50 µl of cells were added to FACS 
tubes, followed by 50 µl of the desired FITC labeled antibody and incubated at 37°C for 
10 minutes. PBS was then added to stop the reaction. FITC was excited at 490 nm and 
emission observed at 520-540 nm, see Appendix 2. 
 
4.1.6   Localisation Studies 
To investigate the localisation of dpp-RGD2 and bpy-RGD
 
within cell organelles, cells 
were harvested after accutase treatment seeded at 1 x 10
5
 cells per well on glass 
coverslips in 24-well plates and grown to ~50% confluence. For confocal microscopy 
measurements the growth medium was removed by washing with PBS buffer (pH 7.4, 
with MgCl2 and CaCl2) and 70 µM of the parent dyes (no peptide) [Ru(bpy)2PIC]
2+
 and 
[Ru(dpp)2PIC]
2+
 and dye-peptide conjugates bpy-RGD and
 
dpp-RGD2 in the same PBS 
solution was added to each well containing cells and incubated for 4 hours at 37°C. 
Cells were washed with PBS, fixed with 3.8 % PFA solution for 10 minutes, blocked 
with 1.5% BSA for 2 hours at room temperature, stained with a 1:250 dilution of a 0.2 
mg/ml stock of CD41 (SZ22) antibody in PBS (pH 7.4) overnight at 4°C followed a 
1:500 dilution of secondary goat anti mouse IgG Alexa Flour 488 antibody for 2 hours 
at room temperature. Luminescence images were recorded on a Zeiss LSM510 Meta 
Confocal microscope using a 64x oil immersion objective lens (NA 1.4). 
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4.2   Results  
4.2.1   Binding Specificity: BSA  
A control experiment to assess the contribution of non-specific binding to the emission 
intensity changes observed in the ruthenium RGD conjugates was carried out using 
Bovine Serum Albumin, BSA, as a model protein which does not possess an RGD 
binding site, see Appendix 2. BSA-dissolved in TrisHCl buffer (150mM NaCl, 1mM 
CaCl2, 20mM TrisHCl, pH 7.4) was titrated into a solution of each ruthenium-peptide 
conjugate in the same buffer, to yield a final concentration of 1.1 μM of both complex 
and protein. The luminescence intensities of bpy-RGD and dpp-RGD after each 
addition of BSA (λexc 450 nm) increased modestly; approximately 2-fold with addition 
of BSA.  The emission change is attributed to non-specific association between complex 
and protein. As described, vide infra, the intensity changes elicited were much lower 
than induced by αIIbβ3 binding and all αIIbβ3 binding studies presented in this Chapter 
were corrected for non-specific binding, by subtracting the BSA/Ru emission intensity 
values from the αIIbβ3/Ru data). 
 
4.2.2   Ruthenium-RGD Binding to Purified, Resting αIIbβ3 
The binding affinity of the peptide probes toward purified, resting αIIbβ3 was then 
similarly investigated by luminescence spectroscopy. αIIbβ3, dissolved in TrisHCl buffer 
(20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl2, pH 7.4) was added sequentially to 
ruthenium-RGD in the same buffer, to yield a final concentration of 0.8 μM of both 
complex and protein. All data was corrected for dye alone (dye alone was subtracted 
from all data, thus dye alone was equal to zero in all cases). The luminescence spectra 
of bpy-RGD, dpp-RGD1 and dpp-RGD2 after each addition of αIIbβ3 (λexc 450 nm), are 
shown in Figures 4.2, (a-c), inset, respectively. To generate the binding curves, changes 
to the emission intensity of each of the probes were monitored at 610 nm. The emission 
intensity increased significantly with increasing αIIbβ3 concentration, an effect attributed 
to changes to the complex’s local microenvironment on protein binding, in particular, to 
inhibition of O2 access to the ruthenium center. The binding of both probes to resting 
integrin is saturable. The final intensity increases were approximately an order of 
magnitude greater for all peptide probes compared to the probes alone in solution. It is 
noteworthy that the absorbance spectra did not change in all cases suggesting the 
emission intensity increases observed are attributed to ruthenium probe binding to the 
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αIIbβ3 integrin protein (Appendix 2). It is also noteworthy that the luminescence 
observed at approximately 520 nm in Figure, 4.2, (a) and (c), inset, emission was not 
observed if excited at this wavelength, thus may be attributed to some form of scatter 
from the protein. It is also important to note that results were not reproducible with dpp-
RGD1, Figure 4.2, (c), due to the instability of the maleimide functionally and so, for 
the remainder of this Chapter, no further studies were carried out with this conjugate.  
 
 
 
 
 
 
 
 
 
 
(a) 
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(b) 
135 
 
 
Figure 4.2: Luminescence titration of BSA (grey) to confirm non-specific binding and 
purified, resting αIIbβ3 (black) by (a) bpy-RGD, (b) dpp-RGD1 and (c) dpp-RGD2.  
Inset: Luminescence emission intensity changes (arb.units) of Ru-RGD following 
sequential addition of purified, resting αIIbβ3. Corrections for dilution were inserted in 
all spectra recorded. Stock concentration was 2.3 µM for both protein and Ru-RGD in 
TrisHCl buffer, pH 7.4, and Ru-RGD was held constant in all cases. (λexc 450 nm, λem 
610 nm. Data are represented as mean ± standard deviation of 3 independent 
measurements (except maleimide, RGD1, due to instability, where n=1).   
 
 
The dissociation constants (Kd) were obtained from the curves presented in Figure 4.2, 
(a-c), and the Sigmaplot calculated values presented in Table 4.1. Bpy-RGD bound to a 
single site on the integrin protein with a Kd = 0.09 ± 0.01 µM, Figure 4.2, (a) and 
Table 4.1. Interestingly, the shape of the binding curve for αIIbβ3 titration against dpp-
RGD2 showed two plateaus indicative of two-step binding, Figure 4.2, (b), with an 
initial Kd = 0.25 ± 0.29 µM, Table 4.1. The second plateau presented Kd = 4.37 ± 0.82 
µM. Similarly, dpp-RGD1 exhibited two-step binding, presenting the highest affinity 
(c) 
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for integrin αIIbβ3 with an initial Kd = 0.16 µM, Figure 4.2, (c), and a second Kd = 1.76 
µM.  
 
The luminescence decay times and time resolved luminescence anisotropy of the 
ruthenium peptide conjugates bound to resting αIIbβ3 are also summarised in Table 4.1. 
An integrin/ruthenium ratio of 1.3:1 was used in all cases. For all three metal 
conjugates, binding to αIIbβ3 lead to an emission which decayed according to bi-
exponential kinetics (see supplemental material). The decays were dominated (>80% of 
amplitude) by a long-lived component >1.1 µs, whereas the short lived component 
(<20% of the amplitude) exhibited a lifetime of <0.5 µs, and was attributed to unbound 
conjugate. The luminescent lifetime of bpy-RGD increased 2 fold to 1.10 ± 0.07 µs on 
integrin binding, compared to 0.52 ± 0.04 µs in the absence of integrin. Whereas, the 
lifetime of dpp-RGD2 increased 3 fold from 0.49 ± 0.07 µs to 1.43 ± 0.04 µs on integrin 
binding. Consistent with the increase in luminescence intensity, a 10 fold increase on 
the luminescence lifetime of dpp-RGD1 is observed on integrin association from 0.20 ± 
0.04 µs to 2.15 µs. These increases in lifetime are consistent with the increased 
emission intensity observed on association of each complex with αIIbβ3.
 
The greater 
sensitivity of both dpp-RGD probes luminescent decay to αIIbβ3 binding is attributed to 
its comparatively greater O2 sensitivity compared with bpy-RGD. 
 
No luminescence anisotropy was observed for the ruthenium-peptide conjugates
 
alone 
in solution, while binding to purified integrin αIIbβ3 induced luminescence anisotropy, 
with a rotational correlation time of 1.50 ± 0.003 µs, 2.7 µs and 2.58 ± 0.04 µs for bpy-
RGD and dpp-RGD1 and dpp-RGD2 respectively. These rotational correlation times are 
consistent with values reported for other ruthenium(II) complexes directly conjugated to 
high molecular weight proteins, suggesting binding of the RGD peptide probes to the 
integrin is occurring.
(27)
 The difference in rotational correlation time between the two 
complexes is notable and suggests that the rotation may be a segmental rotation in the 
case of the bpy based complex. At least it indicates that the binding is different for the 
two complexes, consistent with the binding curves.  
 
4.2.3   Binding Specificity: Eptifibatide 
To determine if bpy-RGD and dpp-RGD2 bind specifically at the RGD binding motif 
on αIIbβ3, a displacement experiment was carried out using Eptifibatide. As mentioned, 
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due to the instability of the maleimide complex, dpp-RGD1, results with this complex 
were not reproducible and so was not studied any further. Eptifibatide is a glycoprotein 
integrin αIIbβ3 inhibitor which binds at the RGD binding motif with a Kd in the nM 
range compared to the µM range indicated for the ruthenium-peptide probes discussed 
here.
(16, 30-32)
 As its binding affinity for αIIbβ3 is 2 to 3 orders of magnitude greater than 
bpy-RGD or dpp-RGD2, it was expected that Eptifibatide would prevent binding of the 
peptide conjugates to the integrin if they compete for same binding site. The effect of 
sequential addition of αIIbβ3 to a solution containing a 1:1 molar ratio of Eptifibatide: 
bpy-RGD or Eptifibatide: dpp-RGD2 on the emission intensities of the ruthenium 
centers is presented in Appendix 2. In both cases only minor increases in emission 
intensity of the ruthenium complex is observed, comparable in magnitude to the 
intensity changes observed on non-specific binding to BSA.   
 
In addition, the effect of sequential addition of αIIbβ3 to each of the metal complexes 
(bpy-RGD or dpp-RGD2), where the integrin has first been incubated with Eptifibatide 
(1:1 molar ratio) is presented in supporting information. Similar, modest intensity 
increases are observed consistent with non-specific interactions only. As Eptifibatide is 
specific for the RGD binding site, these results indicate that its presence inhibits bpy-
RGD or dpp-RGD2 binding to αIIbβ3 and indicates therefore that both complexes bind 
specifically to the RGD ligand binding site. 
 
4.2.4   The Influence of Chemical Activation of αIIbβ3 on Ru-RGD Binding: 
 Mn
2+
 and DTT 
Although “inside-out” αIIbβ3 activation in-vivo is normally regulated by agonist-
generated signaling, αIIbβ3 can also be activated by a range of chemical stimuli including 
Mn
2+ 
and DTT.
(13, 15) 
Thus,
 
to assess the capacity of bpy-RGD and dpp-RGD2 to 
discriminate between nominally activated and resting integrin, the influence of 
treatment of the integrin by Mn
2+ 
and DTT on ruthenium-RGD binding and 
photophysical properties, once bound, were explored.   
 
4.2.4.1   Mn
2+
 Activation 
As described in Chapter 1¸ αIIbβ3 is composed of two non-covalently associated 
subunits, GPIIB (αIIb) and GPIIIa (β3). The presence of divalent cations; Ca
2+ 
and Mg
2+
 
stabilise subunit association of αIIbβ3. Integrins contain multiple cation binding sites that 
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influence its ligand binding affinity as well as activation state. All of the regions 
implicated in ligand recognition lie at, or close to, cation-binding sites, and ligand 
binding and cation binding are intimately linked.
(9, 33, 34)
 
 
It has been shown that Mn
2+
 directly modulates the binding activity of integrins to 
fibrinogen, fibronectin and RGD peptide mimetics.
(34-36)
 For example in 2002, Takagi et 
al.
(17)
 reported a conformational change in the crystal structure of the extracellular 
domain of αVβ3 to a bent conformation in the presence of Ca
2+
 and to an extended 
conformation in the presence of Mn
2+
, giving rise to the ‘switchblade’ hypothesis (the 
extended conformation of αVβ3 represents the active state and the bent shape represents 
the resting state). However, it appears to be unable to maintain the active-like state, 
which led to the suggestion by Arnaut et al.
(37)
 that a co-factor is required such as an 
RGD ligand. Their crystallographic studies indicated that even at very high relative 
concentrations of Mn
2+
 the conformation at the extracellular portion of a related integrin 
αVβ, remained relatively unchanged from its resting state except in the presence of a 
high-affinity RGD ligand.
(9)
 However, Weisel and co-workers have shown that Mn
2+
 
increases integrin affinity for and kinetics of binding to its primary ligand fibrinogen.
(36)
 
 
The emission spectra of bpy-RGD and dpp-RGD2 following 10 minutes
1
 incubation 
with integrin (αIIbβ3/ruthenium-RGD
 
ratio was 1:1) before and after treatment of the 
integrin with Mn
2+
 are shown in Figure 4.3, (i) and (ii). In these experiments Mn
2+
 was 
present in 10–fold excess to integrin. The emission data shown in Figures 4.3 are 
absorption matched (see Appendix 2), so that the emission intensity can be 
quantitatively compared.  
 
Figure 4.3, (i) and (ii), (a–d), show the control cases used to confirm that Mn2+ does not 
directly affect the photophysics of the metal complexes. The results are the same for 
both complexes; no significant change to the emission spectra of the ruthenium-RGD 
conjugate alone in PBS solution with and without Mn
2+
, in the presence of BSA and in 
the presence of BSA and Mn
2+
 is observed. 
 
                                                 
1
 Longer incubation times did not change the spectral data 
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In contrast, treatment of bpy-RGD bound to resting αIIbβ3 with Mn
2+
 caused a significant 
increase (~50%) in the emission quantum yield of the ruthenium conjugate, Figure 4.3, 
(i), (g), compared to the conjugate bound to resting integrin, Figure 4.3, (i), (f).   
 
However, interestingly, where the conjugate probe bpy-RGD was bound to the αIIbβ3 
after the integrin had been first incubated with Mn
2+
, Figure 4.3, (i), (e), the emission 
intensity of bpy-RGD was reduced ~21% compared to the conjugate bound to resting 
integrin.  
 
The behavior was analogous for dpp-RGD2; treatment of resting integrin with Mn
2+
 
after the dpp-RGD2 had been previously incubated with  the αIIbβ3 caused ~23% 
increase in the emission quantum yield of the ruthenium conjugate, Figure 4.3, (ii), (g), 
compared to the conjugate bound to resting integrin, Figure 4.3, (ii), (f). The effect of 
pre-treatment of the integrin with Mn
2+
 before exposure to the ruthenium probe was 
even more significant for dpp-RGD2, Figure 4.3, (ii), (e), whose emission intensity was 
reduced ~40% compared with the dpp-RGD2 bound to the resting (untreated) integrin. 
 
To quantify the effect of Mn
2+
 treatment of αIIbβ3 on it’s binding to the ruthenium 
conjugates the binding curves were obtained for each metal complex to the integrin 
following its incubation with a 10-fold molar excess (23 µM final concentration) of 
Mn
2+
. The binding curves for both metal complexes are shown in Figure 4.3, (iii). For 
bpy-RGD titrated with the Mn
2+
 treated integrin, Kd = 0.11 ± 0.01 µM was calculated. 
This suggests bpy-RGD binds to a single site and that the Kd is unchanged from the 
resting αIIbβ3 (Table 4.1). 
 
In contrast, pre-treatment of the integrin with Mn
2+
 had a significant effect on the 
binding of dpp-RGD2 to the protein. The binding curve, which for the resting integrin 
was a two step process becomes a single step binding process, shown in Figure 4.3, 
(iii), with Kd = 0.17 ± 0.04 µM. This suggests dpp-RGD2 binds to a single site and 
unlike bpy-RGD, the binding constant is smaller for the Mn
2+
 treated αIIbβ3 indicating 
that the complex has higher affinity for the integrin protein following Mn
2+
 treatment, 
see Table 4.3.   
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These results show, rather surprisingly, that the affinity of bpy-RGD for Mn
2+
 treated 
integrin is the same as resting integrin but that binding affinity of dpp-RGD2 for Mn
2+
 
treated integrin is increased compared to resting. This suggests that the counter ligand, 
e.g. bpy versus dpp, plays a role in the interaction of the metal complex RGD conjugate 
with integrin. The differences in the two complexes affinity for the resting integrin and 
the two step binding curve observed for the resting integrin for dpp-RGD2 also concur 
with this observation. It is important to note, however, that, as indicated by the 
Eptifibatide studies described in section 4.2.3; both complexes recognise the RGD 
binding site. 
 
The key differences between for bpy-RGD and for dpp-RGD2 are the size and 
particularly the hydrophobicity. The dpp complex (molecular weight: 1397.24) is 
expected to be approx 25% larger and considerably more hydrophobic than the bpy 
complex (molecular weight: 1748.62). For example, the perchlorate salt of the parent 
complex dpp-RGD2 is not water soluble, whereas the bpy complex is.   
 
Based on the two step binding to the resting integrin it is tempting to speculate that both 
RGD binding and hydrophobic-hydrophobic interactions occur for dpp-RGD2 and that 
the larger size of this complex prevents deep penetration of the complex into the RGD 
binding pocket, which is why for the Mn
2+
 activated complex the binding affinity 
increases. For bpy-RGD, the Kd with the integrin is the same before and after Mn
2+
 
treatment and the association constant to the resting integrin is greater than dpp-RGD2.  
This suggests that  this complex does not experience limited steric accessibility to the 
RGD binding site that Mn
2+
 activation alleviates and this is in good agreement with 
previously reported small peptide mimetic binders.
(38-41)
 
 
Interestingly, addition of Mn
2+
 whether before or after integrin binding to the metal 
complex conjugate had a similar impact on the rotational correlation time of the Ru(II) 
probes once bound. This data is captured in Table 4.1 bpy-RGD showed a decrease in 
rotational correlation time from 1.50 ± 0.03 µs for resting integrin to 1.29 ± 0.03 µs 
following the addition of Mn
2+
 to the Ru(II)-integrin complex. The rotational correlation 
time for bpy-RGD when bound to integrin which had been previously incubated with 
Mn
2+
 was recorded as 1.12 ± 0.01 µs, i.e. the reduction in rotational correlation time 
was greater when the integrin was treated with activator prior to probe binding. 
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Similarly, dpp-RGD2 presented a decrease in rotational correlation time from 2.58 ± 
0.04 µs for resting integrin to 1.72 ± 0.03 µs following the addition of Mn
2+ 
to the 
integrin-probe complex but was lower again at 1.53 ± 0.04 µs when the integrin was 
treated with Mn
2+
 prior to the Ru(II) probe binding. Therefore both peptide probes 
recorded the conformational change in the integrin induced by the Mn
2+
, but 
interestingly pre-association of each of the complexes with the integrin influences the 
final conformational state the integrin attains. 
 
Activation of integrin by Mn
2+
 exerts an influence on the luminescent lifetime of bpy-
RGD or dpp-RGD2, only if the metal complex conjugate binding site is bound to the 
integrin prior to its activation. If the αIIbβ3 is pre-treated with Mn
2+
 prior to its exposure 
to bpy-RGD, there is, within experimental error, no change to the luminescent lifetime 
of the probe; 1.10 ± 0.07 µs  (resting) versus 1.21 ± 0.04 µs (Mn
2+
), Table 4.1. In 
contrast, if the complex is already bound to the integrin prior before it is activated, the 
lifetime of the probe is found to increase to 1.36 ± 0.05, Table 4.1.   
 
Similarly, if the αIIbβ3 is treated with Mn
2+
 prior to its exposure to dpp-RGD2, there is, 
within experimental error, no change to the luminescent lifetime of the probe; 1.43 ± 
0.04 µs (resting) to 1.60 ± 0.13 µs (Mn
2+
), Table 4.1. Whereas, when the probe is 
already bound to the integrin and then treated with Mn
2+
 the lifetime of the probe 
increased dramatically, to 2.42 ± 0.04 Table 4.1. The increase in lifetime to the pre-
bound probe in each instance correlates with the observed increase in emission intensity 
of the final complex following chemical treatment post association to integrin, as shown 
in Figure 4.3, (ii), (f).  
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Figure 4.3: The effect of Mn
2+
 chemical treatment of αIIbβ3 on the luminescence 
spectroscopy of bound (i) bpy-RGD or bound (ii) dpp-RGD2 where Ru-RGD is 
incubated (a) alone in solution , (b) with Mn
2+
, (c) with  BSA, (d) with BSA and Mn
2+
, 
(e) with  αIIbβ3 pre-treated with Mn
2+
, (f) with untreated αIIbβ3 (g) Mn
2+
  post-bind the 
dye probe to untreated αIIbβ3. (iii) bpy-RGD (black circle)
 
and dpp-RGD2 (white circle) 
emission intensity changes following binding to integrin pre-treated with Mn
2+
 and 
corrected for non-specific binding with BSA (grey circle). The αIIbβ3/ruthenium-RGD
 
ratio was 1:1. The stock concentration of bpy-RGD, dpp-RGD2, αIIbβ3 and BSA was 2.3 
µM in TrisHCl buffer pH 7.4 for all experiments. Mn
2+
 concentration was 23 µM (10:1 
Mn
2+
:αIIbβ3 ratio). Ru-RGD concentration
 
was held constant in all cases. λex 450, λem 
610 nm and slit width of 10nm. Data are represented as mean ± standard deviation of 3 
independent measurements.  
(i) (ii) 
(iii) 
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4.2.4.2   DTT Activation 
DTT is a powerful reducing agent, because its oxidised product is stabilised by a six-
membered ring with an internal disulfide bond. The requirement of specific cysteine-
cysteine disulphide bonds for the maintenance of integrin activation is well reported.
(15, 
42, 43) 
Treatment of platelets or integrin with DTT has been shown to increase the ligand 
binding affinity of the integrin
(15, 44)
, attributed to the formation of an active 
conformation of the protein stimulated by disulfide reduction.
(45)
 
 
The effects of DTT treatment of αIIbβ3 on the emission of dpp-RGD2 or bpy-RGD 
binding to the integrin are shown in Figure 4.4, (i) and (ii). In all cases, DTT was added 
in 10–fold molar excess (23 µM final concentration) to the integrin. The emission 
spectra were recorded following 10 minutes incubation of the integrin-probe complex 
with DTT.
2
  
 
Figure 4.4, (i) and (ii), (a-d), present the control experiments where the emission 
spectra of each metal complex conjugate were recorded in the absence of αIIbβ3; alone 
with DTT, in the presence of BSA and in the presence of BSA and DTT. No relative 
change in emission intensity was in these controls when DTT was absent and present 
confirming that DTT has no direct effect on the photophysics of the ruthenium 
conjugate. 
 
Figure 4.4, (i), (g), shows that incubation of the bpy-RGD;αIIbβ3 complex with DTT 
results in a significant increase (~58%) in the emission quantum yield of the ruthenium 
conjugate. Conversely, when αIIbβ3 was incubated with DTT prior to binding to bpy-
RGD, Figure 4.4, (i), (e), the final integrated emission intensity of bpy-RGD once 
bound to the integrin was reduced by approximately 30% on binding to pre-treated 
integrin compared to resting integrin, however is likely due to the lower binding 
constant (Table 4.1). This result confirms that although bpy-RGD, has the same 
reducing effect as dpp-RGD, the effect is slightly weaker for the bpy containing probe 
presenting ~70% decrease while the dpp probe presents ~80% decrease in the final 
integrated emission intensity.  
 
                                                 
2
 Longer incubation times did not change the spectral data 
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Similarly, after dpp-RGD2 had been incubated first with the resting integrin Figure 4.4, 
(ii), (f), the addition of DTT caused a significant increase (~31%) in the emission 
quantum yield of the ruthenium conjugate, Figure 4.4, (ii), (g). Whereas, when αIIbβ3 
was treated with DTT prior to its association with dpp-RGD1, Figure 4.4, (ii), (e), the 
final integrated emission intensity of dpp-RGD2 once exposed to integrin was reduced 
by approximately 80% on binding to pre-treated integrin compared to resting integrin.  
 
Overall, although the magnitude of the emission intensity changes induced by DTT are 
greater, the trend is the same as for Mn
2+
 treatment and suggests, again that pre-binding 
of either ruthenium peptide conjugate to αIIbβ3 influences the final conformation the 
integrin achieves following activator treatment. 
 
To investigate if the changes in emission intensity on integrin activation arise from 
environmental effects due to the change in conformation of the protein or are due to 
differences in binding constant between metal complex and DTT treated integrin 
compared with resting, this parameter, the rotational correlation time from time-
resolved luminescence anisotropy and luminescent lifetimes of the metal complexes 
were studied and are presented in Table 4.1. 
 
Figure 4.4, (iii), shows the binding curve for bpy-RGD with DTT treated αIIbβ3. The 
sigmoidal curve indicates single site binding and Kd was determined to be 0.08 ± 0.01 
µM. Therefore Kd for this complex is the same for resting and DTT treated αIIbβ3, Table 
4.1.   
 
For dpp-RGD2, as observed for Mn
2+
, the binding curve for this complex with the DTT 
treated integrin changed from the two step curve seen for the resting integrin to a single 
step binding curve, Figure 4.4, (iii). Kd was estimated to be 0.15 ± 0.05 µM, Table 4.1, 
indicating dpp-RGD2 binds to a single site with higher affinity compared to the two-
step binding to resting αIIbβ3. 
 
Addition of DTT both prior to or after bpy-RGD association with the integrin αIIbβ3 
resulted in significant decreases in the rotational correlation time of the Ru(II) centre, 
Table 4.1. The rotational correlation time for the metal complex was 1.04 ± 0.01 µs 
following DTT treatment of the Ru:integrin complex (a 14% decrease compared to 
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resting integrin) and this was reduced to 0.59 ± 0.02 μs if αIIbβ3 was exposed to DTT 
prior to its association with bpy-RGD (61% decrease compared to resting integrin).  
 
For dpp-RGD2 the rotational correlation time of this complex was found to be 1.29 ± 
0.03 µs when DTT was applied to the Ru: integrin complex (a 50% decrease compared 
to resting integrin) and this decreased to 0.90 ± 0.02 μs if αIIbβ3 was exposed to DTT 
prior to its association with dpp-RGD2 (65% decrease compared to resting integrin), 
Table 4.1.  
 
Consistent with the behavior observed for Mn
2+
 activation, treating integrin with DTT 
only had a significant effect on the luminescence lifetime of the Ru-RGD compounds if 
the probe was bound to the integrin prior to activation, Table 4.1. The luminescent 
lifetime of bpy-RGD increased to 1.83 ± 0.07 µs following DTT treatment to the 
integrin.  Similarly the lifetime of dpp-RGD2 was found to increase to 2.72 ± 0.04 µs 
for DTT treated integrin, Table 4.1. The increased lifetime for each probe bound to the 
integrin following DTT treatment correlates well with increased emission intensity 
observed for the integrin-probe complexes on DTT treatment, Figure 4.4, (i) and (ii), 
(f).   
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Figure 4.4: The effect of DTT chemical treatment of αIIbβ3 on the luminescence 
spectroscopy of bound (i) bpy-RGD or (ii) dpp-RGD2 where Ru-RGD is incubated (a) 
alone in solution, (b) with DTT, (c) with BSA, (d) with BSA and DTT, (e) with αIIbβ3 pre-
treated with DTT, (f) with untreated αIIbβ3 (g) DTT post-bind the dye probe to untreated 
αIIbβ3. (iii) bpy-RGD (black circle)
 
and dpp-RGD2 (white circle) emission intensity 
changes following binding to integrin pre-treated with Mn
2+
 and corrected for non-
specific binding with BSA (grey circle). The αIIbβ3/ruthenium-RGD
 
ratio was 1:1. The 
stock concentration of bpy-RGD, dpp-RGD2, αIIbβ3 and BSA was 2.3 µM in TrisHCl 
buffer pH 7.4 for all experiments. DTT concentration was 23 µM (10:1 DTT:αIIbβ3 
ratio). Ru-RGD concentration
 was held constant in all cases.  λex 450, λem 610 nm and 
slit width of 10nm. Data are represented as mean ± standard deviation of 3 independent 
measurements. 
(i) (ii) 
(iii) 
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That both lifetime and time-resolved luminescence anisotropy change in response to 
Mn
2+ 
or DTT treatment of the probe: integrin complex indicates that a conformational 
change has been induced by the activator. That there is a difference in the emission 
lifetime of the probe depending on whether it was in place when the integrin was treated 
with the activator or not seems to suggest that its presence influences the final 
conformation achieved and that this state differs depending on Mn
2+
 or DTT activation. 
 
4.2.5   Ruthenium-RGD Specific Binding to Denatured αIIbβ3 
As denaturation of αIIbβ3 will induce gross conformational change in the protein we 
studied its effect on probe binding and photophysics by incubating the integrin at 90°C 
for 1 hour to denature it prior to its exposure to the peptide conjugates. The denaturing 
temperature varies for different proteins, but temperatures above 41°C are reported to 
break the interactions in many proteins and denature them, thus 90°C heat ensures 
effective protein denaturation.
(46, 47)
 We rationalised that by comparing the changes 
induced by denaturing αIIbβ3 on probe binding and photophysics we could benchmark 
somewhat the extent of conformational change induced by DTT and Mn
2+
. The 
emission spectra of bpy-RGD and dpp-RGD2 following incubation with denatured 
integrin (αIIbβ3:ruthenium-RGD
 
ratio was 1:1) is shown in supporting information. The 
binding curves of both peptide probes to αIIbβ3 are shown in Figure 4.5, (i) and (ii), and 
show that both exhibit saturable binding to the integrin. 
   
Interestingly, both metal peptide conjugates associated strongly with the denatured 
integrin and showed significant increases in emission intensity and lifetime on binding 
compared with the free complex, Table 4.1. A Kd of 0.06 ± 0.01 µM was obtained for 
bpy-RGD with denatured integrin, indicating a slightly higher binding affinity than 
αIIbβ3 treated with either DTT or Mn
2+
, Table 4.1 and Figure 4.5, (i). The emission 
quantum yield of the denatured integrin:bpy-RGD increased by ~44% compared to the 
complex bound to resting αIIbβ3 but within experimental error, the lifetime was 
unchanged. Denaturing the protein also caused a large decrease in rotational correlation 
time of the Ru(II) centre presenting a value of 0.46 ± 0.002 µs (roughly 3 times that of 
the probe bound to the resting integrin), Table 4.1.  
 
For dpp-RGD2 the quantum yield of the complex bound to denatured integrin also 
increased, by approximately 30%, compared to resting αIIbβ3 and a Kd value of 1.35 ± 
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0.39 µM was obtained, indicating a lower binding affinity than αIIbβ3 treated with either 
DTT or Mn
2+
, Table 4.1 and Figure 4.5, (ii).   
 
As for the bpy complex, the rotational correlation time of the dpp-RGD2 centre 
decreased dramatically on binding to the denatured protein to 0.23 ± 0.04 µs (resting 
integrin), Table 4.1. Binding of the probe to the denatured integrin concomitantly 
decreased the lifetime of the probe to 0.91 ± 0.09 µs compared with 1.43 ± 0.04 for the 
probe bound to resting integrin.   
 
The very large reduction in rotational time constant observed for both dpp-RGD2 and 
bpy-RGD on binding to denatured integrin compared with resting or indeed Mn
2+
 or 
DTT activated integrin is consistent with disruption of protein secondary and tertiary 
structure expected on heat treatment. The rotational process leading to depolarisation of 
the luminescence in both intact and denatured integrin is likely to be due to segmental 
rather than overall rotation of the protein so direct correlation with the molecular weight 
change of the protein is not expected.  
 
The greater influence of denaturation on the lifetime of dpp-RGD2 compared to bpy-
RGD is attributed to the greater oxygen sensitivity of the former probe. The exposure 
afforded by loss of the RGD binding pocket in the intact protein leads to a greater 
reduction in its luminescence lifetime. Comparison of the rotational correlation times 
for the probes bound to Mn
2+
 and DTT treated integrin compared to denatured integrin 
confirms that these treatments do not denature the integrin and these probes through 
their luminescence anisotropy provide useful markers for the extent of conformational 
change in the integrin. 
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Figure 4.5: Binding curve for (i) bpy-RGD and (ii) dpp-RGD2 with denatured αIIbβ3 
(black circles) and BSA (grey circles). αIIbβ3 was denatured prior to the titrations by 
incubation at 90°C for 1 hour. The emission intensity data presented is corrected for 
contributions to non-specific binding with BSA. The stock concentration of bpy-RGD, 
dpp-RGD1 and αIIbβ3 was 2.3 µM in all cases in TrisHCl buffer pH 7.4.  Ru-RGD was 
held constant in all cases.  λex 450, λem 610 nm and slit width of 10nm. Data are 
represented as mean ± standard deviation of 3 independent measurements. 
(i) 
(ii) 
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Table 4.1:  Rotational correlation times, luminescent lifetimes and dissociation constants of (left) bpy-RGD and (right) dpp-RGD2 dye alone, bound to BSA, 
bound to untreated αIIbβ3, as a function
 
of integrin treatment (Mn
2+
,DTT or denatured)in TrisHCl buffer (pH 7.4) at room temperature as measured by TCSPC 
(λexc 450 nm). r
2
, reduced chi–square values were approximately 1 in all cases confirming statistical significance. Post-bind; Mn2+ or DTT was added after Ru-
RGD had bound to resting αIIbβ3. Pre-treatment; Mn
2+ 
or DTT was pre-incubated with αIIbβ3 prior to addition to Ru-RGD. Denatured; αIIbβ3 was denatured for 
1 hour at 90 °C prior to titration with Ru-RGD.
 
 The stock concentration of Ru-RGD and αIIbβ3 was 2.3 µM. Mn
2+
 and DTT were added at a 10:1 (αIIbβ3: Ru-
RGD) ratio.  Ru-RGD concentration was held constant in all cases. * Lifetime measurements in aerated media. Data are represented as mean ± standard 
deviation of 3 independent measurements. 
bpy-RGD dpp-RGD2 
Integrin 
Treatment 
Fundamental 
Anisotropy 
(R0) 
Rotational 
Correlation 
Time 
(µs) 
Dissociation 
Constant 
(Kd) 
Luminescent 
Lifetime* 
(µs) 
Relative 
Intensity 
(arb. units) 
Fundamental 
Anisotropy 
(R0) 
Rotational 
Correlation 
Time 
(µs) 
Dissociation 
Constant 
(Kd) 
Luminescent 
Lifetime* 
(µs) 
Relative 
Intensity 
(arb. units) 
dye alone - 
- 
- 
0.52 
±  0.04 
0 - - - 
0.49 
± 0.07 
0 
bound to  
resting αIIbβ3 
0.007 
± 0.003 
1.50 
± 0.03 
0.09 
± 0.01 
1.10 
± 0.07 
38 
± 2 
0.04 
± 0.005 
2.58 
± 0.04 
0.25 ± 0.29, 
4.37 ± 0.82 
1.43 
± 0.04 
35 
± 1 
post-bind to αIIbβ3 
(Mn
2+
) 
0.007 
± 0.004 
1.29 
± 0.03 
- 
1.36 
± 0.05 
60 
± 2 
0.03 
± 0.005 
1.72 
± 0.03 
- 
2.42 
± 0.04 
50 
± 2 
pre-treated αIIbβ3  
(Mn
2+
) 
0.002 
± 0.03 
1.12 
± 0.01 
0.11 
± 0.01 
1.21 
± 0.04 
25 
± 2 
0.005 
± 0.001 
1.53 
± 0.04 
0.17 
± 0.04 
1.60 
± 0.13 
15 
± 4 
post-bind to αIIbβ3 
(DTT) 
1.29 
± 0.03 
1.04 
±0.01 
- 
1.83 
± 0.07 
70 
± 2 
0.01 
± 0.003 
1.29 
± 0.03 
- 
2.71 
± 0.04 
57 
± 3 
 pre-treated αIIbβ3  
(DTT) 
0.002 
± 0.003 
0.59 
± 0.02 
0.08 
± 0.01 
1.20 
± 0.12 
12 
± 3 
0.005 
± 0.001 
0.90 
± 0.02 
0.15 
± 0.05 
1.58 
± 0.07 
8 
± 3 
bound to 
denatured αIIbβ3 
0.19 
± 0.03 
0.46 
± 0.002 
0.06 
± 0.01 
1.16 
± 0.05 
123 
± 2 
0.004 
± 0.001 
0.23 
± 0.04 
1.35 
± 0.39 
0.91 
± 0.09 
41 
± 2 
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4.2.6   Cellular Imaging 
4.2.6.1   Localisation of bpy-RGD and dpp-RGD2 with αIIbβ3 
As bpy-RGD and dpp-RGD2
 
presents strong, specific binding to the integrin and can 
report, based on luminescence anisotropy, lifetime and binding constant, on the 
conformational status of the protein we were interested to see if the complexes bind to 
resting integrin within live cells. Two types of Chinese hamster ovary (CHO) cells were 
used in this study: wild type, CHO-WT cells which do not express αIIbβ3 and transfected 
CHO–αIIbβ3 cells which express the resting form of αIIbβ3. As expected for the controls, 
minimal staining with either the parent complex without the peptide; [Ru(bpy)2PIC]
2+
 
and [Ru(dpp)2PIC]
2+
 , Figure 4.6, (a) and ( b), or the peptide probes bpy-RGD and dpp-
RGD2, Figure 4.6 (c) and (d), was observed with CHO-WT cells i.e. when there is no 
integrin expression,. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
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Figure 4.6: (Left) Bright-field and (right) rainbow luminescence confocal image of 
CHO-WT cells incubated with the parent complexes (a) [Ru(dpp)2PIC]
2+
, 
(b)[Ru(bpy)2PIC]
2+
and ruthenium-RGD peptide conjugates (c) dpp-RGD2 and (d)bpy-
RGD. All dyes were added at 70 µM concentration in PBS (pH 7.4) and incubated at 
37°C for 4 hours. Excited at 458 nm, ruthenium luminescence was collected with a long 
pass filter of 615 nm. No luminescence was observed on the cells in both cases.  
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For
 
transfected CHO–αIIbβ3 expressing the resting form of αIIbβ3, similarly, minimal 
staining was observed when these cells were incubated with the parent complex 
[Ru(dpp)2PIC]
2+
 and [Ru(bpy)2PIC]
2+
 presented in Figure 4.7. 
 
Figure 4.7: (Left) Bright-field and (right) rainbow luminescence confocal image of 
transfected CHO–αIIbβ3 cells incubated with the parent complexes (a) [Ru(dpp)2PIC]
2+
 
and (b)[Ru(bpy)2PIC]
2+
. All dyes were added at 70 µM concentration in PBS (pH 7.4) 
and incubated at 37°C for 4 hours. Excited at 458 nm, ruthenium luminescence was 
collected with a long pass filter of 615 nm. No luminescence was observed on the cells 
in both cases. 
 
In contrast, when incubated with dpp-RGD1 CHO–αIIbβ3 exhibited intense ruthenium 
based emission (610 nm) at the cell surface suggesting binding to the cell-surface 
integrin receptor. To confirm this was the case, the cells were incubated with both dpp-
RGD2 and fluorescently labeled αIIb specific antibody, SZ22. Both reagents co-localised 
strongly at the cell surface, as shown in Figure 4.8, (a) (z-stack example is presented in 
Appendix 2), suggesting binding to the cell-surface integrin receptor. An emission 
intensity profile illustrating the extent of co-localisation between dpp-RGD2
 
and the 
SZ22 αIIb integrin specific antibody is presented in Appendix 2. Both intensities 
presented high fluorescence at identical locations. The observed dip in intensity is 
indicative of the absence of nuclear staining. 
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In direct correlation with dpp-RGD2, incubation of bpy-RGD with CHO–αIIbβ3 cells 
exhibited strong co-localisation with SZ22 αIIb integrin specific antibody, as shown in 
Figure 4.8, (b). An emission intensity profile illustrating the extent of co-localisation 
between bpy-RGD2
 and the SZ22 αIIb integrin specific antibody is presented in 
Appendix 2.  
        Bright Field                 Ru-RGD                      SZ22                          Merge 
 
Figure 4.8: Luminescence confocal image of transfected CHO–αIIbβ3 cells expressing 
the resting form of αIIbβ3. (a) Dpp-RGD2 and (b) bpy-RGD, Ru-RGD (red) successfully 
co-localised with αIIb specific antibody, SZ22 (green), represented by merge, yellow. Ru-
RGD was added at 70 µM concentration in PBS (pH 7.4) and incubated at 37°C for 4 
hours. SZ22 was added 1/250 dilution overnight at 4°C and secondary AlexaFluor488 
goat anti-mouse was added 1/500 for 2 hours at room temperature. 458 nm (ruthenium) 
and 488 nm (AlexaFluor) laser excitation.  
 
A total of ~48% integrin expression was determined by flow cytometry, see Appendix 
2, thus ~52% of the CHO–αIIbβ3 cells within the culture do not express the integrin, and 
it was confirmed, that where a cell does not express integrin, it did not bind to either 
dpp-RGD2 or bpy-RGD  and was also not stained by SZ22. A larger area image 
presenting multiple CHO cells both expressing and not expressing integrin αIIbβ3 is 
shown in Figure 4.9, (a) and (b) demonstrating representative and reproducible integrin 
αIIbβ3 staining in both cases. 
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        Bright Field                 Ru-RGD                      SZ22                          Merge 
 
Figure 4.9: Luminescence Confocal image of a transfected CHO–αIIbβ3 cell expressing 
the resting form of integrin αIIbβ3 compared to cells not expressing the integrin protein.  
(a) Dpp-RGD2, Ru-RGD (red) and (b) bpy-RGD, Ru-RGD (red) successfully co-
localised with SZ22 (green) localising on the surface of the cell (merge, yellow). The 
bright field images (grey) in each case represent the cells alone (no dye). Dpp-RGD2 
and. bpy-RGD was added at 70 µM concentration in PBS (pH 7.4) and incubated at 
37°C for 4 hours. SZ22 was added 1/250 dilution overnight at 4°C and secondary 
AlexaFluor488 goat anti-mouse was added 1/500 for 2 hours at room temperature. 458 
nm (ruthenium) and 488 nm (AlexaFluor) laser excitation. No luminescence is observed 
on the cells failing to express the integrin protein. 
 
4.3   Discussion 
Both bpy-RGD and dpp-RGD2 bind with reasonably high affinity to resting integrin 
αIIbβ3 (Table 4.1). Contrasting evidence regarding the ability of RGD to bind to resting 
integrin/platelets has been widely reported.
(38, 40)
 Binding of fibrinogen to resting 
platelets is so weak it is impossible to measure and is tightly regulated by activation of 
platelets through various forms of stimuli (ADP, thrombin etc.).
(40)
 However there is 
evidence that small RGD peptide mimetics can bind with equal to high affinity to both 
resting and activated integrin protein and platelets.
(38)
 For example, Echistatin, which 
contains an RGD sequence, binds with equal affinity to resting and activated 
platelets.
(39)
 Hu et al.
(40)
 suggest two ligand binding pockets exist within integrin αIIbβ3; 
(a) 
(b) 
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one which binds RGD type ligands and the other which binds to fibrinogen.  In this 
latter study, the binding ability of both fibrinogen and Fab-9 (a human antibody 
engineered by phage display to contain an RGD in the antigen binding site) to resting 
versus activated platelets was investigated. Fab-9 bound with equal affinity to both 
resting and activated platelets, whereas in contrast, fibrinogen bound solely to activated 
platelets. Further investigations confirm that the binding sites for RGD ligands and 
fibrinogen are spatially distinct yet coupled allosterically. Thus RGD peptide mimetics 
in contrast to fibrinogen seem to have the ability to bind to the β3 subunit of both resting 
and activated forms of integrin αIIbβ3 and platelets. 
 
The results presented here are consistent with this picture, which indicate that bpy-RGD 
and dpp-RGD2 bind to both resting and activated αIIbβ3 in solution with comparable 
affinity. Bpy-RGD presented the lowest Kd values indicating highest affinity for this 
probe to both resting and treated forms of integrin, which as mentioned may be 
attributed to less steric restriction on the complex accessing the RGD site. Indeed, in 
spite, or perhaps because of the presence of the bulky hydrophobic dpp-RGD2 metal 
complex luminophore, higher Kd values and two step binding of the complex to the 
resting integrin indicates lower affinity for the protein compared to the bpy containing 
conjugate. The binding curves indicate that the metal complex-peptide binds to the 
native integrin in a cooperative manner. The dpp ligands of the complex render the 
metal center hydrophobic; indeed without the peptide, the complex is not soluble in 
water. It is tempting to speculate that in the resting integrin, both RGD binding and 
hydrophobic-hydrophobic interactions between probe and protein binding pocket are 
responsible for the characteristic binding curves observed here. It may also be likely that 
access to the RGD site is sterically hindered compared to the bpy conjugate. 
 
Cierniewski et al.
(48)
 presented a similar two-step binding curve for αIIbβ3 with 
structurally related cyclic RGD (cRGD and cHarGD) peptides. This behavior was 
attributed to peptides binding simultaneously with two distinguishable binding sites 
within the integrin. In this study, fluorescence energy transfer studies indicated that both 
peptides could bind to the same αIIbβ3 molecule with the following stoichiometry: 0.45 
mol of cRGD and 0.85 mol of cHarGD per mol of receptor. The results presented in this 
chapter suggest that the dpp-RGD2 may have the ability to bind to two binding sites 
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within a single integrin αIIbβ3 molecule with comparable stoichiometry to Cierniewski et 
al.
(48)
 
 
Alternatively, it may also be suggested that the metal complex undergoes cooperative 
binding in the resting integrin, perhaps through H-bonding or hydrophobic-hydrophobic 
interactions with the protein when it is in a resting state. The presence of the 
hydrophobic ruthenium, carboxylic acids located on the aspartic acid (D) and serine (S) 
residues of the G-Ahx-GRGDS and C-Ahx-GRGDS peptide moieties can promote 
hydrogen bonding and electrostatic interactions with primary amino groups located on 
the integrin. RGD sequence studies have identified the arginine (R) and (D) residues to 
play a key role in integrin recognition through hydrogen bonding and metal 
coordination interactions.
(9, 49) 
The (D) residue completes the coordination of one of the 
three Mn
2+
 ions at the top of the β3 subunit. Xiong et al.
(9)
 also reported that the glycine 
(G) residue appears to be in close contact with the integrin surface in these structures 
making several hydrophobic interactions with the integrin surface, including contact 
with the carbonyl oxygen of residue arginine
216 in the β3 integrin subunit. Bella and 
Humphries
(50)
 further showed through modeling that when hydrogen atoms are modeled 
on the central (G) residue with standard stereochemistry, the interaction between this 
residue and a carbonyl group in the integrin surface shows all signs of Cα-H···O=C 
hydrogen bonding, a process widely published for the collagen triple helix.
 
Molecular 
dynamic simulations of the docking of RGD-containing fragments on integrin surfaces 
further support the occurrence of these interactions. Results suggest the presence of an 
array of four weak and conventional hydrogen bonds lining up the RGD residues with 
main chain carbonyl groups in the integrin surface. 
 
Interestingly, Sanchez-Cortez and Mrksich recently reported that an XGD peptide 
sequence can bind to the RGD binding pocket once the residue in the X position is basic 
or hydrophobic, suggesting hydrophobic-hydrophobic interactions may play a role in 
binding.
(41)
.  
 
As mentioned, in contrast to both dpp containing ruthenium-RGD probes, bpy-RGD is 
hydrophilic and less bulky than dpp containing probes thus hydrophobic-hydrophobic 
interactions are suggestively eliminated, steric strain is reduced and it is small enough to 
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easily reach the binding site resulting in a single site binding curve with the highest 
affinity binding to the integrin protein. 
 
4.4   Conclusion 
The ability of the novel luminescent, Ru(II) polypyridyl peptide conjugates, dpp-RGD2 
and bpy-RGD to recognise the platelet integrin αIIbβ3 in solution and in live cells was 
explored. In solution, the application of these conjugates to report on integrin binding 
and activation by two commonly known chemical activators Mn
2+ 
and DTT was 
investigated using luminescence emission intensity, time-resolved luminescence 
anisotropy and confocal microscopy. Both probes selectively bind to resting αIIbβ3, and 
control experiments with BSA and the well known pharmaceutical integrin protein 
inhibitor Eptifibatide confirmed dpp-RGD2 and bpy-RGD specificity toward αIIbβ3.  
 
Treatment of integrin αIIbβ3, with Mn
2+ 
and DTT modified integrin conformation and the 
mode of binding of the dpp-RGD2 conjugate to the protein. Predictably DTT proved to 
have the greatest effect on integrin conformation when compared to Mn
2+
. Interestingly 
the conformational modifications to the integrin were strongly influenced by the 
presence of the dpp-RGD2 and bpy-RGD at its RGD recognition site prior to its 
chemical activation. Preliminary evidence suggests that the cooperative binding of the 
(dpp) containing metal complex ligand which is likely to combine hydrophobic-
hydrophobic interactions with RGD recognition site binding and the hydrophilic, single 
site binding bpy-RGD probe alters the final conformation of the integrin achieved with 
both DTT and Mn
2+
 treatment. Nonetheless, dpp-RGD2 and bpy-RGD are useful 
peptide-probes for the assessment of integrin conformation as a result of their efficient 
integrin binding and long luminescent lifetime which provide a means of directly 
probing the activation state of αIIbβ3 integrin through time-resolved luminescence 
anisotropy. Clear distinctions are observed in luminescence intensity, lifetime and 
anisotropy of the peptide probes when they are used to treat integrin which is resting, or 
chemically activated. Indeed clear distinctions are observed between each mode of 
activation or denaturation, reflected in differences in luminescence anisotropy between 
integrin treated with Mn
2+
, DTT or integrin which has been thermally denatured. Such 
probes have significant potential value in elucidating the activation status of integrins, 
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which normally requires expensive and time consuming protocols such as SDS-PAGE 
and immunoprecipitation.
(14, 51)
  
 
Finally, it was demonstrated that dpp-RGD2 and bpy-RGD bind specifically to αIIbβ3 in 
live cells as confirmed by their co-localisation with the SZ22 αIIb integrin specific 
antibody. The parent dyes without the peptide do not bind and when there is no αIIbβ3 
expressed by the cell, dpp-RGD2 and bpy-RGD do not bind.   
 
Integrins are key therapeutic targets in many inflammatory and vascular disorders and 
means of targeting them in live cells and in simply and effectively assessing their 
conformational status may be very useful in diagnostic assays as well as fundamental 
studies into their behavior. We believe such compounds may be more widely useful 
targeting integrins beyond the platelet integrin in thrombosis.  For example, RGD is a 
recognition sequence for approximately 8 integrin proteins and is regarded for example 
as a useful cancer marker. 
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Chapter 5: Ligand Capture of Human Blood 
Platelets to Planar Gold Surfaces and 
Microcavity Arrays 
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5.0   Introduction 
5.0.1   Self-Assembled Monolayer (SAM) Surfaces for Cell/Platelet Adhesion  
Deep understanding of the interaction between biological samples and materials is of 
key importance across a broad range of domains including medicine
(1,2)
 and    
biosensing.
(3,4)
 For example, non-specific protein adsorption can poison sensor surfaces 
significantly reducing sensing abilities of devices. In medicine, such non-specific 
protein adsorption to implantable devices can result in an increased possibility of 
fibrosis and inflammatory complications with users often requiring implantable sensor 
replacements within several day periods. In the case of blood-contacting materials, 
understanding and controlling platelet interactions with surfaces is important across a 
range of domains including diagnostics
(5)
 and medical implants
(6)
. For example, platelet 
adhesion directly or through adsorbed protein on medical implants is important in 
dictating haemocompatibility as it can lead to thrombus formation (blocks blood flow 
leading to heart attack/stroke), see Figure 5.1. In the application of materials in 
biomedicine the interfacial interactions between materials and biological components, 
particularly cells and proteins is critical to the effectiveness and safety of a given 
medical device but remains an unsolved problem and limits clinical application. 
          
Figure 5.1: Example of medical implant stent infection and thrombosis. (Bottom Left) 
Bacterial species attach non-specifically to the surface, secreting carbohydrate slime 
(exopolymer) that imbeds the bacteria and attracts other microbes to the surface for 
protection/nutritional advantages. (Bottom right) Non specific adsorption of thrombus 
related components; platelets, platelet aggregates, inflammatory cells (eosinophils, 
neutrophils, macrophages) and entrapped red blood cells (RBC). Non-specific 
adsorption in these cases may lead to inflammation, fibrosis and thrombus 
formation.
(7,8)
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Mammalian cells exhibit the natural tendency to adhere to a surface to allow for many 
processes such as cell proliferation and differentiation.
(9,10) 
In vivo, most cells adhere to 
the extracellular matrix (ECM), and so, to aid surface adhesion, materials are usually 
coated with proteins from the relevant source e.g. blood. Cells sense the coated surface 
environment via receptors presented at their membranes. These transmembrane 
receptors (e.g. integrin αIIbβ3) form clusters, and associate intracellularly with groups of 
proteins (e.g. talin) which link them to the cytoskeleton forming focal adhesion points 
and consequential adhesion to the modified surfaces.
(11-13)
   
 
The SAM strategy has been most successful for the investigation of integrin adhesion 
with the tripeptide arginine-glycine-aspartic acid (RGD), a sequence recognised by 8 
out of the 24 known integrin proteins. Recently, for example, Yoon et al.
(14) 
demonstrated cell adhesion and detachment up to single cell level using gold surfaces 
modiﬁed with a thiol-functionalised RGD peptide from the perspective of analysis and 
re-culturing in microﬂuidic systems. A thiol SAM on top of the gold surfaces was 
reductively desorbed to spatio-temporally manipulate both cell adhesion and 
detachment. Employing an RGD peptide as a cell adhesion motif provided cells with a 
microenvironment that was as similar as possible to a real in vivo microenvironment. 
 
Cell non-adhesive surfaces or non-fouling surfaces are highly sought after in clinical 
applications, especially for blood-contacting materials e.g. artificial heart devices. 
Poly(ethylene)glycol (PEG) and alkanes are utilised widely in biological studies to form 
ideal stable inert surfaces and to eliminate non-specific adhesion.
(15-17)
 For example, 
Huang and Xiao recently reported the introduction of RGD peptides on Poly(3-
hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) films via PEG containing cross-linkers 
to improve cell adhesion and blood biocompatibility.
(18) 
PHBV biodegradable polyester 
has become a popular choice of substrate in tissue engineering due to its biocompatible 
degradation properties. In this study a 2 mM concentration of PEG was attached to 
PHBV films through NHS-amine conjugation. A 50 μg/ml concentration of RGD 
containing peptides were then attached to the PEG through thiol-maleimide conjugation. 
Cell viability assays suggested that the RGD modified films exhibited increased cell 
compatibility. In addition, serum adsorption investigations by optical wavelength light-
mode spectroscopy (OWLS) and fibrinogen adsorption studies by enzyme-linked 
immunoabsorbent assay (ELISA) on unmodified and modified PHBV surfaces 
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suggested the introduction of PEG chains significantly decreased the nonspecific 
adsorption of proteins from serum and fibrinogen from plasma, effectively decreasing 
the risk of thrombus formation and improving blood compatibility of implanted 
materials. 
 
Most recently, the application of modified surfaces for single cell capture and analysis 
has become of significant interest in an attempt to extend the boundaries of cellular 
research. Single cell detection has the prime advantage of analyzing individual cells 
under specific stimulations, providing information that has previously been hidden in 
large cell population studies. This technique is accompanied by a variety of challenges 
such as maintaining the ability to generate small islands that host single cells while 
retaining cell viability for a prolonged period of time. In addition, the ability to measure 
cell-to-cell signaling mechanisms on a structurally and chemically uniform surface is 
thought to be required to fully understand single cell behavior and cell-matrix 
interactions. 
 
Mundo et al.
(19) 
analyzed the response of osteoblast (Saos-2)  cells on superhydrophobic 
polystyrene (PS) surfaces presented as nano-scale dots produced by a tailored plasma-
etching process. Etching was conducted by the plasma-produced fluorine atoms which 
reacted with carbon and hydrogen at the polymer surface, to produce uniformly covered 
surfaces with dot reliefs of nanometric size. Mean height and lateral size of the 
structures increased with increasing etching time (5 minutes and 10 minutes). For 
example, root-mean-square roughness (rms) values obtained from AFM images of the 
surfaces was  6 ± 2 nm for untreated PS (FLAT), 10 ± 2 nm for 5  minute, and 16 ± 2 
nm for 10 minute etched samples. Correspondingly, mean height values were 17 ± 3, 32 
± 8, and 90 ± 25 nm, respectively. Results indicated that Saos-2 cells responded to 
surfaces with different nanoscale roughness, and showed inhibition toward cell adhesion 
on surfaces of small nanometric size (5 minute etching). SEM and fluorescence 
microscopy studies suggested that compared to standard tissue culture PS surfaces, two 
different cell lines, ATDC5 and Saos-2 cells could not proliferate on superhydrophobic 
PS surfaces and cell morphology was affected, presented in Figure 5.2.This highlights 
the idea that cell adhesion depends on cell type as well as surface, which in this case 
presented inhibited adhesion on superhydrophobic, rough surfaces of small nanotexture 
(5 minute etching time, 32 ± 8 nm height). 
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Figure 5.2: SEM images of SaOs2 osteoblast cells after culture for 24 h, on PS surfaces 
with plasma-etching for (A) 5 minutes and (B) 10 minutes showing in detail filopodia 
interacting with the surface nano-structures. (C–E) shows the effect of nanotopography 
on actin filaments assembly in SaOs2 cells grown for 48 hours on the three fluorinated 
surfaces (planar (C), 5 minutes (D) and 10 minutes (E) etching): green, actin; blue, 
nuclei.
(19) 
 
Cell adhesion studies have been reported widely, whereas, platelet adhesion interactions 
with modified surfaces remains relatively unexplored
. 
Study has recently been made of 
platelet adhesion to gain a better understanding of platelet interactions and for the 
possible development of rapid diagnostic analysis, wherein  Yang et al.
(20)
 carried out a 
similar study on platelets. This group used a combination of electrochemical 
anodisation and SAM techniques to construct superhydrophobic TiO2 nanotube layers 
on a titanium substrate. Contrasting superhydrophilic TiO2 nanotube layers were also 
produced by exposing the superhydrophobic surface to UV irradiation. Results 
suggested the superhydrophobic surfaces present impressive blood compatibility with 
the ability to inhibit platelet adhesion and activation. In contrast, high platelet adhesion 
and spreading was observed on flat titanium substrates and superhydrophillic surfaces, 
presented in Figure 5.3. 
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Figure 5.3: Schematic illustration of platelet morphology and the corresponding 
interactions with different surfaces after 2 hours incubation at 37°C. (A) Plain Ti 
substrate; (B) Superhydrophilic TiO2 nanotubes; and (C) Superhydrophobic TiO2 
nanotubes.
(20) 
 
However limitations to this study exist. Firstly, the results presented were all produced 
from only one healthy donor, with averages and standard deviations from only one 
sample. Four locations on one sample were randomly chosen and the number of 
adhering platelets counted to give an average value per unit area and standard deviation. 
Consequently these averages and standard deviations do not reflect true reproducibility 
of the surfaces presented in this report. In addition, the platelet preparation involved 
simply diluting the platelet-rich-plasma with an equal volume of normal saline solution. 
1 ml of this diluted solution was then added to each surface followed by incubation with 
the surfaces at 37°C. The omission of measuring an accurate platelet count through 
using for example a Sysmex XE-2100 haematology analyser reduces the quantitative 
aspect of this report. This omission is important in addition to the requirement for more 
than one blood donor as the platelet count varies significantly from donor to donor. 
Overall the reproducibility of this report is questionable. To conclusively report the 
effect of these surfaces on platelet adhesion and spreading, an increased number of 
donors and accurate platelet count is required. These aspects are implemented in the 
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similar platelet adhesion study presented in this Chapter. The results presented were 
carried out three times using different donors for each investigation (N=3 for each 
study: two confocal studies (platelet counts and phalloidin and CD62P staining) and 
SEM. Prior to the platelet adhesion assays, accurate platelet counts were also measured 
using a Sysmex XE-2100 haematology analyser (Sysmex KX Series, SYSMEX UK 
LTD) to ensure platelet counts were as close as possible to the 30 x 10
3
/µl used in these 
studies thus strengthening the quantitative aspect of the results presented in this 
Chapter. 
 
5.0.2   Creating Ordered Arrays for Platelet Adhesion/Inhibition 
Bartlett et al.
(21) 
have reported the fabrication of gold nano-cavity arrays using 
polystyrene spheres intended for single cell capture. The advantage of arrays and 
patterned surfaces is the promotion of accuracy and reproducibility in cell capture and 
positioning via the anchorage of probes to the surface through the immobilisation of 
functionally active biological species e.g. peptides. As discussed in Chapter 1, in 
addition to the uniformity of these arrays, our group has reported uniform gold 
nanostructures to provide reproducible plasmonic enhancement of Raman signals, 
which is a useful tool in providing a unique spectrum for individual molecules.
(22) 
Raman signaling is a weak process, requiring enhancement in order to class it as a 
useful technique for the analysis of molecules, thus gold is a popular choice for 
plasmonic platforms as it has reported approximately 4 orders of magnitude 
enhancement to Raman signals compared to glass substrates. Moreover, nano-cavity 
arrays fabricated using nanosphere lithography followed by electrochemical deposition 
of gold are a cheap and reproducible way to fabricate metal surfaces exhibiting 
nanoscale features. Most importantly however, this method offers easy control over 
the diameter and thickness of the nano cavities, which may enable the capture of 
various cells based on size exclusion. The ability to change the shape of these arrays 
has also been published by our group, with the easy control of shape from truncated 
spheres to cuboids.
(23) 
 
Our group has recently demonstrated an additional advantage to these arrays through 
selective chemical modiﬁcation of the gold nano-cavity arrays, accomplished using a 
two step adsorption process exploiting the assembled polystyrene spheres as masks.
(24)
 
This process created ﬁbrinogen patterned cavities with a bioinert/blocking PEG 
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modiﬁed top surface. Application of a reducing state potential to the array readily 
released the protein from the cavities, however denaturing the protein, thus a more 
advanced approach is required. Despite this however, this method provided significant 
advantages for bio-patterning such as easy selective modification and the ability to 
release concentrated pockets of protein electrochemically in a time-controlled manner. 
The curved cavity also provides a larger surface area for the attachment of proteins. As 
mentioned for Jose’s work, the use of gold metal in the preparation of the arrays 
provides plasmonic enhancement which can facilitate sensing, opening up the 
possibility for spatially and rate controlled delivery of biological species, sensor 
development and even single cell capture, the latter of which is investigated and 
presented in this Chapter. 
 
5.0.3   Surface-Enhanced Raman Spectroscopy (SERS) for Platelet Analysis 
Although Raman scattering is a fundamentally weak process, SERS can provide signal 
enhancements of up to 20 orders of magnitude reported at so-called ‘‘hot spots’’ that 
typically occur at junctions between nanostructures.
(25)
 For practical analytical 
application, the SERS substrates must be highly reproducible, stable over time and easy 
to fabricate. However the majority of SERS substrates fail to fulfill all of these 
requirements, with the fabrication of these “hot spot” substrates usually challenging and 
expensive to produce in such a way as to make their enhancement reproducible (e-beam 
lithography). Lithographically prepared cavity arrays with spherical architecture are 
advantageous as the fabrication (template-based lithographies in which nanospheres are 
used as templates through which metal is deposited by vapor or electrochemical 
deposition) is generally simple and cost effective.
(21-24,26-31) 
In addition spherical cavity 
arrays possess the additional advantage of having the ability to tune the plasmon 
resonance from the visible to near-IR spectral regions.
(32-34)
 
 
Raman spectroscopy is being used increasingly in protein, cell, platelet and tissue 
applications. For example, our research group has reported the ability to characterise 
αIIbβ3 protein conformational changes following activation in addition to attempting to 
distinguish differences between resting and activated whole platelets
(35-37)
,
 
while others 
have reported the potential of Raman spectroscopy for the detection of cancer in whole 
tissues
(38-40)
, characterisation of neurodegenerative diseases
(41-43)
, and stem cell 
characterisation
(44,45)
. This technique not only provides important structural 
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information on the molecular composition of a sample, it can also detect many 
biological compositions within cells or tissue such as lipids, proteins and 
carbohydrates. Typically, single cell studies using Raman and SERS require highly 
concentrated samples (e.g. cells grown to 100% confluency), such as the formation of 
cell monolayers over metal substrates, in order to obtain sufficient SERS as reported 
by Feld et al.
(46)
 In addition, the majority of publications regarding SERS of biological 
samples involve the requirement of either fluorescent tags or the attachment of metal 
nanoparticles to the biological sample of interest in order to produce sufficiently high 
intensity for differentiation of cell types.
(47,48) 
Raman or indeed SERS spectroscopy of 
single human blood platelets remains relatively unreported. The few publications to 
date however employ the same experimental set up as for single cell Raman: 
significantly high concentrations of cells and the use of fluorescent labels and/or 
nanoparticles for SERS studies.
(37,42,49-51) 
Unlabeled analysis of single intact platelets 
that does not require extreme concentrated platelet counts via Raman spectroscopy to 
date has not, to our knowledge been reported. 
 
Thrombus formation, a leading cause of death and disability occurs as a result of protein 
adsorption, platelet adhesion and platelet activation. The adsorption of plasma proteins 
to the surface is one of the first events of thrombosis. When a blood vessel ruptures the 
von Willebrand Factor protein (vWF) adheres to the exposed sub-endothelium and 
undergoes conformational changes. Platelets adhere to vWF via the Ib-IX-V 
glycoprotein receptor resulting in platelet activation. Signalling occurs to the αIIbβ3 
(GPIIb/IIIa) integrin receptor resulting in conformational changes, allowing it to bind 
fibrinogen (Fg) leading to consequential clot formation. In addition, collagen, located in 
the matrix underlying vascular endothelial cells, is not exposed to flowing blood. After 
injury, however, blood will flow directly over sub-endothelial structures including 
connective tissue that contains a high percentage of collagen. When collagen becomes 
exposed to flowing blood, platelets rapidly adhere, spread, become activated and begin 
to form an aggregate.  
 
This chapter investigates the interactions of whole human platelets with highly ordered 
gold nanocavity arrays, as a step along the way to the above objectives. We explored the 
effect of different cavity dimensions and surface functionality on platelet capture and 
activation status and compared the effect of surface chemistry on cavity arrays with 
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planar gold surfaces. The substrates were prepared from microlithography via 
electrochemical deposition to produce gold coated planar and cavity surfaces. Self-
assembled monolayers using the αIIbβ3 integrin platelet protein sequence C-Ahx-
GRGDS were prepared to investigate the possibility for spatial guidance of platelet 
adhesion and spreading at the single cell level. Adhesion control was investigated using 
the widely reported bio-inert alkane and PEG platelet adhesion inhibitors at varying 
RGD:alkane and RGD:PEG ratios. The effect of cavity size on platelet adhesion and 
platelet morphology was also investigated, comparing planar gold surfaces 
approximately 100 nm thick to three different microcavity array sizes; 5.4 µm, 1.6 µm 
and 0.98 µm diameter arrays presenting cavity depths of 2.7 µm, 0.7 µm and 0.4 µm 
respectively. In addition, the ability to selectively capture single intact platelets using 
these microcavity arrays was also investigated.   
 
In the resting state, platelets, 2-3 µm in diameter, exist as small disc shaped clear cell 
fragments (e.g. no nucleus). Platelet activation and aggregation, as mentioned, play a 
key role in thrombosis. When platelets activate they change in shape and can assume 
many stages of spreading; branched projections (dendritic), (D), spread-dendritic (SD), 
spread (S) and fully spread (FS), see Figure 5.4. For example, in medical implant 
material development platelet adhesion and activation is not desired and so 
characterizing the morphology of platelets adhered to the developed surface is 
extremely important in assessing the thrombotic risk of the potential implant. Thus 
knowledge of the interactions of proteins and platelets with surfaces is vital towards 
managing and preventing thrombus related diseases.  
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 Figure 5.4: SEM image presenting smooth, discoid, resting platelets (R) and the 4 
stages of platelet spreading bound to modified planar gold surfaces: D – dendritic; SD 
– spread dendritic; S – spread; FS – fully-spread. A platelet aggregate is labelled as A. 
Surfaces were modified as described in section 5.1.3; alkane alone for (R) and 
RGD:alkane 1:1 ratio for (D-SD and A). 30 x 10
3
± 2 x 10
3
/µl washed platelets were 
incubated with the modified surfaces for 45 minutes at 37°C. Platelet fixation, 
dehydration and sputter coating was carried out as described in sections 5.1.6 to 5.1.8. 
Accelerating voltage was 5 kV in all cases. Images are reproducible, with N =3. 
 
In addition to morphological changes, platelets also contain alpha (α) and dense 
granules which excrete their contents into the surrounding environment following 
activation, further progressing platelet activation and aggregation. There are three types 
of granules: 
1. Dense granules – contain Adenosine diphosphate (ADP), calcium and serotonin 
2. Lamda granules – contain enzymes 
3. α-granules – contains many agonists e.g. p-selectin, fibronectin, vWF and 
fibrinogen 
P-selectin, first identified in endothelial cells in 1989, is a 140 kDa transmembrane 
glycoprotein also referred to as CD62P, Granule Membrane Protein 140 (GMP-140) 
and Platelet Activation-Dependent Granule to External Membrane Protein 
(PADGEM).
(52)
 P-selectin is stored in granules called Weibel-Palade bodies and α-
granules in inactivated platelets. Following platelet activation, p-selectin, located in α-
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granules, is rapidly re-located to the platelet surface before being excreted into the 
surrounding environment and so is a prime marker for platelet activation.  
 
Actin exists in two forms: monomeric globules referred to as G-actin and polymeric 
filaments called F-actin. F-actin (microfilaments) is essential for many key cellular 
functions including providing mechanical support, cell migration and providing 
trafficking routes through the cytoplasm to aid signal transduction.
(53) 
Most importantly, 
F-actin is vital for the morphology changes that occur when platelets are activated,  
increasing to 50-80% in activated platelets compared to approximately 40% when 
resting.
(53)
 Distinct actin filament structures have been reported for activated platelets: 
filopodia, lamellipodia, a contractile ring encircling degranulating granules, and thick 
bundles of filaments resembling stress fibers.
(54) 
As a result, F-actin studies of platelets 
are of high importance when investigating morphological changes in platelets. 
 
Phalloidin, a bicyclic peptide, belongs to a family of toxins isolated from the deadly 
Amanita phalloides “death cap” mushroom. It is commonly used in imaging 
applications to selectively label F-actin in fixed and permeabilized cells. Labeled 
phalloidin such as the tetramethylrhodamine B isothiocyanate (TRITC)-phalloidin used 
in this chapter has a 1:1 phalloidin: actin subunit stoichiometric adhesion ratio in cells 
and because of its extreme specificity to F-actin (generally it does not bind to 
monomeric G-actin) it is the prime label of choice for actin staining experiments.
(55, 56)
 
An example of phalloidin staining is presented in Figure 5.5.  
 
175 
 
 
Figure 5.5: Confocal luminescence image example of TRITC-phalloidin stained 
platelets illustrating different actin re-organisations including filopodia, lamellipodia, 
stress fibers and resting platelets presenting concentrated actin that is spherical in 
shape. 30 x 10
3
± 2 x 10
3
/µl washed platelets were incubated with a PEG modified 
planar surface for 45 minutes at 37°C, fixed with 3.8% PFA solution, stained with 
TRITC-phalloidin (1/100 dilution). Luminescence images were recorded using a 40x oil 
immersion objective lens (NA 1.4) with 540 nm HeNe laser excitation.  
 
Using this staining technique the activation status and actin content of platelets was 
found to differ depending on the surface chemistry and surface functionality. Platelet 
adhesion and spreading was found to be greatly influenced by the surface geometry with 
the platelets ability to bind and spread decreasing with decreasing microcavity size. For 
example, platelets bound and retained the ability to spread fully onto 5.4 µm diameter 
cavity arrays, a length consistent with that of maximally extended filopodia, a process 
not seen for the smaller cavity sizes. CD62P (p-selectin) and phalloidin (actin) staining 
was carried out to study the activation status and actin localisation across platelets 
adhered to the various surfaces. The ability to control platelet adhesion and spreading as 
presented in this study is of significant value in analysis as described and also 
biomedically, for example, in the design of medical implantations. 
 
A final objective of our research group is the sensing and analysis of single cells by 
Raman microscopy or electrochemical impedance. In the former case, for platelets, 
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Raman signal is very poor and the use of metallic SERS active substrates capable of 
single cell capture is an attractive proposition. This chapter investigates the use of the 
metallic SERS active substrates capable of single platelet capture for Raman 
microscopy analysis. Using Raman spectroscopy, intense Raman signal intensities for 
single platelets bound at 1.6 µm diameter cavity arrays was observed. Surprisingly, the 
natural biological autofluorescence of the platelets allowed clear observation of the 
platelets on the uniform gold cavity array using white light microscopy. Most 
importantly, this introduced extreme selectivity and specificity to the Raman study as 
spread and non-spread platelets were easily differentiated. Thus a comparison of non-
spread versus fully spread Raman spectra could be investigated, presented in section 
5.2.7. The Raman spectra presented in this section are of extreme importance as the 
ability to selectively choose platelets in either the resting or activated form is of high 
interest, for example, in rapid diagnostic applications.  
 
5.1   Experimental Procedure 
Chemicals 
1-octanethiol (C8H18S, 95%), ethanol (99%), 38% paraformaldehyde (PFA), bovine 
serum albumin (BSA), Tetramethylrhodamine B isothiocyanate (TRITC)-phalloidin 
(λex 540 nm) and fluoroshield mounting media were purchased from Sigma. C-Ahx-
GRGDS (C26H47N10O11S) peptide was purchased from Celtek Peptides. Eptifibatide, 
(N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-aspartyl-L-try 
ptophanyl -L-prolyl-cysteina-mide, cyclic (1–6)-disulfide), was purchased from 
Peptides International. Peptide structure and purity was manufacturer guaranteed, 
presented in Appendix 2. SH-PEG4-COOH (C11H22O6S) was purchased from Quanta 
Biodesign Ltd. Phycoerythrin (PE) labelled mouse anti-human CD62P (λex 488 nm) and 
PE labelled mouse anti-human IgG control (λex 488 nm) was purchased from BD 
Biosciences. 5.43 ± 0.14 µm, 1.73 ± 0.15 µm and 0.96 (± not disclosed) µm diameter 
polystyrene latex spheres were purchased from Bangs Laboratories. Gold was deposited 
using a commercially available gold plating salt solution (Techni Gold 25, from Technic 
Inc) in a conventional three electrode cell using a platinum mesh counter electrode and 
an Ag/AgCl (sat. KCl) reference electrode. A CH Instruments (model 660) was used to 
hold the potential at -1 V to deposit gold.  
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Instrumentation  
AFM, SEM and Raman instrumentation is discussed in greater detail in Chapter 2. AFM 
imaging was carried out using a Veeco Bioscope II Multimode Atomic Force 
Microscope with a Nanoscope III controller. Samples were imaged in tapping mode in 
air using a MikroMasch Ultrasharp noncontact 15 series tip with a resonant frequency 
of approximately 325 KHz and force constant of approximately 40 N/m. All images 
were taken at a scan rate below 0.5Hz and at 512 samples/line resolution. Confocal 
imaging was carried out on a Zeiss LSM510 Meta confocal microscope. SEM imaging 
was carried out on a Hitachi S3400n SEM Tungsten system instrument with all images 
collected using identical conditions at 5.00 kV accelerating voltage. 
 
Raman measurements were carried out using a Peltier cooled (−70 °C) charge coupled 
device (CCD) camera (255×1024 pixels) attached to a HORIBA Jobin-Yvon Labram 
HR 1000 spectrometer coupled to a Digital Instruments Bioscope II with an inverted 
microscope. Samples were excited with a 785 nm diode laser source. The spectrometer 
was equipped with diffraction gratings of 600 grooves/ mm and the slit allowed the 
spectral resolution of 2 cm
−1
.  
 
The area of the laser spot on the samples was 1 µm in diameter. The laser power at the 
sample was set from 1 to 2 mW using the inbuilt laser power control. Data acquisition 
times used in the Raman experiments was 30 seconds. The Raman band of a silicon 
wafer at 520 cm
−1
 was used to calibrate the spectrometer and the accuracy of the 
spectral measurement was estimated to be approximately 2 cm
−1
. The spectral data 
acquired were analyzed using LabSpec software. 
 
5.1.1   Fabrication of Planar Gold Surfaces  
For planar gold surfaces, silicon wafers coated with 1000 Å gold (Au) 525 µm thickness 
over a 50 Å titanium adhesion layer were washed thoroughly with water and acetone. 
Teflon tape was wrapped around half of the gold to produce a 1 cm
2
 final film surface 
area. Electrolyte solutions were degassed with nitrogen for 30 minutes prior to 
deposition. A gold film of controlled thickness (~100 nm) was electrochemically 
deposited from the commercially obtained aqueous gold plating solution. A potential of 
-1 V (scan rate 100 mV/s) versus an Ag/AgCl (sat. KCl) electrode was applied by a 
Model 660 CH Instrument electrochemical workstation. 
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5.1.2   Fabrication of Gold Microcavity Arrays: 5.4 µm, 1.6 µm and 0.98 µm Size 
It is important to note that both the charge (C) passed and potential (V) applied in the 
fabrication of the cavity array substrates varied significantly from batch to batch of 
commercial gold plating salt solution. This issue was discovered during the course of 
this thesis. A lengthy optimisation process was required to define optimum parameters 
for each array size. To define these parameters both C and V were varied over a wide 
range. For example, Figure 5.6, presents the optimisation of V for the 5.4 µm diameter 
arrays. In this study the potential was applied at (a) -0.85, (b) -0.90, (c) -1.0 and (d) -1.1 
V. This study suggested a potential of -1 V presented optimal packing, uniformity and 
diameter size. Both -0.85 and -0.90 V presented loosely packed, shallow cavities, while 
-1.1 V presented gold nucleation a clear indication that the voltage was too high in this 
case. These results were in stark contrast to the two-fold higher charge (3 C at -1V 
potential) required for the previous gold batch used in our research group for the same 
sized diameter cavity arrays.
(57)
 This optimisation procedure was also required for both 
1.6 µm and 0.98 µm diameter arrays which presented an optimal potential of -1 V and 
charge of 0.7 C and 0.4 C respectively, presented in Figure 5.6. In summary it is 
important to note that although gold thickness can be easily manipulated, strenuous 
optimisation is required following exchange to a new batch of commercial gold plating 
solution. 
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Figure 5.6: SEM images of 5.4 µm diameter cavity array (1.7 C) prepared at a potential 
of (a) -0.85V, (b) -0.90V, (c) -1.0V and (d) 1.1V. Results suggest (c) -1V as the optimal 
voltage in the fabrication of 5.4 µm diameter cavity arrays. A thin layer of PS spheres 
was deposited on silicon wafers coated with 1000 Å gold (Au) 525 µm thickness over a 
50 Å titanium adhesion layer and evaporated over night at room temperature. 
Electrodeposition using commercially available gold salt solution was carried out and 
the thickness of the cavities controlled through the amount of charge (C) passed and 
voltage (V) applied in the electrochemical deposition step. 
 
Figure 5.7 presents (a) the fabrication process for the gold microcavity arrays used in 
this Chapter, (b) the two-step adsorption process for selectively modifying the top 
surface and cavity walls with differing thiol species and (c) adsorption process for 
coating the whole cavity array (both top surface and cavity walls), where X is C-Ahx-
GRGDS (C26H47N10O11S), SH-PEG4-COOH (C11H22O10S) or SH-Alkane8-CH3 
(C8H18S, 1-octanethiol), see Figure 5.7, (c). 10 wt % stock solutions of commercially 
available polystyrene (PS) latex spheres with average commercial diameters of 5.43 ± 
0.14 µm, 1.73 ± 0.15 µm and 0.96 µm (± not commercially disclosed, however, SEM 
presented in Figure 5.7 suggests ± 0.02 µm) were diluted to approximately 1 % solution 
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in water in all cases. Before use, the suspension was homogenised by gentle inversion. 
A thin layer of the spheres was deposited on the gold plated silicon wafers and 
evaporated over night at room temperature. Electrodeposition was carried out as 
described in section 5.1.1 for the planar surfaces. The thickness of the cavities were 
controlled through the amount of charge (C) passed in the electrochemical deposition 
step: 1.7 C for 5.4 µm, 0.7C for 1.6 µm and 0.4C for 0.98 µm diameter cavity arrays 
respectively.   
 
Figure 5.7: (a) The fabrication process for the gold microcavity arrays used in this 
chapter, (b) the two-step adsorption process for selectively modifying the top surface 
and cavity walls with differing thiol species and (c) adsorption process for coating the 
whole cavity array (both top surface and cavity walls), where X is thiolated RGD or 
alkane. Electrodeposition was carried out with the thickness of the cavities controlled 
through the amount of charge (C) passed and voltage (V) applied in the electrochemical 
deposition step. 
 
5.1.3   Surface Modification: Thiolated RGD, Alkane or PEG 
Three thiolated species were used in this study; 1-octanethiol (C8H17SH), SH-PEG8-
COOH (C19H37O10SH) and C-Ahx-GRGDS (C26H46N10O11SH) see Figure 5.8, (a). For 
RGD:PEG and RGD:alkane ratio SAMs, it is important to note that the PEG and alkane 
chain lengths were shorter than RGD to ensure availability of the RGD adhesion site for 
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platelet adhesion. In addition, alkyl and PEG SAM studies have reported a direct 
relationship between SAM packing and chain length; as chain length decreases the 
degree of order of the monolayer, packing density and surface coverage decreases. This 
chapter uses moderately long chain lengths (8 to 26 carbons long), strengthening the 
potential for good lateral interaction with the gold surface increasing the probability of 
highly ordered, densely packed SAM formation in all cases. 
 
Alkanes are highly crystalline molecules. Upon exposure of the gold surface to a 
thiolated alkane solution, a bond between gold and sulfur forms with approximately 
90% of the monolayer reported to form within minutes.
(58,59)
 The hydrocarbon backbone 
of the alkane initially lies horizontally to the metal surface.
(60)
 A slower organisation 
process follows; alkyl chain rearrangement and Van der Waals inter-chain interactions 
produce densely packed and ordered hexagonal arrays of long chain molecules in the 
trans conformation.
(61)
 The resulting alkyl chain SAMs adopts a highly crystalline 
structure with the extended all-trans conformation chains at an approximate 30° tilt 
angle from the surface, Figure 5.8, (b).
(60,62)
 Alkane modified surfaces resist protein 
adsorption through simple modification of their head group e.g. using a hydrophobic 
methyl (CH3) head group. 
 
PEG is a highly flexible/mobile molecule. In aqueous solution the chains are solvated 
and disordered with up to three water molecules reportedly associated with each PEG 
repeat unit. This flexibility/mobility is due to the conformational freedom of the –C-C-
O- backbone of PEG due to unrestricted rotation around the C-O bonds. At low 
densities, PEG assumes random coil “mushroom” conformation; PEG chains do not 
overlap and empty spaces exists between them. As the density increases, the PEG 
chains cannot maintain the random coil state and must stretch to be accommodated and 
may overlap. At high densities, the chains will be more completely stretched, termed the 
“brushed” regime, Figure 5.8, (c).(63) PEG modified surfaces are reported to resist 
protein adsorption by “steric stabilisation”. Adsorption of proteins to the surface cause 
compression of the flexible PEG chains, entropy is lost generating a repulsive 
interaction which may repel the protein from the surface, termed excluded volume-steric 
repulsion. Osmotic repulsion may also occur and is related to the low interfacial energy 
at the PEG-water interface and the ability of the PEG chains to bind water tightly 
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(hydrogen bonding). Based on this mechanism the proteins may be kept away from the 
surface by a water barrier.
(64) 
  
   
 
Figure 5.8: (a) Chemical structure of 1-octanethiol (C8H18S), Thiol-dPEG®4-acid 
(C11H22O6S,) and C-Ahx-GRGDS (C26H47N10O11S) used in this chapter. (b) Alkane 
forms a densely packed, uniform SAM at a 30° angle from gold surface, reproduced 
from reference (57). (c) Illustration of PEG SAM conformation depending on the PEG 
chain density, the PEG conformation on surface changes from non-overlapping 
“mushrooms” to fully extended “brushes”, modified from reference (57,58).(62,63) 
Mushroom Overlap 
Brush 
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Selectively modified arrays were prepared through the two step adsorption process 
presented in Figure 5.7, (b), the arrays were first immersed in a 1 µM concentration of 
X1-thiol (RGD or alkane) overnight at room temperature. The top surface modified 
arrays where then immersed in THF for 3 hours to remove the PS spheres followed by 
immersion in a 1 µM concentration of X2-thiol (RGD or alkane).  
 
To chemically modify the whole surface, Figure 5.7, (c), following removal of the PS 
spheres via immersion in THF for 3 hours, the whole cavity array was immersed in a 1 
µM ethanol solution of thiolated C-Ahx-GRGDS, alkane or PEG over night at room 
temperature. To tailor the surface in terms of blocking non-specific adhesion, the 
cavities were functionalised with varying RGD:PEG and RGD:alkane ratios via 
overnight incubation at room temperature. RGD:PEG and RGD:alkane were incubated 
at a 1:1, 1:5 and 1:10 ratios for planar surfaces and a 1:5 and 1:10 ratio for the 
microcavity arrays where RGD concentration for SAM surface formation was 1 µM in 
all cases. The surfaces were then characterised by electrochemical analysis, Raman 
spectroscopy and SEM. 
  
5.1.4   Cyclic Voltammetry (CV) 
In this study, the electrolyte consisted of a 0.1 M solution of sulphuric acid (H2SO4). 
CV measurements of both bare gold and gold functionalised with thiolated RGD, PEG, 
alkane (1 µM concentration for SAM formation in each case), RGD:PEG and 
RGD:Alkane (1:1, 1:5 and 1:10 ratios, where RGD concentration was 1µM in all cases) 
were carried out, cycled between –1.4 V and 1.5 V using a 0.1 (V/s) scan rate on a CH 
Instrument Model 660 work station. 
 
5.1.5   Preparation of Washed Human Blood Platelets 
30 ml human blood was drawn into a syringe containing 5 ml acid citrate dextrose 
(ACD) buffer to prevent coagulation. 200 ml modified HEPES platelet buffer was 
prepared as specified below (made up fresh everyday) and kept at room temperature: 
   – 20 ml Glucose Dextrose D (6mM) 
   – 20 ml NaCl (0.13M), NaHCO3 (9mM), sodium citrate (10mM),                  
      HEPES (10mM), KCl (3mM) 
    – 20 ml KH2PO4 (0.81 mM) 
    – 2 ml MgCl2 6H2O (0.9mM) 
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The pH was adjusted to 7.36 with acid-citrate dextrose (ACD) buffer. 5 ml of blood was 
transferred to a 15 ml tube and spun at 150 x g for 10 minutes at room temperature to 
separate the plasma from the red and white blood cells.  The PRP (Platelet Rich Plasma) 
upper phase was transferred to a 50 ml tube. The pH was adjusted to 6.8 with ACD 
buffer. A final concentration of 1 µM Prostaglandin (PGE1, 1 mM stock concentration) 
was added (1 μl for every ml PRP) to prevent platelet activation. The platelets were 
collected by centrifugation at 720 x g for 10 minutes and the top layer containing the 
plasma was removed and discarded. Using 500 µl platelet buffer the platelet layer was 
carefully removed and placed in a 15 ml tube without disrupting the bottom layer of 
remaining red blood cells. 80 μl of the platelet suspension was used to determine the 
platelet concentration. Platelet counts were measured using a Sysmex XE-2100 
haematology analyser (Sysmex KX Series, SYSMEX UK LTD). Platelets were allowed 
sit for 1 hour before use. 
 
5.1.6   Platelet Capture to Planar Gold Surfaces and Gold Microcavity Arrays 
A 1.8 mM final concentration of CaCl2 was added to the platelets to reverse the effect of 
PGE1. Platelets were diluted to a final 30 x10
3
 ± 2 x10
3/μl platelet concentration in 
platelet buffer. The platelets were incubated with the arrays at 37 °C for 45 minutes. 
Bound platelets were washed three times with PBS pH 7.4. Live bound platelets were 
incubated with PE-CD62P (2 mg/ml stock, 1/100 dilution) for 15-20 minutes. Following 
incubation, CD62P stained platelets were fixed with 3.8% PFA solution for 10 minutes 
at room temperature for confocal studies. For all other studies bound unlabeled platelets 
were fixed with 3.8% PFA solution for 10 minutes at room temperature for confocal 
studies or 2.5% gluteraldehyde for 3 hours at room temperature for SEM investigations. 
For TRITC-phalloidin staining (2 mg/ml stock), fixed platelets were permeabilized with 
0.01% triton X-100 solution for 30 minutes at room temperature. TRITC-phalloidin 
(1/100 dilution) was added to the platelet bound cavities and incubated for 30 minutes at 
room temperature. The platelet bound cavities were mounted using fluoroshield 
mounting media before imaging or dehydrated and sputter coated for SEM 
investigations, described in sections 5.1.7 and 5.1.8. 
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5.1.7   Platelet Dehydration 
To dehydrate the adherent platelets for SEM imaging, samples were incubated in 5%, 
10%, 20%, 40%, 60%, 80% and 100% acetone for 15-20 minutes at a time. Samples 
were allowed to air dry for 2 hours before sputter coating as described in section 5.1.8. 
 
5.1.8   Gold Sputter Coating 
The platelet bound gold cavity arrays were mounted onto carbon surfaces adhered to 
aluminium SEM stubs. Gold films were deposited over the platelet bound arrays using 
argon flow, at pressures between 3 and 4 x10
-1
 mBars for 2 minutes at a voltage of 
approximately 40 mA. These conditions result in good quality gold layers with a 
thickness of approximately 30 nm. Gold coated samples were then imaged using a 
Hitachi S3400n SEM Tungsten system instrument. All images were collected using 
identical conditions at 5.00 kV accelerating voltage unless otherwise stated. 
 
5.2   Results  
5.2.1   Characterisation of Planar Gold Surfaces and Microcavity Arrays 
5.2.1.1   Scanning Electron Microscopy (SEM) 
Self assembly of the PS spheres is a simple, flexible method for producing highly 
ordered arrays of different sizes and shapes such as nanocavities and cuboid arrays.
(21-
24,29) 
Figure 5.9, (i), (a-d) shows the planar (a) and nano-structured gold cavities (b-d) 
after removal of the template in THF. Larger area images presenting the uniformity of 
each array size are shown in Appendix 3. Well-ordered, close-packed arrays were 
observed for all diameter sizes with the largest cavities (5.43 µm diameter) presenting 
the best order and packing. The open diameter of the cavities was determined using 
SEM to be 5.42 ± 0.01 µm, 1.60 ± 0.02 µm and 0.98 ± 0.02 µm, presented in Figure 
5.9, (i). 
 
The top and interior surface areas of the gold cavity arrays were estimated by SEM 
image analysis using image J software. The surface area of a single cavity was 
calculated using the equation for the area of a truncated sphere, 3πr2, where r is the 
radius of the sphere. The number of cavities in a defined area (225 µm
2 
in all cases) was 
calculated from the SEM image using Image J software. The total interior surface area 
of the cavity array was determined by multiplying the number of cavities determined 
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from the SEM image by the surface area of a single cavity. The top surface area was 
determined by subtracting the area of all cavities from the total area of the image. 
Figure 5.9, (ii), shows the top surface and internal cavity areas determined for each 
cavity size. Results suggest that the cavity wall interior and top surface areas increase 
with increasing cavity size: 0.98 µm (240 ± 9 and 15 ± 9 µm
2
), 1.6 µm (375 ± 27 and 
150 ± 27 µm
2
) and 5.4 µm (622 ± 49 and 397 ± 49 µm
2
) diameter cavity array sizes 
respectively.  
 
The cavity depth/ film thickness (t) of the cavities could also be estimated from simple 
trigonometry using Eqn. 5.1: 
 
 
  
   
       (Eqn. 5.1) 
 
 
 Where r is the known radius of the template sphere (commercial data sheet diameter 
value) and rpore is the radius of the electrochemically deposited sphere pore mouth 
(SEM measured diameter value) 
 
The choice of the sign for the ± term depends on whether the film is thicker or thinner 
than the radius of the template sphere. The estimated film thickness for 5.4, 1.6 and 0.98 
µm diameter cavity array sizes is presented in Figure 5.9, (ii). For the 5.4 µm diameter 
array size: the 2.72 µm radius spheres employed here and an open radius of 2.71 µm, 
the film thickness was estimated to be either 2.95 or 2.49 ± 0.01 µm. For 1.6 µm 
diameter array size: the 0.865 µm radius spheres employed here and an open radius of 
0.80 µm, the film thickness was estimated to be either 1.19 or 0.54 ± 0.02 µm. Finally 
for the 0.98 µm diameter array size: the 0.48 µm radius spheres employed here and an 
open radius of 0.48 µm, the film thickness was estimated to be 0.48 ± 0.02 µm.   
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(i) 
 
(ii)    Cavity Diameter 
(µm) 
Top Surface 
Area 
(µm
2
) 
Cavity Interior 
Surface Area 
(µm
2
) 
Estimated  
Film Thickness, (t) 
(µm) 
5.42 ± 0.01  397 ± 49  622 ± 49 2.95, 2.48 ± 0.01 
1.60 ± 0.02 150 ± 27 375 ± 27 1.19, 0.54 ± 0.02 
0.98 ± 0.02 15 ± 9 240 ± 9 0.49 ± 0.02 
Figure 5.9: (i) SEM images of (a) planar gold surface, (b) 5.4 µm, (c) 1.6 µm and (d) 
0.98 µm diameter cavity array sizes. A thin layer of PS spheres was deposited on the 
silicon wafers coated with 1000 Å gold (Au) 525 µm thickness over a 50 Å titanium 
adhesion layer and evaporated over night at room temperature. The thickness of the 
cavities were controlled by the amount of charge (C) passed in the electrochemical 
deposition step; 1.7 C for 5.4 µm, 0.7 C for 1.6 µm and 0.4 C for 0.98 µm diameter 
cavity arrays respectively. PS spheres were removed by immersion in THF for 3 hours. 
Accelerating voltage was 5 kV in all cases. (ii) Active surface area for top surface and 
cavity wall interior of 5.4 µm, 1.6 µm and 0.98 µm diameter cavity array sizes. Data 
are represented as mean ± standard deviation of 3 independent measurements.  
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5.2.1.2   Atomic Force Microscopy (AFM)  
As the electrons in SEM can sometimes accelerate too far into the substrate limiting the 
characterisation of the surfaces, AFM was carried out to provide a more quantitative 
surface characterisation. The planar gold surfaces and three microcavity array sizes 
presented in Figure 5.10, (a-d), are clearly distinguished with AFM.  
 
Figure 5.10: AFM images of (a) planar gold surface, (b) 5.4 µm, (c) 1.6 µm and (d) 
0.98 µm diameter cavity arrays formed by electrodeposition through a polystyrene 
sphere template as described in section 5.1.2. Samples were imaged in tapping mode in 
air using a MikroMasch Ultrasharp noncontact 15 series tip with a resonant frequency 
of approximately 325 KHz and force constant of approximately 40 N/m. All images 
were taken at a scan rate below 0.5Hz and at 512 samples/line resolution. (Images were 
collected by Dr. Úna Prendergast). 
 
The surface roughness, height and diameter of the microcavity arrays were characterised 
further using AFM, Table 5.1. The planar surface, electrochemically deposited to ~ 100 
nm thickness is rough with a root mean square (RMS) roughness of 12.03 ± 0.25 nm. 
Electrochemically depositing the gold cavity arrays resulted in increasing surface 
roughness with increasing cavity size. Moderate surface roughness of tens of 
189 
 
nanometers (planar surface), increased surface roughness for 0.98 µm diameter cavities 
(232 ± 8 nm) and 1.6 µm diameter cavities (300 ± 49 nm) and significant surface 
roughness using 5.4 µm diameter cavity arrays (673 ± 41 nm) was observed. 
 
The average gold film thickness of each cavity array size could also be estimated via 
AFM, presented in Table 5.1. The measurement images are presented in Appendix 3.  
Film thicknesses of 2.7 ± 0.4 µm for 5.4 µm, 0.7 ± 0.2 µm for 1.6 µm and 0.4 ± 0.04 
µm for 0.96 µm cavity arrays were presented. These values correlate well with SEM 
imaging using Eqn. 5.1 also presented in Table 5.1. As discussed, cavity depths can be 
controlled manually during the electrochemical deposition step by changing the charge 
(C) that is passed through the electrochemical cell. The total charge passed for the 
cavity arrays were 1.7 C for 5.4 µm, 0.7 C for 1.6 µm and 0.4 C for 0.98 µm diameter 
cavity arrays.   
 
Table 5.1 also presents the average diameter of each cavity size calculated using AFM: 
5.44 ± 0.17 µm, 1.60 ± 0.13 µm and 0.98 ± 0.05 µm. These values are also in good 
correlation with those reported for SEM also presented in Table 5.1, thus strengthening 
the reproducibility of these highly ordered arrays.  
 
Using the film thickness (t) and diameter (d) of the cavity array measured from AFM 
the normalised thickness (tN) values could be calculated as follows and are presented in 
Table 5.1:  
   
               (Eqn. 5.2) 
 
Due to the reproducibility of these surfaces, a quantitative comparison of platelet 
adhesion, spreading and activation could be investigated on surfaces with not only 
varying cavity sizes but also with varying surface roughness ranging from rough to 
significantly rough (12 – 670 nm range). 
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Table 5.1: Summarised AFM measurements and SEM measurements presenting the following topographical characteristics: AFM measured 
*
Root 
mean square (RMS) roughness, Rq, averaged over the entire surface, 
†
average AFM measured film thickness of cavities from base to top surface, SEM 
estimated film thickness of cavities from base to top surface calculated using Eqn. 5.1, AFM normalised film thickness tN, AFM measured 
‡
average 
diameter of the cavity openings and SEM measured average diameter of the cavity openings. Data are represented as mean ± standard deviation of 3 
independent measurements. (AFM measurements were collected by Dr. Úna Prendergast). 
Substrate 
AFM 
Rq
*
 
(nm) 
SEM 
Film 
Thickness 
(μm) 
AFM 
Film 
Thickness
†
 
(μm) 
AFM 
Normalised Film 
Thickness, tN 
(μm) 
AFM 
Cavity 
Diameter 
‡
 
(μm) 
SEM 
Cavity  
Diameter 
(μm) 
Planar (~100 nm thick) 12.03 ± 0.25 N/A N/A N/A N/A N/A 
5.4 μm cavity 672.67 ± 41.1 2.95 ± 0.01 2.74 ± 0.38 0.50 ± 0.38 5.44 ± 0.17 5.42 ± 0.01 
1.6 μm cavity 300 ± 48.91 0.54 ± 0.02 0.72 ± 0.15 0.45 ±  0.15 1.60 ±  0.13 1.60 ± 0.02 
0.98 μm cavity 232.33 ± 8.14 0.48 ± 0.02 0.43 ± 0.04 0.49 ± 0.04 0.98 ± 0.05 0.98 ± 0.02 
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5.2.1.3   Planar Gold Surfaces and Microcavity Arrays: Surface Modification 
5.2.1.3.1   Planar Gold Surfaces: CV 
Gold-sulfur bonding interactions through reversible adsorption and desorption 
voltammetric methods have been widely studied.
(60,65)
 Furthermore, cyclic voltammetry 
(CV) can provide information on the surface area of a substrate from the gold oxide 
reduction peak area. The calculation of electrochemical area was achieved by applying 
Eqn. 5.3–5.4 to the voltammetric data, where AG is the geometric area, A is the 
electrochemical area and Ap is the area under the voltammetric peak of interest. The 
charge passed during the reduction of a monolayer of gold oxide is 390 µCcm
−2
 and, 
following correction for double layer charging, the reduction peak yields an area of 
0.037 cm
2
 corresponding to a roughness factor (ratio of the microscopic to geometric 
areas) of 1.2.   
       
2rAG 
                                                                     
Eqn. 5.3 
 
   
2390 

Ccm
A
A
p

                                                    Eqn. 5.4 
 
Voltammetry was carried out on all thiol modified planar surfaces and thiol modified 
cavity array size surfaces to confirm chemical modification and also to determine the 
extent of surface coverage for all treated surfaces. The active surface area of the gold 
electrode was determined by cycling the potential in acidic electrolyte so as to create 
and subsequently reduce a gold oxide monolayer on the exposed underlying electrode. 
 
Figure 5.11 shows CVs of all modified surfaces for planar gold substrates. Table 5.2 
summarises the calculated electrochemical areas of said surfaces. Figure 5.11, (a), 
presents CVs of an unmodified planar gold electrode before and after the self-assembly 
of thiolated RGD, alkane and PEG (2 mm radius gold electrodes were immersed in 1 
µM concentration of desired thiol for 24 hours at room temperature in all cases) when 
cycled between –1.4 V and 1.5 V in 0.1 M H2SO4 at 100 mVs
-1
. The bare electrode 
exhibited well-defined waves associated with gold oxide formation and reduction at 
potentials of +1.19 V and +0.71 V, respectively.   
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Alkane SAM formation on gold is well known to involve rapid adsorption to give a film 
with a high defect density which slowly anneals to give a perfect monolayer.
(61,66-68) 
The 
area under the gold oxide reduction peak centered at approximately +0.709 V decreased 
by approximately 85% following monolayer deposition. This was attributed to the 
formation of close packed SAM formation on the electrode surface. 
 
Figure 5.11, (a), also shows surface modification of the gold disc electrode after 
immobilisation of the C-Ahx-GRGDS peptide. Three oxidation peaks were observed at 
+0.236 V, +1.013 V and +1.197 V following RGD deposition onto a planar gold 
electrode. The anodic peak at +1.197 V and the reduction peak centered at 
approximately +0.711 V corresponded to the gold oxide formation and the gold oxide 
reduction peak of the underlying gold disc electrode. Significantly, the charge under the 
oxide reduction peak, +0.711 V, increased 99% following RGD deposition 
corresponding to an apparent gold area of 0.09 cm
2
 compared to 0.07 cm
2 
for bare gold 
alone demonstrating that the enhanced electrical sensitivity of the developed RGD 
electrode may be due to the increased surface area. It is important to note that the 
peptide bond may also be oxidised which may be reflected in the observed increase in 
surface area. The oxidation peaks observed at +0.236 V and +1.013 V may be related to 
the carboxylic acid terminus on the peptide. These peaks were also observed for the 
PEG alone surface and as PEG contains a carboxylic acid terminus also it is highly 
suggested that these peaks arise as a results of electron transfer between the carboxylic 
acid and to the positively charged Au surface. 
 
For PEG deposition the electrochemical area increased by approximately 98% (0.08 
cm
2
) compared to the bare gold electrode.  Both RGD and PEG modifications presented 
the most significant changes to the electrochemical areas compared to all other modified 
surfaces. This suggests that in both cases very defective layers are formed on the 
surface. Defects may occur as a result of both external and intrinsic factors. External 
factors include the cleanliness, preparation, and purity of the adsorbates. Intrinsically, 
SAMs form defects due to the thermodynamics of formation, e.g. thiol SAMs on gold 
typically exhibit etch pits (gold monoatomic vacancy islands) likely due to extraction of 
adatoms(atoms that lie on a crystal surface) from the substrate and formation of adatom-
adsorbate moieties.
(69,70)
 It is also important to note that this phenomenon was only 
observed for the RGD and PEG modified planar gold surfaces. SAM formation on the 
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three sized cavity arrays (5.4, 1.6 and 0.98 µm) with either RGD or PEG presented 
decreased surface areas suggesting close SAM packing by both thiols at the cavity array 
surfaces. 
 
Figure 5.11, (b), illustrates CVs for alkane alone, RGD:alkane 1:1, 1:5 and 1:10 ratios. 
Overall, it was found that as the alkane concentration increased, the current intensity of 
the redox peaks decreased. As the concentration of alkane thiol increased, the specific 
active areas of both the anodic and cathodic currents decreased considerably. 
Particularly, the cathodic reaction was inhibited more significantly than the anodic 
reaction. In addition, the characteristic redox peaks of RGD at +0.236 V and +1.013 V 
diminished as the concentration of alkane thiol increased. The electrochemical area for 
the 1:1, 1:5 and 1:10 RGD:alkane ratios were calculated to be 0.01 cm
2
, 0.02 cm
2
 and 
0.01 cm
2
. 
 
The CVs of RGD with increasing ratios of PEG are shown in Figure 5.10, (c). 
Increased electroactive areas with increasing PEG concentration was observed with 
calculated electrochemical areas of 0.11 cm
2
, 0.09 cm
2
, and 0.08 cm
2
 respectively. The 
current intensities of both RGD and PEG SAMs were approximately 93% higher than 
that of alkane.  
  
Figure 5.11: CVs in 0.1 M H2SO4 at 100 mVs
-1
 of (a) unmodified gold, alkane alone, 
PEG alone and RGD alone in ascending order from the bottom of the graph. (b) Alkane 
alone, RGD:alkane 1:1 ratio, RGD:alkane 1:5 ratio and RGD:alkane 1:10 ratio in 
ascending order from the bottom of the graph. (c) PEG alone, RGD:PEG 1:1 ratio, 
RGD:PEG 1:5 ratio and RGD:PEG 1:10 ratio in ascending order from the bottom of 
the graph. (CVs were collected by Dr. Elaine Spain). 
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Table 5.2: Summary table of the gold reduction peak (V) calculated electrochemical 
area (cm
2
) for all modified planar modified surfaces. (Electrochemistry conducted by 
Dr. Elaine Spain). 
Gold Planar Electrodes 
Gold 
Reduction 
Peak (V) 
Electrochemical 
Area 
(cm
2
) 
Unmodified Gold 0.711 0.07 
Alkane alone 0.709 0.01 
RGD alone 0.711 0.09 
RGD:alkane 1:1 Ratio 0.731 0.01 
RGD:alkane 1:5 Ratio 0.728 0.02 
RGD:alkane 1:10 Ratio 0.732 0.01 
PEG alone 0.725 0.08 
RGD:PEG 1:1 Ratio 0.681 0.11 
RGD:PEG 1:5 Ratio 0.723 0.09 
RGD:PEG 1:10 Ratio 0.723 0.08 
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5.2.1.3.2   Gold Microcavity Arrays: CV 
CV data for the 5.4 µm, 1.6 µm and 0.98 µm diameter array sizes is presented in Figure 
5.12, (a-i). In this study the following surface modifications were investigated: bare 
gold alone, alkane alone, RGD alone, RGD:alkane 1:5 and 1:10 ratios and selective 
modification of the top surface and interior walls of the gold nanocavity arrays. 
 
Figure 5.12 illustrates the controls bare (a, d and g) gold alone, (b, e and h) alkane 
alone and (c, f and i) RGD alone overlays for 5.4 µm (a-c), 1.6 µm (d-f) and 0.98 µm 
(g-i) diameter cavity array sizes respectively. As for the planar surface, bare gold for all 
cavity array sizes presented well defined waves associated with gold oxide formation 
and reduction at potentials of 1.38 V and 0.61 V (5.4 µm), 1.36 V and 0.60 V (1.6 µm) 
and 1.18 V and 0.71 V (0.98 µm).  
 
As for the planar surfaces, a decrease in the charge under the oxidation reduction peak 
and decreased electrochemical areas were observed for all alkane treated surfaces. 
Alkane alone presented approximately 98%, 41% and 54% decrease in the gold 
reduction peak centered at approximately + 0.60 V to +0.71 V for 5.4 µm, 1.6 µm and 
0.98 µm diameter cavity array sizes respectively, is in good correlation with the planar 
surfaces and is attributed to close packed SAM formation.  
 
RGD alone presented a 1%, 27% and 78% increase in the charge under the reduction 
peak (+0.60 to +0.71 V) for 5.4 µm, 1.6 µm and 0.98 µm diameter array sizes 
respectively compared to bare planar gold alone. The corresponding gold surface areas 
increased dramatically for RGD alone with increasing cavity size presenting 0.08 cm
2
, 
3.12 cm
2 
and 6.06 cm
2
 for 0.98, 1.6 and 5.4 µm diameter array sizes respectively.   
 
In the case of the smaller cavity arrays (0.98 and 1.6 µm size), selective modification of 
RGD at the top surface and alkane on the cavity walls had similar effects to RGD alone, 
while results similar to alkane alone were presented when alkane was at the top surface 
and RGD on the cavity wall. In contrast, 5.4 µm diameter cavity arrays presented results 
comparable to alkane alone when RGD was at the top surface and alkane on the cavity 
walls. When alkane was at the top surface and RGD on the cavity walls, the CV was 
more comparable to that of RGD alone. 
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Overall significant increases in the electrochemical area was observed for the cavity 
array sizes with a distinct pattern of increasing surface area with increasing cavity size. 
In summary, the electrochemical surface area increase as follows: planar>0.98>1.6>5.4 
µm cavity array surfaces.                          
 
Figure 5.12: CVs in 0.1 M H2SO4 at 100 mVs
-1
 for 5.4 (a-c), 1.6 (d-f) and 0.98 µm (g-i) 
diameter cavity arrays. Labels (a), (d) and (g) present unmodified gold, alkane alone, 
and RGD alone are presented in ascending order from the bottom of the graph. Labels 
(b), (e) and (h) present alkane alone, RGD:alkane 1:5 ratio, RGD:alkane 1:10 ratio 
and alkane at the top surface with RGD in the cavity walls in ascending order from the 
bottom of the graph. The final labels (c), (f) and (i) present RGD alone (bottom) and 
RGD at the top surface with alkane on the cavity walls (top). (CVs collected by Dr. 
Elaine Spain). 
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Table 5.3: Summary table of the gold reduction peak (V) calculated electrochemical 
area (cm
2
) of (a) 5.4, (b) 1.6 and (c) 0.98 µm diameter cavity array modified surfaces. 
(Electrochemistry conducted by Dr. Elaine Spain). 
(a) 
5.4 µm Cavity Array 
Gold Reduction Peak  
(V) 
Electrochemical Area 
(cm
2
) 
Unmodified Gold 0.611 8.69 
Alkane alone 0.714 0.13 
RGD alone 0.562 6.06 
RGD at the top surface, 
Alkane on the cavity walls 
0.641 4.69 
Alkane at the top surface, 
RGD on the cavity walls 
0.670 2.99 
RGD:alkane 1:5 Ratio 0.721 0.18 
RGD:alkane 1:10 Ratio 0.697 0.70 
(b) 
1.6 µm Cavity Array 
Gold Reduction Peak 
(V) 
Electrochemical Area 
(cm
2
) 
Unmodified Gold 0.559 `4.11 
Alkane alone 0.616 1.93 
RGD alone 0.579 3.12 
RGD at the top surface, 
Alkane on the cavity walls 
0.588 2.16 
Alkane at the top surface, 
RGD on the cavity walls 
0.610 1.07 
RGD:alkane 1:5 Ratio 0.607 1.40 
RGD:alkane 1:10 Ratio 0.708 0.45 
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(c) 
0.98 µm Cavity Array 
Gold Reduction Peak 
(V) 
Electrochemical Area 
(cm
2
) 
Unmodified Gold 0.70 0.28 
Alkane alone 0.768 0.03 
RGD alone 0.765 0.01 
RGD at the top surface, 
Alkane on the cavity walls 
0.734 0.08 
Alkane at the top surface, 
RGD on the cavity walls 
0.765 0.02 
RGD:alkane 1:5 Ratio 0.734 0.01 
RGD:alkane 1:10 Ratio 0.743 0.01 
 
5.2.1.4   Reductive Desorption of Thiolated RGD, Alkane and PEG 
Reduction of the surface bound thiol in a SAM, leads to its desorption and measuring 
surface oxide before and after desorption can provide a quantitative measure of extent 
of surface coverage by thiol.
(60,65) 
Therefore electrochemical desorption on all 
chemically modified surfaces was carried out with the electrode in contact with a 0.1 M 
solution of sulphuric acid (H2S04) electrolyte solution. CV measurements of both bare 
gold and gold functionalised with thiolated RGD, PEG, alkane (were carried out, cycled 
between –1.4 V and 1.5 V using a scan rate of 0.1 (V/s) on the CH Instrument Model 
660 work station. Figure 5.13, (a-c), presents the desorption voltammograms for the 
planar electrodes modified with RGD alone, alkane alone and PEG alone. As the 
desorption data for all remaining treated planar and microcavity array surfaces were 
similar they are presented in Appendix 3.   
 
Electrochemical desorption studies presented significant enhancement of the distinct 
wave associated with gold oxide formation and reduction at a potential of 
approximately 1.4 V and 0.7 V following desorption from all planar and cavity array 
surfaces. A reductive peak at a potential of approximately -1.1 V which is characteristic 
of thiol desorption from a gold surface was also observed in all cases, strongly 
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supporting the idea that adhesion to gold occurs via the thiol functional group of alkane, 
RGD and PEG. Overall electrochemical studies suggest successful and reversible thiol 
bonding to the gold surface for all modified surfaces presented in this chapter. 
 
Figure 5.13: CVs in 0.1 M H2SO4 at 100 mVs
-1
presenting electrochemical desorption of 
(a) RGD alone, (b) alkane alone and (c) PEG alone from planar gold surfaces. Before 
and after desorption is represented by the black line and grey line respectively. Inset:  
(CVs collected by Dr. Elaine Spain). 
 
5.2.1.5   Raman Spectroscopy  
For the microcavity arrays presented in this chapter, PS sphere removal was confirmed 
by Raman spectroscopy, presented in Figure 5.14. Spectra are offset manually for 
visual clarity. Before THF treatment (black spectra) the spectrum is dominated by 
polystyrene peaks, evident from aromatic ring breathing modes at 1008, 1208 and 1625 
cm
-1
. The features around 1008 cm
-1
 and 1476 cm
-1
 arise from skeletal vibrations of C-C 
stretching mode and CH2 scissor vibrations respectively. After THF treatment (red 
spectra), these distinct peaks are eliminated suggesting successful template removal. 
The Raman spectra presented are in agreement with Raman results shown previously by 
our group for the confirmation of PS on gold substrates of different sizes to those 
presented here.
(22)
 The broad peak observed at 1200-1600 cm
-1
 for bare cavity arrays 
was reproducible and is not observed for planar gold surfaces. Although there is no 
literature to support this, it is suggested to be induced by the cavity topography.  
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Figure 5.14: Raman spectra of 5.4 µm diameter cavity arrays with PS sphere template 
(black) and polystyrene removed following THF treatment (red) suggested via 
elimination of the distinct PS peak at approximately 1001 cm
-1
. 633 nm excitation 
wavelength and an exposure time of 30 seconds. 
 
As discussed in the introduction, our group have reported significant plasmonic 
enhancement of Raman signals nanopores.
(22)
 It was expected, therefore, that self-
assembly of the RGD peptide on the gold cavity surface would provide enhancement of 
the Raman signal permitting the monolayer to be seen. Figure 5.15 presents the Raman 
spectrum of C-Ahx-GRGDS peptide solid on glass compared to the spectrum obtained 
for the peptide self-assembled monolayer on a 5.4 µm diameter cavity array, with an 
excitation wavelength of 633 nm and exposure time of 30 seconds in both cases.  
 
The spectra of the RGD peptide is characterised by peaks at approximately 1240 cm
-1
 
(Amide III), 1455 cm
-1
 (CH bending), 1060/1550 cm
-1 
(NH2 rocking), 1455 cm
-1
 (C-H 
bending), 1700 cm
-1
 (carbonyl of aspartic acid), 2900 cm
-1
 (C-H stretching) and 2500 
cm
-1
 (S-H). These peaks are comparable to those reported previously by our group and 
to literature values.
(57,71)
 The surface enhancement factor (SEF) for molecules on the 5.4 
µm gold cavity array was determined using Eqn. 5.6: 
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 SEF = (IAu/NAu)/(Iglass/Nglass) = (IAu/Iglass)*(Nglass/NAu)         Eqn. 5.6 
 
Where IAu and Iglass denote the integrated intensities of Raman peaks of the C-Ahx-
GRGDS complex on the gold nanocavity arrays and as a solid on a glass slide 
respectively. NAu and Nglass represent the corresponding number of molecules 
estimated to be present in the focus (1 µm diameter) of the gold and glass samples 
respectively. 
 
The ratio of IAu and Iglass was determined from the area under the curve of the most 
intense Raman bands of the C-Ahx-GRGDS complex, which are seen at 1240 cm
-1
 
(Amide III), 1455 cm
-1
 (CH bending), 1060/1550 cm
-1 
(NH2 rocking) and 1455 cm
-1
 (C-
H bending). The average ratio from these bands was 6.30 ± 1.5 (IAu/Iglass). The 
number of molecules resident in the laser focus (1 µm diameter) on the gold cavity array 
was determined electrochemically. The charge under the oxidation curve from the cyclic 
voltammogram was used to calculate the number of molecules in the laser focus and 
was reported to be 2.136 x 10
11 
molecules/µm
2
.
(57)
 The laser focus is reported to contain 
approximately 5 x 10
6
 more molecules in the confocal volume for a solid compared 
with a monolayer on the gold substrate.
(72)
 This gives an overall enhancement factor 
(SEF) of 3 x 10
7
 for the C-Ahx-GRGDS modified gold nanocavity array compared to 
C-Ahx-GRGDS solid on glass. This SEF is comparable to values reported for 
nanostructured metal surfaces by other groups.
(32,73)
 
 
It is also important to note that from the Raman spectra, it is clear that RGD has bound 
to the gold substrate via thiol bonding as the S-H bond peak is clearly observed at 
approximately 2500 cm
-1
 for the solid on glass and is absent in the monolayer on gold. 
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Figure 5.15: Raman of C-Ahx-GRGDS solid on glass (black) and SERS observed on C-
Ahx-GRGDS attached to a 5.4 µm diameter gold cavity array (grey). 633 nm excitation 
wavelength and an exposure time of 30 seconds. Adhesion of C-Ahx-GRGDS is 
observed by the elimination of the distinct S-H peak at 2500 cm
-1
.  
 
5.2.2   Planar Gold Surfaces: Platelet Capture 
5.2.2.1   Platelet Morphology (SEM) 
SEM imaging provides additional morphological information of the platelets that 
confocal may not and so was employed first to investigate in detail, the effects of 
chemical modifications on platelet morphology. Using Figure 5.4 as a reference, the 
morphology of platelets bound to the chemically modified planar gold surfaces was 
investigated at high resolution using SEM. It is important to note that the substrate 
surface area, platelet concentration, volume, incubation times and temperature were 
identical for all modified surfaces: 1 cm
2
, 150 µl volume of 30 x 10
3
/µl ± 2 x 10
3
/µl 
platelets and 45 minutes incubation at 37°C.  Figure 5.16 presents SEM images of 
planar surfaces of (a) bare gold alone, (b) alkane alone, (c) RGD alone and (d) PEG 
alone. Both bare gold alone (a) and alkane alone (b) controls presented minimal 
adhesion. RGD alone (c) presented increased platelet adhesion with the majority of 
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platelets assuming early stage dendritic spreading highlighted in the magnified image 
presented in (e). PEG alone (d) presented enhanced platelet adhesion with mostly full 
platelet spreading (f).  
 
 
Figure 5.16: SEM images of platelets adhered to planar gold surfaces modified with (a) 
gold alone, (b) alkane alone, (c) RGD alone and (d) PEG alone. (e & f) Magnified 
images illustrating the minimal spreading of platelets bound to an (e) RGD modified 
planar surface and full spreading of platelets bound to a (f) PEG modified planar 
surface. 30 x 10
3 
± 2 x 10
3
/µl washed platelets were incubated with the modified 
surfaces for 45 minutes at 37°C. Accelerating voltage was 5 kV in all cases. Images are 
reproducible, with N =3. 
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5.2.2.2   Adhesion Control: RGD:PEG and RGD:alkane Ratio SAMs  
Adhesion control was investigated using varying RGD:alkane and RGD:PEG ratios of 
1:1, 1:5 and 1:10 (RGD concentration for SAM formation was 1 µM in all cases), 
Figure 5.17. All ratios presented comparable results to PEG alone with full platelet 
spreading in all cases.  
 
Interestingly, RGD:alkane 1:1 and 1:5 ratios presented similar platelet adhesion but 
with increased platelet spreading compared to RGD alone. An RGD:alkane 1:10 ratio 
significantly reduced platelet adhesion. 
 
Figure 5.17: SEM images of platelets adhered to planar gold surfaces modified with 
RGD:PEG ratios of (a) 1:1, (b) 1:5, (c) 1:10 and RGD:alkane ratios of (d) 1:1. (e) 1:5 
and (f) 1:10. C-Ahx-GRGDS concentration for SAM formation was 1 µM in all cases. 
30 x 10
3
± 2 x 10
3
/µl washed platelets were incubated with the modified surfaces for 45 
minutes at 37°C. Accelerating voltage was 5 kV in all cases. Images are reproducible, 
with N =3. 
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5.2.2.3   Quantitative Platelet Adhesion Count 
Figure 5.18 presents a quantitative comparison of platelet adhesion for the chemically 
modified planar surfaces. Platelet counts of TRITC-phalloidin stained platelets were 
measured using Image J software. The substrate surface area, platelet concentration, 
volume, incubation times and temperature were identical for all modified surfaces: 1 
cm
2
, 150 µl volume of 30 x 10
3
/µl ± 2 x 10
3
/µl platelets for 45 minutes at 37°C 
respectively.  
 
Bare gold and alkane surfaces alone presented minimal adhesion: 21,666 ± 2,886 and 
22,500 ± 11,456 platelets/cm
2
 respectively. RGD alone, RGD:alkane 1:1 and 1:5 ratios 
presented similar platelets counts of 750,000 ± 26,463, 895,000 ± 55,170 and 964,166 ± 
60,017 platelets/cm
2
. RGD:alkane 1:10 ratio presented approximately 83% decrease in 
platelet adhesion (124,166 ± 5,773 platelets/cm
2
) compared to RGD alone. 
 
In correlation with SEM, PEG presented enhanced platelet adhesion presenting similar 
platelet counts for PEG alone, RGD:PEG 1:1, 1:5 and 1:10 ratios: 2,542,500 ± 167,388, 
2,597,500 ± 114,755 platelets/cm
2
, 2,113,333 ± 404,693 platelets/cm
2
 and 2,001,667 ± 
114,409 platelets/cm
2
 respectively. 
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Figure 5.18: Bar graph presenting platelet count/cm
2
 versus chemically modified 
planar gold surfaces: gold alone, alkane alone, RGD alone, RGD:alkane 1:1,1:5 and 
1:10 ratios, PEG alone and RGD:PEG 1:1, 1:5 and 1:10 ratios. N = 3 in all cases. 30 x 
10
3
± 2 x 10
3
/µl washed platelets were incubated with the modified surfaces for 45 
minutes at 37°C. Bound platelet surfaces were fixed with 3.8% PFA solution, stained 
for TRITC-phalloidin (1/100 dilution) and imaged using a 40x oil immersion objective 
lens (NA 1.4) with 540 nm HeNe laser excitation. Platelet counts were carried out using 
Image J software. Data are represented as mean ± standard deviation of 3 independent 
measurements.  
 
5.2.2.4   Activation Status: CD62P and Phalloidin Staining 
As discussed earlier, p-selectin (CD62P) rapidly transports towards the platelet 
membrane and actin undergoes significant reorganisation following platelet activation. 
Thus confocal luminescence studies using both p-selectin (PE-CD62P) and actin 
(TRITC-phalloidin) staining was investigated to study the effects of the chemically 
modified surfaces on platelet activation.  
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5.2.2.4.1   Glass Activated Platelets Control 
Platelets are reported to spontaneously activate on glass substrates.
(54,74)
 Thus CD62P 
and phalloidin staining was first assessed in a simple control experiment using glass 
slides. Figure 5.19 presents confocal luminescence images of glass activated platelets 
bound to a glass slide and stained for p-selectin (PE-CD62P) (green) and actin (TRITC-
phalloidin) (red). No significant actin reorganisation was observed in this control study 
whereas CD62P localised primarily around the platelet membrane, a distinct sign of 
platelet activation. 
 
A second control study was carried out using an IgG isotype control (an antibody of the 
same isotype as a primary antibody with no relevant specificity to the target antigen). 
IgG was used as negative control to highlight any non-specific background signal from 
the specific CD62P staining, presented in Appendix 3. Insignificant luminescence was 
observed for IgG suggesting PE-CD62P staining is specific. 
 
A final control study using BSA (non-fouling agent) coated surfaces presented 
significantly less platelet adhesion with any bound platelets in the resting state, 
presented in Appendix 3. Actin and CD62P staining presented concentrated spherical 
shape staining; a distinct pattern for resting platelets further suggesting that the CD62P 
staining pattern presented in Figure 5.19 is representative of platelet activation e.g. 
membrane localised CD62P staining.  
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Figure 5.19: Confocal luminescence images of glass activated platelets. Top: 
backscatter (grey), CD62P (green) and phalloidin (red). Bottom: (left panel) merge 
presenting CD62P and phalloidin co-localisation and (right panel) magnified section of 
image illustrating platelet activation via CD62P (green) localisation around the platelet 
membrane. 30 x 10
3
± 2 x 10
3
/µl washed platelets were incubated with the modified 
surfaces for 45 minutes at 37°C and stained for CD62P (1/100 dilution) and phalloidin 
(1/100 dilution). Luminescence images were recorded using a 40x oil immersion 
objective lens (NA 1.4) with 488 nm Argon (CD62P) and 540 nm (phalloidin) HeNe 
laser excitation.  
 
5.2.2.4.2   RGD and PEG Alone SAMs 
Following the CD62P and phalloidin staining control study on glass activated platelets a 
confocal microscopy study of both CD62P and phalloidin staining on all modified 
planar gold surfaces was investigated to assess platelet activation.  
 
Figure 5.20 shows representative images of planar surfaces modified with RGD alone 
and PEG alone, labeled accordingly. As shown for SEM, both gold alone and alkane 
alone inhibited platelet adhesion (presented in Appendix 3). RGD alone presented 
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concentrated spherical shaped CD62P and phalloidin staining indicating bound platelets 
are in the resting state. In contrast, PEG adhesion lead to fully spread and activated 
platelets with CD62P diffusion and relocation towards the periphery of the platelets. 
Phalloidin staining presented significant actin reorganisation following platelet adhesion 
with the formation of actin stress fibers. In the early stages of spreading CD62P and 
phalloidin co-localise intensely as seen for the RGD alone surfaces but once 
spreading/activation occurs drastic differences can be observed between both labeling 
agents for the PEG surfaces suggesting advanced activation.
 
 
               CD62P    Phalloidin           Merge 
 
Figure 5.20: Confocal luminescence images of platelets bound to planar gold surfaces 
modified with (a) RGD alone and (b) PEG alone SAM surfaces and stained for PE-
CD62P (green) and TRITC-phalloidin (red). 30 x 10
3
± 2 x 10
3
/µl washed platelets were 
incubated with the modified surfaces for 45 minutes at 37°C and stained for CD62P 
(1/100 dilution) and phalloidin (1/100 dilution,). Luminescence images were recorded 
using a 40x oil immersion objective lens (NA 1.4) with 488 nm Argon (CD62P) and 540 
nm (phalloidin) HeNe laser excitation. Images are reproducible, with N =3. 
 
5.2.2.4.3   Adhesion Control: RGD:Alkane and RGD:PEG Ratio SAMs 
Consistent with SEM studies, RGD:PEG ratios of (a) 1:1, (b) 1:5 and (c) 1:10 presented 
similar platelet spreading in all cases, Figure 5.21 Significant CD62P diffusion towards 
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the periphery of the platelets was observed and phalloidin staining presented intense 
longitudinal actin stress fiber formation. RGD:PEG 1:10 ratio presented clear signs of 
advanced stage CD62P relocation with a distinct increase in CD62P luminescence 
intensity at the platelet membrane as well as actin re-organisation.  
       CD62P    Phalloidin           Merge  
 
Figure 5.21: Confocal luminescence images of platelets bound to planar gold surfaces 
modified with (a) RGD:PEG 1:1 ratio, (b) RGD:PEG 1:5 ratio and (c) RGD:PEG 1:10 
ratio SAM surfaces stained for PE-CD62P (green) and TRITC-phalloidin (red). 30 x 
10
3
± 2 x 10
3
/µl washed platelets were incubated with the modified surfaces for 45 
minutes at 37°C and stained for CD62P (1/100 dilution) and phalloidin (1/100 
dilution,). Luminescence images were recorded using a 40x oil immersion objective lens 
(NA 1.4) with 488 nm Argon (CD62P) and 540 nm (phalloidin) HeNe laser excitation. 
Images are reproducible, with N =3. 
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Consistently, RGD:alkane 1:1, 1:5 and 1:10 ratios, presented in Figure 5.22, contrast 
with PEG presenting similar results to the RGD alone case. CD62P and phalloidin 
staining although diffuse remains mostly located at the centre of the platelets suggesting 
platelets are in the resting state.  
        CD62P     Phalloidin           Merge  
 
Figure 5.22: Confocal luminescence images of platelets bound to planar gold surfaces 
modified with (a) RGD:alkane 1:1 ratio, (b) RGD:alkane 1:5 ratio and (c) RGD:alkane 
1:10 ratio SAM surfaces for PE-CD62P (green) and TRITC-phalloidin (red). 30 x 10
3
± 
2 x 10
3
/µl washed platelets were incubated with the modified surfaces for 45 minutes at 
37°C and stained for CD62P (1/100 dilution) and phalloidin (1/100 dilution,). 
Luminescence images were recorded using a 40x oil immersion objective lens (NA 1.4) 
with 488 nm Argon (CD62P) and 540 nm (phalloidin) HeNe laser excitation. Images 
are reproducible, with N =3. 
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Cell adhesion inhibition via modification of the surface with alkane is widely reported 
(e.g. neuronal stem cell and fibroblast inhibited adhesion) while platelet adhesion 
remains unexplored.
(75,76)
 Our results correlate with reported cell adhesion inhibition 
studies where platelet adhesion inhibition was observed for the alkane modified 
surfaces, Figure 5.16.  
 
Widely contrasting results regarding cell/protein adhesion to gold have been reported 
with it initially thought that adhesion was enhanced only for rough surfaces.
(77-79) 
It has 
since emerged the adhesion of cells to surfaces depends on not only the cell type but a 
much wider range of factors including topography, surface wettability, roughness and 
substrate type.
(14-16,75,77,80)
 The SEM study presented in Figure 5.16 suggests optimal 
platelet inhibition on gold alone which has a surface roughness (Rq) of ~12 nm.  
 
As discussed in Chapter 1, section 1.8.2, Groth et al.
(81)
 reported the effect of PEG 
surface functionality on the adhesion of human fibroblast cells. Studies suggested 
significantly higher spreading of human fibroblasts attached to NH2 and COOH in 
comparison to CH3, PEG and OH surfaces, attributed to a mid-range surface aqueous 
wettability in both cases. The PEG surfaces prepared in this study are COOH 
terminated, which may account for the significant platelet adhesion and spreading 
observed in Figure 5.16, (d & f), Figure 5.17, Figure 5.20, (b), and Figure 5.21. In 
addition, forming PEG SAMs via immersion has been shown previously to have an 
impact on PEG biocompatibility with increased protein and cell adhesion reported for 
the immersion technique compared to electrochemical SAM formation.
(82)
 Thus the 
biocompatibility of PEG has been reported to depend greatly on PEG chain length, 
density and even depends on the method of SAM formation onto the surface.
(82-84) 
 
As all PEG surfaces presented approximately the same level of adhesion, spreading and 
activation it is suggested that PEG is the adhesion target in all surfaces presented here 
regardless of the presence of RGD, however future work is required to strengthen this 
statement e.g. RGD, Eptifibatide or PEG release of platelets from the PEG surface will 
confirm if the adhesion is RGD or PEG driven. 
 
The effectiveness of the RGD peptide can be modified by decreasing the RGD 
concentration (increasing the non-fouling agent concentration e.g. alkane), a 
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phenomenon which has been reported in literature.
(15,16) 
Interestingly, RGD:alkane 1:1
 
and 1:5 ratios presented similar platelet adhesion to RGD alone but with increased 
spreading. One possibility is that introducing alkane ratios to the monolayer forms more 
densely packed RGD areas, which in turn increases platelet spreading. Alternatively, as 
the alkane is very crystalline and RGD very mobile in nature and with RGD being 
slightly longer in length than the alkane chain, increasing the alkane concentration may 
enhance the steric availability of the RGD moiety thus enhancing platelet adhesion and 
spreading. 
 
An
 
RGD:alkane 1:10 ratio effectively inhibited platelet adhesion in this study 
suggesting that there is a balance between the concentration of RGD that is required to 
offer optimal focal adhesion points and its steric availability. AFM imaging was 
attempted to investigate if clusters of RGD could be observed at higher height across 
the surface but proved inconclusive using the tips available. Future work using 
functionalised AFM tips may provide more information on the clustering nature of the 
RGD moiety on the surface. 
 
5.2.3   Gold Microcavity Arrays: Platelet Capture  
As surface chemistry controls both adhesion and activation status of platelets, we were 
interested to see if changing the surface geometry had any significant effect on platelet 
adhesion, spreading and activation status. Nano-patterned surfaces have been shown to 
affect adhesion based solely on their physical structure. For example, Ivanova et al.
(85)
 
have most recently reported the first example of a new class of nano-patterned 
biomaterials that create a non-adhesive and bactericidal surface based solely on the 
physical structure using the natural Clanger Cicoda (Psaltoda claripennis) specimen 
wing (shown to have a natural hydrophobic and homogeneous nano-pattern on the 
dorsal and ventral sides of the wing). Gold coating of cicada wings was previously 
shown by this group to signiﬁcantly alter the surface properties while preserving both 
the topographical structure and subsequently the bactericidal effect suggesting that the 
mechanism is solely biophysical with no biological role play.
(86)
 Consequently, this 
group proposed a biophysical model of the interactions between bacterial cells and 
cicada wing surface nanostructures suggesting that mechanical properties, in particular 
cell rigidity, are key factors in determining bacterial resistance/sensitivity to the 
bactericidal nature of the wing surface.  
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SEM and AFM confirmed that the wing was composed of an array of uniform 
nanopillar structures, hexagonally arranged and approximately 170 nm apart from 
centre to centre. Using SEM and confocal microscopy the effect of rigidity on the 
bactericidal properties of the nanopatterned surface was investigated through the 
attachment of naturally rigid species of gram positive cocci Planococcus meritimus and 
S. aureus and gram positive rod-shaped bacterium Bacillus sublicis on the cicada wing 
surfaces. Results confirmed all three species were unaffected by the nanopillar 
structures strengthening the suggestion that rigidity plays a key role in the resistance 
nature of the wing surface. This theory was investigated further by decreasing the 
rigidity of the surface-resistant strains through microwave irradiation of the cells which 
rendered them susceptible to the bactericidal nature of the wing surfaces. Significant 
changes to cell morphology following adhesion to the nanostructured surfaces were 
observed via fluorescence microscopy. These ﬁndings demonstrate the potential beneﬁts 
of incorporating nanopatterns such as those on the cicada wing into the design of 
antibacterial nanomaterials. Thus the effect of changing the surface geometry on platelet 
adhesion, spreading and activation was investigated as part of this chapter. 
 
From the planar surface investigations presented in this chapter it was decided that PEG 
treatment be omitted from further investigations due to its propensity for uncontrolled 
platelet adhesion and elusive platelet activation. As no significant differences were 
observed between RGD:alkane 1:1 and 1:5 ratios, the 1:1 ratio was also eliminated from 
further studies. The effect of surface geometry and cavity size on platelet adhesion, 
morphology and activation status was studied, comparing three different microcavity 
array sizes; 5.4 µm, 1.6 µm and 0.98 µm.  
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5.2.4   Gold Cavity Array: 5.4 µm Diameter  
5.2.4.1   Platelet Morphology (SEM) 
SEM was used to investigate, at high resolution, the effects of surface geometry and 
cavity size on platelet morphology following adhesion to the modified 5.4 µm diameter 
cavity arrays. Figure 5.23 presents SEM images of platelets bound to 5.4 µm diameter 
gold microcavity array surfaces with (a) bare gold alone, (b) alkane alone and (c) RGD 
alone. In correlation with the planar gold surfaces, bare gold and alkane alone presented 
little platelet adhesion with any bound platelets in the early spreading stages. 
 
RGD in contrast, Figure 5.23, (c) presented the 4 stages of platelet spreading: dendritic, 
spread dendritic, spread and fully spread platelets. Filopodia spreading was optimal only 
with the RGD modified cavity array. Fully spread platelets were only observed inside 
the cavities. The release of granules is suggested for RGD alone, thought to be the small 
spherical structure, labeled accordingly in Figure 5.23, (c). This is a phenomenon not 
observed in any other treated surface. α–granules are destined for release during platelet 
activation and are essential to normal platelet activity, secreting fibrinogen and von 
Willebrand factor (vWf), adhesive proteins which mediate platelet-platelet and platelet-
endothelial interactions. α-granules have a reported size range of ~200-500 nm, a size 
comparable to the suggested granule presented in Figure 5.23, (c).
(87)
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Figure 5.23: Scanning electron microscopy images of platelet adhesion to 5.4 µm 
diameter cavity arrays with unmodified (a) gold alone and surfaces chemically modified 
with (b) alkane alone and (c) RGD alone SAMs. 30 x 10
3
± 2 x 10
3
/µl platelets were 
incubated with the modified surfaces for 45 minutes at 37°C. Platelet fixation, 
dehydration and sputter coating was carried out as described in sections 5.1.6 to 5.1.8. 
Accelerating voltage was 5 kV in all cases. Images are reproducible, with N =3. 
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5.2.4.2   Adhesion Control: RGD:Alkane Ratio SAMs  
Adhesion control was investigated further using the alkane thiol at RGD:alkane SAM 
ratios of 1:5 and 1:10, Figure 5.24, (a & b). An RGD:alkane 1:5 ratio (a) presented 
bound platelets in the early spreading stages e.g. spread dendritic. An RGD:alkane 1:10 
ratio, (b), however, inhibited platelet spreading with any bound platelets present in the 
resting state, presented by the smooth discoid morphology. 
 
Figure 5.24: Scanning electron microscopy images of platelet adhesion at 5.4 µm 
diameter cavity arrays chemically modified with (a) RGD:alkane 1:5 ratio and (b) 
RGD:alkane 1:10 ratio SAMs. 30 x 10
3 
± 2 x 10
3
/µl washed platelets were incubated 
with the modified surfaces for 45 minutes at 37°C. Platelet fixation, dehydration and 
sputter coating was carried out as described in sections 5.1.6 to 5.1.8. Accelerating 
voltage was 5 kV in all cases. Images are reproducible, with N =3. 
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5.2.4.3   Selective Surface Modification  
The effect of selectively modifying the cavity array is presented in Figure 5.25, (a) and 
(b). In the case where RGD was at the top surface and alkane was on the cavity walls, 
(a) platelets bound solely to the top surface and presented early stage spreading. When 
the space was available, platelets fully spread, for example on defective areas such as 
the one outlined in (a), right panel. In contrast, platelets bound solely and spread fully 
inside RGD modified cavities with alkane at the top surface, (b). Alkane selectively 
modified areas inhibited platelet adhesion in both cases.  
 
Figure 5.25: Scanning electron microscopy images of platelet adhesion at 5.4 µm 
diameter cavity arrays selectively modified with (a) RGD at the top surface and alkane 
on the cavity walls and (b) alkane at the top surface and RGD on the cavity walls. 30 x 
10
3
± 2 x 10
3
/µl washed platelets were incubated with the modified surfaces for 45 
minutes at 37°C. Platelet fixation, dehydration and sputter coating was carried out as 
described in sections 5.1.6 to 5.1.8. Accelerating voltage was 5 kV in all cases. Images 
are reproducible, with N =3. 
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5.2.4.4   Platelet Treatment with Mn
2+
, DTT and Eptifibatide 
Given the apparent ability to modify platelet adhesion by surface chemistry/structure we 
were interested to know if chemical activation of the platelets moderated this behaviour. 
The effect of chemical treatment on platelet adhesion was investigated using platelet 
integrin αIIbβ3 “activators” Mn
2+ 
and DTT. The whole cavity array, both top surface and 
cavity walls were modified with an RGD SAM in all cases via immersion in a 1 µM 
ethanol solution of C-Ahx-GRGDS overnight at room temperature. In all cases platelets 
were treated according to modified literature methods
(88-90)
; 1 mM concentration and 15-
20 minutes incubation at room temperature. The effect of incubating 30 x 10
3
 ± 2 x 
10
3
/µl platelets with a 1 mM solution of Mn
2+
 or DTT for 15-20 minutes at room 
temperature prior to adhesion to the chemically modified surfaces on platelet 
morphology is presented in Figure 5.26. Mn
2+ 
had little impact on platelet morphology, 
observing all stages of spreading compared to RGD alone (Figure 5.23). DTT pre-
treatment reduced adhesion and eliminated full platelet spreading with the majority of 
platelets in the spread dendritic stage.  
 
Eptifibatide, an RGD sequence containing drug and known integrin αIIbβ3 binding 
inhibitor was employed as a control to investigate the adhesion affinity of platelets to 
the RGD modified surfaces and to provide evidence that it is ligand adhesion to integrin 
which is responsible for surface adhesion e.g. not non-specific interactions as is likely to 
be the case for PEG adhesion observed for the planar gold surfaces. The whole cavity 
array, both top surface and cavity walls were modified with an RGD SAM. The effect 
of incubating 30 x 10
3
 ± 2 x 10
3
/µl platelets with a 1 mM solution of Eptifibatide for 15-
20 minutes at room temperature prior to adhesion to the chemically modified RGD 
surface on platelet morphology was investigated. Eptifibatide treatment
 
had little impact 
on platelet morphology, and the 4 stages of spreading were observed similar to RGD 
alone, suggesting that platelet integrin has a higher affinity for the RGD SAM surfaces 
compared to Eptifibatide in solution. This is in stark contrast to Chapter 3, where 
Eptifibatide successfully inhibited integrin binding to the ruthenium-RGD conjugates, 
suggesting Eptifibatide has a greater affinity for integrin in solution compared to the 
ruthenium-RGD peptide conjugates.  
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Figure 5.26: Scanning electron microscopy images of platelet adhesion at 5.4 µm 
diameter cavity arrays where platelets were pre-treated with a 1 mM solution of (a) 
Mn
2+
, (b) DTT or (c) Eptifibatide for 15-20 minutes at room temperature prior to 
incubation with the modified surfaces. The whole cavity array was modified with an 
RGD SAM via immersion in a 1 µM ethanol solution of C-Ahx-GRGDS overnight at 
room temperature in all cases. 30 x 10
3
± 2 x 10
3
/µl washed platelets were incubated 
with the modified surfaces for 45 minutes at 37°C. Platelet fixation, dehydration and 
sputter coating was carried out as described in sections 5.1.6 to 5.1.8. Accelerating 
voltage was 5 kV in all cases. Images are reproducible, with N =3. 
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5.2.4.5   Platelet Adhesion Reversibility 
The effect of incubating untreated platelets already bound to an RGD modified array, 
Figure 5.27, (a & b), where the whole array, both top surface and cavity walls is 
modified with an RGD SAM (after 45 minute incubation at 37°C) with a 1 mM solution 
of Eptifibatide, Figure 5.27, (c), or RGD, Figure 5.27, (d), for 15-20 minutes at 37°C 
was investigated. Importantly, adhesion was found to be reversible on RGD ligand 
exposure in both cases, indicating platelet adhesion on the RGD modified surface is 
ligand mediated. Bound platelets are highlighted with a red circle in all cases. 
 
Figure 5.27: Scanning electron microscopy images of (a & c) untreated platelet 
adhesion at 5.4 µm diameter arrays modified with an RGD SAM, and when bound 
platelets were incubated post-bind with a 1 mM solution of (c) Eptifibatide or (d) RGD 
for 15-20 minutes at 37°C. 30 x 10
3
± 2 x 10
3
/µl platelets were incubated with the 
modified surfaces for 45 minutes at 37°C. Accelerating voltage was 5 kV in all cases. 
Images are reproducible, with N =3. 
 
 
Dark patches 
are suggested 
to be platelet 
residue 
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5.2.4.6   Quantitative Platelet Adhesion Count 
Figure 5.28 presents a quantitative comparison of platelet adhesion on each chemically 
modified 5.4 µm diameter cavity array surface. Platelet counts of TRITC-phalloidin 
stained platelets were measured using Image J software. The substrate surface area, 
platelet concentration, volume, incubation times and temperature were identical for all 
modified surfaces: 1 cm
2
, 150 µl volume of 30 x 10
3
/µl ± 2 x 10
3
/µl platelets for 45 
minutes at 37°C.  
 
In correlation with the planar gold surfaces, bare gold and alkane alone modified 
surfaces presented minimal adhesion: 23,333 ± 3,818 and 17,500 ±7,500 respectively. 
RGD alone presented the highest platelet count of 3,766,666 ± 40,414 platelets/cm
2
, 
approximately 80% greater than the platelet count observed for RGD alone planar gold 
arrays. The significant increase in platelet adhesion may be attributed to the increased 
surface area formed by the curved topography of the array: calculated top surface area 
and inner cavity wall area of 397 ± 49 µm
2
 and 622 ± 49 µm
2
 respectively. 
 
Introducing alkane at an RGD:alkane ratio of 1:5 reduced the platelet count by 76% ( 
915,933 ± 88,400 platelets/cm
2
) compared to RGD alone indicating that the RGD 
concentration is reduced at his ratio. In correlation with the planar gold surfaces, an 
RGD:alkane 1:10 ratio presented a significant 98% decrease in platelet count: 100,000 ± 
27,838 platelets/cm
2
. 
 
Selective modification of the top surface with alkane and the inner cavity walls with 
RGD presented a 75% decrease in platelet adhesion (1,042,500 ± 131,790 platelets/cm
2
) 
compared to RGD alone, while selectively coating the top surface with RGD and inner 
cavity walls with alkane presented an 80% decrease in platelet adhesion (756,666 ± 
52,816 platelets/cm
2
) compared to RGD alone. As discussed, the top surface area and 
inner cavity wall area for the 5.4 µm diameter array was calculated to be 397 ± 49 µm
2
 
and 622 ± 49 µm
2
 respectively suggesting the surface area of the top surface is 
approximately 1.5 times less than the interior cavity wall area. This is in correlation 
with the platelet counts observed here.  
 
Pre-treating 30 x 10
3 
± 2 x 10
3
/µl platelets with a 1 mM solution of the chemical 
“activating” agents Mn2+ or DTT or Eptifibatide for 15-20 minutes at room temperature 
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prior to adhesion to the chemically modified 5.4 µm diameter cavity array surfaces was 
also investigated. In all cases the whole cavity array was chemically modified with an 
RGD SAM only. Pre-treating platelets with Mn
2+
 prior to incubation with the 
chemically modified array presented a 66% decrease in platelet adhesion (1,278,333 ± 
103,511 platelets/cm
2
) compared to RGD alone. Pre-treatment with DTT instigated an 
even greater reduction of 83% in platelet adhesion (656,666 ± 78,763 platelets/cm
2
) 
compared to RGD alone. Pre-treating platelets with the commercial RGD cyclic drug 
Eptifibatide presented a similar platelet count to RGD alone: 3,323,333 ± 
10,615platelets/cm
2
. 
 
In correlation with SEM, incubating platelets with 1 mM solutions of either Eptifibatide 
or RGD for 15-20 minutes at 37°C after they had already bound to the RGD modified 
array (Following 45 minute incubation with the modified surfaces at 37°C) removed the 
majority of platelets from the array surfaces suggesting platelet adhesion to the RGD 
modified array surfaces is reversible. The platelet count was reduced by 77% (88,333 ± 
12,829 platelets/cm
2
) following incubation with Eptifibatide and by 91% (35000 ± 
13,228 platelets/cm
2
) when incubated with RGD. 
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Figure 5.28: Bar graph presents platelet count/cm
2
 at 5.4 µm diameter cavity array 
diameter surface versus surface modification/ platelet treatment. 30 x 10
3
± 2 x 10
3
/µl 
washed platelets were incubated with the modified surfaces for 45 minutes at 37°C. 
Bound platelets were fixed with 3.8% PFA solution, stained with TRITC-phalloidin 
(1/100 dilution) and imaged using a 40x oil immersion objective lens (NA 1.4) with 540 
nm HeNe laser excitation. Platelet counts were measured using Image J software. Data 
are represented as mean ± standard deviation of 3 independent measurements.  
 
5.2.4.7   Activation Status: CD62P and Phalloidin Staining 
5.2.4.7.1   Adhesion Control: RGD alone and RGD:alkane Ratio SAMs 
Further insight into the activation status of the surface bound platelets was sought by 
using CD62P and phalloidin staining, Figure 5.29, (a-c). RGD alone (a), RGD:alkane 
1:5 (b) and 1:10 ratios (c) presented CD62P and phalloidin staining at the centre of the 
platelets indicating bound platelets were in the resting state. As seen for the planar gold 
surfaces, an RGD:alkane 1:10 ratio presented significantly reduced platelet adhesion 
with any bound platelets in the resting state. 
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      Bright field            CD62P                  Phalloidin                    Merge 
 
Figure 5.29: Confocal luminescence images of platelet adhesion at 5.4 µm diameter 
arrays chemically modified with (a) RGD alone, (b) RGD:alkane 1:5 ratio and (c) 
RGD:alkane 1:10 ratio and stained for PE-CD62P (green) and TRITC-phalloidin (red). 
RGD concentration for SAM formation was 1 µM in all cases). 30 x 10
3
± 2 x 10
3
/µl 
washed platelets were incubated with the modified surfaces for 45 minutes at 37°C and 
stained for CD62P (1/100 dilution) and phalloidin (1/100 dilution,). Luminescence 
images were recorded using a 40x oil immersion objective lens (NA 1.4) with 488 nm 
Argon (CD62P) and 540 nm (phalloidin) HeNe laser excitation. Images are 
reproducible, with N =3. 
 
5.2.4.7.2   Selective Surface Modification  
As described, selective modification at the top surface with RGD and the cavity walls 
with alkane presented specific adhesion of platelets only to the RGD modified surface, 
see Figure 5.30, (a).  
 
In contrast, as shown for SEM, when RGD is on the cavity walls and alkane at the top 
surface of the array, platelets bind and fully spread inside the cavity, Figure 5.30, (b). 
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This result was reproducible, see Appendix 3. Both CD62P and phalloidin co-localise 
and shows possible signs of platelet activation with CD62P relocating towards the edges 
of the platelets and actin forming concentrated fluorescence at the edges of the platelets 
also. However fluorescence enhancement as a result of the gold cavity array cannot be 
ruled out for the observed increase in fluorescence intensity around the rim of the 
cavity.
(22,30,31,91,92)  
Fluorescent lifetime imaging microscopy (FLIM) is suggested as a 
future experiment to provide better insight on whether fluorescence enhancement is 
occurring by measuring changes to the lifetime of the fluorescent labels. 
          Bright field                      CD62P                Phalloidin           Merge  
 
Figure 5.30: Confocal luminescence images of platelet adhesion at 5.4 µm diameter 
arrays selectively modified with (a) RGD at the surface and alkane on the cavity walls 
and (b) alkane at the top surface and RGD on the cavity walls and stained for PE-
CD62P (green) and TRITC-phalloidin (red). 30 x 10
3
± 2 x 10
3
/µl washed platelets were 
incubated with the modified surfaces for 45 minutes at 37°C and stained for CD62P 
(1/100 dilution) and phalloidin (1/100 dilution,). Luminescence images were recorded 
using a 40x oil immersion objective lens (NA 1.4) with 488 nm Argon (CD62P) and 540 
nm (phalloidin) HeNe laser excitation. Images are reproducible, with N =3. 
 
5.2.4.7.3   Platelet Treatment with Mn
2+
, DTT and Eptifibatide  
The effect of incubating 30 x 10
3
 ± 2 x 10
3
/µl platelets with a 1 mM solution of the 
platelet integrin αIIbβ3 “activators” Mn
2+ 
and DTT for 15-20 minutes at room 
temperature prior to adhesion to the chemically modified surfaces on platelet activation 
status is presented in Figure 5.31. The whole cavity array, both top surface and cavity 
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walls were modified with an RGD SAM in all cases. Mn
2+
 treated platelets presented 
similar adhesion to RGD alone, Figure 5.31, (a). CD62P and phalloidin presented high 
intensity at the centre of the platelets suggests platelets are resting.  
 
DTT treated platelets presented mostly dendritic, non-spread platelets, Figure 5.31, (b). 
CD62P and phalloidin presented high intensity at the centre of the platelets suggests 
platelets are resting. However platelet adhesion affinity for the RGD Surface, as 
described, was a lot lower for DTT compared to Mn
2+
.  
 
Pre-treatment of the platelets with Eptifibatide prior to adhesion to the surface presented 
no difference to untreated platelets. CD62P and phalloidin localised at the centre of the 
platelets, indicating platelets are resting, Figure 5.31, (c).  
        Bright field                   CD62P                Phalloidin                       Merge 
 
Figure 5.31: Confocal luminescence images of platelet adhesion at 5.4 µm diameter 
arrays where platelets were pre-treated with 1 mM of (a) Mn
2+
, (b) DTT or (c) 
Eptifibatide and stained for PE-CD62P (green) and TRITC-phalloidin (red). The whole 
array surface was modified with an RGD SAM via immersion in a 1 µM ethanol 
solution of C-Ahx-GRGDS overnight at room temperature. 30 x 10
3
± 2 x 10
3
/µl washed 
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platelets were incubated with the modified surfaces for 45 minutes at 37°C and stained 
for CD62P (1/100 dilution) and phalloidin (1/100 dilution,). Luminescence images were 
recorded using a 40x oil immersion objective lens (NA 1.4) with 488 nm Argon 
(CD62P) and 540 nm (phalloidin) HeNe laser excitation. Images are reproducible, with 
N =3. 
 
5.2.5   Gold Cavity Arrays: 1.6 µm Diameter 
The effect of surface geometry on platelet adhesion was investigated further using 
cavity arrays with a smaller diameter of 1.6 µm. 
 
5.2.5.1   Platelet Morphology (SEM) 
SEM was used to investigate, at high resolution, the effects of surface geometry and 
cavity size on platelet morphology following platelet adhesion to the modified 1.6 µm 
diameter cavity arrays using Figure 5.14 as a platelet morphology reference. The array 
surfaces were chemically modified via immersion in a 1 µM ethanol solution of the 
desired thiol overnight at room temperature. The sample surface area, platelet 
concentration, volume, incubation times and temperature were identical for all modified 
surfaces: 1 cm
2
, 150 µl volume of 30 x 10
3
/µl ± 2 x 10
3
/µl platelets for 45 minutes at 
37°C. In correlation with the planar gold surfaces and the 5.4 µm diameter arrays, both 
bare gold alone and alkane alone presented insignificant platelet adhesion, presented in 
Figure 5.32. Platelets are highlighted with a red circle in all cases. 
Figure 5.32: Scanning electron microscopy image of platelet adhesion to (a) gold alone 
and (b) alkane alone modified surfaces on 1.6 µm diameter arrays. 30 x 10
3
± 2 x 10
3
/µl 
washed platelets were incubated with the modified surfaces for 45 minutes at 37°C. 
Accelerating voltage was 5 kV in all cases. Images are reproducible, with N =3. 
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5.2.5.2   Adhesion Control: RGD Alone and RGD:alkane Ratio SAMs  
SEM following platelet exposure to RGD alone, RGD:alkane 1:5 and 1:10 ratio 
modified 1.6 µm diameter arrays are shown in Figure 5.33, (a-c). RGD alone showed 
adhesion of single platelets over single cavities. Filopodia are fully extended in this 
case, full platelet spreading is minimal. Introduction of alkane reduced filopodial 
extension slightly for the 1:5 ratio and almost completely for 1:10 ratio, correlating with 
both the planar and 5.4 µm diameter array SEM studies. For the larger area images 
(right panels), platelets are highlighted with red circles. 
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Figure 5.33: Scanning electron microscopy image of platelet adhesion to 1.6 µm 
diameter arrays. (a) RGD alone, (b) RGD:alkane 1:5 ratio and (c) RGD:alkane 1:10 
ratio modified surfaces on 1.6 µm diameter arrays. For the larger area images (right 
panels), platelets are highlighted with red circles. 30 x 10
3
± 2 x 10
3
/µl washed platelets 
were incubated with the modified surfaces for 45 minutes at 37°C. Platelet fixation, 
dehydration and sputter coating was carried out as described in sections 5.1.6 to 5.1.8. 
Accelerating voltage was 5 kV in all cases. Images are reproducible, with N =3. 
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5.2.5.3   Selective Surface Modification  
The effect of selectively modifying the 1.6 µm diameter cavity array is presented in 
Figure 5.34. Where RGD was at the top surface and alkane on the cavity walls, Figure 
5.34, (a), platelet morphology was similar to RGD alone presenting extended filopodia. 
In contrast, when alkane was at the top surface and RGD on the cavity walls, platelets 
bound inside the RGD modified cavity with significantly reduced filopodial extension. 
For the larger area images (right panels), platelets are highlighted with red circles. 
 
Figure 5.34: Scanning electron microscopy image of platelet adhesion at 1.6 µm 
diameter arrays selectively modified with (a) RGD at the top surface and alkane on the 
cavity walls and (b) alkane at the top surface and RGD on the cavity walls. For the 
larger area images (right panels), platelets are highlighted with red circles. 30 x 10
3
± 2 
x 10
3
/µl washed platelets were incubated with the modified surfaces for 45 minutes at 
37°C. Platelet fixation, dehydration and sputter coating was carried out as described in 
sections 5.1.6 to 5.1.8. Accelerating voltage was 5 kV in all cases. Images are 
reproducible, with N =3. 
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5.2.5.4   Platelet Treatment with Mn
2+
, DTT and Eptifibatide  
Pre-treating 30 x 10
3
± 2 x 10
3
/µl platelets with a 1 mM solution of the chemical 
“activating” agents Mn2+ or DTT or the cyclic RGD drug Eptifibatide for 15-20 minutes 
at room temperature prior to adhesion to the chemically modified 1.6 µm diameter 
cavity array surfaces was also investigated. In all cases the whole cavity array was 
chemically modified with an RGD SAM. 
 
Figure 5.35 presented similar results to those described for the 5.4 µm diameter array. 
Filopodia extensions were present for Mn
2+
 treated platelets. In contrast, for DTT 
treated platelets decreased filopodial elongation was observed. Pre-treatment of platelets 
with Eptifibatide presented similar adhesion to RGD alone albeit with reduced 
filopodial extension; filopodia were present but did not spread to the extent observed for 
RGD alone. For the larger area images (right panels), platelets are highlighted with red 
circles. 
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Figure 5.35: Scanning electron microscopy image of platelet adhesion to 1.6 µm 
diameter gold arrays where platelets were pre-treated with a 1 mM solution of (a) 
Mn
2+
and (b) DTT or (c) Eptifibatide. For the larger area images (right panels), 
platelets are highlighted with red circles. The whole array was modified with an RGD 
SAM via immersion in a 1 µM ethanol solution of C-Ahx-GRGDS overnight at room 
temperature. 30 x 10
3
± 2 x 10
3
/µl washed platelets were incubated with the modified 
surfaces for 45 minutes at 37°C. Platelet fixation, dehydration and sputter coating was 
carried out as described in sections 5.1.6 to 5.1.8. Accelerating voltage was 5 kV in all 
cases. Images are reproducible, with N =3. 
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5.2.5.5   Platelet Adhesion Reversibility 
The effect of incubating untreated platelets already bound to the array (after 45 minute 
incubation at 37°C) with a 1 mM solution of Eptifibatide or RGD for 15-20 minutes at 
37°C is presented in Figure 5.36, (b & d). In correlation with the 5.4 µm diameter array 
SEM studies, incubation of bound platelets with both Eptifibatide and RGD reversed 
platelet adhesion in both cases. For the larger area images (right panels), platelets are 
highlighted with red circles. 
Figure 5.36: Scanning electron microscopy images of platelet adhesion to modified 1.6 
µm diameter cavity arrays where platelets were pre-treated with a 1 mM solution of (a) 
Eptifibatide or (c) RGD for 15-20 minutes at room temperature prior to incubation with 
the modified surfaces or when bound platelets were incubated post-bind with a 1 mM 
solution of (b) Eptifibatide or (d) RGD for 15-20 minutes at 37°C. For the larger area 
images (right panels), platelets are highlighted with red circles. The whole array was 
modified with an RGD SAM via immersion in a 1 µM ethanol solution of C-Ahx-
GRGDS overnight at room temperature. 30 x 10
3
± 2 x 10
3
/µl washed platelets were 
incubated with the modified surfaces for 45 minutes at 37°C. Platelet fixation, 
dehydration and sputter coating was carried out as described in sections 5.1.6 to 5.1.8. 
Accelerating voltage was 5 kV in all cases. Images are reproducible, with N =3. 
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5.2.5.6   Quantitative Platelet Adhesion Count 
A quantitative comparison of platelet number for all modified 1.6 µm diameter cavity 
array surfaces is presented in Figure 5.37. Platelet counts were measured using Image J 
software, and example images from each treatment platelet count is shown in Appendix 
3. The substrate surface area, platelet concentration, volume, incubation times and 
temperature were identical for all modified surfaces: 1 cm
2
, 150 µl volume of 30 x 
10
3
/µl ± 2 x 10
3
/µl platelets for 45 minutes at 37°C.  
 
As for the planar surfaces and 5.4 µm array platelet adhesion to bare gold and alkane 
surfaces alone modified 1.6 µm diameter cavity arrays presented little platelet adhesion: 
65,833 ± 12,829 and 43,333 ± 9,464 platelets/cm
2
 respectively. RGD alone (whole array 
modified with RGD SAM) presented the highest platelet count: 1,570,833 ± 171.506 
platelets/cm
2
. Counts were approximately 2 times less than that observed for the 5.4 µm 
diameter cavity arrays. As described, the 1.6 µm diameter cavity arrays presented a top 
surface area and cavity interior surface area of approximately 150 ± 27 and 375 ± 27 
um
2
 respectively. The top surface area is approximately 2.5 times smaller and the 
interior cavity wall approximately 1.5 times smaller than those calculated for the 5.4 µm 
diameter array, thus a 2-3 fold decrease in platelet count for the RGD alone modified 
1.6 µm diameter array was estimated. Results are in good correlation with this 
estimation, with a 59% decrease in platelet count observed for the 1.6 µm RGD alone 
modified array compared to the larger 5.4 µm diameter RGD alone modified cavity 
array. 
 
Platelet adhesion control using RGD:alkane SAM ratios of 1:5 and 1:10 was also 
investigated. In correlation with the 5.4 µm diameter cavity arrays and planar gold 
surfaces, RGD:alkane 1:5 ratio presented a 55% reduction in platelet adhesion (715,833 
± 72,858 platelets/cm
2
) compared to RGD alone, while RGD:alkane 1:10 ratio 
presented a 90% decrease in platelet count (163,333 ± 17,017 platelets/cm
2
)
 
compared 
to RGD alone suggesting, as discussed, that RGD availability is too low at the 
RGD:alkane 1:10 ratio. 
 
Selective modification with RGD at the top surface and alkane on the cavity walls 
presented a comparable platelet count (1,580,000 ± 56,623 platelets/cm
2
) to RGD alone 
suggesting that selective modification in this case has no significant effect on platelet 
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adhesion. In contrast however, coating the cavity walls with RGD and the top surface 
with alkane decreased the platelet count by approximately 68% (503,333 ± 73,922 
platelets/cm
2
). As mentioned, the 1.6 µm diameter cavity arrays presented a top surface 
area and cavity interior surface area of approximately 150 ± 27 and 375 ± 27 µm
2
 
respectively suggesting the top surface area is almost 3 times smaller than the cavity 
walls suggesting that platelet adhesion may be 3 times less for RGD selectively at the 
top surface, however this was not the case.  
 
Pre-treating 30 x 10
3
± 2 x 10
3
/µl platelets with a 1 mM solution of the chemical 
“activating” agents Mn2+ or DTT or the cyclic RGD drug Eptifibatide for 15-20 minutes 
at room temperature prior to adhesion to the chemically modified 1.6 µm diameter 
cavity array was also investigated. In all cases the whole cavity array was chemically 
modified with an RGD SAM. Pre-treating the platelets with Mn
2+ 
(1,393,333 ± 55,075 
platelets/cm
2
) did not affect platelet adhesion compared to RGD alone, while DTT 
presented a 59% reduction in platelet count (932,500 ± 68,053 platelets/cm
2
) compared 
to RGD alone. In contrast, in correlation with the 5.4 µm diameter cavity array, 
Eptifibatide (1,140,833 ± 96,187 platelets/cm
2
) presented a comparable platelet count to 
RGD alone. 
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Figure 5.37: Bar graph presenting platelet count/cm
2
 at 1.6 µm diameter cavity array 
surface versus surface modification/ platelet treatment. 30 x 10
3
± 2 x 10
3
/µl washed 
platelets were incubated with the modified surfaces for 45 minutes at 37°C. Bound 
platelets were fixed with 3.8% PFA solution, stained with TRITC-phalloidin (1/100 
dilution) and imaged using a 40x oil immersion objective lens (NA 1.4) with 540 nm 
HeNe laser excitation. Platelet counts were measured using Image J software. Data are 
represented as mean ± standard deviation of 3 independent measurements.  
 
5.2.5.7   Activation Status: CD62P and Phalloidin Staining  
5.2.5.7.1   Adhesion Control: RGD Alone and RGD:alkane Ratio SAMs 
The activation status of the surface bound platelets was investigated using CD62P and 
phalloidin staining. Bare gold and alkane alone presented minimal adhesion with any 
bound platelets in the resting state, presented in Appendix 3. RGD alone, RGD:alkane 
1:5 ratio and RGD:alkane 1:10 ratio (Figure 5.38,  (a-c)) presented concentrated 
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CD62P and phalloidin staining at the centre of the platelets suggesting platelets are in 
the resting state in all cases. In correlation with 5.4 µm array studies, this was 
intensified even further for the RGD:alkane 1:10 ratio with additional reduced platelet 
adhesion. 
            Bright field               CD62P                Phalloidin               Merge 
 
Figure 5.38: Confocal luminescence images of platelet adhesion to 1.6 µm diameter 
cavity arrays modified with (a) RGD alone, (b) RGD:alkane 1:5 ratio and (c) 
RGD:alkane 1:10 ratio SAMs and stained for PE-CD62P (green) and TRITC-phalloidin 
(red). RGD concentration for SAM formation was 1 µM in all cases. 30 x 10
3
± 2 x 
10
3
/µl washed platelets were incubated with the modified surfaces for 45 minutes at 
37°C and stained for CD62P (1/100 dilution) and phalloidin (1/100 dilution,). 
Luminescence images were recorded using a 40x oil immersion objective lens (NA 1.4) 
with 488 nm Argon (CD62P) and 540 nm (phalloidin) HeNe laser excitation. Images 
are reproducible, with N =3. 
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5.2.5.7.2   Selective Surface Modification  
Selective modification with RGD at the top surface and alkane on the cavity walls and 
vice versa are presented in Figure 5.39. In all cases CD62P and phalloidin are 
concentrated at the centre of the platelets indicating platelets are in the resting state. 
       Bright field                   CD62P                   Phalloidin                     Merge  
 
Figure 5.39: Confocal luminescence images of platelet adhesion to 1.6 µm diameter 
cavity arrays selectively modified with (a) RGD at the top surface and alkane on the 
cavities and (b) alkane at the top surface and RGD on the cavities and stained for PE-
CD62P (green) and TRITC-phalloidin (red). 30 x 10
3
± 2 x 10
3
/µl washed platelets were 
incubated with the modified surfaces for 45 minutes at 37°C and stained for CD62P 
(1/100 dilution) and phalloidin (1/100 dilution,). Luminescence images were recorded 
using a 40x oil immersion objective lens (NA 1.4) with 488 nm Argon (CD62P) and 540 
nm (phalloidin) HeNe laser excitation. Images are reproducible, with N =3. 
 
5.2.5.7.3   Platelet Treatment with Mn
2+
, DTT or Eptifibatide  
The effect of incubating 30 x 10
3
 ± 2 x 10
3
/µl platelets with a 1 mM solution of the 
widely reported platelet integrin αIIbβ3 “activators” Mn
2+ 
and DTT for 15-20 minutes at 
room temperature prior to adhesion to the chemically modified surfaces on platelet 
activation status is presented in Figure 5.40 (An RGD SAM covers the whole cavity 
array, both top surface and cavity walls in all cases). In all cases, CD62P and phalloidin 
presented concentrated staining at the centre of the platelets indicating platelets are 
resting state in all cases. The circular truncations observed in all cases are attributed to 
fluorescence enhancement from the gold substrate. 
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Figure 5.40: Confocal luminescence images of platelet adhesion to 1.6 µm diameter 
arrays where platelets were pre-treated with 1 mM of (a) Mn
2+
, (b) DTT or (c) 
Eptifibatide and stained for PE-CD62P (green) and TRITC-phalloidin (red). The whole 
surface was covered with a C-Ahx-GRGDS SAM in all cases. 30 x 10
3
± 2 x 10
3
/µl 
washed platelets were incubated with the modified surfaces for 45 minutes at 37°C and 
stained for CD62P (1/100 dilution) and phalloidin (1/100 dilution,). Luminescence 
images were recorded using a 40x oil immersion objective lens (NA 1.4) with 488 nm 
Argon (CD62P) and 540 nm (phalloidin) HeNe laser excitation. Images are 
reproducible, with N =3. 
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5.2.6   Gold Cavity Array: 0.98 µm Diameter Size 
The effect of surface geometry on platelet adhesion was investigated further using 
cavity arrays with a smaller diameter of 0.98 µm. 
 
5.2.6.1   Platelet Morphology (SEM) 
Using Figure 5.14 as a reference, the morphology of platelets bound to the chemically 
modified 0.98 µm diameter gold microcavity arrays was investigated. The surface area, 
platelet concentration, volume, incubation times and temperature were identical for all 
modified surfaces: 1 cm
2
, 150 µl volume of 30 x 10
3
/µl ± 2 x 10
3
/µl platelets for 45 
minutes at 37°C. SEM images of platelet adhesion to bare gold alone and alkane alone 
were comparable to the other two array sizes presenting little platelet adhesion to the 
surface, Figure 5.41. Platelets are highlighted with a red circle in both cases. 
 
Figure 5.41: Scanning electron microscopy images of platelets adhesion at 0.98 µm 
diameter cavity arrays modified with (a) bare gold alone and (b) alkane alone. Platelets 
are highlighted with a red circle in both cases. 30 x 10
3
± 2 x 10
3
/µl washed platelets 
were incubated with the modified surfaces for 45 minutes at 37°C. Platelet fixation, 
dehydration and sputter coating was carried out as described in sections 5.1.6 to 5.1.8. 
Accelerating voltage was 5 kV in all cases. Images are reproducible, with N =3. 
 
5.2.6.2   Adhesion Control: RGD alone and RGD:alkane SAMs  
RGD alone, Figure 5.42, (a), presented platelet adhesion with advanced filopodial 
elongation. Similar to both 1.6 and 5.4 µm diameter cavity array sizes, (b) RGD:alkane 
1:5 ratio presented reduced filopodial elongation while (c) 1:10 ratio inhibited filopodial 
extensions. In all cases, platelet spreading did not exceed first stage dendritic spreading. 
For the larger area images (right panels), platelets are highlighted with red circles. 
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Figure 5.42: Scanning electron microscopy images of platelet adhesion at 0.98 µm 
diameter cavity arrays modified with (a) RGD alone, (b) RGD:alkane 1:5 ratio and (c) 
RGD:alkane 1:10 ratio.  For the larger area images (right panels), platelets are 
highlighted with red circles. C-Ahx-GRGDS concentration for SAM surface formation 
was 1 µM in all cases. 30 x 10
3
± 2 x 10
3
/µl washed platelets were incubated with the 
modified surfaces for 45 minutes at 37°C. Platelet fixation, dehydration and sputter 
coating was carried out as described in sections 5.1.6 to 5.1.8. Accelerating voltage 
was 5 kV in all cases. Images are reproducible, with N =3. 
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5.2.6.3   Selective Surface Modification  
Selective modification of the array with RGD at the top surface and alkane on the cavity 
walls, Figure 5.43, (a), presented similar adhesion to RGD alone but with reduced 
filopodial elongation. When alkane is at the top surface and RGD is on the cavity walls, 
Figure 5.43, (b), platelet spreading was inhibited with complete inhibition of filopodial 
elongation. For the larger area images (right panels), platelets are highlighted with red 
circles. 
 
Figure 5.43: Scanning electron microscopy images of platelet adhesion at 0.98 µm 
diameter cavity arrays selectively modified with (a) RGD at the top surface and alkane 
on the cavity walls and (b) alkane at the top surface and RGD on the cavities. For the 
larger area images (right panels), platelets are highlighted with red circles. C-Ahx-
GRGDS (1 µM conc.) covered the entire array in both cases. 30 x 10
3
± 2 x 10
3
/µl 
washed platelets were incubated with the modified surfaces for 45 minutes at 37°C. 
Platelet fixation, dehydration and sputter coating was carried out as described in 
sections 5.1.6 to 5.1.8. Accelerating voltage was 5 kV in all cases. Images are 
reproducible, with N =3. 
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5.2.6.4   Platelet Treatment with Mn
2+
, DTT and Eptifibatide  
The effect of incubating 30 x 10
3
 ± 2 x 10
3
/µl platelets with a 1 mM solution of the 
widely reported platelet integrin αIIbβ3 “activators” Mn
2+ 
or DTT for 15-20 minutes at 
room temperature prior to adhesion to the chemically modified surfaces on platelet 
morphology is presented in Figure 5.44, (a & b). The whole cavity array, both top 
surface and cavity walls were modified with an RGD SAM in all cases.  
 
Both Mn
2+
 and DTT chemical activation presented platelet adhesion with reduced 
filopodial elongation. In correlation with the other two array sizes, DTT produced a 
significantly greater reduction in filopodial elongation.  
 
The effect of incubating 30 x 10
3
 ± 2 x 10
3
/µl platelets with a 1 mM solution of the 
commercial cyclic RGD Eptifibatide drug for 15-20 minutes at room temperature prior 
to adhesion to the chemically modified surfaces is presented in Figure 5.44, (c). In 
correlation with the other two array sizes, Eptifibatide pre-treatment had no significant 
effect presenting platelet morphology and is identical to that of RGD alone. For the 
larger area images (right panels), platelets are highlighted with red circles. 
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Figure 5.44: Scanning electron microscopy images of platelet adhesion at 0.98 µm 
diameter cavity arrays modified where platelets were pre-treated with 1 mM (a) Mn
2+
 
and (b) DTT and (c) Eptifibatide. RGD (1 µM conc.) covered the entire array in all 
cases. For the larger area images (right panels), platelets are highlighted with red 
circles. 30 x 10
3
± 2 x 10
3
/µl washed platelets were incubated with the modified surfaces 
for 45 minutes at 37°C. Platelet fixation, dehydration and sputter coating was carried 
out as described in sections 5.1.6 to 5.1.8. Accelerating voltage was 5 kV in all cases. 
Images are reproducible, with N =3. 
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5.2.6.5   Platelet Adhesion Reversibility 
The effect of incubating untreated platelets already bound to the RGD modified array 
(after 45 minute incubation at 37°C) with a 1 mM solution of Eptifibatide or RGD for 
15-20 minutes at 37°C is presented in Figure 5.45, (b & d). In agreement with the other 
two array sizes, incubating bound platelets with either Eptifibatide or RGD effectively 
removed the majority of bound platelets suggesting that adhesion is reversible and that 
it is ligand mediated; 93% and 99% decrease in platelet count for Eptifibatide and RGD 
incubation respectively. Platelets are highlighted with red circles in all cases. 
Figure 5.45: Scanning electron microscopy images of platelet adhesion at RGD SAM 
modified 0.98 µm diameter cavity arrays where platelets were pre-treated with a 1 mM 
solution of (a) Eptifibatide or (c) RGD for 15-20 minutes at room temperature prior to 
incubation with the modified surfaces or when bound platelets were incubated post-bind 
with a 1 mM solution of (b) Eptifibatide or (d) RGD for 15-20 minutes at 37°C. For the 
Platelets are highlighted with red circles in all cases ((d) presented no platelets). 30 x 
10
3
± 2 x 10
3
/µl washed platelets were incubated with the modified surfaces for 45 
minutes at 37°C. Platelet fixation, dehydration and sputter coating was carried out as 
described in sections 5.1.6 to 5.1.8. Accelerating voltage was 5 kV in all cases. Images 
are reproducible, with N =3. 
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5.2.6.6   Quantitative Platelet Adhesion Count 
Figure 5.46 presents a quantitative comparison of platelet adhesion on each chemically 
modified 0.98 µm diameter cavity array surface. Platelet counts of TRITC-phalloidin 
stained platelets were measured using Image J software. The substrate surface area, 
platelet concentration, volume, incubation times and temperature were identical for all 
modified surfaces: 1 cm
2
, 150 µl volume of 30 x 10
3
/µl ± 2 x 10
3
/µl platelets for 45 
minutes at 37°C.  
 
In correlation with the planar gold surfaces, 5.4 and 1.6 µm diameter cavity array 
surfaces, bare gold and alkane alone surfaces presented insignificant adhesion; 45,000 ± 
11,456 platelets/cm
2
 and 39,166 ± 11,814 platelets/cm
2
 respectively. RGD alone 
presented the highest platelet count of 1,109,166 ± 12,583 platelets/cm
2
 which is 
approximately 3 times less than that observed for RGD alone on the 5.4 µm diameter 
cavity arrays. As discussed, the top surface area and inner cavity wall area for the 0.98 
µm diameter array was calculated to be 15 ± 9 µm
2
 and 240 ± 9 µm
2
 respectively 
suggesting the surface area of the top surface is approximately 26 times less and the 
interior cavity wall area approximately 2.6 times less than the 5.4 µm diameter surface 
areas. The decreased adhesion observed for the RGD alone modified 1.6 µm array is in 
correlation with this calculation. Introducing bioinert alkane at an RGD:alkane 1:5 ratio 
caused a 15% reduction in platelet count (946,666 ± 96,382 platelets/cm
2
), while an 
RGD:alkane 1:10 ratio presented a significant 99% decrease in platelet count (104,166 
± 36,429 platelets/cm
2
). 
 
Selective modification with RGD at the top surface and alkane on the cavity walls 
presented a comparable platelet count (1,457,500 ± 30,310 platelets/cm
2
) to RGD alone 
suggesting that selective modification in this case has no significant effect on platelet 
adhesion. In contrast, selective modification with alkane at the top surface and RGD on 
the cavity walls significantly decreased the platelet count by approximately 90% 
(150,000 ± 35,000 platelets/cm
2
). As discussed, the top surface area and inner cavity 
wall area for the 0.98 µm diameter array was calculated to be 15 ± 9 µm
2
 and 240 ± 9 
µm
2
 respectively suggesting the surface area of the top surface is approximately 16 
times less than the interior cavity wall area. Thus it was estimated that platelet adhesion 
would be approximately 16 times less for RGD at the top surface compared to RGD on 
the cavity walls. This is not the case, however, selective modification with RGD at the 
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top surface and the cavity walls with alkane presented 10 times greater adhesion 
compared to selective modification with alkane at the top surface and the cavity walls 
with RGD.  
 
Pre-treating 30 x 10
3
± 2 x 10
3
/µl platelets with a 1 mM solution of the chemical 
“activating” agents Mn2+ or DTT or the cyclic RGD drug Eptifibatide for 15-20 minutes 
at room temperature prior to adhesion to the chemically modified 0.98 µm diameter 
cavity array surfaces was also investigated. In all cases the whole cavity array was 
chemically modified with an RGD SAM via immersion with 1 µM C-Ahx-GRGDS 
overnight at room temperature. Pre-treating the platelets with Mn
2+ 
(990,000 ± 110,566 
platelets/cm
2
) presented a 32% decrease in platelet count compared to RGD alone, 
while DTT produced significantly 52% decrease in platelet count (697,500 ± 60,673 
platelets/cm
2
) compared to RGD alone. In correlation with both 1.6 and 5.4 µm array 
sizes, Eptifibatide (1,047,500 ± 156,244 platelets/cm
2
) had a minor effect on platelet 
adhesion with an similar count to that of RGD alone. 
 
In agreement with SEM, incubating platelets with 1 mM solutions of either Eptifibatide 
or RGD for 15-20 minutes at 37°C after they had already bound to the RGD modified 
array (Following 45 minute incubation with the modified surfaces at 37°C) removed the 
majority of platelets from the array surfaces; the platelet count was reduced by 93 % 
(81,666 ± 12,332 platelets/cm
2
) following incubation with Eptifibatide and by 99 % 
(27,500 ± 9,013 platelets/cm
2
) following incubation with RGD. 
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Figure 5.46: Bar graph presenting platelet count/cm
2
 at 0.98 µm diameter cavity array 
surface versus surface modification/ platelet treatment. 30 x 10
3
± 2 x 10
3
/µl washed 
platelets were incubated with the modified surfaces for 45 minutes at 37°C. Bound 
platelets were fixed with 3.8% PFA solution, stained for TRITC-phalloidin (1/100 
dilution) and imaged using a 40x oil immersion objective lens (NA 1.4) with 540 nm 
HeNe laser excitation. Platelet counts were measured using Image J software. Data are 
represented as mean ± standard deviation of 3 independent measurements.  
 
5.2.6.7   Activation Status: CD62P and Phalloidin Staining 
5.2.6.7.1   Adhesion Control: RGD alone and RGD:alkane Ratio SAMs 
The activation status of the surface bound platelets was investigated using CD62P and 
phalloidin staining. In correlation with the two larger array sizes, RGD alone, 
RGD:alkane 1:5 and 1:10 ratio presented concentrated CD62P and phalloidin 
localisation at the centre of platelets indicating platelets are in the resting state, Figure 
5.47, (a-c).  
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    Bright field                   CD62P             Phalloidin                    Merge 
Figure 5.47: Confocal luminescence images of platelets bound to 0.98 µm diameter 
cavity arrays modified with (a) RGD alone, (b) RGD:alkane 1:5 ratio and (bottom) 
RGD:alkane 1:10 ratio and stained for PE-CD62P (green) and TRITC-phalloidin (red). 
RGD concentration for SAM formation was 1 µM in all cases. 30 x 10
3
± 2 x 10
3
/µl 
washed platelets were incubated with the modified surfaces for 45 minutes at 37°C and 
stained for CD62P (1/100 dilution) and phalloidin (1/100 dilution,). Luminescence 
images were recorded using a 40x oil immersion objective lens (NA 1.4) with 488 nm 
Argon (CD62P) and 540 nm (phalloidin) HeNe laser excitation. Images are 
reproducible, with N =3. 
 
5.2.6.7.2    Selective Surface Modification  
When RGD is at the top surface and alkane on the cavity walls, CD62P and phalloidin 
staining is centrally concentrated in the platelets indication platelet are in the resting 
state. In correlation with the quantitative platelet count, when alkane is at the top surface 
and RGD is on the cavity walls platelet adhesion is reduced with any bound platelets 
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presenting intense CD62P and phalloidin staining at the centre of the platelets indicating 
platelets are in the resting state, Figure 5.48. 
    Bright field                   CD62P                 Phalloidin                      Merge 
 
Figure 5.48: Confocal luminescence images of platelets bound to 0.98 µm diameter 
cavity arrays selectively modified with (a) RGD at the top surface and alkane on the 
cavities and (b) alkane at the top surface and RGD on the cavities and stained for PE-
CD62P (green) and TRITC-phalloidin (red). 30 x 10
3
± 2 x 10
3
/µl washed platelets were 
incubated with the modified surfaces for 45 minutes at 37°C and stained for CD62P 
(1/100 dilution) and phalloidin (1/100 dilution,). Luminescence images were recorded 
using a 40x oil immersion objective lens (NA 1.4) with 488 nm Argon (CD62P) and 540 
nm (phalloidin) HeNe laser excitation. Images are reproducible, with N =3. 
 
5.2.6.7.3   Platelet Treatment with Mn
2+
, DTT and Eptifibatide 
The effect of incubating 30 x 10
3
 ± 2 x 10
3
/µl platelets with a 1 mM solution of the 
widely reported platelet integrin αIIbβ3 “activators” Mn
2+ 
and DTT for 15-20 minutes at 
room temperature prior to adhesion to the chemically modified surfaces on platelet 
activation status is presented in Figure 5.49. The whole cavity array, both top surface 
and cavity walls were modified with an RGD SAM in all cases. All three treatments 
presented concentrated CD62P and phalloidin staining at the centre of the platelets, 
indicating platelets are resting in all cases. 
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    Bright field                   CD62P             Phalloidin                    Merge 
 
Figure 5.49: Confocal luminescence images of platelet adhesion at 0.98 µm diameter 
arrays where platelets were pre-treated with 1 mM of (a) Mn
2+
, (b) DTT or (c) 
Eptifibatide and stained for PE-CD62P (green) and TRITC-phalloidin (red). The whole 
surface was covered with a C-Ahx-GRGDS SAM in all cases. 30 x 10
3
± 2 x 10
3
/µl 
washed platelets were incubated with the modified surfaces for 45 minutes at 37°C and 
stained for CD62P (1/100 dilution) and phalloidin (1/100 dilution,). Luminescence 
images were recorded using a 40x oil immersion objective lens (NA 1.4) with 488 nm 
Argon (CD62P) and 540 nm (phalloidin) HeNe laser excitation. Images are 
reproducible, with N =3. 
 
5.2.7   Gold Cavity Arrays: Summary 
The effect of surface modification on platelet adhesion, spreading and activation was 
similar across all three array sizes. As with the planar gold surfaces, bare gold alone and 
alkane alone presented minimal platelet adhesion in all cases. The adhesion 
effectiveness of the RGD peptide was modified by decreasing the relative RGD 
concentration (a phenomenon which has been reported in literature for a variety of cell 
types (osteoblasts, 3T3 fibroblasts, B16 and MDA 231 cell lines), although not 
previously investigated for platelets.
(15,16) 
RGD:alkane 1:10 ratio effectively inhibited 
253 
 
platelet adhesion, spreading and activation across all three cavity sizes indicating the 
amount of RGD on the surface is too low to compete with alkane inhibition of adhesion. 
These results suggest that there is a balance between the concentration of RGD that is 
required to offer optimal size and distance between focal adhesion point, on the 
expectation that domains of RGD and alkane thiol will form in the mixed monolayers 
and steric availability for platelet adhesion.  
 
Introducing selective chemical modification using the two-step adsorption process 
described in section 5.1.2 (RGD at the top surface and alkane on the cavity walls and 
vice versa) yielded interesting results. Using the same chemistry, both the positioning 
and spreading ability of adhering platelets was easily and extensively controlled across 
the three cavity diameter sized arrays. The influence of surface topography on platelet 
adhesion and spreading was highlighted in this study. It was found that even though the 
surface area was larger in the cavity compared to the top surface area for all cavity sizes 
platelet adhesion was reduced dramatically when RGD was on the cavity walls and 
alkane at the top surface of both 1.6 µm and 0.98 µm diameter cavity array sizes. This 
suggests that the topography is influencing platelet adhesion in these cases as the cavity 
diameter is small, RGD availability is reduced which in turn reduces platelet adhesion. 
 
As described, the widely reported chemical stimuli Mn
2+
 and DTT have been shown to 
induce conformational changes to the integrin protein resulting in active-like states of 
integrin in free solution.
(93-96) 
These stimuli have also been shown to increase integrin 
expressing cell and platelet adhesion to surfaces modified with physiological ECM 
ligands such as fibrinogen and fibronectin (both contain RGD sequences).
(88,89)
 
Surprisingly, although Mn
2+
 is suggested to induce conformational changes to integrin 
in free solution, as presented in Chapter 4, no significant change in platelet adhesion, 
morphology or activation was observed following Mn
2+
 treatment compared to 
untreated platelet adhesion and morphology to all RGD SAM modified cavity sized 
arrays (0.98, 1.6 and 5.4 µm diameter sizes).  
 
Smith et al.
(90) 
investigated the effect of Ca
2+
 and Mn
2+
 divalent cation treatment on 
αIIbβ3 whole platelet adhesion to fibrinogen coated polystyrene tissue culture surfaces 
(96 well plates). Ca
2+
 was found to induce rapid adhesion of platelets to fibrinogen with 
an apparent rate constant (k1app) of 8.2 x 10
5 
m
-1
s
-1
, while Mn
2+
 treatment presented a 
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relatively lower slow association rate of k1app = 10
4
 m
-1
s
-1
. In the course of performing 
αIIbβ3 whole platelet adhesion to fibrinogen with Mn
2+
 it was found that adhesion 
required extended incubation periods of 2-3 hours while Ca
2+
 proceeded rapidly (few 
minutes). 
 
Smith et al.
(90)
, investigated cation effects further by studying the ability of Ca
2+
 and 
Mn
2+
 to support platelet aggregation measured across a variety of ion concentrations. 
Platelets treated with either cation were stimulated with ADP and light transmission 
through the suspension was recorded with a Scienco aggregometer over a 5 minute time 
period. Platelets were found to aggregate well in Ca
2+
 with maximum aggregation at 2 
mM Ca
2+
 while aggregation was severely retarded in Mn
2+
. Interestingly, increasing 
Mn
2+
 from 50 to 500 µM abolished aggregation completely. As Mn
2+
 treated platelet 
adhesion to fibrinogen required 2-3 hours incubation, the 5 minute aggregometer time 
period was increased to 20 minutes and found that Mn
2+
 did support aggregation but at a 
slower rate to Ca
2+
. In addition, Ca
2+
 generated large aggregations while Mn
2+
 formed 
numerous smaller aggregates.  
 
It is clear that the influence of Mn
2+
 on platelet adhesion and function is significantly 
slower and less significant than the alternative Ca
2+
 cation. From the above report it is 
suggested Mn
2+ 
effects are both concentration and time dependant. Thus as mentioned, 
an Mn
2+
 concentration assay on platelet adhesion may determine the optimal Mn
2+
 
concentration required for the platelet studies presented in this chapter. In this chapter, 
Mn
2+
 was incubated with the platelets for 15-20 minutes at room temperature prior to 
incubation with the modified surfaces for 45 minutes at 37°C. From the results reported 
by Smith et al.
(90)
 longer incubation times may aid in optimising the Mn
2+
 effect on 
platelets in this study.  This will be explored in future work. 
 
A similar study carried out by Wilkins et al.
(88)
 investigated the effects of both Mn
2+
 and 
DTT treatment on integrin expressing human B cell adhesion to fibronectin coated 
polystyrene tissue culture surfaces and found both treatments to increase cell adhesion 
to the ligand coated surfaces. The incubation times of both chemical treatments were 
slightly longer than the times carried out in this chapter; 30 minute incubation with 
either chemical activator prior to incubation with the surfaces with an incubation time of 
1 hour at 37°C. As with Mn
2+
, DTT may also be concentration dependant. The 
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concentration dependence study reported by Wilkins group presented a half maximal 
activity at 2–5 mM and interestingly, loss of adhesion at concentrations in excess of 50 
mM. In correlation with these findings, DTT treatment of platelets in this chapter 
resulted in a significant decrease in adhesion to modified array surfaces suggesting the 1 
mM concentration used in this chapter may be too high. Thus as for Mn
2+
, it is 
suggested that a DTT concentration and time dependence study may provide a better 
insight into the effect of DTT treatment on platelet adhesion in this chapter. 
 
Surprisingly incubating 30 x 10
3 
± 2 x 10
3
/µl platelets with a 1 mM solution of 
Eptifibatide for 15-20 minutes at room temperature prior to incubation with the three 
microcavity array sizes (C-Ahx-GRGDS SAM modified whole array in all cases) 
presented no significant change in platelet adhesion compared to untreated platelet 
adhesion to the three cavity array sizes. This suggests that a 1 mM concentration of 
Eptifibatide may not be sufficient to bind to the abundant RGD adhesion sites on the 30 
x 10
3 
± 2 x 10
3
/µl platelet concentration used in the study. However, assuming that 
approximately 40,000 integrins are present on the surface per platelet
(97)
, the 
concentration of integrin in the 150 µl volume of platelets added to the modified surface 
is calculated to be approximately 30 nM, thus a 1 mM concentration of Eptifibatide 
should be more than sufficient to block all RGD sites on the 30 x 10
3
± 2 x 10
3
/µl 
platelet concentration used in this study. It is therefore suggested, in correlation with the 
chemical stimuli Mn
2+
 and DTT, that the Eptifibatide effects are time dependant, thus 
future work investigating longer incubation times is required to ensure effective 
blocking of the RGD adhesion sites located on the αIIbβ3 integrin abundant platelet 
surfaces.  
 
Platelet adhesion and spreading was also found to decrease with decreasing cavity 
diameter size, Figure 5.50. Recent studies suggest a more complicated influence of 
topography on cell behaviour. A wide range of cell responses to different surface 
topographies have been reported and have suggested that cellular response to 
topography can be influenced not only by the size and density of the features but also by 
their regularity.
(18,80,91,98,99) 
For random features the response appears to be cell type 
dependent.
(19,100)
 The type of feature also matters.
(19,20,101,102)
 Substrates presenting 
grooves and ridges promoted cell adhesion and migration along these features with the 
feature geometry dictating cell morphology.
(103)
 Similarly, epithelial cells preferentially 
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adhered to V-shaped grooved surfaces rather than to flat surfaces.
(104)
 Correlating results 
were recently published with preferential adherence to pyramid shaped surfaces rather 
than flat surfaces also.
(91)
 Conversely, substrates presenting ordered arrays of 
nanopillars or pits appear to impede adhesion.
(105,106)
 Thus, it is clear that a complex 
interplay of both topography and surface chemistry exists on platelet adhesion. This 
chapter reports, for the first time, through surface modification and topography, 
selective, reproducible control over platelet adhesion, spreading and activation to 
chemically modified planar gold surface and highly ordered microcavity arrays. 
 
   Cavity Diameter 
(µm) 
Top Surface Area 
(µm
2
) 
Cavity Interior Surface Area 
(µm
2
) 
5.42 ± 0.01  397 ± 49  622 ± 49 
1.60 ± 0.02 150 ± 27 375 ± 27 
0.98 ± 0.02 15 ± 9 240 ± 9 
Figure 5.50: Bar graph representing platelet count/cm
2
 versus cavity array size.  The 
whole array is modified with a C-Ahx-GRGDS SAM in all cases. A significant decrease 
in platelet count with decreasing cavity diameter size can be clearly observed. 30 x 10
3
± 
2 x 10
3
/µl washed platelets were incubated with the modified surfaces for 45 minutes at 
37°C, fixed with 3.8% PFA solution, stained for TRITC-phalloidin (1/100 dilution) and 
imaged using a 40x oil immersion objective lens (NA 1.4) with 540 nm HeNe laser 
excitation. Platelet counts were measured using Image J software. Data are represented 
as mean ± standard deviation of 3 independent measurements.  
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5.2.8   Surface Enhanced Raman Spectroscopy (SERS) of Platelets 
This chapter illustrates for the first time, the ability to obtain clear SERS Raman data of 
single platelets bound to highly ordered C-Ahx-GRGDS modified 1.6 μm diameter 
sized gold cavity arrays. 
 
Figure 5.51 presents a white light image obtained by the Raman instrument used for 
this study. Interestingly, due to the autofluorescence of the platelets they are clearly 
distinguishable from the cavity array surface (highlighted by white circles). Cavities, 
dendritic and spread platelets (labeled accordingly) are all defined using the white light 
image introducing selectivity to the platelets chosen for analysis. As a result a 
comparison study between dendritic and spread platelet was viable. 
 
Figure 5.51: White light microscopy image (255×1024 pixels) of platelets bound to a 
1.6μm cavity array where cavities, dendritic and spread platelets are distinguishable 
from one another. 30 x 10
3
± 2 x 10
3
/µl washed platelets were incubated with the 
modified surfaces for 45 minutes at 37°C. Image was obtained using a 100 x objective 
lens. 
 
Figure 5.52 presents Raman spectra of platelets bound to a glass surface for 3 
independent samples. 30 x 10
3
/µl washed platelets were prepared, incubated with the 
glass surface and fixed as described in section 5.1.5 and 5.1.6. Unsurprisingly the 
backscatter from the glass dominated the spectra with significant scatter interference 
from 900–2000 cm-1. A suggestive minor peak at approximately 870 cm-1 is present 
Dendriti
c 
Fully Spread 
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which may be assigned to PFA residue as has been reported previously.
(107)
 Overall no 
relevant peaks representative of platelets was observed. Thus, it was concluded that 
Raman spectroscopy on platelets bound to the glass surfaces could not be achieved. 
 
Figure 5.52: Raman spectra of 3 independent samples of platelets bound to a glass 
surface. 30 x 10
3
± 2 x 10
3
/µl washed platelets were incubated with the glass surface for 
45 minutes at 37°C. Spectra were obtained using 785 nm laser excitation, 10 mW power 
and 30 second exposure time. The spectrum is reproducible, with N =3. 
 
Figure 5.53 presents Raman spectra of platelets bound to a highly ordered 1.6 µm 
diameter gold cavity array, where the whole array is coated with C-Ahx-GRGDS. 30 x 
10
3
/µl washed platelets were prepared, incubated with the cavity array and fixed as 
described in section 5.1.5 and 5.1.6. All vibrational modes are consistent with those 
reported previously for live platelets and pure integrin αIIbβ3.
(35,42,51)
 Cysteine vibration 
associations are suggested at approximately 445 cm
-1
 (C-S region) and 501 cm
-1 
(gauche-gauche-gauche cysteine isomer). Tryptophan is suggested at approximately 
733 cm
-1
. A tyrosine vibration association is suggested at approximately 767 cm
-1
. 
Vibration bands associated with phenylalanine amino acid residue may be observed 
around 615 cm
-1
, 1612 cm
−1
 and 1000 cm
−1
. The band at 906 cm
-1
 may be associated 
with a (Cα-C-N) peptide bond in stretch vibration. 1106 cm-1 and 1201 cm-1 represents 
phenyl stretching and C-H bending in Tyrosine. Tryptophan and histidine bands may be 
the peaks found at 1358 cm
-1
 1579 cm
-1
. In plane ring vibration are suggested at 1150 
cm
-1
 and 1301 cm
-1
. Amide III vibrations are presented at 1238 cm
-1
 and 1358 cm
-1
, 
indicative of an α-helix. The vibrational band located at 1481 cm-1 is undefined but may 
be due to C-H deformation of proteins and lipids. An Amide I associated vibration is 
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presented at 1658 cm
-1
 and comes from stretch vibration of carbonyl double bond in the 
peptide backbone. It is important to note that the relative signature bands for 
haemoglobin at 759 cm
-1
, 1231 cm
-1
, 1568 cm
-1
, 1626 cm
-1
 and 1640 cm
-1
 are absent 
from the spectra indicating platelets samples are pure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.53: Raman spectra presenting dendritic (red) and spread (black) platelets 
bound to 1.6 μm cavity arrays modified with an RGD SAM across the whole array. 785 
nm laser excitation and 30 second exposure time was used in all cases. 30 x 10
3
± 2 x 
10
3
/µl washed platelets were incubated with the modified surfaces for 45 minutes at 
37°C and fixed with 3.8% PFA. * May be attributed to PFA residue. Spectra represent 
one sample. An overlay of 3 independent samples for both dendritic and spread 
platelets is presented in Appendix 3. This data is reproducible, with N =3. 
 
Sample preparation of biological materials for Raman is important as the experimental 
design implemented may have an impact on the interpretation of spectra. Few studies 
have investigated how fixation affects the Raman spectra of fresh tissue samples. From 
those reported, the majority have found PFA to have minimal effect on the Raman 
spectra. For example Bot et al.
(108)
 observed minimal effects of PFA fixation on the 
spectra of rabbit. Similarly, Shim and Wilson observed no major alterations to the 
Raman spectra upon fixation of hamster tissues. Thompson et al.
(109)
 investigated the 
Spread Platelet  
Dendritic Platelet 
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effect of three fixation products on the ability to distinguish between healthy and cancer 
lymphocytes. Results showed PFA-fixed cell groups overlap the unfixed cell groups to a 
greater extent than the alternative fixatives. Further studies using PCA analysis 
confirmed the PFA-fixed normal and cancer cell groups were distinguishable, indicating 
that PFA fixation does not adversely affect the identification of cancer cells by Raman 
spectroscopy (>99% for the unfixed and PFA-fixed cells accurately classified as cancer 
cells by cross-validation PCA analysis). Results concluded that although PFA fixation 
induced changes in the Raman spectrum of a cell, the changes can be considered 
insignificant as they do not result in misclassification of normal and cancer cells.  
 
During the course of this study, platelet transportation was required for Raman analysis. 
Consequently platelet fixation was required to avoid platelet activation, thus, for the 
Raman study presented in this chapter PFA was chosen due to its reported minimal 
effects on the Raman spectra of biological samples. Meade et al.
(107) 
report the following 
peak assignments for PFA; 874-908 cm
-1
 (CH2 twist), 1043 cm
-1
 (C-O), 1249 cm
-1
 (O-
H deformation) and 1491 cm
-1
 (CH2 deformation). Only one possible PFA residue band 
at approximately 903 cm
-1 
is observed but is more likely due to a (Cα-C-N) peptide 
bond in stretch vibration, Figure 5.53. It is also important to note that apart from the 
peak observed at 1238 cm
-1
 (Amide III), the RGD peptide modified 1.6 µm cavity did 
not generate any of the main Raman bands associated with C-Ahx-GRGDS complex 
which are seen at 1240 cm
-1
 (Amide III), 1455 cm
-1
 (CH bending), 1060/1550 cm
-1 
(NH2 rocking) and 1455 cm
-1
 (C-H bending), Figure 5.13 and Appendix 3. Thus all 
peak assignments presented in Figure 5.53 are deemed platelet specific. Future studies 
will focus on live platelet Raman analysis to avoid any possible fixative residue 
contributions. The preliminary Raman spectra presented here have exciting implications 
for rapid diagnostic applications. In particular, the ability to selectively choose platelets 
in either the resting or activated form is of significant interest for both diagnostics and 
for insight into the basic biochemistry of platelets 
 
As over 50% of the protein content on a platelet surface is expected to be integrin and 
this content increases in activated platelet, it is anticipated that SERS may be a useful 
marker of platelet activation and potentially of thrombotic status. The work is 
preliminary but we can conclude that this platform may be a useful start for a diagnostic 
assay of platelet activation. 
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5.3   Conclusions 
Although the process of platelet activation has been extensively studied from a 
biochemical perspective, the effect of physical and spatial cues in the microenvironment 
on platelet adhesion and spreading remain unclear.  Understanding and controlling 
platelet interaction with surfaces is important across a range of domains including 
diagnostics and medical implants, while intact platelet capture in which the activation 
status of the platelet is controlled may be useful in a diagnostic device.   
 
The influence of cavity dimensions and surface functionality on platelet capture and the 
activation status of the captured platelet were examined. Cavity arrays were prepared 
from microlithography via electrochemical deposition to produce gold modified planar 
and cavity surfaces. Monolayers of the αIIbβ3 integrin platelet protein sequence C-Ahx-
GRGDS were self-assembled at the gold surfaces via the thiol functionality to 
investigate the spatial guidance of platelet adhesion and spreading at the single cell 
level. Adhesion control was investigated using the widely reported alkane and PEG 
platelet adhesion inhibitors at varying RGD:alkane and RGD:PEG ratios. The effect of 
cavity size on platelet adhesion and platelet morphology was investigated, comparing 
planar gold surfaces approximately 100 nm thick to three different microcavity array 
sizes; 5.4 µm, 1.6 µm and 0.98 µm diameter sizes. In a final study, the ability to 
selectively capture single intact platelets using these microcavity arrays was also 
investigated.   
 
RGD SAM surfaces were concluded from the compositions explored here to be the best 
surface for platelet adhesion, retaining the platelets in the resting and early stage 
spreading state. Alkane was found to inhibit platelet adhesion in all cases while PEG 
enhanced platelet adhesion spreading and activation on planar gold surfaces. Results 
confirmed the ability to control platelet adhesion and spreading with platelet adhesion 
and spreading found to be greatly influenced by the surface geometry. Platelets adhesion 
and spreading ability was found to decrease with decreasing microcavity size and 
surface area. Platelets adhered and retained the ability to spread fully onto 5.4 µm cavity 
arrays, a length consistent with that of maximally extended filopodia, a process not 
observed for the smaller cavity sized arrays. 
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CD62P selectin and phalloidin staining was carried out to study the activation status and 
actin localisation across the varying surfaces. Using this staining technique the 
activation status and actin content of platelets was found to differ depending on the 
surface chemistry and surface functionality utilised. In conclusion, this chapter presents 
the ability to control platelet adhesion, spreading and activation  through both chemical  
and topographical modification which is of significant value biomedically and may be 
useful for example in the design of medical implantations. 
 
Most interestingly preliminary examples of our ability to capture single platelets over a 
single cavity and obtain intense Raman spectra of a single platelet were observed. 
Platelets bound to glass failed to present any Raman peaks illustrative of platelets on the 
surface while SERS enhancement using highly ordered 1.6 µm diameter arrays 
identified distinct peaks associated with platelet components. The ability to selectively 
choose platelets at different spreading stages using white light microscopy is an 
advantage of this approach. Distinction between dendritic and spread platelets could be 
observed with the absence of peaks at 733, 767, 904, 1150, 1201, 1481 and 1541 cm
-1
 
for the dendritic platelet while clear intense peaks at these positions was clearly 
observed for spread platelets. The preliminary evidence for the potential usefulness of 
these platforms assessing platelet activation status is an exciting outcome as it may have 
value in future rapid diagnostic applications to provide molecular insight into platelet 
biochemistry or assess thrombotic risk. 
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6.0   Introduction 
6.0.1   Stokes Shifted Ruthenium and BODIPY Probes in Neurological Studies 
Ruthenium based complexes are a subject of intensive research for their high 
luminescence, environmental sensitivity (i.e. oxygen sensitive) and long luminescent 
lifetimes. Synthetic advances have enabled the functionalisation of these complexes 
with biological ligands, thereby allowing the entire complex to transverse cell 
membranes, significantly heightening the potential use of metal based complexes in 
biomedical imaging and diagnostics, an example of which is clearly presented in 
Chapter 4 of this thesis.
(1-7)  
 
Although the application of ruthenium complexes as labels in cell imaging has become 
an area of intensive interest over the past 6-7 years, the application of these metal 
complexes in tissue staining remains largely unexplored with the majority of those 
published limited to the measurement of oxygen distribution throughout tissue.
(8-11)
 One 
of the few alternative examples was reported by Cook et al.
(12)
 who investigated the 
ability of a novel ruthenium complex, ammoniated ruthenium oxychloride (which binds 
to calcium proteins) to act as a luminescent label for (Aβ) amyloid-β plaques in vitro, 
presenting itself as a possible biomarker for the onset of neurodegenerative Alzheimer’s 
disease (AD). The intense red colour of the ruthenium complex comes from its visible 
absorption spectrum with a strong band centred at approximately 540 nm, and results in 
the transmission of red light. Optical imaging presented red staining of the Aβ plaques 
in brain tissue sections from a Tg2576 Alzheimer’s disease mouse model. Fluorescence 
staining of the same Aβ plaques with the commercially available fluorescent amyloid 
binding dye control, thioflavinT (ThT), co-localised well with the ruthenium red 
complex indicating the potential of this dye as an amyloid plaque tissue imaging agent. 
 
BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) chromophores
 
have many 
functions such as tuneable laser dyes
(13)
, chemosensors
(14)
 and fluorescent switches
(15)
. 
In contrast to ruthenium, BODIPY possesses sharp and high fluorescent emission, 
chemical and photostability, high absorption coefficients and high fluorescent quantum 
yields. The instability of inorganic molecules to continuous light, especially in the 
presence of oxygen has resulted in the need for more robust molecules. BODIPY, in 
contrast to ruthenium, is a low triplet yielding molecule and so phosphorescence is 
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rarely seen. Thus compound degradation via self-produced singlet oxygen is less of a 
problem with BODIPY derivatives compared to other dyes. 
 
The potential of BODIPY as a biological label did not surface until the late 1980’s. In 
1998, Farinas and Verkman successfully labelled specific sites in living cells with 
BODIPY.
(16)
 Hapten (phOX ligand specific for the sFV antibody receptor) conjugates 
labelled with the fluorescent BODIPY probe bound with high affinity and co-localised 
specifically to the single-chain antibody receptor, sFV, expressed in the endoplasmic 
reticulum (ER), Golgi, and plasma membrane of cDNA (encoding sFV) transfected 
living Chinese hamster ovary (CHO) cells. In correlation with ruthenium probes, 
BODIPY has been intensively studied in cellular imaging but remains largely 
unexplored in tissue imaging. 
 
Urano et al.
(17)
 recently developed a series of pH sensitive BODIPY dyes that target the 
human epidermal growth factor receptor type 2 (HER2) for tumour tissue imaging in 
vivo. Using N, N-dialkylated analines as the reactive moiety towards protons, 
substitution of the N-alkyl group causes a pKa shift, allowing the development of a 
series of pH tuneable BODIPY compounds. The two carboxylic groups on the 2,6-
dicarboxyethyl-1,3,5,7-tetramethyl BODIPY complex allowed for conjugation to the 
HER2 cancer-targeting monoclonal antibody, herceptin. In vitro, fluorescence 
microscopy of labelled herceptin with NIH3T3/HER2 expressing cells presented 
staining after 2 hours incubation and was found to co-localise well with the 
commercially available lysotracker red DND-99 dye, a specific label for tracking acidic 
organelles in live cells. In contrast, incubation of the HER2 expressing cells with the 
parent 2,6-dicarboxyethyl-1,3,5,7-tetramethyl BODIPY complex control presented non-
specific fluorescence throughout the whole cell. 
 
For in vivo investigations, both in situ and ex vivo spectrally resolved luminescence 
imaging of freshly resected lungs bearing metastatic NIH/3T3 HER2 tumours was 
carried out with the parent complex control and the pH-sensitive probes. The parent 
complex presented highly non-specific fluorescence from non-tumour bearing lung 
tissue and the heart, whilst all pH sensitive agents produced signals solely from HER2 
positive tumours with elimination of any background fluorescence demonstrating the 
potential of using pH sensitive BODIPY dyes for tumour imaging with improved 
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specificity by targeting acidic tumour organelles with the additional advantage of 
minimising signals from non target tissue. 
 
Ono et al.
(18)
 have previously reported a dual single photon emission computed 
tomography (SPECT)/fluorescent probe based on the BODIPY scaffold, for the imaging 
of Aβ plaques in vivo. Despite good affinity for synthetic Aβ(1−42) aggregates and the 
clear labelling of Aβ plaques in brain tissue sections of Tg2576 transgenic 
mouse models of Alzheimer's disease, the BODIPY based probe was not suitable for 
imaging in vivo due to its poor uptake into the brain. Others have also reported 
BODIPY-based probe targeting Aβ plaques.(19, 20) These derivatives also showed high 
affinity for Aβ plaques in vitro but have not been applied to imaging in vivo, possibly 
due to low brain uptake and the visible wavelength characteristics of the BODIPY 
complexes.  
 
It was noted by Ono et al.
(18)
 that many Aβ-imaging probes for positron emission 
tomography (PET) applied in clinical trials possess a dimethylamino styryl group as a 
consensus structure. Thus, this group have recently attempted to improve BODIPY Aβ-
imaging suitability, developing a new BODIPY-based Aβ probe, (BAP-1), through the 
addition of a dimethyamino styryl group. In vitro, BAP-1 showed high affinity for Aβ 
aggregates (aggregates were formed in PBS pH 7.4 solution following incubation at 
37°C for 48 hours). Ex vivo fluorescent staining of brain tissue sections from Tg2576 
mice after the injection of BAP-1 showed selective binding of Aβ plaques with little 
nonspecific binding, co-localising well with the commercially available fluorescent 
amyloid binding probe, ThT. However, in vivo, imaging experiments using Tg2576 
mice and age-matched controls were also investigated and presented no significant 
difference between the two groups due to non-specific accumulation of BAP-1in the 
scalp in both groups, concluding that further modification of the BODIPY scaffold is 
still required.  
A distinct disadvantage exists for conventional BODIPY dyes; they exhibit absorption 
maxima in the visible region where tissue penetration of light is shallow and thus less 
optimal for non invasive in vivo imaging. To be a credible tissue imaging contrast 
reagent a luminescent probe should absorb and emit in the near-infrared (NIR) region, 
to minimise the absorption of water, scattering of light and autofluorescence or light 
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absorption by tissue and cells. Thus, the development of novel NIR luminophores that 
present ideal NIR probe characteristics such as: fluorescence emission at 650-900 nm 
(within the biological window), high fluorescence quantum yield, narrow 
excitation/emission, high chemical and photostability, low toxicity, and excellent 
biocompatibility, producing greater tissue penetration are required to improve the 
potential of BODIPY as a probe in non invasive in vivo tissue imaging. Thus the 
feasibility of using two Stokes shifted probes; VIS emitting BODIPY and NIR emitting 
BODIPY for tissue imaging, specifically the hippocampus and cortex tissue regions and 
pituitary gland tissue of adult mice was investigated as part of this chapter. 
 
The onset of neurological diseases such as Alzheimer’s disease can be directly 
attributed to physical changes in the hippocampus and cortex regions of the brain. Thus 
the ability to label brain cell clusters in these regions with fluorescent dyes is of 
significant importance to further understanding neurology, or the physical changes that 
occur during the onset of this disease. For example, the pituitary gland is an endocrine 
gland composed of three lobes: anterior, intermediate and posterior. This gland presents 
itself as a pea-sized protrusion at the base of the brain. This tissue is composed of ﬁve 
secretory cell types; corticotropes, thyrotropes, gonadotropes, somatotropes and 
lactotropes.
(21)
 These cells produce hormones that regulate adrenal function, thyroid 
function, reproduction, growth and lactation each dedicated to a production of a 
different hormone.
(22)
  
 
To date, investigations into live neurological tissue is typically achieved using 
genetically altered animals that express fluorescent proteins such as green fluorescent 
protein (GFP) corresponding to the various cell types, i.e. somatotropes presented in 
Figure 6.1.
(23-25)
 Such animal models are often costly and many difficulties can occur 
during breeding. The ability to mark a specific cell type using a fluorescent label 
directly, rather than the complex process of genetic modification has the potential to 
revolutionise tissue imaging. Key issues in exogenous dyes for these purposes are 
limited depth and penetration in live or fixed tissue, self-quenching at high 
concentrations, high toxicity and shallow light penetration. As mentioned, the 
development of NIR imaging probes is essential for deep tissue light penetration and 
low autoﬂuorescence. Thus the feasibility of using two Stokes shifted probes; 
ruthenium(II) polypyridyl complexes with various ligand modifications, VIS emitting 
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BODIPY and NIR emitting BODIPY for imaging hippocampus and cortex tissue and 
pituitary gland tissue of adult mice was investigated. 
 
Figure 6.1: Confocal luminescence image of a pituitary gland tissue section of a male 
mouse model genetically modified to express green fluorescent protein (GFP) labelled 
somatotrope cells; 4,6-diamidino-2-phenylindole (DAPI, blue) and GFP (green). 
Pituitaries were fixed by perfusion with buffered 4% paraformaldehyde, paraffin 
embedded, sectioned at 6 µm, and DAPI (1 µM) stained for 10 minutes at room 
temperature. After PBS washes, sections were mounted in Mowiol. Images were taken 
using a Leica SP2 confocal microscope and Leica software.
(26)
 
 
Amyloid-β (Aβ), as mentioned, is an extracellular peptide of 36-43 amino acids that is 
processed from the amyloid precursor protein (APP). Studies suggest that the transition 
of monomeric Aβ to fibrillized Aβ plays an important role in the pathology of 
Alzheimer’s disease.(27, 28) The most common fluorescent reporter for the investigation 
of these transitions to date is thioflavinT (ThT).
(27)
 ThT is a benzothiazole dye which 
presents minimal fluorescence in aqueous solution or in the presence of monomeric Aβ, 
whereas the fluorescence increases or “switches on” by several orders of magnitude in 
the presence of fibrils and so has become a robust imaging agent for Aβ 
investigations.
(28)
 
 
Dipyridophenazine (dppz) containing ruthenium(II) complexes, discussed in detail in 
Chapter 3 of this thesis, have been used in a wide variety of applications including DNA 
detection
(29, 30)
, DNA cleavage
(31)
 and cell imaging
(32)
. Due to its light switching nature, 
this complex has the potential to act as a reporter for Aβ monomer-fibrillar transitions. 
Most recently, Cook et al.
(33)
 reported the use of a luminescent dipyridophenazine 
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ruthenium(II) complex, [Ru(bpy)2(dppz)]
2+
 (where bpy is 2,2-bipyridine; dppz is 
dipyrido[3,2-a:20,30-c] phenazine) to monitor Aβ fibrillization using steady state and 
time resolved luminescence spectroscopy.
 
The complex presented inhibited 
luminescence in the presence of monomeric Aβ and significant luminescence 
enhancement in the presence of Aβ fibril aggregates. In addition, comparative studies 
using ThT presented comparable results indicating the potential of the ruthenium 
complex as a probe for Aβ fibrillization studies.  
 
The environmental sensitivity of ruthenium complexes provides these dyes with distinct 
advantages compared to ThT. For example, the long luminescent lifetime allows the 
measurement of longer lived dynamics in biomolecules i.e. protein binding which may 
strengthen Aβ fibrillization investigations. Thus, the ability of the dppz containing 
ruthenium complex synthesised as part of this thesis, [Ru(dppz)2PIC]
2+
 to bind to Aβ 
aggregates was also investigated, presented in section 6.2.3. 
 
6.1   Experimental Procedure  
Chemicals 
38% paraformaldehyde solution (PFA), sodium chloride (NaCl), magnesium chloride 
(MgCl2), calcium chloride (CaCl2), glucose, dimethyl sulfoxide (DMSO), 250G agar, 
PBS pH 7.4,  1,1,1,3,3,3-Hexafluoro-2-Propanol (HFIP), Aβ 1-40 segment, Aβ 1-42 
segment, fluoroshield mounting medium and 4',6-diamidino-2-phenylindole (DAPI) 
were purchased from Sigma.  
 
Instrumentation 
Confocal imaging was carried out on a Zeiss LSM510 Meta confocal microscope. AFM 
imaging was carried out using a Veeco Bioscope II Multimode Atomic Force 
Microscope with a Nanoscope III controller. Samples were imaged in tapping mode in 
air using a MikroMasch Ultrasharp noncontact 15 series tip with a resonant frequency 
of approximately 325 KHz and force constant of approximately 40 N/m. All images 
were taken at a scan rate below 0.5Hz and at 512 samples/line resolution. SEM samples 
were sputter coated with a thin layer of gold (~30nm thick) and imaged using a Hitachi 
S3400n SEM, Tungsten system instrument a 5.00 kV accelerating voltage. 
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6.1.1   Tissue Sample Preparation 
The feasibility of using two Stokes shifted probes; ruthenium(II) polypyridyl complexes 
with various ligand modifications, a VIS emitting BODIPY and an NIR emitting 
BODIPY as probes in imaging two regions of the mouse were investigated: brain and 
pituitary glands. Mice were female and no older than 8 weeks old. The preparation of 
both live and fixed tissue samples is described in sections 6.1.1.1 and 6.1.1.2. All 
animal studies complied with the animal welfare guidelines of the European 
Community, and/or UK Home Office guidelines, as appropriate (agreement no. 
34.128).  
 
6.1.1.1   Pituitary Gland Tissue Preparation 
Fixed Tissue: 
Freshly extracted pituitary gland was placed in 3.8% PFA and incubated overnight at 
4°C to ensure complete fixation. As the pituitary gland is small and fragile in nature, it 
was required to set the sample in agar to provide rigidity for the slicing process. 25 g of 
Agar was placed in 50 ml PBS (pH 7.4) and micro-waved until the mixture became 
clear. The agar was allowed cool, just before setting the agar was poured into a 25cm
2
 
dish. The pituitary sample was immersed in the setting agar and allowed to set fully for 
20 minutes at 4°C. Slices approximately 100 µm thick were cut using the Leica VT 
1000S slicer. Samples were stored in PBS at 4°C until required. 
 
Live Tissue: 
For live tissue sample preparation artificial cerebrospinal fluid (ACSF) solution was 
prepared fresh as follows:  
 
1. 1.982 g/L glucose 
2. 1.2 ml MgCl2 (1M stock solution) 
3. 100 µl CaCl2 (1M stock solution) 
 
An Integraslice 7550 PSDS chamber was filled with ACSF solution and allowed to 
equilibrate to 0°C. The tissue sample was placed onto the Integraslice 7550 PSDS stage 
located in the equilibrated chamber. Slices approximately 100 µm thick were taken and 
placed in 12-well plates containing ACSF solution. Samples were stained with the 
desired dye for a time ranging from 2 to 20 minutes at room temperature. Following 
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incubation, samples were washed with PBS pH 7.4, stained with DAPI (300 nM) for 10 
minutes at room temperature, mounted using fluoroshield mounting media and allowed 
dry for 1 hour at room temperature before imaging using a Zeiss LSM510 Meta 
Confocal microscope. 
 
6.1.1.2   Brain Tissue Preparation 
Freshly extracted brain was prepared for both live and fixed imaging as described for 
the pituitary glands in section 6.1.1.1. 
 
6.1.2   Preparation of Purified Amyloid-β Peptide (Aβ) 
Purified Aβ peptide, Aβ 1-40 and Aβ 1-42 were prepared according to a method 
modified from literature.
(33)
 The peptide solid was first allowed to equilibrate to room 
temperature for 30 minutes to avoid condensation upon opening the vial. The first step 
in re-suspending the lyophilised peptide was HFIP treatment. 1mg of peptide was 
diluted in 1 ml 100% HFIP. The clear solution containing the dissolved peptide was 
then aliquoted as desired into centrifuge tubes and evaporated in the fume hood for 3 
hours. When all HFIP had evaporated, samples were stored at -20°C until required. 
Immediately prior to use, the HFIP-treated aliquot was re-suspended to a concentration 
of 70 µM in the desired buffer for unaggregated or aggregated preparation detailed in 
section 6.1.2.1 and 6.1.2.2. 
 
6.1.2.1   Aβ Unaggregated 
The HFIP-treated aliquots prepared in section 6.1.2 were re-suspended in 2% 
DMSO/H2O to a final concentration of 70 µM. The solution was vortexed for 15 
seconds and used immediately. For confocal imaging, A final concentration of 70 µM 
unaggregated Aβ and [Ru(dppz)2PIC]
2+
 was spotted on a glass slide and incubated at 
37°C for 20 minutes. Samples were washed with deionised water, mounted with 
fluoroshield mounting media and allowed to dry for 1 hour prior to confocal imaging. 
For SEM and AFM imaging, a final concentration of 70 µM unaggregated Aβ was 
spotted on either a glass slide (for AFM) or gold planar surface (SEM) and incubated at 
37°C for 20 minutes. Following incubation samples were washed with deionised water 
and allowed to air dry for 2 hours prior to AFM or SEM imaging 
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6.1.2.2   Aβ Aggregated 
The HFIP-treated aliquots prepared in section 6.1.2 were re-suspended in DMSO (to 
produce a final 2% DMSO concentration). The DSMO dissolved peptide was made up 
to a final 70 µM concentration with 10mM HCl and 150mM NaCl. The solution was 
vortexed for 15 seconds and incubated at 37°C for 5 weeks (Aβ 1-40) or 24 hours (Aβ 
1-42) prior to use. For confocal, AFM and SEM imaging, samples were prepared as 
described for unagreggated Aβ in section 6.1.2.1. 
 
6.2   Results and Discussion 
6.2.1   Stokes Shifted Ruthenium and BODIPY Probes in Tissue Imaging 
This work was carried out as part of an abroad placement which took place in Professor 
Patrice Mollards research group, Institut Génomique Fonctionnelle (IGF), Montpellier, 
France under the supervision of Dr. Emmet O’Reilly. The aim of this study was to 
assess the feasibility of using two Stokes shifted probes; ruthenium(II) polypyridyl 
complexes synthesised as part of Chapter 3 of this thesis and two BODIPY complexes 
(synthesised by Dr. Aaron Martin), a VIS emitting and NIR BODIPY complex as 
imaging agents for both brain and pituitary tissue imaging. The extent of tissue 
penetration and the quality of images achieved using each dye for brain and pituitary 
gland tissue imaging is presented. A comparative study of both live and fixed imaging 
of pituitary gland and brain tissue slices was also investigated. 
 
The chemical structures of all Stokes shifted ruthenium(II) polypyridyl complexes 
investigated are presented in Figure 6.2, (a). All ruthenium complexes presented similar 
photophysics as discussed in Chapter 3 of this thesis; λabs at 450 nm and λem at 610 nm 
(160 nm Stokes shift). All dpp containing complexes are hydrophobic. The dppz 
containing complex is a hydrophobic “switch” complex presenting little luminescence 
in water. All bpy containing complexes are hydrophilic (highly water soluble).  
 
The chemical structures of the two BODIPY complexes used for comparison are 
presented in Figure 6.2, (b). BODIPY-1 is a VIS emitting probe with λabs, at 532 nm 
and λem at 547 nm (15 nm Stokes shift), while BODIPY-2 is an NIR emitting probe with 
λex at 557 nm and λem at 723 nm presenting a significantly large Stokes shift of 166 nm.  
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Figure 6.2: Chemical structure of (a) ruthenium complexes; hydrophobic 
[Ru(dpp)2PIC]
2+
, hydrophobic “switching”[Ru(dppz)2PIC]
2+
 and hydrophilic [Ru(bpy) 
2PIC]
2+
and (b) VIS and NIR emitting BODIPY complexes used as part of this Chapter. 
X denotes the range of functional group investigated. 
 
6.2.1.1   Pituitary Glands: Fixed Tissue Imaging 
As the application of ruthenium(II) polypyridyl dyes to imaging brain tissue samples 
has not been reported previously, a preliminary optimisation study was carried out to 
establish the optimal staining parameters required for tissue imaging. Fixed Pituitary 
gland slices 100 µm thick were incubated with 70 µM or 7 µM [Ru(dpp)2PIC]
2+ 
for 2 
minutes at room temperature, presented in Figure 6.3. Following incubation, samples 
were washed with PBS pH 7.4 and stained for DAPI (300 nM) for 10 minutes at room 
temperature. Samples were mounted using fluoroshield mounting media and allowed 
dry for 1 hour before imaging. Figure 6.3 (a) showed both dye saturation and 
aggregation, thus 70 µM was deemed too concentrated. In contrast, incubation of the 
pituitary gland tissue with 7 µM [Ru(dpp)2PIC]
2+
 presented optimal intensity with dye 
diffusion observed throughout the whole cytoplasm, but with suggested nuclear 
exclusion. Single cell differentiation was clearly presented concluding 7 µM 
concentration and an incubation time of 2 minutes as the optimal parameters for 
pituitary gland tissue staining. 
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Figure 6.3: Confocal luminescence images of pituitary gland tissue sections 
approximately 100 µm thick fixed with 3.8% PFA and incubated with (a) 70 µM or (b) 7 
µM [Ru(dpp)2PIC]
2+
 for 2 minutes at room temperature. Following incubation, samples 
were washed with PBS pH 7.4, DAPI stained (300 nM) for 10 minutes at room 
temperature and mounted prior to imaging using 375 nm (blue, DAPI), 488 nm (red, 
ruthenium) laser excitation and 63 x oil immersion. 
 
Following this optimisation, using Figure 6.1 as a reference, a confocal study 
employing the range of complexes presented in Figure 6.2 was carried out, comparing 
the effects of the hydrophobic dpp, hydrophilic bpy and “light-switching” dppz 
containing ruthenium complexes and the additional effect of ligand functionality on the 
staining of mice tissue. 
 
Figure 6.4 presents confocal luminescence images of 100 µm thick pituitary gland 
tissue sections fixed with 3.8% PFA and incubated with a 7 µM concentration of  
hydrophobic (a) [Ru(dpp)2PIC-COOH]
2+
, (b) [Ru(dpp)2PIC-NO2]
2+
, (c) [Ru(dpp)2PIC-
NH2]
2+
 or (d) [Ru(dpp)2PIC-NHS]
2+
 complexes for 2 minutes at room temperature. 
Following ruthenium incubation, samples were washed with PBS pH 7.4 and stained for 
DAPI (300 nM) for 10 minutes at room temperature. Samples were mounted using 
fluoroshield mounting media and allowed dry for 1 hour before imaging. Both (b) 
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[Ru(dpp)2PIC-NO2]
2+
 and (c) [Ru(dpp)2PIC-NH2]
2+
 presented lower intensities 
compared to the –COOH and –NHS derivatives. Chapter 3 presented lowest quantum 
yields for both –NO2 and –NH2 and so the lower intensities presented are unsurprising. 
Despite this, all functionalities presented comparable results which were also similar to 
the GFP labelled tissue example presented in Figure 6.1. Ruthenium diffused 
throughout the whole cytoplasm, but with nuclear exclusion as demonstrated by co-
staining with DAPI. Single cell differentiation can be made on the basis that the nucleus 
is so clearly defined due to total nuclear exclusion of the dye. As the cells are so tightly 
packed, unless a clear, extremely specific membrane marker is used, the only alternative 
way to distinguish the individual stains is via nuclear staining, or in this case total 
nuclear exclusion. Thus, the ability to mark a specific cell type using a label such as 
ruthenium rather than making a genetic modification proves promising. Future 
conjugation of specific membrane markers to these dyes may enhance the potential of 
these dyes as suitable tissue imaging agents. 
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Figure 6.4: Confocal luminescence images of pituitary gland tissue sections 
approximately 100 µm thick fixed with 3.8% PFA and incubated with 7 µM 
(a)[Ru(dpp)2PIC-COOH]
2+
, (b) [Ru(dpp)2PIC-NO2]
2+
, (c)[Ru(dpp)2PIC-NH2]
2+
 or 
(d)[Ru(dpp)2PIC-NHS]
2+
 for 2 minutes at room temperature. Following incubation, 
samples were washed with PBS pH 7.4, DAPI stained (300 nM dilution) for 10 minutes 
at room temperature and mounted prior to imaging using 375 nm (blue, DAPI), 488 nm 
(red, ruthenium) laser excitation and 63x oil immersion. N=3 in all cases. 
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Ruthenium diffused throughout the whole cytoplasm, but with nuclear exclusion as 
demonstrated by co-staining with DAPI, highlighted further by the fluorescence 
intensity profile for [Ru(dpp)2PIC-NHS]
2+
 presented in Figure 6.5. The intensity 
profiles for [Ru(dpp)2PIC-COOH]
2+
, [Ru(dpp)2PIC-NO2]
2+
 and [Ru(dpp)2PIC-NH2]
2+
, 
located in Appendix 3, are comparable to that presented for [Ru(dpp)2PIC-NHS]
2+
 in 
Figure 6.5.  
 
Figure 6.5: Luminescence intensity profile of a pituitary gland tissue section 
approximately 100 µm thick fixed with 3.8% PFA and incubated with 7 µM 
[Ru(dpp)2PIC-NHS]
2+
 for 2 minutes at room temperature. Following incubation, 
samples were washed with PBS pH 7.4, DAPI stained (300 nM) for 10 minutes at room 
temperature and mounted prior to imaging using 375 nm (blue, DAPI), 488 nm (red, 
ruthenium) laser excitation and 63x oil immersion. White arrow reflects the intensity 
profile presented. Results are representative of N=3.  
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Figure 6.6 presents the Z-stacked luminescence image (35 µm z-stack depth and 0.44 
µm step) of a 100 µm thick pituitary gland tissue section fixed with 3.8% PFA and  
incubated with 7 µM [Ru(dpp)2PIC-NHS]
2+
 for 2 minutes at room temperature. 
Following incubation, samples were DAPI stained (300 nM), mounted and allowed dry 
for 1 hour prior to imaging. The ruthenium complex presents successful penetration 
throughout the tissue section with whole cytoplasm staining and nuclear exclusion 
demonstrated by co-staining with DAPI. What is particularly interesting is that 
ruthenium penetrates deeper into the tissue section compared to the commercial DAPI 
nuclear dye even though DAPI was incubated for 10 minutes compared to 2 minutes for 
the ruthenium complexes. Substantial dye permeation throughout the tissue was 
observed. It is important to note that the COOH and NHS functionalities presents 
efficient binding to amine containing molecules.
(34, 35)
 Thus, in both cases, binding to 
amine containing proteins throughout the tissue may attribute to the observed increased 
luminescence intensity. Similar dye penetration was observed for dpp and bpy 
containing ruthenium complexes, presented in Appendix 3. 
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Figure 6.6: Luminescence confocal Z-stack image (225 x 225 µm image size, 35 µm z-
stack depth and 0.44 µm step) of a pituitary gland tissue section approximately 100 µm 
thick fixed with 3.8% PFA, incubated with 7 µM [Ru(dpp)2PIC-NHS]
2+
 for 2 minutes at 
room temperature. DAPI stained (300 nM) and mounted prior to imaging using 375 nm 
(blue, DAPI), 488 nm (red, ruthenium) laser excitation and 40x oil immersion. Results 
are representative of N=3. 
 
Figure 6.7 presents the luminescence confocal images of pituitary gland tissue sections 
approximately 100 µm thick fixed with 3.8% PFA and incubated with a 7 µM 
concentration of hydrophilic (a) [Ru(bpy)2PIC-COOH]
2+
 or (b) [Ru(bpy)2PIC-NHS]
2+
 
for 2 minutes at room temperature. Following incubation samples were DAPI stained 
(300 nM) for 10 minutes at room temperature, mounted and allowed dry for 1 hour prior 
to imaging. Similar to the dpp containing complexes, both [Ru(bpy)2PIC-COOH]
2+
 and 
[Ru(bpy)2PIC-NHS]
2+
 permeated fully into the entire tissue section and distributed 
throughout the entire cytoplasm with the exception of nucleus, as demonstrated by co-
staining with DAPI, highlighted further in the intensity profile presented in Figure 6.8. 
Cell differentiation, however is less clear; the ability to differentiate between cells is 
particularly lower for the –NHS derivative. As the hydrophobic NHS derivative, 
[Ru(dpp)2PIC-NHS]
2+
 (Figure 6.5) presented efficient cell differentiation it is suggested 
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that the reduced cell differentiation observed in Figure 6.7 is attributed more to the 
hydrophilicity of the bpy containing complex. The hydrophilicity of both complexes 
renders them relatively unaffected by the surrounding aqueous environment and so they 
diffuse to a greater extent compared to the hydrophobic (dpp and dppz) complexes 
which tend a non-aqueous environment. 
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Figure 6.7: Confocal luminescence images of pituitary gland tissue sections 
approximately 100 µm thick fixed with 3.8% PFA and incubated with 7 µM 
(a)[Ru(bpy)2PIC-COOH]
2+
or (b) [Ru(bpy)2PIC-NHS]
2+
 for 2 minutes at room 
temperature. Following incubation, samples were washed with PBS pH 7.4, DAPI 
stained (300 nM) for 10 minutes at room temperature and mounted prior to imaging 
using 375 nm (blue, DAPI), 488 nm (red, ruthenium) laser excitation and 63x oil 
immersion. Results are representative of N=3. 
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Figure 6.8: Luminescence intensity profile of a pituitary gland tissue section 
approximately 100 µm thick fixed with 3.8% PFA and incubated with 7 µM 
[Ru(bpy)2PIC-COOH]
2+
 for 2 minutes at room temperature. Following incubation, 
samples were washed with PBS pH 7.4, DAPI stained (300 nM) for 10 minutes at room 
temperature and mounted prior to imaging using 375 nm (blue, DAPI), 488 nm (red, 
ruthenium) laser excitation and 63x oil immersion. White arrow reflects the intensity 
profile presented. Results are representative of N=3. 
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Figure 6.9 presents a Z-stacked luminescence image (26 µm z-stack depth and 0.44 µm 
z-stack step) of a pituitary gland tissue section 100 µm thick fixed with 3.8% PFA and 
incubated with 7 µM [(Ru(bpy)2PIC-NHS]
2+
 for 2 minutes at room temperature. Similar 
to [Ru(dpp)2PIC-NHS]
2+
, substantial tissue penetration again to a greater extent than the 
commercial DAPI dye was observed. 
 
Figure 6.9: Luminescence confocal Z-stacked image (225 x 225 µm image size, 26 µm 
z-stack depth and 0.44 µm z-stack step) of a  pituitary gland tissue section 
approximately 100 µm thick fixed with 3.8% PFA and incubated with 7 µM 
[Ru(bpy)2PIC-NHS]
2+
 for 2 minutes at room temperature. Following incubation, 
samples were washed with PBS pH 7.4, DAPI stained (300 nM) for 10 minutes at room 
temperature and mounted prior to imaging using 375 nm (blue, DAPI), 488 nm (red, 
ruthenium) laser excitation and 40x oil immersion. Results are representative of N=3. 
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Figure 6.10 presents the luminescence confocal images of the hydrophobic “light-
switching” [Ru(dppz)2PIC-COOH]
2+
 dye, incubated with a 100 µm thick pituitary gland 
tissue section fixed in 3.8% PFA (7 µM concentration and 2 minute incubation at room 
temperature). Following incubation the samples were DAPI stained (300 nM) for 10 
minutes at room temperature, mounted and allowed dry for 1 hour before imaging. In 
correlation with the behaviour of both the dpp and bpy containing dyes, the dppz 
containing complex distributed throughout the entire cytoplasm with the exception of 
nucleus, as demonstrated by co-staining with DAPI, highlighted further in the intensity 
profile presented in Figure 6.11. 
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Figure 6.10: Confocal luminescence images of pituitary gland tissue sections 
approximately 100 µm thick fixed with 3.8% PFA and incubated with 7 µM 
[Ru(dppz)2PIC-COOH]
2+ 
for 2 minutes at room temperature. Following incubation, 
samples were washed with PBS pH 7.4, DAPI stained (300 nM) for 10 minutes at room 
temperature and mounted prior to imaging using 375 nm (blue, DAPI), 488 nm (red, 
ruthenium) laser excitation and 63x oil immersion. Results are representative of N=3. 
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Figure 6.11: Luminescence intensity profile of a pituitary gland tissue section 
approximately 100 µm thick fixed with 3.8% PFA and incubated with 7 µM 
[Ru(dppz)2PIC-COOH]
2+
 for 2 minutes at room temperature. Following incubation, 
samples were washed with PBS pH 7.4, DAPI stained (300 nM) for 10 minutes at room 
temperature and mounted using 375 nm (blue, DAPI), 488 nm (red, ruthenium) laser 
excitation and 63 x oil immersion. White arrow reflects the intensity profile presented. 
Results are representative of N=3. 
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Figure 6.12 presents a Z-stacked luminescence image (31 µm z-stack depth and 0.44 
µm z-stack step) of 7 µM [Ru(dppz)2PIC-COOH]
2+ 
incubated with a fixed pituitary 
gland tissue section approximately 100 µm thick for 2 minutes at room temperature. 
Following incubation the sample was DAPI stained (300 nM) for 10 minutes at room 
temperature, mounted and allowed dry for 1 hour before imaging.  In contrast to the 
previous ruthenium complexes, significantly less tissue permeation was observed for 
[Ru(dppz)2PIC-COOH]
2+
. It is suggested that this issue may be resolved by 
implementing a longer incubation time, an aspect investigated further in section 6.2.2.2. 
 
Figure 6.12: Luminescence confocal Z-stacked image (225 x 225 µm image size, 31 µm 
z-stack depth and 0.44 µm z-stack step) of a pituitary gland tissue section approximately 
100 µm thick fixed with 3.8% PFA and incubated with 7 µM [Ru(dppz)2PIC-COOH]
2+
 
for 2 minutes at room temperature. Following incubation, samples were washed with 
PBS pH 7.4, DAPI stained (300 nM) for 10 minutes at room temperature and mounted 
prior to imaging using 375 nm (blue, DAPI), 488 nm (red, ruthenium) laser excitation 
and 40x oil immersion. Results are representative of N=3. 
 
As mentioned, BODIPY complexes have been intensively studied in cellular imaging 
but their potential as tissue imaging agents remain unexplored. A distinct disadvantage 
for conventional BODIPY dyes is that they possess absorption maxima in the visible 
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region where tissue penetration of light is shallow and thus less optimal for non invasive 
in vivo imaging. Thus, the development of NIR imaging probes are essential for deep 
tissue light penetration and low autoﬂuorescence such as the BODIPY-2 complex 
studied as part of this chapter. Thus the ability of two organic, highly luminescent 
carboxy terminated BODIPY complexes in pituitary gland tissue imaging was 
investigated; VIS emitting BODIPY-1 and NIR emitting BODIPY-2. 
 
Figure 6.13 presents confocal luminescence images of pituitary gland tissue sections 
approximately 100 µm thick, fixed with 3.8 % PFA and incubated with a 5 µM 
concentration of (a) BODIPY-1 and (b) BODIPY-2 for 2 minutes at room temperature. 
Following incubation, samples were DAPI (300 nM) stained for 10 minutes at room 
temperature, mounted and allowed dry for 1 hour before imaging. Like the ruthenium 
metal complexes, single cell differentiation can be made on the basis that the nucleus is 
so clearly defined due to total nuclear exclusion of the dye. As the cells are so tightly 
packed, unless a clear, extremely specific membrane marker is used, the only alternative 
way to distinguish the individual stains is via nuclear staining, or in this case total 
nuclear exclusion. Thus, the ability to mark a specific cell type using a fluorescent label 
such as BODIPY rather than making a genetic modification proves promising. Through 
conjugation of specific membrane markers, these dyes have the potential to provide 
greater specificity to issue imaging.  
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Figure 6.13: Confocal luminescence images of pituitary gland tissue sections 
approximately 100 µm thick fixed with 3.8% PFA and incubated with a 5 µM 
concentration of (a) BODIPY-1 or (b) BODIPY-2 for 2 minutes at room temperature. 
Following incubation, samples were washed with PBS pH 7.4, DAPI stained (300 nM) 
for 10 minutes at room temperature and mounted prior to imaging using 375 nm (blue, 
DAPI), 540 nm (green, BODIPY) laser excitation and 63x oil immersion. Results are 
representative of N=3. 
 
Figure 6.14 presents the Z-stacked luminescence image (35 µm z-stack depth and 0.44 
µm z-stack step size) of 5 µM BODIPY-2 incubated with a fixed pituitary gland tissue 
section approximately100 µm thick for 2 minutes at room temperature. Following 
incubation the sample was DAPI stained (300 nM) for 10 minutes at room temperature, 
mounted and allowed dry for 1 hour before imaging. In correlation with the dpp and bpy 
containing ruthenium complexes, BODIPY permeated efficiently, distributing 
throughout the whole 35 µm depth Z-stack. However, in contrast to the ruthenium 
complexes, the intensity is concentrated at the surface and periphery of the sample, 
suggesting greater penetration is presented for the NIR emitting BODIPY probe.   
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Figure 6.14: Luminescence confocal Z-stacked image (225 x 225 µm image size, 35 µm 
z-stack depth and 0.44 µm z-stack step) of a pituitary gland tissue section approximately 
100 µm thick fixed with 3.8% PFA and incubated with 5 µM BODIPY-2 for 2 minutes at 
room temperature. Following incubation, samples were washed with PBS pH 7.4, DAPI 
stained (300 nM) for 10 minutes at room temperature and mounted prior to imaging 
using 375 nm (blue, DAPI), 540 nm (green, BODIPY) laser excitation and 40x oil 
immersion. Results are representative of N=3. 
 
6.2.1.2   Pituitary Glands: Live Tissue Imaging 
The process of formaldehyde cell fixation is widely known to permeabilize the cell 
membrane.
(36, 37)
 Thus the ability of these dyes to image live tissue was also 
investigated. The ability of [Ru(dpp)2PIC-NHS]
2+
, [Ru(bpy)2PIC-NHS]
2+
 and 
[Ru(dppz)2PIC-COOH]
2+
 to stain live pituitary gland tissue were compared. Figure 
6.15 presents confocal luminescence images of live pituitary gland tissue sections 
approx 100 µm thick incubated with 7 µM of (a) [Ru(dpp)2PIC-NHS]
2+
, (b) 
[Ru(bpy)2PIC-NHS]
2+
 or (c) [Ru(dppz)2PIC-COOH]
2+
. It is important to note that apart 
from the highly water soluble bpy complex, DMSO was required fully dissolve the 
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ruthenium dyes in the PBS pH 7.4 buffer; a 0.07% DMSO final concentration was used 
for both dpp and dppz containing complexes. All three dyes presented significant but 
low emission, however, the dye diffused throughout the whole cell as well as in the 
surrounding matter. This is in contrast to the defined cell differentiation observed for 
the same dyes in fixed tissue samples. The results presented here are not surprising as 
the inability of these dyes to penetrate the live cell membrane without the aid of a cell-
penetrating peptide has been previously reported.
(5)
 It is important to note that a 
significantly higher laser intensity power was required to observe luminescence and so 
should not be directly compared to the intensities observed for the fixed samples. At the 
laser intensity power used for the fixed samples, effectively no luminescence is 
observed (presented in Appendix 3). 
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Figure 6.15: Confocal luminescence images of live pituitary gland tissue sections 
approximately 100 µm thick incubated with a 7 µM concentration of (a)[Ru(dpp)2PIC-
NHS]
2+
,(b)[Ru(bpy)2PIC-NHS]
2+
 or (c)[Ru(dppz)2PIC-COOH]
2+ 
for 2 minutes at room 
temperature. Following incubation, samples were washed with PBS pH 7.4, fixed with 
3.8% PFA for 10 minutes at room temperature, DAPI stained (300 nM) for 10 minutes 
at room temperature and mounted prior to imaging using 375 nm (blue, DAPI), 488 nm 
(red, ruthenium) laser excitation and 63x oil immersion. Results are representative of 
N=3. 
 
The effect of incubation time on tissue permeation of [Ru(dppz)2PIC-COOH]
2+
 
throughout the tissue sample was investigated, presented in Figure 6.16. Live pituitary 
gland tissue sections were incubated with 7 µM [Ru(dppz)2PIC-COOH]
2+
 for (a) 2, (b) 
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5, (c) 10, (d) 15 or (e) 20 minutes to assess the effect of incubation time on dye 
penetration and localisation. No significant change in either intensity or localisation 
occurred over the specified time range. After 20 minutes incubation cell differentiation 
was noted however not to the extent observed for the same dye in fixed pituitary tissue 
samples. A 10
-6
 M dye concentration is very low and so increasing dye concentration 
may help optimise live tissue staining. In addition, the more aqueous environment of the 
live cells may also attribute to lower luminescence intensities. Our results indicate that 
ruthenium dyes present relatively poor transport across the cell membrane with diffuse 
staining and reduced cell differentiation in live tissue samples compared to fixed tissue 
imaging. 
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Figure 6.16:  Confocal luminescence images of live pituitary glands sections 
approximately 100 µm thick incubated with a 7 µM concentration of [Ru(dppz)2PIC-
COOH]
2+
 for (a) 2, (b) 5, (c) 10, (d) 15 or (d) 20 minutes at room temperature. 
Following incubation, samples were washed with PBS pH7.4, fixed with 3.8% PFA for 
10 minutes at room temperature, DAPI stained (300 nM) for 10 minutes at room 
temperature and mounted prior to imaging using 375 nm (blue, DAPI), 488 nm (red, 
ruthenium) laser excitation and 63 x oil immersion. Results are representative of N=3. 
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The ability of BODIPY to stain live pituitary gland tissue was also investigated using 
the red-shifted NIR BODIPY-2 probe. Figure 6.17 presents a luminescence confocal 
image of a live pituitary gland tissue section approximately 100 µm thick incubated 
with 5 µM BODIPY-2 for 2 minutes at room temperature. In contrast to the fixed 
samples, live staining of pituitary gland tissue proved promising. Cell differentiation is 
clearly observed with significantly enhanced localisation around the cell membrane. 
The more aqueous environment of the live tissue sample is suggested to drive this 
hydrophobic probe to the membrane region of the cell suggesting the hydrophobicity of 
the dye strengthens its potential as a tissue imaging agent. 
      DAPI             BODIPY         Merge 
 
Figure 6.17: Confocal luminescence image of a live pituitary gland section 
approximately 100 µm thick incubated with 5 µM BODIPY-2 for 2 minutes at room 
temperature. After incubation, the sample was washed with PBS pH 7.4, fixed with 
3.8% PFA for 10 minutes at room temperature, DAPI stained (300 nM) for 10 minutes 
at room temperature and mounted prior to imaging using 375 nm (blue, DAPI), 540 nm 
(green, BODIPY) laser excitation and 63 x oil immersion. Results are representative of 
N=3. 
 
6.2.1.3   Brain Tissue (Hippocampus/Cortex): Live Tissue Imaging 
As the hippocampus and cortex regions are suggested to play a prime role in the onset 
of neurodegenerative diseases such as AD, the value of Stokes shifted ruthenium and 
BODIPY probes as image contrast agents in live brain tissue imaging was also 
investigated. Figure 6.18 presents live brain tissue sections approx 100 µm thick, 
incubated with a 7 µM concentration of (a) [Ru(dpp)2PIC-NHS]
2+
, (b) [Ru(bpy)2PIC-
NHS]
2+
 or (c) [Ru(dppz)2PIC-COOH]
2+
 for 2 minutes at room temperature.  
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Significant background matter staining was observed in all cases. Brain tissue matter is 
made up of two main components; white and grey matter. White matter consists mostly 
of glial cells (non-neuronal) and myelinated axons (composed largely of lipid tissue 
veined with capillaries) that transmit signals from one region of the cerebrum to 
another, while grey matter is composed of neurons. This non-specific staining is a 
limitation to using these dyes as labels alone. Nonetheless, promising results are 
presented as all three dyes present signs of single cell differentiation with concentrated 
staining and localisation around single cells, excluding the nucleus.  
 
Figure 6.18: Confocal luminescence images of live brain tissue sections approximately 
100 µm thick incubated with 7µM concentrations of (a) [Ru(dpp)2PIC-NHS]
2+
,(b) 
[Ru(bpy)2PIC-NHS]
2+
or (c) [Ru(dppz)2PIC-COOH]
2+
 for 2 minutes at room 
temperature. After incubation, samples were washed with PBS pH 7.4, fixed with 3.8% 
PFA for 10 minutes at room temperature and mounted prior to imaging using 488 nm 
(red, ruthenium) laser excitation and 63 x oil immersion. Results are representative of 
N=3. 
 
The comparative ability of BODIPY-1 and BODIPY-2 to selectively stain cells within 
live brain tissue sections was also investigated, presented in Figure 6.19. Results 
correlate well with those presented for the fixed pituitary gland tissue presenting 
significantly high background staining in both cases. The dyes showed no signs of 
selective cell staining or cell differentiation. Interestingly, however, clear truncations 
are present, as localised concentrated spots of BODIPY are evident throughout the 
whole sample background tissue suggesting BODIPY is binding to alternative 
biological species within the sample. It is suggested that the dye is localising in a 
specific organelle, possibly mitochondria or endoplasmic reticulum (ER), a pattern 
observed previously by our group for similar BODIPY complexes.
(38)
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Moriarety et al.
(38)
 compared the potential of two BODIPY derivatives; a visible 
emitting fluorophore (BODIPY-VIS) and an NIR emitting BODIPY flourophore with a 
Stokes shift of approximately 165 nm as contrast reagents for live mammalian cells; 
CHO, cervical cancer (HeLa), Kelly and SK-N-AS neuroblastoma cell lines and SP2/0-
Ag 14 murine myeloma spleen cells suspension cells. The compounds were rendered 
water soluble by their conjugation to polyethelene glycol (PEG). BODIPY co-staining 
with the commercially available organelle localising dyes; LysoTracker® (lysosomes), 
MitoTracker® (mitochondria), DiOC6 (ER low concentration and mitochondria at high 
concentration) and DAPI (nucleus) revealed all dyes exhibited good cell uptake and 
were shown to be nuclear excluding, localising predominantly within the lipophillic 
organelles; the endoplasmic reticulum and mitochondria.  
 
Grey matter, as mentioned, is one of two major components of the central nervous 
system, consisting of neuronal cell bodies, neuropil (dendrites and axons), glial cells 
(non-neuronal) and capillaries. The soma (main part of the neuron in which dendrites 
branch off of) contains many organelles, including granules called Nissl granules. These 
granules are rough endoplasmic reticulum (RER) with rosettes of free ribosomes, and 
are the site of protein synthesis. Thus, it is suggested that BODIPY may be localising in 
the RER of the soma containing neurons located within the grey matter of the brain 
tissue sections. 
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Figure 6.19: Confocal luminescence images of live brain tissue sections approximately 
100 µm thick incubated with a 5 µM concentration of (a) BODIPY-1 or (b) BODIPY-2 
for 2 minutes at room temperature. Samples were washed with PBS pH 7.4, DAPI 
stained (300 nM) for 10 minutes at room temperature and mounted prior to imaging 
using 375 nm (blue, DAPI), 540 nm (green, BODIPY) laser excitation and 63 x oil 
immersion. Results are representative of N=3. 
 
6.2.2   [Ru(dppz)2PIC]
2+
 binding to Aβ aggregates: Aβ1-40 and Aβ1-42 
Mutation studies regarding the 40 and 42 residue of Aβ indicate that both Aβ 1-40 and 
Aβ 1-42 play a role in Aβ aggregation, a phenomenon reported to contribute the 
neurodegenerative disorder; Alzheimer’s disease.(39) The amyloid cascade hypothesis 
suggests that the transition of monomeric, unaggregated Aβ to fibrillized Aβ plays an 
important role in the pathology of AD, thus luminescent imaging agents for these 
residues is of significant interest biomedically.
(39)
 Thus, the ability of [Ru(dppz)2PIC]
2+
 
to bind to Aβ aggregates was investigated. Figure 6.20 presents AFM images of (a) 
unaggregated and (b) aggregated Aβ 1-40.   
 
Aβ 1-40 peptide solutions were prepared according to a method modified from 
literature.
(40)
 The first step in re-suspending the lyophilised peptide was treatment with 
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HFIP solvent to remove any pre-existing structures in the peptide stock. 1 mg of Aβ 1-
40 peptide was dissolved in 1 ml 100% HFIP and transferred in 100 µl aliquots to 
centrifuge tubes. As HFIP is a corrosive alcohol, it was removed by evaporation in the 
fumehood for 3 hours. Immediately prior to use, the HFIP treated aliquot was 
completely dissolved in 2% DMSO/dH20 to a final concentration of 70 µM. The 
solution was vortexed for 15 minutes and used immediately. Stine et al.
(40)
, using AFM, 
previously investigated the effect of HFIP, DMSO and dH2O treatment on Aβ 1-40 and 
suggested that no aggregation occurred if the peptide was pre-treated with HFIP. When 
HFIP treated peptide was dissolved in DMSO the peptide solution was found to present 
no aggregation for the first 24 hours and so is ideal for unaggregated Aβ 1-40 studies. 
 
Previous studies have indicated that acidic pH favours fibrillogenesis for Aβ.(41, 42) Stine 
et al.
(40) 
also investigated the effects of pH as well as incubation time and temperature 
on Aβ fibril formation. Results showed an acidic pH using 10 mM HCl with 5 weeks 
incubation at 37 °C was required for fibril formation. In addition, a concentration study 
ranging from 10 to 100 µM concentration of Aβ 1-40 peptide suggested 50 µM as the 
minimal concentration required for fibril formation. Thus for the preparation of 
aggregated Aβ 1-40 peptide solutions in this study, the HFIP treated aliquot was 
completely re-suspended in DMSO (to produce a final 2% DMSO concentration) and 
made up to a final 70 µM concentration with 10 mM HCl and 150 mM NaCl. The 
solution was vortexed for 15 seconds and incubated at 37°C for 5 weeks prior to use. 
 
Distinct differences between unaggregated and aggregated Aβ 1-40 was observed. 
Figure 6.20, (a) presents unaggregated Aβ 1-40; the observed small circular solids on 
the gold substrate may be attributed to oligomer formation, reported previously by Stine 
et al.
(40)
 In contrast Figure 6.20, (b) presents aggregated Aβ 1-40, observed as distinct 
large aggregates with the presence of fibrils.  
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Figure 6.20: AFM images of (a) unaggregated and (b) aggregated Aβ 1-40. HFIP-
treated Aβ 1–40 in 2% DMSO was diluted to 70 µM in dH20 for unaggregated or 10 
mM HCl for fibrils/aggregated Aβ. Unaggregated preparations were used immediately 
while fibril preparations were incubated for 5 weeks at 37 °C respectively. Following 
preparation, both preparations were incubated with glass slides for 30 minutes at 37°C 
and imaged in tapping mode in air using a Mikro Masch Ultrasharp noncontact 15 
series tip with a resonant frequency of approximately 325 KHz and force constant 
of approximately 40 N/m. All images were taken at a scan rate below 0.5Hz and at 512 
samples/line resolution. (Images were collected by Dr. Úna Prendergast). Result is N 
=1. 
 
Figure 6.21 presents confocal luminescence images of (a) unaggregated and (b) 
aggregated Aβ 1-40 incubated with [Ru(dppz)2PIC]
2+
. As described, HFIP-treated Aβ 
1–40 in 2% DMSO was diluted to 70 µM in dH20 for unaggregated and 10 mM HCl for 
fibrils/aggregated Aβ 1–40. Unaggregated preparations were used immediately while 
fibril preparations were incubated for 5 weeks at 37 °C respectively. A final 
concentration of 70 µM [Ru(dppz)2PIC]
2+
 was added to 70 µM Aβ 1–40 and incubated 
for 30 minutes at 37 °C. Following incubation, samples were washed with PBS pH 7.4, 
mounted using fluoroshield mounting media and allowed dry for 1 hour prior to 
imaging. 
 
Unaggregated Aβ 1–40 prepared in de-ionised H2O (dH2O) presented no luminescence 
following incubation with [Ru(dppz)2PIC]
2+
, Figure 6.21, (a). In contrast significant 
luminescence from [Ru(dppz)2PIC]
2+
 bound to Aβ 1–40 aggregates is clearly observed 
in Figure 6.21, (b). Results suggest the ability of the complex to bind to Aβ aggregates.  
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Figure 6.21: Confocal luminescence images of (a) unaggregated and (b) aggregated Aβ 
1-40 incubated with [Ru(dppz)2PIC]
2+
. HFIP-treated Aβ 1–40 in 2% DMSO was 
diluted to 70 µM in dH20 for unaggregated and 10 mM HCl for fibrils/aggregated Aβ. 
Unaggregated preparations were used immediately. Fibril preparations were incubated 
for 5 weeks at 37 °C. A final concentration of 70 µM [Ru(dppz)2PIC]
2+
 was added to 70 
µM Aβ and incubated for 30 minutes at 37 °C. Samples were imaged using 488 nm (red, 
ruthenium) laser excitation and 63x oil immersion. Results are representative of N=3. 
 
The potential of [Ru(dppz)2PIC]
2+
 as an amyloid probe was strengthened further via 
incubation with the widely reported longer hydrophobic amyloid sequence, Aβ 1-42, 
presented in Figure 6.22. Stine et al.
(40)
 also investigated Aβ 1-42 and confirmed this 
peptide to form aggregates more rapidly and to a greater extent than the Aβ 1-40 
segment. In this study, HFIP-treated Aβ 1–42 in 2% DMSO was diluted to 70 µM in 
dH20 for unaggregated and 10 mM HCl for fibrils/aggregated Aβ. Unaggregated 
preparations were used immediately while fibril preparations were incubated for 24 
hours at 37 °C respectively. A final concentration of 70 µM [Ru(dppz)2PIC]
2+
 was 
added to 70 µM Aβ 1–40 and incubated for 30 minutes at 37 °C. Following incubation, 
samples were washed with PBS pH 7.4, mounted using fluoroshield mounting media 
and allowed dry for 1 hour prior to imaging. 
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In agreement with the 1-40 residues, luminescence was inhibited when ruthenium was 
incubated with unaggregated Aβ 1-42 whereas significant luminescence was observed 
following incubation with Aβ 1-42 aggregations. In correlation with Stine et al.(40), 
confocal studies presented less fibrillar formation and more of a solid aggregate 
formation after 24 hours incubation at 37°C compared to 5 weeks incubation for Aβ 1-
40, suggesting that Aβ 1-42 induces more significant aggregation compared to Aβ 1-40. 
This result is highlighted in the SEM images presented in Figure 6.23. 
 
Figure 6.22: Confocal luminescence images of (a) unaggregated and (b) aggregated Aβ 
1-42 incubated with [Ru(dppz)2PIC]
2+
. As described, HFIP-treated Aβ 1–42 in 2% 
DMSO was diluted to 70 µM in dH20 for unaggregated and 10 mM HCl for 
fibrils/aggregated Aβ 1–42. Unaggregated preparations were used immediately while 
fibril preparations were incubated for 24 hours at 37 °C. A final concentration of 70 
µM [Ru(dppz)2PIC]
2+
 was added to 70 µM Aβ 1–42 and incubated for 30 minutes at 37 
°C. Following incubation, samples were washed with PBS pH 7.4, mounted using 
fluoroshield mounting media and imaged using 488 nm (red, ruthenium) laser 
excitation and 63x oil immersion. Results are representative of N=3. 
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Figure 6.23: Scanning electron microscopy image of (a) left: unaggregated, right: 
aggregated Aβ 1-40 compared to (b) left: unaggregated and right: aggregated Aβ 1-42. 
HFIP-treated Aβ 1–40 and Aβ 1–42  in 2% DMSO was diluted to 70 µM in dH20 for 
unaggregated or 10 mM HCl for fibrils/aggregated Aβ. Unaggregated preparations 
were used immediately while fibril preparations were incubated for 24 hours for Aβ 1–
42 or 5 weeks at 37 °C for Aβ 1–40 respectively. In all cases, 70 µM Aβ was incubated 
with a gold planar surface for 30 minutes at 37 °C and imaged at 5.00 kV accelerating 
voltage. Results are representative of N=3. 
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6.3   Conclusion  
This chapter investigated the feasibility of using two Stokes shifted probes; 
ruthenium(II) polypyridyl complexes with various ligand modifications and two 
carboxy terminated organic VIS and NIR emitting BODIPY complexes as probes for 
brain and pituitary gland tissue imaging. Significant luminescence intensity, tissue 
penetration and cell differentiation was observed for all ruthenium complexes incubated 
with fixed tissue samples. Of the dpp, bpy and dppz containing complexes studied, both 
dpp and dppz presented the best cell differentiation. In contrast, little fluorescence 
intensity in live tissue was observed. Non-specific background staining of brain matter 
surrounding the cell clusters was observed for all live tissue imaging 
 
BODIPY studies, presented greater tissue penetration compared to the metal complexes. 
In agreement with the ruthenium complexes, significant luminescence intensity, tissue 
penetration and cell differentiation was observed for both BODIPY complexes 
incubated with fixed tissue samples. In contrast to ruthenium, efficient luminescence 
intensity, tissue permeation and cell differentiation was observed for live pituitary gland 
tissue staining using the BODIPY-2 complex. Non-specific background staining of the 
grey matter surrounding the cell clusters was observed for all brain tissue imaging. 
 
Future work will focus on introducing specificity to these complexes, through the 
conjugation of peptides specific for the cells or through the widely reported octaarginine 
cell-penetrating peptide.
(3, 5, 7)
 This should eliminate any non-specific background 
staining. Although results are preliminary, both ruthenium and BODIPY present 
significant potential as suitable imaging agents for brain and pituitary tissue 
investigations with the advantage of deep tissue/cell penetration and nuclear exclusion. 
 
Results presented diffuse staining throughout the whole tissue for both ruthenium and 
BODIPY. Single cell differentiation was not viable. However, single cell differentiation 
could be made on the basis that the nucleus was so clearly defined due to total nuclear 
exclusion of the dye. As the cells were so tightly packed, unless a clear, extremely 
specific membrane marker was used, the only alternative way to distinguish the 
individual stains was via nuclear staining, or in this case total nuclear exclusion. As 
mentioned, investigations into live neurological tissue is typically achieved using 
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genetically altered animals that express fluorescent proteins such as green fluorescent 
protein (GFP) corresponding to the various cell types, i.e. somatotropes. Such animal 
models are often costly and many difficulties can occur during breeding. Thus, the 
ability to mark a specific cell type using a fluorescent label such as ruthenium or 
BODIPY directly, rather than the complex process of genetic modification has the 
potential to revolutionise tissue imaging.  
 
Preliminary studies investigating the potential of [Ru(dppz)2PIC]
2+
 as a luminescent 
probe for Aβ investigations demonstrated the ability of ruthenium to bind to two widely 
reported Aβ aggregate forming sequences; Aβ 1-40 and Aβ 1-42 with distinct 
differences in fibrillar aggregation observed using AFM, SEM and confocal 
microscopy. Further studies are required to confirm binding specificity to these Aβ 
aggregates. As suggested for the tissue studies, introducing specificity via conjugation 
of a targeting peptide may enhance the application of the ruthenium complex as a probe 
for Aβ aggregation studies. For example, point mutations within the hydrophobic core 
of Aβ have identified residues 16–20 (KLVFF) as essential for fibril formation and are 
suggested to be the minimal sequence required to bind to Aβ 1-40.(43-45) Thus 
conjugating KLVFF to the [Ru(dppz)2PIC]
2+
 complex may introduce specificity to the 
binding and fibrillar formation of Aβ. As mentioned, the long luminescent lifetime of 
ruthenium allows the measurement of longer lived dynamics in biomolecules i.e. protein 
binding. Future investigations measuring the time-resolved luminescent lifetimes of the 
aggregate bound ruthenium complex will be key in distinguishing between the different 
forms of aggregation formed which may strengthen the potential application of this 
ruthenium(II) poylpyridyl complex as a luminescent marker in Aβ monomer-fibrillar 
transitions. 
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7.0   Conclusions and Future Work  
The work presented focussed on novel tools for the study of the platelet integrin αIIbβ3 
specific RGD peptide sequence and associated blood platelets. Integrin αIIbβ3 is the 
central protein in haemostasis and thrombosis, its activation is the first step in a cascade 
of biochemical processes which leads to platelet activation, spreading and clotting. The 
mechanism of integrin activation and molecular details of platelet activation are still 
being worked out so tools which aid in this process are useful both in diagnostics and 
therapeutics. 
 
The first part of this thesis presented the synthesis of metal complex RGD bioconjugates 
for application as probes for integrin detection and for assessing conformational change 
(following activation) and as cellular contrast agents for the surface receptor. Chapter 3 
detailed the synthesis and a comparative study of the photophysical characterization of a 
series of ruthenium(II) polypyridyl complexes containing the hydrophobic (dpp), 
hydrophilic (bpy) and water sensitive (dppz) ligands. Although these complexes had 
been synthesised previously, this is the first study to conjugate these metal complexes to 
the αIIbβ3 specific RGD sequence. NO2, NH2, COOH, NHS and maleimide 
functionalized ruthenium complexes containing (bpy), (dpp) or (dppz) ligands were 
synthesized. Two synthesis pathways were investigated for the conjugation process: 
maleimide-cysteine and NHS-amine conjugation pathways.  
 
Both maleimide-cysteine and NHS-amine pathways presented successful. However 
maleimide was later found to be highly unstable, proving both time-consuming and 
unreliable. Thus the N-Hydroxysuccinimide (NHS)-amine pathway was deemed the 
optimal pathway for ruthenium-RGD conjugation. Three novel ruthenium-RGD 
conjugates were synthesised; [Ru(dpp)2PIC-Mal-RGD]
2+
, [Ru(dpp)2PIC-RGD]
2+
 (via 
NHS pathway) and [Ru(bpy)2PIC-RGD]
2+
 (via NHS pathway). Comparable 
photophysics including long aqueous lifetime, red emission characteristics, large Stokes 
shifts and oxygen sensitivity were observed for parent and peptide conjugated 
complexes. Although following conjugation to the RGD peptide moiety a noticeable 
increase in lifetime was observed for both (dpp) containing complexes, a phenomenon 
reported previously to be attributed to some weak exclusion of oxygen from the metal 
centre as well as increased solubility in water. 
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In Chapter 4, the ability of the three ruthenium-RGD probes to recognise purified 
integrin αIIbβ3 in solution and in live cells was investigated; [Ru(dpp)2PIC-Mal-RGD]
2+
, 
[Ru(dpp)2PIC-RGD]
2+
 and [Ru(bpy)2PIC-RGD]
2+
. In solution the application of these 
conjugates to report on integrin binding and activation by two commonly known 
chemical activators Mn
2+ 
or DTT was studied using luminescence emission intensity, 
time-resolved rotational correlation time and confocal microscopy. All three ruthenium-
RGD probes selectively bound to “resting” αIIbβ3. Control experiments with BSA and 
the well known pharmaceutical integrin protein inhibitor Eptifibatide suggested probe 
specificity toward αIIbβ3. Treatment of integrin αIIbβ3 with Mn
2+ 
or DTT induced integrin 
conformational changes and the mode of binding of the dpp containing probes to the 
protein. DTT had the greatest effect on integrin conformation when compared to Mn
2+
. 
Interestingly the conformational changes to the integrin were strongly influenced by the 
presence of the ruthenium-RGD probes at its RGD recognition site prior to its chemical 
activation.  Preliminary evidence suggested that the cooperative binding of the dpp 
containing metal complex ligands which was likely to combine hydrophobic-
hydrophobic interactions with RGD recognition site binding, altered the final 
conformation of the integrin achieved with DTT or Mn
2+
 treatment. This cooperative 
binding was not observed with the hydrophilic bpy containing probe strengthening the 
suggestion that hydrophobicity is playing a role in the cooperative binding pattern 
observed for the dpp complexes.  
 
Nonetheless, all ruthenium-RGD probes were found to be useful peptide-probes for the 
assessment of integrin conformation as a result of their efficient integrin binding and 
long luminescent lifetime which provided a means of directly probing the activation 
state of αIIbβ3 integrin through time-resolved rotational correlation time. Clear 
distinctions were observed in luminescence intensity, lifetime and rotational correlation 
time of all metal complex probes when bound to integrin which was resting, chemically 
activated or thermally denatured. Our work indicates that on the basis of intensity, 
lifetime and rotational correlation time these complexes can be used to discriminate 
against different conformational states of the integrin.  
 
The value of [Ru(dpp)2PIC-RGD]
2+  
and
 
[Ru(bpy)2PIC-RGD]
2+ 
complex conjugates as 
integrin specific probes in live cells was then demonstrated. Both probes bound 
specifically to αIIbβ3 in live integrin expressing Chinese hamster ovary (CHO) cells as 
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confirmed by their co-localization with the SZ22 αIIb integrin specific antibody. The 
parent dye without the peptide did not bind and when there was no αIIbβ3 expressed by 
the cell, [Ru(dpp)2PIC-RGD]
2+  
and
 
[Ru(bpy)2PIC-RGD]
2+ 
did not bind.   
 
The second part of this thesis focussed on using self-assembled monolayers (SAMs) of 
the platelet integrin specific peptide C-Ahx-GRGDS sequence for the investigation of 
single platelet capture to gold cavity array surfaces. The effect of both surface chemistry 
and surface topography on platelet adhesion, morphology and activation status was 
studied. In particular, the ability to selectively capture single platelets across/over single 
cavities and the ability to carry out surface-enhance Raman spectroscopy (SERS) on 
single platelets was also demonstrated. 
 
Chapter 5 exploited scanning electron microscopy, confocal fluorescence microscopy 
and Raman spectroscopy to examine the interactions of whole human platelets with 
both planar gold surfaces and highly ordered gold nanocavity arrays. The effect of 
surface chemistry on platelet capture and activation status was explored. The gold 
arrays were prepared from microlithography via electrochemical deposition to produce 
gold coated planar and cavity surfaces. Monolayers of the αIIbβ3 integrin platelet protein 
sequence C-Ahx-GRGDS were self-assembled at the surfaces to investigate the spatial 
guidance of platelet binding and spreading at the single cell level. Platelet adhesion 
control was investigated using the widely reported alkane and PEG cell/platelet binding 
inhibitors at varying RGD/alkane and RGD/PEG ratios. The effect of cavity size on 
platelet binding and platelet morphology was also investigated, comparing gold planar 
surfaces approximately 100 nm thick to three different microcavity array sizes; 5.4 µm, 
1.6 µm and 0.98 µm. In addition, the ability to selectively capture single intact platelets 
using these microcavity arrays was also investigated.   
 
Confocal fluorescence microscopy and scanning electron microscopy confirmed platelet 
adhesion and spreading for all gold surfaces. RGD modified surfaces provided the most 
ideal environment for platelet adhesion presenting high platelet counts while retaining 
platelets in the resting/early spreading stage. Alkane inhibited binding with any bound 
platelets in the resting state, while PEG presented enhanced binding, spreading and 
activation in all cases. Platelet binding and spreading was found to be greatly influenced 
by the surface geometry with the platelets ability to bind and spread decreasing with 
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decreasing microcavity size. Platelets bound and retained the ability to spread fully onto 
5.4 µm cavity arrays, a length consistent with that of maximally extended filopodia and 
also presented suggested granule secretion, a process not seen for the planar surfaces or 
smaller cavity sizes. In addition, incubating platelets after they had bound to the surface 
with a 1 mM solution of RGD or Eptifibatide removed the majority of platelets from the 
surface, suggesting binding is reversible. Biomedically, this result is of significant 
interest, as the ability to remove bound platelets from biomedical devices i.e. stents may 
help reduce the risk of thrombus formation. 
CD62P selectin (α-granules) and phalloidin (actin) staining was carried out to study the 
activation status and actin localization across the varying surfaces. Using this staining 
technique the activation status and actin content of platelets was found to differ greatly 
depending on the surface chemistry and surface functionality. Overall, this chapter 
indicated that based on relative area available and surface chemistry modification, 
platelet spreading and activation could be inhibited. Platelet binding was also reversible 
via incubation with a 1 mM final concentration of RGD or Eptifibatide after platelets 
had adhered to the RGD SAM modified surfaces. 
 
This Chapter also illustrated for the first time, the ability to capture single platelets 
across/over single cavity on RGD modified 1.6 µm diameter arrays and more 
importantly, to obtain intense Raman intensity signal on the single platelets bound to the 
highly ordered array. It was suggested that these platelets may bind over the cavity at 
reported “hot spot” SERS sites of the array resulting in significant enhancement of 
Raman signals on the platelet. Correspondingly, a comparison of Raman signal from 
platelets bound to glass and from single platelets bound to the gold cavity arrays 
showed intense Raman signals from the latter, compared to weak and fluorescence 
superimposed signals from the former. One of the key advantages of SERS with 
biological materials, apart from the obvious signal enhancement, is that the surface can 
quench autofluorescence leading to additional improvements in S/N ratio. The ability to 
select and collect Raman spectra from individual platelets that were spread compared to 
the majority of platelets that were non-spread, was demonstrated. Thus a very 
preliminary comparison of both dendritic and spread SERS spectra was possible. This is 
a significant result, as the ability to not only obtain spectra from a single platelet, but to 
have the option to also choose between platelets of different stages of spreading 
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generates significant specificity to the analysis of platelets using the Raman 
spectroscopy technique.  
 
Chapter 6 also investigated the potential of two Stokes shifted probes; Ru(II) 
polypyridyl complexes and near infra-red (NIR) BODIPY (the latter was synthesized by 
Dr. Aaron Martin) as potential imaging agents in small animal tissue imaging. All 
materials explored diffused readily into fixed tissue and presented nuclear exclusion, a 
significant advantage in terms of cell differentiation. Efficient dye penetration 
throughout the tissue (at least 35 µm) and concentrated staining throughout single cells 
providing easy cell differentiation in pituitary gland tissue section for all complexes. 
Interestingly, dye penetration for all complexes, both ruthenium (with the exception of 
[Ru(dppz)2PIC]
2+
) and BODIPY presented significantly greater depth penetration than 
the commercial DAPI nucleus stain. In contrast, however, live imaging of the same 
tissue and hippocampus/cortex brain image tissue presented relatively unsuccessful 
results. In particular, brain tissue imaging presented significant non-specific staining of 
the background grey matter which interfered with the ability to differentiate between 
cell clusters. Despite this, nuclear exclusion was still evident confirming future work 
with these dyes as imaging agents is promising. Currently, the only method of cell 
differentiation between cell clusters of this nature is through the use of genetically 
modified green fluorescent protein (GFP) labelled mice which is both time consuming 
and extremely costly. In future, the introduction of target peptides to these dyes will be 
of significant value in this area with the results presented in this thesis providing 
significant potential for these dyes as novel neurological tissue imaging agents. 
 
Chapter 6 also presented a preliminary investigation into the potential of 
[Ru(dppz)2PIC]
2+
 to act as a luminescent probe for Aβ amyloid aggregation 
investigations. Amyloid-β as mentioned earlier is an extracellular peptide fragment. 
Studies suggest that the transition of monomeric Aβ to fibrillized-Aβ plays an important 
role in the pathology of AD. It was suggested that ruthenium would present minimal 
fluorescence in aqueous solution or in the presence of monomeric Aβ; whereas the 
fluorescence would increase or “switch on” by several orders of magnitude in the 
presence of fibrils due to its light switching nature. The ability of [Ru(dppz)2PIC]
2+
 to 
bind to the two widely reported Aβ aggregate forming sequences Aβ 1-40 and Aβ 1-42 
was presented; Aβ 1-42 has been shown to present greater aggregation than the Aβ 1-40  
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sequence. Preliminary results correlated with this, presenting distinct differences 
between Aβ 1-40 and Aβ 1-42 using atomic force microscopy, scanning electron 
microscopy and confocal microscopy.  
 
Future work to emerge from this thesis will focus on extending and quantifying the 
application of the ruthenium probes produced here in multimodal SERS/luminescence 
imaging. Further work concerning the attachment of alternative target specific peptides 
to these complexes i.e. talin (binds to β3 tail of integrin αIIbβ3) may provide a better 
insight into integrin activation and signalling pathways. On a wider scale, it is proposed 
to study the singlet oxygen generating ability of these transition metal-RGD peptide 
probes that may possibly result in the targeted (through RGD) cell death of cancer cells. 
Further experiments will include assessment of the ruthenium conjugates as multimodal 
imaging probes to determine intracellular pH and oxygen levels using Raman and FLIM 
measurements respectively which may in turn provide the ability to differentiate 
between normal and cancer cells.  
 
In addition, future work is required to strengthen further the suggestion the platelet 
adhesion is RGD specific. Pre-treating platelets for 15 minutes at room temperature 
with a 1 mM solution of RGD prior to incubation with the modified array will help 
confirm if platelet adhesion is RGD specific. This experiment is particularly important 
for the PEG modified planar surfaces. Platelet adhesion, spreading and activation was 
significant for all PEG modified surfaces. Thus this future study will help strengthen the 
statement that this platelet adhesion pattern is PEG specific.  
 
Additional experiments exploring the concentration dependence of Mn
2+,
 DTT or 
Eptifibatide is required. No significant changes in platelet adhesion was observed for 
either Mn
2+
 or Eptifibatide while an unusual reduction in platelet adhesion was observed 
for DTT treated platelets. This is in contrast to the statistically significant 
conformational changes observed for the treatment of purified integrin in solution with 
either Mn
2+
 or DTT presented in Chapter 4. This suggests that although conformational 
changes seem to occur to the purified integrin protein in solution, it is not sufficient to 
alter either the adhesion ability or activation status of whole platelet binding to the RGD 
modified surfaces. However it is very surprising that Eptifibatide treatment did not bind 
and block the RGD binding pocket of integrin on the platelets which in turn would have 
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inhibited binding to the RGD modified surfaces. It may therefore suggest that the effect 
of these species on platelets is concentration and time dependant. Broadening the 
investigation of platelet activation with physiological stimuli such as thrombin will 
provide greater insight into physiological platelet activation on platelet adhesion to the 
modified surfaces also and will provide insights into how real-life samples will behave.  
 
This study presented the ability to control platelet adhesion, spreading and activation 
through both chemical modification and surface topography. This is of significant 
interest, as the ability to control platelets in this manner would provide as a platform in 
investigating platelets at their differing spreading stages. The second advantage 
resulting from this thesis was the ability to capture single whole platelets over single 
cavities while retaining them in a resting or non-spread state. The size exclusion of 
binding is also of key interest across medical device applications such as stents where 
platelet adhesion must be discouraged.  
 
One of the most exciting aspects of this thesis was the demonstrated ability to obtain 
intense Raman signal intensities from single platelets as well as the ability to choose 
between non-spread to fully spread platelets. Further studies using these arrays may 
provide useful in investigating the differences in Raman signals between resting and 
activated platelets which may in the future provide the basis for rapid diagnostics using 
these arrays in Raman analysis. Future work will need to focus on providing sufficient 
replicates of this method for statistically robust differentiation. 
 
Further studies will focus on binding specificity to these Aβ aggregates. As suggested 
for the tissue studies, introducing increased specificity via conjugation of a targeting 
peptide may be of significant interest in progressing studies regarding the ruthenium 
complex as a probe for Aβ aggregation studies. For example, point mutations within the 
hydrophobic core of Aβ have identified residues 16–20 (KLVFF) as essential for fibril 
formation and found to be the minimum sequence required to bind to Aβ 1-40. 
Conjugating KLVFF to the [Ru(dppz)2PIC]
2+
 complex may introduce specificity to the 
binding and fibrillar formation of Aβ which may strengthen the application of this 
ruthenium(II) poylpyridyl complex as a biomarker in Aβ monomer-fibrillar transitions. 
 
321 
 
 
Integrins are key therapeutic targets in many inflammatory and vascular disorders and 
means of targeting them in live cells and in simply and effectively assessing their 
conformational status may be very useful in diagnostic assays as well as fundamental 
studies into their behaviour. It is believed that compounds such as those presented in 
this thesis may be more widely useful targeting integrins beyond the platelet integrin in 
thrombosis. For instance, RGD is a recognition sequence for approximately 8 integrin 
proteins and is regarded for example as a useful cancer marker. Future work 
investigating the specificity of these probes towards RGD expressing cancer cells may 
prove useful in broadening the application of these ruthenium-RGD conjugates as 
biomarkers.  
 
In addition, understanding and controlling platelet interactions with surfaces is 
important across a range of domains including diagnostics and medical implants. For 
example, platelet adhesion directly or through adsorbed protein on medical implants is 
important in dictating hemocompatibility as it can lead to thrombus formation. Future 
work investigating the effect of surface chemistry and topography using highly ordered 
cavity arrays may prove useful in broadening the application of these surfaces in platelet 
diagnostics. Overall, this thesis introduces some new probes and tools which look as 
though they may have significant value and insight to offer in study and prevention of 
thrombosis. 
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Appendix 1: NMR, High Resolution Mass 
Spectrometry and Quantum Yields 
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Figure 1.5A: 
1
H-NMR of [PIC-COOH] in DMSO-d
6
. 
 
 
 
 
Figure 1.6A: 
1
H-NMR of [PIC-NO2] in DMSO-d
6
. 
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Figure 1.7A: 
1
H-NMR of [PIC-NH2] in DMSO-d
6
. 
 
 
 
 
Figure 1.8A: 
1
H-NMR of (DPPZ) in DMSO-d
6
. 
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Figure 1.9A: 
1
H-NMR of [Ru(dpp)2Cl2]
2+
 in DMSO-d
6
. 
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Figure 1.10A: (Top) Mass spectrum of of [Ru(dpp)2PIC-NO2]
2+
. (Bottom) 
1
H-NMR 
of [Ru(dpp)2PIC-NO2]
2+
 in DMSO-d
6
. 
 
 
327 
 
 
 
 
 
 
Figure 1.11A: (Top) Mass spectrum of [Ru(dpp)2PIC-NH2]
2+
.(Bottom) 
1
H-NMR of 
[Ru(dpp)2PIC-NH2]
2+
 in DMSO-d
6
. 
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Figure 1.12A: (Top) mass spectrum of [Ru(dpp)2PIC-COOH]
2+
.(Bottom)
 1
H-NMR of 
[Ru(dpp)2PIC-COOH]
2+
 in DMSO-d
6
. 
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Figure 1.13A: (Top) Mass spectrum of [Ru(dpp)2PIC-NHS]
2+
.(Bottom) 
1
H-NMR of 
[Ru(dpp)2PIC-NHS]
2+
 in DMSO-d
6
. 
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Figure 1.14A: (Top) Mass spectrum of [Ru(dpp)2PIC-Maleimide]
2+
. (Bottom)  
1
H-
NMR of [Ru(dpp)2(PIC-Maleimide)]
2+
 in DMSO-d
6
. 
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Figure 1.15A: 
1
H-NMR of [Ru(dppz)2Cl2]
2+
 in DMSO-d
6
. 
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Figure 1.16A: (Top) Mass spectrum of [Ru(dppz)2PIC-COOH]
2+
.(Bottom) 
 1
H-NMR 
of [Ru(dppz)2PIC-COOH]
2+
 in DMSO-d
6
. 
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Figure 1.17A: (Top) Mass spectrum of [Ru(bpy)2PIC-NHS]
2+
. (Bottome) 
1
H-NMR of 
[Ru(bpy)2PIC-NHS]
2+
 in DMSO-d
6
. 
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Figure 1.18A: Quantum yield of (a)[Ru(dpp)2PIC-NO2]
2
,(b)[Ru(dpp)2PIC-NH2]
2+
, (c)[Ru(dpp)2PIC-COOH]
2+
, (d) [Ru(dpp)2PIC-NHS]
2+
, 
(e)[Ru(dpp)2PIC-Maleimide]
2+
, and (f) [Ru(dpp)2PIC-Mal-RGD]
2+
 in acetonitrile. Excitation ~465 nm, emission 610 nm, slit width 10 nm.
(a) (b) (c) 
(d) (e) (f) 
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Figure 1.24A: Quantum yield of (a)[Ru(dpp)2PIC-RGD]
2+
 in acetonitrile, (b) [Ru(bpy)2PIC-NHS]
2+
 in acetonitrile (red) and PBS pH 7.4 (blue), 
(c)[Ru(bpy)2PIC-RGD]
2+
 in acetonitrile (red) and PBS pH 7.4 (blue) and (d)[Ru(dppz)2PIC-COOH]
2+
 in acetonitrile. Excitation 460 nm (dpp) 
and 452 nm (bpy/dppz), emission 610 nm, slit width 10 nm.
(a) (b) 
(c) (d) 
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Fig 1.28A:  MALDI-TOF MS characterisation of peptides synthesised as part of this thesis. (a) C-Ahx-GRGDS (HRMS-MALDI-TOF): 748.86 
m/z (M
+
) calculated, 748.91 m/z (M
+
), observed. (b)  C-Ahx-KVGFFKR (HRMS-MALDI-TOF) 1097.51 m/z (M
+
) calculated, 1097.50 m/z (M
+
) 
observed. (c) Pal-C-Ahx-KVGFFKR (HRMS-MALDI-TOF) 1335.93 m/z (M
+
) calculated, 1335.39 m/z (M
+
) observed. 
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(a) 
 
(b) 
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(c) 
 
Fig 1.29A:MALDI-TOF MS characterisation of ruthenium-RGD peptides 
synthesised as part of this thesis. (a) [Ru(dpp)2PIC-Maleimide-RGD]
2+
 (HR-
MALDI-TOF) 1956.34 m/z (M
+
) calculated, 1956.72 m/z (M
+
), observed. (b) 
[Ru(dpp)2PIC-RGD]
2+
 via NHS (HR-MALDI-TOF) 1748.57 m/z (M
+
) calculated, 
1748.62 m/z (M
+
) observed. (c) [Ru(bpy)2PIC-RGD]
2+
(HR-MALDI-TOF) 1397.09 
m/z (M
+
) calculated, 1397.23 m/z (M
+
) observed 
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Appendix 2: Absorption and emission Spectra, Flow 
Cytometery (FACS), Time-resolved Luminescence 
Lifetime, Time-resolved Luminescence Anisotropy, 
Dissociation Constant and Confocal Microscopy  
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Figure 2.1A: (a) UV/VIS example of integrin αIIbβ3 following concentration via amicon ultra centrifugal filter unit (MWCO 30 kDa). Using the 
extinction coefficient value of αIIbβ3 (Ɛ = 2.23x10
5
) and the absorbance maximum value the concentration of the integrin protein could be 
calculated using the Beer Lambert Law; A = ƐCL. UV/VIS spectra of binding of [Ru(dpp)2PIC-RGD]
2+
 to (b) resting αIIbβ3 protein, (c) αIIbβ3 
pre-treated with Mn
2+
, (d) αIIbβ3 pre-treated with DTT and (e) denatured αIIbβ3.  No increase in absorbance was observed at the MLCT (450nm) 
transition of the Ru(II) complex confirming that any change in emission intensity were not a result of dye concentration changes 
(a) (b) (c) 
(d) (e) 
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Figure 2.2A:  UV/VIS spectra of binding of [Ru(bpy)2PIC-RGD]
2+
 to (a) resting αIIbβ3 protein, (b) αIIbβ3 pre-treated with Mn
2+
, (c) αIIbβ3 pre-
treated with DTT and (d) denatured αIIbβ3.  No increase in absorbance was observed at the MLCT (450nm) transition of the Ru(II) complex 
confirming that any change in emission intensity were not a result of dye concentration changes 
(a) (b) 
(c) (d) 
342 
 
 
 
Figure 2.3A: (i) Emission intensity (arb. units) changes of dpp-RGD1
 
(black), dpp-RGD2 
and bpy-RGD (red) non-specific binding to BSA. (ii) Displacement control experiment 
presenting the emission intensity (arb. units) changes of dpp-RGD1 (grey) or bpy-RGD 
(green) when αIIbβ3 is pre-incubated with Eptifibatide prior to binding to ruthenium-RGD 
and when dpp-RGD (orange) or bpy-RGD (red) is pre-incubated with Eptifibatide prior to 
the sequential addition of purified αIIbβ3.Corrections for dilution were inserted in all spectra 
recorded. Stock concentration was 2.3 µM in TrisHCl buffer, pH 7.4 for BSA, Ru-RGD and 
Eptifibatide. Ruthenium was held constant in all cases. λexc 450 nm, λem 610 nm and slit 
width of 10 nm. 
(i) 
(ii) 
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Figure 2.4A: Luminescence emission intensity changes (arb. units) of (i) bpy-RGD 
and (ii) dpp-RGD2 following sequential addition of denatured αIIbβ3. Corrections for 
dilution were inserted in all spectra recorded.  Stock concentration of dpp-RGD2, 
bpy-RGD and αIIbβ3 was 2.3 µM in TrisHCl buffer, pH 7.4. bpy-RGD and dpp-RGD2 
was held constant in all cases.(λexc 450 nm, λem 610 nm).   
 
 
(ii) 
(i) 
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 (a) Wild type, CHO-WT   
 
(b) Transfected CHO-αIIbβ3 
 
Figure 2.5A: The % expression of integrin αIIbβ3 on two CHO cell types; CHO-WT 
(no integrin) and transfected CHO- αIIbβ3. Two FITC labelled antibodies were used; 
CD41 (binds to resting and activated αIIbβ3) and PAC-1 (binds to activated αIIbβ3).  
(a) No integrin expression levels were observed for the contro CHO-WT cells for 
both resting and activated forms of integrin. (b) High integrin expression, ~47% 
(CD41) and very little activated integrin expression, ~4% (PAC-1) was observed for 
CHO-αIIbβ3 cells.  FITC was excited at 490 nm and emission observed at 520-540 
nm. 
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(1)  Anisotropy data example for [Ru(dpp)2PIC-RGD]
2+
 dye alone in solution 
  
(2) Anisotropy data example or non-specifically bound [Ru(dpp)2PIC-RGD]
2+
 to 
BSA protein   
 
(3) Anisotropy data example for [Ru(dpp)2PIC-RGD]
2+
 bound to resting integrin  
 
 
346 
 
(4)   Anisotropy data example for [Ru(dpp)2PIC-RGD]
2+
 bound to integrin treated 
with Mn
2+
 post-bind. 
  
(5)   Anisotropy data example for [Ru(dpp)2PIC-RGD]
2+
 bound to integrin pre-
treated with Mn
2+
  
 
(6)   Anisotropy data example for [Ru(dpp)2PIC-RGD]
2+
 bound to integrin treated 
with DTT post-bind. 
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(7)   Anisotropy data example for [Ru(dpp)2PIC-RGD]
2+
 bound to integrin pre-
treated with DTT. 
 
(8)   Anisotropy data example for [Ru(dpp)2PIC-RGD]
2+
 bound to integrin denatured 
at 90°C for 1 hour. 
 
Figure 2.6A:  Examples of Rotational correlation times (anisotropy) of 
[Ru(dpp)2PIC-RGD]
2+ 
as a function of resting integrin, BSA (non-specific binding), 
integrin activation state (Mn
2+
 and DTT) and denatured integrin in TrisHCl buffer 
(pH 7.4) at room temperature as measured by TCSPC (λexc 450 nm). Post-bind; 
where Mn
2+ 
or DTT was added after [Ru(dpp)2PIC-RGD]
2+
 had successfully bound 
to resting αIIbβ3.  Pre-treatment; where Mn
2+ 
or DTT was pre-incubated with αIIbβ3 
prior to addition to [Ru(dpp)2PIC-RGD]
2+
. r
2
, reduced chi–square value, model 
was approximately 1, confirming results to be statistically significant in all cases. 
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(1)  Anisotropy data example for [Ru(bpy)2PIC-RGD]
2+
 dye alone in solution 
 
(2) Anisotropy data example for [Ru(bpy)2PIC-RGD]
2+
 bound to resting integrin  
 
 
(3) Anisotropy data example for [Ru(bpy)2PIC-RGD]
2+
 bound to integrin treated 
with Mn
2+
 post-bind. 
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(4) Anisotropy data example for [Ru(bpy)2PIC-RGD]
2+
 bound to integrin pre-treated 
with Mn
2+
  
(5) Anisotropy data example for [Ru(bpy)2PIC-RGD]
2+
 bound to integrin treated 
with DTT post-bind. 
 
(6) Anisotropy data example for [Ru(bpy)2PIC-RGD]
2+
 bound to integrin pre-treated 
with DTT. 
 
 
350 
 
 (7) Anisotropy data example for [Ru(bpy)2PIC-RGD]
2+
 bound to integrin denatured 
at 90°C for 1 hour. 
 
Figure 2.7A: Examples of Rotational correlation times (anisotropy) of 
[Ru(bpy)2PIC-RGD]
2+ 
as a function of resting integrin, integrin activation state 
denatured integrin in TrisHCl buffer (pH 7.4) at room temperature as measured by 
TCSPC (λexc 450 nm). Post-bind; where Mn
2+ 
or DTT was added after [Ru(bpy)2PIC-
RGD]
2+
 had successfully bound to resting αIIbβ3.  Pre-treatment; where Mn
2+ 
or DTT 
was pre-incubated with αIIbβ3 prior to addition to [Ru(dpp)2PIC-RGD]
2+
. r
2
, 
reduced chi–square value, model was approximately 1, confirming results to be 
statistically significant in all cases. 
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Figure 2.8A : SigmaPlot 12.0 dissociation constant (KD) analysis data of [Ru(bpy)2PIC-RGD]
2+
 binding to (a) resting, untreated integrin, (b) integrin 
pre-treated with Mn
2+,
 (c) integrin pre-treated with DTT and (d) integrin thermally denatured at 90°C for 1 hour. 
Parameter Values  
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Std. Errors  
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Figure 2.9A : SigmaPlot 12.0 dissociation constant (KD) analysis data of [Ru(dpp)2PIC-RGD]
2+
 two-step binding to (a, b) resting, untreated integrin 
and single step binding to (c) integrin pre-treated with Mn
2+,
 (d) integrin pre-treated with DTT and (e) integrin thermally denatured at 90°C for 1 
hour.
Parameter Values  
   Bmax 76.2708 
   Kd 4.3684e-6 
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(i) 
   
 
(ii) 
 
Figure 2.10A:  Luminescencent confocal images presenting (i) colocalization with the αIIb 
specific antibody SZ22 and (ii) z-stack image, 19µm depth (λex = 458 nm and 488 nm) of 
transfected CHO-αIIbβ3 cell incubated with [Ru(dpp)2PIC-RGD]
2+
 (70 × 10
−6
 M), 
confirming staining is localized at the surface of the cell in conjunction with the αIIbβ3 
surface transmembrane receptor protein. 458 nm (ruthenium) and 488 nm (AlexaFluor) 
laser excitation. 
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Figure 2.11A:  Luminescencent fluorescence emission intensity profile of Ru-RGD2 (red) 
with the αIIb specific antibody SZ22 (green) in a transfected CHO-αIIbβ3 cell. The arrow 
located on the top panel presents the area of emission intensity profiled. 458 nm (ruthenium) 
and 488 nm (AlexaFluor) laser excitation. 
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 (i)        
 
(ii) 
 
Figure 2.12A:  Luminescencent confocal images presenting (i) cross-section and (ii) z-stack 
image, 19µm depth (λex = 458 nm, λem = 610 nm) of transfected CHO-αIIbβ3 cell incubated 
with [Ru(bpy)2PIC-RGD]
2+
 (70 × 10
−6
 M), confirming staining is localized at the surface of 
the cell in conjunction with the αIIbβ3 surface transmembrane receptor protein. 458 nm 
(ruthenium) and 488 nm (AlexaFluor) laser excitation. 
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Figure 2.13A:  Luminescencent fluorescence emission intensity profile of Ru-RGD2 (red) 
with the αIIb specific antibody SZ22 (green) in a transfected CHO-αIIbβ3 cell. The arrow 
located on the top panel presents the area of emission intensity profiled. 458 nm (ruthenium) 
and 488 nm (AlexaFluor) laser excitation. 
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Appendix 3:  Scanning Electron Microscopy,  
Atomic Force Microscopy, Cyclic Voltammetry  
and Confocal Microscopy 
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Figure 3.1A: Large scale SEM imaging of (a) 5.4, (b) 1.6 and (c) 0.98 μm cavity 
array surfaces confirming highly ordered arrays with minimal defects in all cases. 5-
20 kV accelerating voltage was applied in all cases. 
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Figure 3.2A: AFM characterization of (a) 5.4, (b) 1.6 and (c) 0.98 μm cavity arrays. 
Left: Depth and diameter of the cavities. Right: RMS (root mean square) surface 
roughness, Rq of each cavity array size averaged over the entire surface.  
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Figure 3.3A: Cyclic voltagrams in 0.1 M H2SO4 at 100 mVs
-1
presenting 
electrochemical desorption of (a) RGD/alkane 1:1 ratio, (b) RGD/alkane 1:5 ratio 
and  (c) RGD/Alkane 1:10 ratio on gold planar electrode surfaces. 0.4 V and 0.7 V 
represents distinct gold oxidation reduction peaks. Inset: -1.1 V peak which is characteristic 
of thiol desorption from a gold 
 
Figure 3.4A: Cyclic voltagrams in 0.1 M H2SO4 at 100 mVs
-1
presenting 
electrochemical desorption of (a) RGD/PEG 1:1 ratio, (b) RGD/PEG 1:5 ratio and  
(c) RGD/PEG 1:10 ratio on gold planar electrode surfaces. 0.4 V and 0.7 V represents 
distinct gold oxidation reduction peaks. Inset: -1.1 V peak which is characteristic of thiol 
desorption from a gold 
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Figure 3.5A: Cyclic voltagrams in 0.1 M H2SO4 at 100 mVs
-1
presenting 
electrochemical desorption of 5.4μm cavity arrays chemically modified with (a) 
RGD only (b) alkane only and  (c) RGD/Alkane 1:5 ratio, (d) RGD/Alkane 1:10 
Ratio (e) RGD on the surface alkane in the cavity and (f) alkane on the surface and 
RGD in the cavity. 0.4 V and 0.7 V represents distinct gold oxidation reduction peaks. 
Inset: -1.1 V peak which is characteristic of thiol desorption from a gold 
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Figure 3.6A: Cyclic voltagrams in 0.1 M H2SO4 at 100 mVs
-1
presenting 
electrochemical desorption of 1.6 μm cavity arrays  chemically modified with (a) 
RGD only (b) alkane only and  (c) RGD/Alkane 1:5 ratio, (d) RGD/Alkane 1:10 
Ratio (e) RGD on the surface alkane in the cavity and (f) alkane on the surface and 
RGD in the cavity. 0.4 V and 0.7 V represents distinct gold oxidation reduction peaks. 
Inset: -1.1 V peak which is characteristic of thiol desorption from a gold 
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Figure 3.7A: Cyclic voltagrams in 0.1 M H2SO4 at 100 mVs
-1
presenting 
electrochemical desorption of 0.98 μm cavity arrays chemically modified with (a) 
RGD only (b) alkane only and  (c) RGD/Alkane 1:5 ratio, (d) RGD/Alkane 1:10 
Ratio (e) RGD on the surface alkane in the cavity and (f) alkane on the surface and 
RGD in the cavity. 0.4 V and 0.7 V represents distinct gold oxidation reduction peaks. 
Inset: -1.1 V peak which is characteristic of thiol desorption from a gold 
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Figure 3.8A: Luminescent confocal image example of platelets bound to surface 
modified gold 1.6 μm cavity array surfaces and analysed with Image J software. 
Phase contrast was used in all cases. Blue dots incdicate platelet counts. Platelets 
imaged on (a) gold only, (b) alkane only, (c) RGD only, (d) RGD/alkane 1:5 ratio, 
(e) RGD/akane 1:10 ratio, (f) RGD on the surface and alkane in the cavity, (g) 
alkane on the surface and RGD in the cavity (h) Mn
2+
 pre-treated, (i) DTT pre-
treated, (j) Eptifibatide pre-treated, (k) Eptifibatide post-bind and (l) RGD post-bind 
. RGD concentration was 1μM in all cases. All treatments were applied at 1 mM 
concentration. Bound platelets were imaged using TRITC-phalloidin. Luminescence 
images were using a 40x oil immersion objective lens (NA 1.4) with 540 nm HeNe 
laser excitation. 
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Figure 3.9A: Confocal luminescence images of platelet binding at 5.4 µm diameter arrays 
selectively modified with (a) RGD at the surface and alkane on the cavity walls and (b) 
alkane at the top surface and RGD on the cavity walls and stained for PE-CD62P (green) 
and TRITC-phalloidin (red). 30 x 10
3
± 2 x 10
3
/µl platelets were incubated with the modified 
surfaces for 45 minutes at 37°C and stained for phalloidin (1/100 dilution). Luminescence 
images were recorded using a 40x oil immersion objective lens (NA 1.4) with 488 nm Argon 
(CD62P) and 540 nm (phalloidin) HeNe laser excitation.  
       Backscatter                             IgG 
 
Figure 3.10A: Luminescent confocal image of platelets bound to glass and stained 
for PE-IgG control. Luminescence images were recorded using a 40x oil immersion 
objective lens (NA 1.4) with 488 nm argon laser excitation. 
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Figure 3.11A: Luminescent confocal images of platelets bound to BSA coated glass 
and stained for both PE-CD62P(green) and TRITC-phalloidin (red). Luminescence 
images were recorded using a 40x oil immersion objective lens (NA 1.4) with 488 nm 
argon and 540 HeNe laser excitation. 
 
Figure 3.12A: Luminescent confocal images of platelets bound to (a) gold only and 
(b) alkane only coated gold planar surface and stained for both PE-CD62P (green) 
and TRITC-phalloidin (red). Luminescence images were recorded using a 40x oil 
immersion objective lens (NA 1.4) with 488 nm argon and 540 HeNe laser excitation 
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Figure 3.13A: Luminescent confocal images of platelets bound to (a) gold only and 
(b) alkane only coated gold 5.4 μm cavity arrays and stained for both PE-CD62P 
(green) and TRITC-phalloidin (red). Luminescence images were recorded using a 
40x oil immersion objective lens (NA 1.4) with 488 nm argon and 540 HeNe laser 
excitation 
 
Figure 3.14A: Luminescent confocal image of platelets bound to (a) gold only and 
(b) alkane only coated gold 1.6 μm cavity arrays and stained for both PE-CD62P 
(green) and TRITC-phalloidin (red). Luminescence images were recorded using a 
40x oil immersion objective lens (NA 1.4) with 488 nm argon and 540 HeNe laser 
excitation 
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Figure 3.15A: Luminescent confocal images of platelets bound to (top) gold only and 
(bottom) alkane only coated gold 0.98 μm cavity arrays and stained for both PE-
CD62P(green) and TRITC-phalloidin (red). Luminescence images were recorded 
using a 40x oil immersion objective lens (NA 1.4) with 488 nm argon and 540 HeNe 
laser excitation 
 
Figure 3.16A:  (Top) Raman  spectra and (bottom) peak assignments of gold cavity 
arrays immobilized with C-Ahx-GRGDS. Raman signals taken from different 
‘hotspots’ on the cavities. Excitation wavelength 758nm with an exposure time of 10 
seconds.  Spectra were measured by Dr. Colm Mallon and Niamh Hayes (M. Sc). 
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Figure 3.17A: Luminescence intensity profiles of pituitary gland sections approx. 
100 μm thick fixed with 3.8% PFA and incubated with (a) [Ru(dpp)2PIC-
COOH]
2+
,(b) [Ru(dpp)2PIC-NO2]
2+
 and (c) [Ru(dpp)2PIC-NH2]
2+
. 7 μM 
concentration and 2 minute incubation time in each case. Samples were DAPI 
stained (1/3000 dilution) and mounted prior to imaging. 375 nm (blue,DAPI) and 
488 nm (red, ruthenium) laser excitation. 63x oil immersion. White arrows reflect 
the intensity profiles presented. 
(c) 
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Figure 3.18A: Confocal luminescence image of a pituitary gland section approx. 100 
μm thick fixed with 3.8% formaldehyde incubated with (a) [Ru(dpp)2PIC-NHS]
2+
. 7 
μM concentration,2 minute incubation. Sample was DAPI stained (1/3000 dilution) 
and mounted prior to imaging. 375 nm (blue,DAPI) and 488 nm (red, ruthenium) 
laser excitation. 63x oil immersion. Laser intensity was identical to that used for 
fixed pituitary tissue samples presented in section 6.2.2.1, confirming no 
luminescence at this intensity for live imaging. 
 
 
